PSYCHOSOMATIC MEDICINE
INTEGRATING PSYCHIATRY & MEDICINE

158TH ANNUAL MEETING
ATLANTA, GEORGIA, MAY 21-26, 2005

AMERICAN PSYCHIATRIC ASSOCIATION

ATLANTA, GA • MAY 21–26, 2005
May 21, 2005

Dear Colleagues and Guests:

Welcome to the 158th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care.

This year’s Annual Meeting theme is “Psychosomatic Medicine: Integrating Psychiatry and Medicine.” Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Presidential Symposia, from 2:00-5:00 p.m., on Monday, Tuesday, and Wednesday. An entire track of sessions, presented in collaboration with the National Institute of Mental Health has been scheduled throughout the meeting.

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in Atlanta. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there. Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 5:30 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented during the Convocation by author, Trisha Meili, who will discuss her traumatic attack in her lecture entitled, “I am the Central Park Jogger: A Story of Hope and Possibility.”

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Marian Butterfield and the members of the Scientific Program Committee and to the APA staff who work on the Annual Meeting. Welcome to Atlanta.

Sincerely,

Michelle B. Riba, M.D.
APA President
May 21, 2005

Dear APA Members and Guests:

Welcome to Atlanta, GA, and the 158th Annual Meeting of the American Psychiatric Association. This historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme “Psychosomatic Medicine: Integrating Psychiatry and Medicine,” chosen by our President, Dr. Michelle B. Riba. Let me draw your attention to just a few of the many exciting sessions presented this week. Several Presidential Symposia will be presented each day on Monday-Wednesday from 2:00 p.m.-5:00 p.m.

The Business Meeting and the Opening Session will be held at the Georgia World Congress Center on Sunday, May 22. The Convocation of Distinguished Fellows also will be held there on Monday evening, May 23, 5:30-6:30 p.m. During the Convocation, author Trisha Meili, will discuss her trauma narrative and story of healing and hope when she presents the William C. Menninger Memorial Lecture entitled, “I am the Central Park Jogger: A Story of Hope and Possibility.”

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. We have chosen topics to interface with our Annual Meeting theme, including depression and cardiovascular disease and psycho-oncology. This session has become an excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only.

A special series of sessions will be presented in collaboration with the National Institute of Mental Health. Outstanding leaders in psychiatry and neuroscience research will present across formats from lectures to symposia and discussion groups. Notably, Nobel Laureate Dr. Eric Kandel will discuss neuroscience and its relationship to the “self.” The APA is very appreciative of their support of these sessions. For detailed information on the sessions, please consult the separate program on this series, which is included your registration packet.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting. Once again, welcome to Atlanta. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Marian I. Butterfield, M.D.
Chairperson, Scientific Program Committee
the last event of the evening. and opens one hour prior to show opening and closes one hour after participating hotels. Refer to the city map on page XII for the location of hotels in relation to the Congress Center.

Located in A2/A3 Foyer, Level 1, Georgia World Congress Center. Hours of operation: Tuesday, May 17, through Thursday, May 26, and opens one hour prior to show opening and closes one hour after the last event of the evening.

APPA JOB BANK
Visit the APA on-site Job Bank at APA 2005! The online APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA's Annual Meeting. Candidates and employers are encouraged to activate their resumes and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank.

APPA COMMUNICATIONS OFFICE/PRESS OFFICE
Located in Rooms A311/312, Level 3, Georgia World Congress Center. Hours of operation will be: Saturday, May 21, 11:00 a.m.-5:00 p.m.; Sunday-Thursday, May 22-25, 8:00 a.m.-6:00 p.m.; and Thursday, May 26, 8:00 a.m.-12 noon. This room is for the use of registered press and credentialed public relations representatives only.

DAILY BULLETIN
The Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Rooms A311/312, Level 3, by 12 noon prior to the date of publication.

RESIDENTS’ RESOURCE CENTER
Located in International Meeting Rooms 2/3, International Level, Atlanta Marriott. The Residents’ Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 22, through Wednesday, May 25. Daily activities are scheduled for residents (such as the Residents Only Discussion Groups and Resident Summits) and for medical students as well. Meet and network with leaders in psychiatry and your colleagues. Resources specifically for residents and medical students are available here.
REGISTRATION

Admission to all sessions by registration badge

Located in the Halls A1-3, Level 1, Georgia World Congress Center. Hours of operation: Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30 a.m.-5:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.; and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

**APA MEMBERS**

- Full-Time Registration (North American Members) $275.00
- Full-Time Registration (International Members) $275-$470*
- Members-in-Training (Member Class MT) $275.00
- Daily Registration (North American Members) $140.00
- Daily Registration (International Members) $215.00

**NONMEMBERS**

- Full-Time Registration $790.00
- Nonmember Residents, Students, Advocacy $50.00
- Group Members, or Mental Health Chaplains $95.00
- Daily Registration (all Nonmember categories) $400.00
- Medical Students $400.00

**GUEST REGISTRATION**

One only per full-time registrant $100.00

Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to verify status at the same address. APA members cannot register as a “guest”; they must register as an APA member.

One-Day Exhibit Hall Only Pass (18 and older) $10.00

(Only paid registrant can purchase an exhibit hall pass)

On-site fees can be paid by cash, check, money order, American Express, VISA, or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Professionals/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day[s] they present).

**NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS** must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Member Center Guide, and New Research Program and Abstracts Books, and for most categories, a copy of the Syllabus.

REGISTRATION BADGES

Badges are required for all sessions including the Opening Session and exhibit hall. Only an APA member badge will admit you to the Business Meeting.

**Badge Color Codes:**


Registered exhibitors will receive red badges, which allow access only to his/her own booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT

Ticket purchase required for CME Courses

Located in Halls A1-3 Level 1, Georgia World Congress Center. Hours of operation are the same as registration. Tickets for CME Courses not sold by April 23 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 21. You must show your registration badge before you can enroll in courses.

**APA ART ASSOCIATION**

Located in the Exhibit Halls A1-3, Level 1, Georgia World Congress Center and open during the commercial exhibit hours, the exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

**APA ALLIANCE BOOTH**

Located in the Building A Foyer, Level 4, Georgia World Congress Center. Hours of operation: Saturday, May 21, through Wednesday, May 25, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Alliance’s program schedule and information on membership.

**APA PERIODICALS**

Staff of The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, The American Journal of Geriatric Psychiatry, Journal of Neuropsychiatry and Clinical Neurosciences, Psychosomatics, and APA’s CME journal, Fees, will be on hand to demonstrate online access for subscribers, answer questions regarding submissions, and show authors and reviewers how to use Manuscript Central, the new web-based manuscript submission and review system. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the booth. Complimentary copies of Psychiatric News will be available at stands located throughout Georgia World Congress Center. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Annual Meetings Office. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper’s consideration may be left with staff at the Periodicals Exhibit.
CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Better understand new research findings in the fields of psychiatry and neuroscience;
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for category 1 CME credit. Sessions in the following program formats are designated as category 1:
- Advances in Psychotherapy, Advances in Psychosomatic Medicine, Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Medical Updates, New Research Young Investigators' Oral/Slide Sessions, Presidential Symposium, Research Advances in Medicine, Review of Psychiatry, Roundtable Discussion, Scientific and Clinical Reports, Symposia, and Workshops.
- Other scientific sessions not listed may be reported as category 2 (Debates, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and Research Consultations).

Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME CREDITS. RECORDING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the Certificate of Attendance log sheet found in the front of the 2005 Annual Meeting CME Syllabus & Proceeding Summary Book. Credit is earned on an hour-for-hour basis. A parchment Certificate of Attendance is also available.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 credits of CME activities within a three-year reporting period. At least 60 credits must be in category 1 activities.

CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. Staff will be available in the APA Member Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. Before you leave the meeting, please complete your form and drop it in one of the evaluation boxes located throughout the meeting sites or consider the options below.

You can receive a parchment Certificate of Attendance at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator Center, or APA Member Center, all located in Georgia World Congress Center). A personalized Certificate of Attendance will be available by completing the computerized general evaluation in the Building A Foyer, Level 4, Georgia World Congress Center, or after the meeting, by completing the online general evaluation on the APA website. Please complete the general evaluation one time only.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

AUDIO RECORDINGS OF SESSIONS

Audiotapes and CDs of most sessions are available shortly after each session concludes and may be purchased at the Audiotape Booth located in the Building A Foyer, Level 4, Georgia World Congress Center.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except Master Educator Clinical Consultations, the Clinical Case Conferences, and the Continuous Clinical Case Conferences, or unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional taping firm to audiotape sessions. Badges of personnel representing this firm will clearly identify them. Registrants are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.
GUIDE TO THE PROGRAM BOOK

Below you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. NOTE: To make it easier for you to plan your day, we have prepared a separate “Days-at-a-Glance,” which is included in your registration packet.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in Georgia World Congress Center, and we will be glad to help you. Also, all APA staff will be wearing green badges. Please feel free to direct your questions to them.

TABLE OF CONTENTS

Floor Plans for Georgia World Congress Center, Atlanta Hilton, Omni: .................................................................VI-XI
City Map ............................................................................................................................................................ XII
Local Information .................................................................................................................................................. XIII
Special Acknowledgments .................................................................................................................................. XIV-XVII
Format Descriptions ........................................................................................................................................ XVII-XVIII
Disclosure Information ......................................................................................................................................... XIX-XXXIII
Saturday Sessions .............................................................................................................................................. 1-4
Sunday Sessions ................................................................................................................................................ 5-12
Monday Sessions ............................................................................................................................................... 13-37
Audio tape Sales Information .............................................................................................................................. 38
Tuesday Sessions ................................................................................................................................................ 39-62
Wednesday Sessions .......................................................................................................................................... 63-84
Thursday Sessions ............................................................................................................................................ 85-99
Topic Index ........................................................................................................................................................ 100-115
Participant Index ............................................................................................................................................... 116-126
Call for 2006 Annual Meeting Papers ............................................................................................................. 127
2005 Institute on Psychiatric Services .................................................................................................................. 128
American Psychiatric Foundation Special Events ............................................................................................... 129
American Psychiatric Publishing Inc. .................................................................................................................. 130-131
Psychiatry Online.com ....................................................................................................................................... 132
Industry-Supported Symposia ........................................................................................................................... 133-155
APA Member Center ......................................................................................................................................... Back Cover

News reports or summaries of APA presentations contained in these program materials may not be published or broadcast before the local time and date of the presentation.

Refer to the APA Exhibits Guide for information on Exhibits, Publishers' Bookfair, and Dining Facilities in the Georgia World Congress Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.
Hilton Atlanta
Third Floor

Third Floor

<table>
<thead>
<tr>
<th>Room</th>
<th>Dimensions LxW</th>
<th>Square Feet*</th>
<th>Ceiling Height</th>
<th>Theatre</th>
<th>Schoolroom 2 per 6'</th>
<th>Schoolroom 3 per 6'</th>
<th>Banquet</th>
<th>Reception**</th>
<th>Conference</th>
<th>Exhibits 10' x 10'</th>
<th>Exhibits 6' x 10'</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presidential Court</td>
<td>130x48</td>
<td>5,987</td>
<td>9'10&quot;</td>
<td>400</td>
<td>144</td>
<td>216</td>
<td>350</td>
<td>550</td>
<td>N.A.</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Carter</td>
<td>37x23</td>
<td>851</td>
<td>9'10&quot;</td>
<td>90</td>
<td>34</td>
<td>51</td>
<td>60</td>
<td>80</td>
<td>34</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Jackson</td>
<td>48x30</td>
<td>1,440</td>
<td>9'10&quot;</td>
<td>120</td>
<td>46</td>
<td>69</td>
<td>80</td>
<td>130</td>
<td>40</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Madison</td>
<td>48x23</td>
<td>1,104</td>
<td>9'10&quot;</td>
<td>110</td>
<td>44</td>
<td>66</td>
<td>90</td>
<td>105</td>
<td>40</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Monroe</td>
<td>48x30</td>
<td>1,440</td>
<td>9'10&quot;</td>
<td>120</td>
<td>46</td>
<td>69</td>
<td>90</td>
<td>130</td>
<td>40</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Roosevelt</td>
<td>48x24</td>
<td>1,152</td>
<td>9'10&quot;</td>
<td>110</td>
<td>44</td>
<td>66</td>
<td>90</td>
<td>105</td>
<td>40</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Jefferson</td>
<td>26x23</td>
<td>598</td>
<td>10'8&quot;</td>
<td>50</td>
<td>18</td>
<td>27</td>
<td>40</td>
<td>50</td>
<td>26</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Washington</td>
<td>26x23</td>
<td>598</td>
<td>10'8&quot;</td>
<td>50</td>
<td>18</td>
<td>27</td>
<td>40</td>
<td>50</td>
<td>26</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Adams</td>
<td>26x23</td>
<td>598</td>
<td>10'8&quot;</td>
<td>50</td>
<td>18</td>
<td>27</td>
<td>40</td>
<td>50</td>
<td>26</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
</tbody>
</table>

*The square feet numbers are based on usable square footage. Capacities take into consideration placement of bars, cocktail rounds, food stations and experience of the hotel.
### Fourth Floor

<table>
<thead>
<tr>
<th>Room</th>
<th>Dimensions L x W</th>
<th>Square Feet</th>
<th>Ceiling Height</th>
<th>Theatre</th>
<th>Schoolroom 2 per 6'</th>
<th>Schoolroom 3 per 6'</th>
<th>Banquet</th>
<th>Reception**</th>
<th>Conference</th>
<th>Exhibits 10' x 10'</th>
<th>Exhibits 8' x 10'</th>
</tr>
</thead>
<tbody>
<tr>
<td>State Room</td>
<td>26x24</td>
<td>624</td>
<td>9'11&quot;</td>
<td>70</td>
<td>22</td>
<td>33</td>
<td>40</td>
<td>70</td>
<td>24</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Club Room</td>
<td>28x26</td>
<td>728</td>
<td>9'11&quot;</td>
<td>80</td>
<td>22</td>
<td>33</td>
<td>40</td>
<td>80</td>
<td>24</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>State/Club</td>
<td>52x26</td>
<td>1,352</td>
<td>9'11&quot;</td>
<td>115</td>
<td>42</td>
<td>63</td>
<td>90</td>
<td>115</td>
<td>40</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Council Room</td>
<td>26x24</td>
<td>624</td>
<td>9'11&quot;</td>
<td>70</td>
<td>22</td>
<td>33</td>
<td>40</td>
<td>70</td>
<td>24</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Cabinet Room</td>
<td>28x26</td>
<td>728</td>
<td>9'11&quot;</td>
<td>80</td>
<td>22</td>
<td>33</td>
<td>40</td>
<td>80</td>
<td>24</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Council/Cabinet</td>
<td>52x26</td>
<td>1,352</td>
<td>9'11&quot;</td>
<td>115</td>
<td>42</td>
<td>63</td>
<td>90</td>
<td>115</td>
<td>40</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Embassy Room</td>
<td>25x27</td>
<td>675</td>
<td>9'11&quot;</td>
<td>75</td>
<td>22</td>
<td>33</td>
<td>50</td>
<td>75</td>
<td>24</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Board Room</td>
<td>25x23</td>
<td>575</td>
<td>9'11&quot;</td>
<td>65</td>
<td>20</td>
<td>30</td>
<td>40</td>
<td>65</td>
<td>24</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Directors Room</td>
<td>25x27</td>
<td>675</td>
<td>9'11&quot;</td>
<td>75</td>
<td>22</td>
<td>33</td>
<td>50</td>
<td>75</td>
<td>24</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Board/Directors</td>
<td>50x25</td>
<td>1,250</td>
<td>9'11&quot;</td>
<td>115</td>
<td>42</td>
<td>63</td>
<td>90</td>
<td>115</td>
<td>40</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Assembly Room</td>
<td>19'3&quot;x25'7&quot;</td>
<td>490</td>
<td>9'11&quot;</td>
<td>50</td>
<td>12</td>
<td>18</td>
<td>30</td>
<td>60</td>
<td>16</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Congressional Room</td>
<td>21'9&quot;x25'7&quot;</td>
<td>555</td>
<td>9'11&quot;</td>
<td>60</td>
<td>16</td>
<td>24</td>
<td>40</td>
<td>60</td>
<td>18</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
<tr>
<td>Legislative Room</td>
<td>21'9&quot;x25'7&quot;</td>
<td>555</td>
<td>9'11&quot;</td>
<td>60</td>
<td>16</td>
<td>24</td>
<td>40</td>
<td>60</td>
<td>18</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
</tbody>
</table>

*The square feet numbers are based on usable square footage. Capacities take into consideration placement of bars, cocktail rounds, food stations and experience of the hotel.*
Southern hospitality, hot attractions, and good weather year round lure visitors to Atlanta. Indoors and outdoors, there's plenty to do. A tour around Centennial Olympic Park and the CNN Center can't be missed, especially with both just steps away from the Georgia World Congress Center. Also downtown are the Underground Atlanta shopping and entertainment district, World of Coca-Cola, and an arts scene that's become one of the country's best. The Atlanta Ballet - the country's oldest ballet company, the Atlanta Opera, and the Atlanta Symphony Orchestra put on spectacular classical and contemporary performances, and the High Museum of Art features world-renowned paintings from well-known artists. The Atlanta Botanical Garden is great for individual exploration or a special group event, and the tour around Centennial Olympic Park and the CNN Center can't be missed, especially with both just steps away from the Georgia World Congress Center. Sports fans - those who play and those who watch - will have a ball in Atlanta. Games featuring the Atlanta Braves (MLB), Hawks (NBA), Thrashers (NHL), and Falcons (NFL) are always full of excitement. Golfers will enjoy the city's 57 public golf courses, and those looking to relax or jog will find the city's 34 public parks ample space. A day at Six Flags Over Georgia or Stone Mountain Park is also a nice treat.

TRANSPORTATION FACTS
Hartsfield-Jackson Atlanta International Airport
Largest passenger terminal complex in the world and world's busiest passenger airport. Eighty percent of the U.S. population is within a two-hour flight of Atlanta. It is just 10 miles from downtown Atlanta.
American Airlines (800) 433-7300
Continental Airlines (800) 525-1700
Delta Air Lines (800) 325-1999
Northwest Airlines (800) 225-3160
US Air (800) 428-3222
United Airlines (800) 241-6522

MARTA - Metro Atlanta Rapid Transit Authority (404) 848-4711
39 rail stations and 154 bus routes
$1.75 fare
Fare transfers between bus and rail
Taxi
Fare from airport to downtown and convention district:
$25 for one passenger
$13 per person for two passengers
$10 per person for three or more passengers
Fare within the downtown business district:
$6 for one passenger
$1 per person for two or more passengers

TOURS/VISITOR INFORMATION
APA has contracted with Event Transportation System to provide a limited number of local tours. Detailed information may be viewed on pages 21 and 22. You may also sign up for tours by going to the APA website www.psych.org and clicking on the direct link to the tour company. For further information on Atlanta, visit www.atlanta.net

BANKS/FINANCIAL SERVICES
Bank of America (404) 581-2121
600 Peachtree Street, NE, 133 Peachtree Street, 44 Courtland Street, 66 Courtland Street, 250 Williams Street, 35 Broad Street, 140 Decatur Street, 206 Piedmont Avenue, 244 Washington Street, 333 Piedmont Avenue, 206 Mitchell Street

SunTrust Bank, Atlanta (404) 585-8234
225 Peachtree Street, 303 Peachtree Street, 449 Auburn Avenue, 100 Edgewood Avenue, 1 Park Place, 55 Park Place

Wachovia Bank, Atlanta, (404) 322-1320
191 Peachtree Street, NE, 240 Peachtree Street, 312 South Tower - 1 CNN Center, 645 State Street

MEDICAL EMERGENCIES
Grady Health System (404) 616-4382
80 Butler Street, SE
Grady Memorial Hospital (404) 616-4307
Emergency/1 Level Trauma, Urgent Care (404) 616-0600

Piedmont Hospital (404) 605-5000
A full-service hospital located in Buckhead

APA GOLF TOURNAMENT
The Golfers of the APA (GAPA) invite you to participate in their 2005 golf tournament to benefit the American Psychiatric Foundation. We are tentatively scheduling afternoon rounds on three different courses. The three afternoons are Sunday, May 22; Monday, May 23; and Tuesday, May 24 with transportation from the Georgia World Congress Center. You may play one afternoon or any combination of days. If you are interested in registering for this event, please contact W. Stanley Jennings, Jr., M.D., at 804-320-7881 or by mail, W.S. Jennings, Jr., M.D., 7149 Jahnke Road, Richmond, VA 23225.

ATLANTA AT A GLANCE
Did You Know Atlanta Has ....
• 130 retail centers
• 57 public golf courses
• 100 streets that include the word Peachtree
• The largest toll-free telephone dialing area in the world (7,000 square miles of toll-free calling)
• The largest suburban office park in the United States (Perimeter Center, 3.5 million square feet of office and retail space on 400 acres)
• The largest cable-supported dome stadium in North America (Georgia Dome)
• The 14th largest mall in the country (Mall of Georgia, 1.7 million square feet)
• The world's largest bas-relief sculpture and the world's largest exposed mass of granite (Stone Mountain Park)
• The largest federal regional concentration outside of Washington, D.C.
• The largest 10K road race in the world (Peachtree Road Race, with 55,000 participants)
• The oldest continually operating ballet company in the nation (Atlanta Ballet, since 1929)
• The longest escalator in the nation (CNN Center, eight stories)
• The tallest hotel in the Western Hemisphere (Westin Peachtree Plaza, 73 stories and 723 feet tall)
• The tallest building in the Southeast (Bank of America Plaza, 56 stories and 1,023 feet tall)
• The second-largest theater organ in the nation (Fox Theatre)
• More shopping center space per capita than any other U.S. city except Chicago.
The American Psychiatric Association expresses its deep appreciation for the following:

**Abbott Laboratories:** partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.

**Alkenes:** support of the Industry-Supported Symposium, "Alcoholism: Translating Emerging Science Into Clinical Practice," Tuesday, May 24, 7:00 p.m.

**American Academy of Psychiatry and the Law:** co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 22, 2:30 p.m.

**American Association of Psychiatric Administrators:** co-support of the Administrative Psychiatry Award Lecture, Monday, May 23, 9:00 a.m.

**American Psychiatric Foundation:** support of the Disaster Psychiatry Fellowship; and the APIRE Practice Research Network.

**Association of Women Psychiatrists:** support of the joint AWP/APA Women's Caucus reception and meeting, Monday, May 23, 7:00 p.m.; co-support of the Alexandra Symonds Award Lecture, Monday, May 23, 11:00 a.m.

**AstraZeneca Pharmaceuticals:** support of the Industry-Supported Symposium, "Bipolar Disorder: Treating Through the Entire Spectrum," Sunday, May 22, 7:00 p.m.; "Dual Diagnosis: The Scope of the Problem," Monday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Agitation and Psychosis in Alzheimer's Disease and Parkinson's Disease," Monday, May 23, and Tuesday, May 24, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support of the APA/AstraZeneca Minority Fellowship and reception, Tuesday, May 24, 7:00 p.m.; the American Psychiatric Foundation "Conversations" event, Tuesday, May 24, 5:30 p.m.; the George Tarjan Award Lecture, Monday, May 23, 2:00 p.m.; and the APIRE/AstraZeneca Young Minds in Psychiatry Award.

**Bristol-Myers Squibb Company:** co-support of the Industry Supported Symposium, "Expanding Uses of Atypical Antipsychotics: Addressing Real-World Challenges," Saturday, May 21, 6:00 p.m.; "Emerging Best Practices in the Management of Behavioral Emergencies," Sunday, May 22, 7:00 p.m.; and "Insulin Resistance and Metabolic Syndrome in Neuropsychiatry," Monday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Managing the Spectrum of Bipolar Disorder: Minimizing the Burden of Disease," Monday and Tuesday, May 23-24, 7:00 a.m.; and the support of the President's Dessert and Reception.

**Bristol-Myers Squibb Sweden:** support of the Luncheon for U.S. and International Residents, "Patients Who Want to Die: Are they Suicidal and Where Do They Fit Into DSM?" Sunday, May 22, 12 noon; and Global Psychiatry: A Session for U.S. and International Residents, Sunday, May 22, 2:00 p.m.

**Center for Mental Health Services:** support of the APIRE Practice Research Network (PRN); and the APA's HIV-related education programs and materials.

**Center for Substance Abuse Treatment:** support of the APIRE Practice Research Network (PRN); and an audience response system for the course, "Office-Based Buprenorphine Treatment of Opioid-Dependent Patients."

**Cephalon, Inc.:** support of the Industry-Supported Symposium, "Achieving Remission in Depression: Is the Bar Set Too High or Too Low?" Saturday, May 21, 6:00 p.m.; "Exploring Cognitive Function: From Brain to Bedside," Sunday, May 22, 7:00 p.m.; and "Impact of Stress and Anxiety on Brain and Body," Wednesday, May 25, 7:00 p.m.

**Cyberonics, Inc.:** support of the Industry-Supported Symposium, "Brain Stimulation: New Treatments for Mood Disorders," Sunday, May 22, 8:00 a.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.

**Eisai, Inc.:** co-support of the Industry-Supported Symposium, "Advances in Cholinergic Therapy: Alzheimer's Disease and Beyond," Tuesday, May 24, 7:00 p.m.

**Eli Lilly and Company:** support of the Industry-Supported Symposium, "Dealing With Depression: The Added Burden to Medical Patients," Saturday, May 21, 6:00 p.m.; "BPD: Pathophysiology Treatment and Course," Sunday, May 22, 8:00 a.m.; and "Beyond Neurochemistry: The Implications of Neurocircuitry for Understanding and Managing Psychiatric Disorders," Sunday, May 22, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support for the "David Lozovsky Memorial Symposium on the 15-year Evolution of Russian-Soviet Psychiatry," Wednesday, May 25, 2:00 p.m.; and the APA/Lilly Resident Research Awards.

**Estate of Agnes Purcell McGavin:** support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

**Estate of Dorothy C. Kempf:** support of APIRE/Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

**Estate of Judah Marmor, M.D.:** support of the Judah Marmor Award Lecture, Tuesday, May 24, 11:00 a.m.

**Estate of Kun-Po Soo, M.D., Ph.D.:** support of the Kun-Po Soo Award Lecture, Tuesday, May 24, 9:00 a.m.

**Forest Laboratories, Inc.:** support of the Industry-Supported Symposium, "Integrating Neurobiology and Psychopathology Into Evidence-Based Treatment of Social Anxiety Disorder," Saturday, May 21, 6:00 p.m.; "Spotlight on the Uniqueness of Depression and Anxiety in the Elderly," Sunday, May 22, 8:00 a.m.; "Alzheimer's Disease Pathways to Practice: Assessing Diagnosis and Outcome..."
SPECIAL ACKNOWLEDGMENTS

Measures," Sunday, May 22, 1:30 p.m.; and "Untangling Depression and Anxiety: A Challenge for Scientists and Clinicians," Sunday, May 22, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; and support of the registration portfolios.

**GlaxoSmithKline:** support of the Industry-Supported Symposia, "Psychosomatic Illness: A 21st-Century Perspective," Saturday, May 21, 6:00 p.m.; "Systematic Treatment of Bipolar Disorder: Bringing Evidence into Practice," Sunday, May 22, 8:00 a.m.; "Bipolar Disorder Management: A New Edition," Monday, May 23, 7:00 p.m.; and "Seasonal Affective Disorder: New Concepts, Practical Strategies," Tuesday, May 24, 7:00 p.m.; the Industry-Supported Symposium, "Bipolar Disorder Across the Life Cycle: Special Considerations," Wednesday, May 25 and Thursday, May 26, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support of the APA/GlaxoSmithKline Fellowship Program and reception; the annual contribution to the APA Presidential Fund; and the APA/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry.

**Harding Foundation:** co-support of the Oskar Pfister Award Lecture, Wednesday, May 25, 9:00 a.m.

**Ittleson Foundation:** support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

**Janssen Pharmaceutica and Research Foundation:** support of the Industry-Supported Symposia, "Management of Disruptive Behavioral and Pervasive Developmental Disorders," Saturday, May 21, 12:30 p.m.; "Antipsychotic Drugs, Mood Stabilizers, and the Metabolic Syndrome," Sunday, May 22, 8:00 a.m.; and "Relapse Prevention in Schizophrenia: Defining a Path From Pharmacologic Intervention to Long-Term Functional Recovery," Sunday, May 22, 1:30 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.

**Judd Marmor Endowment:** support of the Judd Marmor Award.

**Lilly Research Laboratories, a Division of Eli Lilly & Company:** support of the APA/Lilly Psychiatric Research Fellowship.

**Merck & Co., Inc.:** support of the APA/Merck & Co., Inc. Early Academic Career Research Award.

**National Institute of Mental Health:** co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Tuesday, May 24, 2:00 p.m.; and the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP); and the Special Annual Meeting Program Track.

**National Institute on Alcohol Abuse and Alcoholism:** co-support of the Research Colloquium for Junior Investigators.

**National Institute on Drug Abuse:** co-support of the Research Colloquium for Junior Investigators; support of annual meeting activities of trainees of the APIRE Drug Abuse Research Scholars Program.

**Neurocrine Biosciences, Inc.:** co-support of the Industry-Supported Symposium, "Clinical Interventions for the Treatment of Insomnia Associated With Psychiatric and Comorbid Medical Illnesses," Sunday, May 22, 1:30 p.m.

**Ortho-McNeil Pharmaceuticals:** support of the Industry-Supported Symposia, "The Developmental Trajectory of Impulsivity," Saturday, May 21, 6:00 p.m.; and "Too Little, Too Much: What Is Disordered Eating?" Sunday, May 22, 8:00 a.m.

**Otsuka America Pharmaceutical, Inc.:** co-support of the Industry Supported Symposium, "Expanding Uses of Atypical Antipsychotics: Addressing Real-World Challenges," Saturday, May 21, 6:00 p.m.; "Emerging Best Practices in the Management of Behavioral Emergencies," Sunday, May 22, 7:00 p.m.; "Insulin Resistance and Metabolic Syndrome in Neuropsychiatry," Monday, May 23, 7:00 p.m.; co-support of the Industry-Supported Breakfast Symposium, "Managing the Spectrum of Bipolar Disorder: Minimizing the Burden of Disease," Monday, May 23, and Tuesday, May 24, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support of the International Medical Graduates (IMG) Resource Center; and the Minority Mental Health.

**Pfizer, Inc.:** support of the Industry-Supported Symposia, "The Impact of Depression and Anxiety on Well-Being Across the Life Cycle," Saturday, May 21, 12:30 p.m.; "Bipolar Disorder: Psychiatric and Medical Implications for Optimal Patient Management," Saturday, May 21, 6:00 p.m.; "Fibromyalgia: A Disorder at the Medicine and Psychiatry Interface," Sunday, May 22, 1:30 p.m.; and "From Molecular Insight to Clinical Outcomes: Recent Advances in Schizophrenia Treatment," Sunday, May 22, 7:00 p.m.; co-support of the Industry-Supported Symposia, "Clinical Interventions for the Treatment of Insomnia Associated With Psychiatric and Comorbid Medical Illnesses," Sunday, May 22, 1:30 p.m.; and "Advances in Cholinergic Therapy: Alzheimer's Disease and Beyond," Tuesday, May 24, 7:00 p.m.; support of the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 23, 7:00 a.m.; the Psychiatric Services Achievement Awards; the American Psychiatric Foundation Film Fest, Monday, May 23, 7:00 p.m.; the "Abstracts-On-Disk" Program; and the APA Daily Bulletin newspaper.

**Professional Risk Management Services, Inc.:** co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 22, 2:30 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.
SPECIAL ACKNOWLEDGMENTS

Sanofi-Aventis, Inc.: support of the Industry-Supported Symposium, "Challenges at the Interface of Psychiatric, Medical, and Sleep Disorders," Tuesday, May 24, 7:00 p.m.; and support of the Residents, Medical Students, and Training Directors Luncheon, Sunday, May 22, 12 noon.

Sepracor, Inc.: support of the Industry-Supported Symposium, "Insomnia in Special Populations: Is This Insomnia or Something Else?" Monday, May 23, 7:00 p.m.

Shire US, Inc.: support of the Industry-Supported Symposium, "ADHD Through the Lifecycle: New Findings and Clinical Implications," Sunday, May 22, 7:00 p.m.; "It's Not Just for Kids: ADHD in Adolescence and Adulthood," Tuesday, May 24, 7:00 p.m.; and the APA/Shire Child and Adolescent Psychiatry Fellowships.

Solvay Pharmaceuticals Inc.: support of the coffee service in the exhibit hall.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.


UCB Pharma, Inc.: support of the Industry-Supported Symposium, "Anxiety: Diverse Populations and Presentations, Unique Individuals and Treatments," Saturday, May 21, 12:30 p.m.

University of California-Davis, Department of Psychiatry: support of the Residents, Fellows, and Medical Student’s Reception, Monday, May 23, 6:30 p.m.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.

Van Ameringen Foundations: support of the Arnold van Ameringen Award in Psychiatric Rehabilitation.

Wyeth Pharmaceuticals: support of the Industry-Supported Symposium, "Panic Disorder: Current Concepts and Future Directions," Sunday, May 22, 8:00 a.m.; "Anxiety Disorders: Understanding the Interconnection Between Emotional and Physical Symptoms," Sunday, May 22, 1:30 p.m.; "Overcoming Traditional Dilemmas in Treating Depressive Illnesses: Evidence-Based Updates," Monday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Advances in the Treatment of Mood and Anxiety Disorders in Women," Monday, May 23 and Tuesday, May 24, 7:00 a.m.; the APA/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; the Jeanne Spurlock, M.D. Congressional Fellowship; the daily in-house TV program, "APA News Network;" partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; and co-sponsorship of the Alexandra Symonds Award Lecture, Monday, May 23, 11:00 a.m.
ADVANCES IN PSYCHOSOMATIC MEDICINE
This three-and-one-half hour session will summarize important, new clinical and research findings in the care of psychiatric disorders in the medically ill. The symposium will be presented by selected authors from: The American Psychiatric Publishing Textbook of Psychosomatic Medicine; edited by James L. Levenson, M.D. The first four presenters will cover heart disease, cancer, obstetrics and gynecology, and transplantation, reviewing the epidemiology, clinical features, diagnosis and assessment, etiology, differential diagnosis, and treatment of psychiatric disorders in their area of specialty. The fifth speaker will review in depth, psychopharmacology in the medically ill. The textbook is the official textbook of the Academy of Psychosomatic Medicine. Psychosomatic medicine is the newest, formally recognized psychiatric subspecialty, but this session will address issues of relevance to most psychiatrists.

ADVANCES IN PSYCHOTHERAPY
This three-and-one-half hour session will summarize important, new clinical and research findings in the treatment of selected psychiatric disorders, with emphasis on psychotherapeutic interventions. The symposium will be based in part, on material contained in the American Psychiatric Publishing textbook edited by Glen Gabbard, M.D., and entitled, The Treatments of Psychiatric Disorders, Third Edition. Authors of selected chapters from the textbook will present material from their chapters. The topics were selected by the editor to represent disorders of particular current interest to psychiatrists and to focus on aspects of psychotherapy that may be of great importance to APA members.

ADVANCES IN RESEARCH
During this two-hour session, a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCES
The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation is encouraged throughout. Participants are requested to attend both sessions in their entirety. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATE
Experts in the field, including psychiatrists and non-psychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the group. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FOCUS LIVE
These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of FOCUS, will lead lively multiple choice question based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

MASTER EDUCATOR CLINICAL CONSULTATIONS
These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATES
These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.
FORMAT DESCRIPTIONS

NEW RESEARCH
This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators’ Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators’ Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it’s one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY
There will be four, three-and-one-half hour sessions presented, based on the annual American Psychiatric Publishing Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as “Industry-Supported Symposia” in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions (either Issue or Component), which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.

Media Workshops are three-hour sessions held Monday-Thursday, in which a feature-length film is shown and discussed.
The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A “financial interest” may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may include, holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2005 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter’s affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter’s name and the company’s name are listed, along with the page number the presenter appears on in this Program Book. The nature of the presenter’s relationship with the disclosed company is indicated by the following codes: consultant or advisory board, full-time employment, research/grant support, speakers’ bureau, stock or other financial options, other financial or business relationships. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page XXXVI, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene G. Abel, M.D.</td>
<td>Abel Screening, Inc.; Institute for Child Molestation Research and Prevention</td>
<td>41</td>
</tr>
<tr>
<td>Donald E. Addington, M.D.</td>
<td>Eli Lilly and Company</td>
<td>71</td>
</tr>
<tr>
<td>Marilyn Ader, Ph.D.</td>
<td>Janssen Pharmaceutica Products, LP</td>
<td>7</td>
</tr>
<tr>
<td>Nassima Ait-Daoud, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.</td>
<td>31, 56</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>GlaxoSmithKline; Abbott Laboratories, Inc.; Eli Lilly and Company; Sanofi-Synthelabo Pharmaceuticals, Inc.; Bristol-Myers Squibb; Pfizer Inc.; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica Products, LP</td>
<td>28</td>
</tr>
<tr>
<td>George S. Alexopoulos, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Cephalon Inc.; Janssen Pharmaceutica Products, LP; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Meyers; GlaxoSmithKline</td>
<td>6, 11</td>
</tr>
<tr>
<td>Jon G. Allen, Ph.D.</td>
<td>American Psychiatric Publishing, Inc.</td>
<td>20</td>
</tr>
<tr>
<td>Michael H. Allen, M.D.</td>
<td>Abbott Laboratories, Inc.; Janssen Pharmaceutica Products, LP; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Pfizer Inc.; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; Alexza</td>
<td>12</td>
</tr>
<tr>
<td>Jonathan E. Alpert, M.D.</td>
<td>Organon Pharmaceuticals Inc.; Pharmanet; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; Aspect Medical Systems, Inc.; Pfizer Inc.</td>
<td>4</td>
</tr>
<tr>
<td>Sonia Ancoli-Israel, Ph.D.</td>
<td>King Pharmaceutical; Takeda Pharmaceuticals; Neurocrine Biosciences; Sepracor Inc.</td>
<td>9, 36</td>
</tr>
<tr>
<td>Allan A. Anderson, M.D.</td>
<td>Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Products, LP; Forest Pharmaceuticals, Inc.</td>
<td>49</td>
</tr>
<tr>
<td>Raymond F. Anton, Jr., M.D.</td>
<td>Bristol-Myers Squibb; Ortho McNeil Pharmaceutical Inc.; Alkermes Pharmaceuticals; Pfizer Inc.</td>
<td>31, 62</td>
</tr>
<tr>
<td>Jose C. Appolinario, M.D.</td>
<td>Janssen Pharmaceutica Products, LP; Abbott Laboratories, Inc.</td>
<td>59</td>
</tr>
<tr>
<td>Michael R. Arambula, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals</td>
<td>35</td>
</tr>
<tr>
<td>Kimberly A. Arlinghaus, M.D.</td>
<td>UCB Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories, Inc.; Pfizer Inc.; Forest Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica Products, LP; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>49</td>
</tr>
<tr>
<td>Scott C. Armstrong, M.D.</td>
<td>Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Forest Pharmaceuticals, Inc.</td>
<td>41</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Lesley M. Arnold, M.D.</td>
<td>Pfizer Inc.(^1), Eli Lilly and Company(^2), Wyeth Pharmaceuticals(^3), Cypress Bioscience Inc.(^4)</td>
<td>10, 39</td>
</tr>
<tr>
<td>Darryl Atherholt</td>
<td>Janssen Pharmaceutica Products, LP (^5)</td>
<td>44</td>
</tr>
<tr>
<td>Evelyn Atia, M.D.</td>
<td>Pfizer Inc.(^3)</td>
<td>59</td>
</tr>
<tr>
<td>Alan A. Axelson, M.D.</td>
<td>Pfizer Inc.(^2), Lilly Research Laboratories, a division of Eli Lilly and Company(^4), Highmeirz Blue Cross Blue Shield(^5)</td>
<td>17</td>
</tr>
<tr>
<td>Rahn K. Bailey, M.D.</td>
<td>Eli Lilly and Company(^6), Janssen Pharmaceutica Products, LP (^6), Bristol-Myers Squibb (^6)</td>
<td>66</td>
</tr>
<tr>
<td>F. M. Baker, M.D.</td>
<td>Pfizer Inc.(^7)</td>
<td>79, 92</td>
</tr>
<tr>
<td>Claudia F. Baldassano, M.D.</td>
<td>Elan Pharmaceuticals(^1), AstraZeneca Pharmaceuticals(^1), GlaxoSmithKline(^1), Eli Lilly and Company(^8)</td>
<td>5, 13</td>
</tr>
<tr>
<td>John J. Barry, M.D.</td>
<td>GlaxoSmithKline(^1), Neuropace(^1), Cyberonics, Inc.(^1)</td>
<td>95</td>
</tr>
<tr>
<td>Bernard D. Beitman, M.D.</td>
<td>Pfizer Inc.(^2), GlaxoSmithKline(^1)</td>
<td>27, 68, 93</td>
</tr>
<tr>
<td>Ruth M. Benca, M.D.</td>
<td>Takeda Pharmaceuticals(^1), Wyeth Pharmaceuticals(^1), Neurocrine Biosciences Inc.(^1)</td>
<td>36</td>
</tr>
<tr>
<td>John L. Beyer, M.D.</td>
<td>GlaxoSmithKline(^1)</td>
<td>54</td>
</tr>
<tr>
<td>Joseph Biederman, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division(^1), Eli Lilly and Company(^2), Medtronic(^1), Proctor &amp; Gamble(^1), Ortho McNeil Pharmaceutical Inc.(^1), Solvay Pharmaceuticals, Inc.(^1)</td>
<td>12, 48, 57, 80</td>
</tr>
<tr>
<td>Angela Birnbaum, M.D.</td>
<td>Ovation Pharmaceuticals(^1), UCBS Pharmaceuticals(^1)</td>
<td>80</td>
</tr>
<tr>
<td>Carlos Blanco-Jerez, M.D.</td>
<td>Pfizer Inc.(^3)</td>
<td>3</td>
</tr>
<tr>
<td>Michael Blumenfield, M.D.</td>
<td>Pfizer Inc.(^2), Forest Pharmaceuticals, Inc.(^1), Shire Ridgewood Pharmaceuticals(^1)</td>
<td>14</td>
</tr>
<tr>
<td>William Blumentals, Ph.D.</td>
<td>Proctor &amp; Gamble Pharmaceuticals(^2)</td>
<td>54</td>
</tr>
<tr>
<td>Carley Bonds, M.D.</td>
<td>Pfizer Inc.(^4), Abbott Laboratories, Inc.(^1)</td>
<td>76</td>
</tr>
<tr>
<td>Howard E. Book, M.D.</td>
<td>The American Psychological Association Press(^6)</td>
<td>5, 8, 93</td>
</tr>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>Abbott Laboratories, Inc.(^1), AstraZeneca Pharmaceuticals(^1), Bristol-Myers Squibb(^1), Eli Lilly and Company(^6), Janssen Pharmaceutica Products, LP(^1), Lilly Research Laboratories, a division of Eli Lilly and Company(^4), National Institute of Mental Health(^1), Parke Davis(^3), Pfizer Inc.(^4), R.W. Johnson Pharmaceuticals Institute(^1), Sanofi-Synthelabo Pharmaceuticals, Inc.(^1), Smith Kline Beecham(^5), Stanley Foundation(^5), UCB Pharmaceuticals, Inc.(^1)</td>
<td>55, 76</td>
</tr>
<tr>
<td>Theron C. Bowers, Jr., M.D.</td>
<td>AstraZeneca Pharmaceuticals(^4)</td>
<td>25, 45</td>
</tr>
<tr>
<td>John M. Bradford, M.B.</td>
<td>Pfizer Inc.(^4)</td>
<td>41</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>Pfizer Inc.(^1), Eli Lilly and Company(^4), Abbott Laboratories, Inc.(^3), Forest Pharmaceuticals, Inc.(^1), GlaxoSmithKline(^1)</td>
<td>2, 31</td>
</tr>
<tr>
<td>William Breitbart, M.D.</td>
<td>Cephalon Inc.(^1), GlaxoSmithKline(^1), Wyeth Pharmaceuticals(^3)</td>
<td>49</td>
</tr>
<tr>
<td>J. Douglas Bremer, M.D.</td>
<td>GlaxoSmithKline(^1)</td>
<td>20, 60</td>
</tr>
<tr>
<td>Ronald Brenner, M.D.</td>
<td>Bristol-Myers Squibb(^1), Eli Lilly and Company(^2), Janssen Pharmaceutica Products, LP(^1)</td>
<td>43</td>
</tr>
<tr>
<td>E. Sherwood Brown, M.D.</td>
<td>AstraZeneca Pharmaceuticals(^1), GlaxoSmithKline(^3), Forest Pharmaceuticals, Inc.(^1), Bristol-Myers Squibb(^1)</td>
<td>36</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>Janssen Pharmaceutica Products, LP(^1), Novartis Pharmaceuticals Corporation(^1), Shire Ridgewood Pharmaceuticals(^1), McNeil Consumer Healthcare(^1), Eli Lilly and Company(^3)</td>
<td>1, 5, 51</td>
</tr>
<tr>
<td>Robert W. Buchanan, M.D.</td>
<td>Janssen Pharmaceutica Products, LP(^1), Organon Pharmaceuticals Inc.(^1)</td>
<td>62, 80</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>Abbott Laboratories, Inc.(^3), AstraZeneca Pharmaceuticals(^3), Eli Lilly and Company(^4), Bristol-Myers Squibb(^3), Janssen Pharmaceutica Products, LP(^1), Novartis Pharmaceuticals Corporation(^1), Pfizer Inc.(^1), Novartis Pharmaceuticals Corporation(^1), Pfizer Inc.(^1)</td>
<td>12, 36, 68</td>
</tr>
<tr>
<td>Cathy L. Budman, M.D.</td>
<td>Eli Lilly and Company(^4)</td>
<td>68</td>
</tr>
<tr>
<td>Don Buesching, Ph.D.</td>
<td>Eli Lilly and Company(^3)</td>
<td>25</td>
</tr>
<tr>
<td>Stephen E. Buie, M.D.</td>
<td>Wyeth Pharmaceuticals(^4)</td>
<td>74</td>
</tr>
<tr>
<td>Cynthia M. Bulik, Ph.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.(^1), Power Changes LLC(^5)</td>
<td>6, 59, 71</td>
</tr>
<tr>
<td>Kathryn A. Burns, M.D.</td>
<td>Eli Lilly and Company(^4)</td>
<td>49</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>George Bush, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceuticals; Johnson and Johnson PRD; Novartis Pharmaceuticals; Shire Ridgewood Pharmaceuticals; McNeil Consumer Healthcare</td>
<td>12</td>
</tr>
<tr>
<td>Marian I. Butterfield, M.D.</td>
<td>Bristol-Myers Squibb; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>10, 20, 28, 42, 57, 82</td>
</tr>
<tr>
<td>Daniel J. Buysse, M.D.</td>
<td>Sepracor Inc.</td>
<td>53</td>
</tr>
<tr>
<td>Joseph R. Calabrese, M.D.</td>
<td>National Institute of Mental Health; Abbott Laboratories, Inc.; Ciba-Geigy Inc.; Merck &amp; Co., Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; MacArthur Foundation; National Alliance for Research in Schizophrenia and Affective Disorders; Parke-Davis Pharmaceuticals; R.W. Johnson Pharmaceuticals Research Institute; Sandoz Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Stanley Foundation; Tap Holdings, Inc.; UCB Pharmaceuticals; Wyeth Pharmaceuticals; Novartis Pharmaceuticals Corporation; Parke-Davis Pharmaceuticals; Warner Lambert; Shire Ridgewood Pharmaceuticals; Teva Pharmaceuticals</td>
<td>11, 25, 67, 76</td>
</tr>
<tr>
<td>William H. Campbell, M.D.</td>
<td>Pfizer Inc.</td>
<td>7, 41, 65</td>
</tr>
<tr>
<td>Ana E. Campo, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Pfizer Inc.; Ortho McNeil Pharmaceutical Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>25</td>
</tr>
<tr>
<td>John V. Campo, M.D.</td>
<td>Eli Lilly and Company; Forest Pharmaceuticals, Inc.</td>
<td>14, 40</td>
</tr>
<tr>
<td>Gabrielle A. Carlson, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceuticals, LP; Abbott Laboratories, Inc.</td>
<td>36</td>
</tr>
<tr>
<td>Linda L. Carpenter, M.D.</td>
<td>Organon Pharmaceuticals Inc.; Cephalon Inc.; GlaxoSmithKline; Pfizer Inc.; National Institute of Mental Health; US Dept of Defense; Cyberonics; Merck &amp; Co., Inc.; Corcept Therapeutics; Medtronic; UCB Pharmaceuticals; Somerset Pharmaceuticals Inc.; AstraZeneca Pharmaceuticals</td>
<td>4, 37</td>
</tr>
<tr>
<td>Diana Carter, M.S.</td>
<td>GlaxoSmithKline; Lundbeck</td>
<td>63</td>
</tr>
<tr>
<td>David A. Casey, M.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceuticals, LP; Forest Pharmaceuticals, Inc.</td>
<td>47, 69</td>
</tr>
<tr>
<td>Daniel Castellanos, M.D.</td>
<td>Janssen Pharmaceutical Products, LP; AstraZeneca Pharmaceuticals</td>
<td>43</td>
</tr>
<tr>
<td>Ruby C. Castilla-Puentes, M.D.</td>
<td>GlaxoSmithKline</td>
<td>22, 54</td>
</tr>
<tr>
<td>Carlyle H. Chan, M.D.</td>
<td>Eli Lilly and Company; Forest Pharmaceuticals, Inc.; Pfizer Inc.</td>
<td>26, 40, 51</td>
</tr>
<tr>
<td>Kiki D. Chang, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.; Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Shire Ridgewood Pharmaceuticals; UCB Pharmaceuticals; National Institute of Mental Health; Heinz C. Prechter Foundation; National Alliance for Research in Schizophrenia and Depression; Klingenstein Third Generation Foundation; American Psychiatric Association</td>
<td>11, 48, 76</td>
</tr>
<tr>
<td>Joseph A. Cheong, M.D.</td>
<td>Janssen Pharmaceutical Products, LP; AstraZeneca Pharmaceuticals; Cortex Pharmaceuticals; Allergens Pharmaceuticals; Ivax; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>46, 65, 86</td>
</tr>
<tr>
<td>John A. Chiles, M.D.</td>
<td>Janssen Pharmaceutical Products, LP; AstraZeneca Pharmaceuticals; Cortex Pharmaceuticals; Eli Lilly and Company; Pfizer Inc.</td>
<td>45</td>
</tr>
<tr>
<td>Eric J. Christopher, M.D.</td>
<td>Janssen Pharmaceutical Products, LP</td>
<td>81</td>
</tr>
<tr>
<td>Michelle O. Clark, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.</td>
<td>66, 76</td>
</tr>
<tr>
<td>Daniel J. Cauw, M.D.</td>
<td>Cypress Bioscience, Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Paula Clayton, M.D.</td>
<td>Forest Pharmaceuticals, Inc.</td>
<td>31</td>
</tr>
<tr>
<td>Emile F. Coccaro, M.D.</td>
<td>Eli Lilly and Company; Abbott Laboratories, Inc.; GlaxoSmithKline; Forest Pharmaceuticals, Inc.; Ortho McNeil Pharmaceutical Inc.; AstraZeneca Pharmaceuticals</td>
<td>32</td>
</tr>
<tr>
<td>Lee S. Cohen, M.D.</td>
<td>Berlex Laboratories, Inc.; Janssen Pharmaceutical Products, LP; Ortho McNeil Pharmaceutical Inc.; Eli Lilly and Company; Wyeth Pharmaceuticals; Pfizer Inc.; AstraZeneca Pharmaceuticals; Forest Pharmaceuticals, Inc.; GlaxoSmithKline</td>
<td>66</td>
</tr>
<tr>
<td>Michael Cohen, B.S.</td>
<td>EEG Spectrum International</td>
<td>63, 74</td>
</tr>
<tr>
<td>Ian A. Cook, M.D.</td>
<td>Aspect Medical Systems, Inc.; Eli Lilly and Company; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>17</td>
</tr>
<tr>
<td>Gabriela Cora-Locatelli, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline</td>
<td>56</td>
</tr>
<tr>
<td>Suzanne Craft, Ph.D.</td>
<td>GlaxoSmithKline</td>
<td>37</td>
</tr>
<tr>
<td>Leslie J. Crofford, M.D.</td>
<td>Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Cypress Bioscience, Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Catherine C. Crone, M.D.</td>
<td>Pfizer Inc.</td>
<td>47</td>
</tr>
</tbody>
</table>

XXI
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott J. Crow, M.D.</td>
<td>Eli Lilly and Company; Ortho McNeil Pharmaceutical Inc.; Pfizer Inc.; GlaxoSmithKline</td>
<td>6</td>
</tr>
<tr>
<td>Jeffrey L. Cummings, M.D.</td>
<td>Pfizer Inc.; Eisai, Inc.; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Praxis Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Forest Pharmaceuticals, Inc.; Bristol-Myers Squibb; Roche Laboratories, a member of the Roche Group; Aventis Pharmaceuticals; Cortex Pharmaceuticals Pharmaceutical; Lundbeck; Myriad Genetics, Inc.</td>
<td>9, 13, 39</td>
</tr>
<tr>
<td>Cheryl Davenport</td>
<td>Merrill Lynch</td>
<td>43</td>
</tr>
<tr>
<td>Jonathan S. Davine, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Pfizer Inc.; Ortho McNeil Pharmaceutical Inc.; Organon Pharmaceuticals Inc.; Wyeth Pharmaceuticals; Abbott Laboratories, Inc.; Bristol-Myers Squibb; Elan Pharmaceuticals; Forest Pharmaceuticals, Inc.</td>
<td>30, 86</td>
</tr>
<tr>
<td>Lori L. Davis, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.; Abbott Laboratories, Inc.; Bristol-Myers Squibb; Elan Pharmaceuticals; Forest Pharmaceuticals, Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Deborah Deas, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Corcept Therapeutics; GlaxoSmithKline; Wyeth Pharmaceuticals; Abbott Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Cephalon Inc.</td>
<td>3, 36</td>
</tr>
<tr>
<td>Charles DeBattista, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Pfizer Inc.; Ortho McNeil Pharmaceutical Inc.; Janssen Pharmaceutica Products, LP; Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Shire Ridgewood Pharmaceuticals</td>
<td>3, 35, 77</td>
</tr>
<tr>
<td>Melissa P. DelBello, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Pfizer Inc.; Ortho McNeil Pharmaceutical Inc.; Janssen Pharmaceutica Products, LP; Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Shire Ridgewood Pharmaceuticals</td>
<td>3, 35, 77</td>
</tr>
<tr>
<td>Pedro L. Delgado, M.D.</td>
<td>National Institute of Mental Health; Eli Lilly and Company; GlaxoSmithKline; Wyeth Pharmaceuticals; Forest Pharmaceuticals, Inc.</td>
<td>55, 64</td>
</tr>
<tr>
<td>Diana L. Dell, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Berlex Laboratories, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; TAP Pharmaceuticals Product, Inc.</td>
<td>66</td>
</tr>
<tr>
<td>Mark Demitrack, M.D.</td>
<td>Neurontics, Inc.; Wyeth Pharmaceuticals; Eli Lilly and Company</td>
<td>84</td>
</tr>
<tr>
<td>Davangere P. Devanand, M.D.</td>
<td>Pfizer Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica Products, LP; Organon Pharmaceuticals Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Michael Devin, M.D.</td>
<td>Eli Lilly and Company</td>
<td>1</td>
</tr>
<tr>
<td>Mantosh J. Dewan, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica Products, LP</td>
<td>3, 18, 54, 79</td>
</tr>
<tr>
<td>Andrea F. DiMartini, M.D.</td>
<td>National Institute of Alcohol Abuse and Alcoholism (NIAAA)</td>
<td>40</td>
</tr>
<tr>
<td>Lisa B. Dixon, M.D.</td>
<td>Bristol-Myers Squibb; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica Products, LP</td>
<td>29, 55, 84, 93</td>
</tr>
<tr>
<td>John P. Docherty, M.D.</td>
<td>Nutrition 21, Inc.; Bristol-Myers Squibb; Janssen Pharmaceutica Products, LP; Forest Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals; Abbott Laboratories, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Eli Lilly and Company</td>
<td>31, 70</td>
</tr>
<tr>
<td>Manfred Doepfner, M.D.</td>
<td>Eli Lilly and Company</td>
<td>34</td>
</tr>
<tr>
<td>Martin Dossenbach, M.D.</td>
<td>Eli Lilly and Company</td>
<td>89</td>
</tr>
<tr>
<td>Alysa Doyle, Ph.D.</td>
<td>Eli Lilly and Company; McNeil Pharmaceuticals</td>
<td>57</td>
</tr>
<tr>
<td>Robert Drake, M.D.</td>
<td>Johnson and Johnson PRD</td>
<td>29</td>
</tr>
<tr>
<td>Douglas A. Drossman, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Solvay Pharmaceuticals, Inc.; GlaxoSmithKline</td>
<td>53</td>
</tr>
<tr>
<td>Roxanne Dryden-Edwards, M.D.</td>
<td>Eli Lilly and Company</td>
<td>18</td>
</tr>
<tr>
<td>Sanjay Dubie, M.D.</td>
<td>Eli Lilly and Company</td>
<td>28, 67</td>
</tr>
<tr>
<td>David W. Dunn, M.D.</td>
<td>Eli Lilly and Company; Shire Ridgewood Pharmaceuticals; AstraZeneca Pharmaceuticals; The National Institute of Neurological Disorders and Stroke (NINDS); O'Neil; UCB Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Organon Pharmaceuticals Inc.; Forest Pharmaceuticals, Inc.; Cyberonics, Inc.; Merck &amp; Co., Inc.; Cypress Bioscience, Inc.; Corcept Therapeutics; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Shire Ridgewood Pharmaceuticals; Somerset Pharmaceuticals Inc.; Osaka America Pharmaceutical, Inc.</td>
<td>95</td>
</tr>
<tr>
<td>David L. Dunner, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Organon Pharmaceuticals Inc.; Forest Pharmaceuticals, Inc.; Cyberonics, Inc.; Merck &amp; Co., Inc.; Cypress Bioscience, Inc.; Corcept Therapeutics; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Shire Ridgewood Pharmaceuticals; Somerset Pharmaceuticals Inc.; Osaka America Pharmaceutical, Inc.</td>
<td>37</td>
</tr>
<tr>
<td>Helen L. Egger, M.D.</td>
<td>Pfizer Inc.</td>
<td>19</td>
</tr>
<tr>
<td>Omar Elhaj, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Abbott Laboratories, Inc.; Pfizer Inc.</td>
<td>25, 67</td>
</tr>
<tr>
<td>James M. Ellison, M.D.</td>
<td>GlaxoSmithKline; Forest Pharmaceuticals, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals; Bristol-Myers Squibb</td>
<td>75</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Javier I. Escobar, M.D.</td>
<td>Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb, Otsuka America Pharmaceutical, Johnson and Johnson PRD, Wyeth Pharmaceuticals</td>
<td>18, 59, 64</td>
</tr>
<tr>
<td>Raymond A. Faber, M.D.</td>
<td>Forest Pharmaceuticals, Inc., Bristol-Myers Squibb, Janssen Pharmaceutical Products, LP, Pfizer Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Francisco Fernandez, M.D.</td>
<td>Wyeth Pharmaceuticals, Forest Pharmaceuticals, Inc., Pfizer Inc., Eli Lilly and Company</td>
<td>20, 43, 51</td>
</tr>
<tr>
<td>Naomi Fineberg, M.A.</td>
<td>AstraZeneca Pharmaceuticals, Janssen Pharmaceutical Products, LP, Lundbeck</td>
<td>79</td>
</tr>
<tr>
<td>Sebern F. Fisher, M.A.</td>
<td>EEG Spectrum International, Forest Pharmaceuticals, Inc.</td>
<td>74</td>
</tr>
<tr>
<td>James N. Flack, M.D.</td>
<td>Janssen Pharmaceutical Products, LP</td>
<td>19</td>
</tr>
<tr>
<td>Lois T. Flaherty, M.D.</td>
<td>Merck &amp; Co., Inc., Pfizer Inc.</td>
<td>20, 85</td>
</tr>
<tr>
<td>Marshal Folstein, M.D.</td>
<td>CNS Vital Signs LLC</td>
<td>68</td>
</tr>
<tr>
<td>Brent P. Forester, M.D.</td>
<td>Eli Lilly and Company, Wyeth Pharmaceuticals, Novartis Pharmaceuticals Corporation, Janssen Pharmaceutical Products, LP, Abbott Laboratories, Inc., AstraZeneca Pharmaceuticals, Pfizer Inc.</td>
<td>75</td>
</tr>
<tr>
<td>Paul T. Francis, Ph.D.</td>
<td>Pfizer Inc., Eisai Inc., Lundbeck, Forest Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>Pfizer Inc., Pfizer Italiana, Eli Lilly and Company, Forest Pharmaceuticals, Inc.</td>
<td>4</td>
</tr>
<tr>
<td>Robert Freedman, M.D.</td>
<td>Abbott Laboratories, Inc., The Dept. of Veteran Affairs</td>
<td>41</td>
</tr>
<tr>
<td>Matthew Freedman, M.D.</td>
<td>Shire Ridgwood Pharmaceuticals, GlaxoSmithKline, Ortho McNeil Pharmaceutical Inc., AstraZeneca Pharmaceuticals</td>
<td>19, 34, 95</td>
</tr>
<tr>
<td>Lara R. Fuchs, M.D.</td>
<td>GlaxoSmithKline</td>
<td>66</td>
</tr>
<tr>
<td>Manuel Garcia, M.D.</td>
<td>Pfizer Inc.</td>
<td>45</td>
</tr>
<tr>
<td>Bradley N. Gaynes, M.D.</td>
<td>Pfizer Inc.</td>
<td>58</td>
</tr>
<tr>
<td>Osvaldo Gaytan, Jr., M.D.</td>
<td>Pfizer Inc., AstraZeneca Pharmaceuticals, Janssen Pharmaceutical Products, LP</td>
<td>79</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Alan J. Gelenberg, M.D.</td>
<td>Pfizer Inc.¹,³; Wyeth Pharmaceuticals¹,³; Cyberonics, Inc.¹,³; Eli Lilly and Company¹; Vela Pharmaceuticals¹; Best Practice¹; Bristol-Myers Squibb¹; AstraZeneca Pharmaceuticals¹; GlaxoSmithKline¹; Roche Laboratories, a member of the Roche Group¹; ZARS¹; Express Scripts¹</td>
<td>22</td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>Neotensus, Inc. (now Neurontics Inc.)¹,³; Janssen Pharmaceutica Products, LP³; Lilly Research Laboratories, a division of Eli Lilly and Company³; GlaxoSmithKline¹; Solvay/Duphar¹,²; Parke Davis¹,²; Cortex Pharmaceuticals¹; Aventis Pharmaceuticals¹; Daiichi Pharma, Inc.; Picker International (now Philips); Dantec (Medtronic); Cyberonics, Inc.; Dupont Pharma; Mediphysics/Amersham; Cephas Corp.¹,³</td>
<td>6, 15, 47</td>
</tr>
<tr>
<td>Anna M. Georgiopoulos, M.D.</td>
<td>GlaxoSmithKline³</td>
<td>82</td>
</tr>
<tr>
<td>S. Nassir Ghaemi, M.D.</td>
<td>Janssen Pharmaceutica Products, LP¹,³; AstraZeneca Pharmaceuticals¹,³; Novartis Pharmaceuticals Corporation¹; Abbott Laboratories, Inc.; Elan Pharmaceuticals¹; GlaxoSmithKline¹; Forest Pharmaceuticals, Inc.; Eli Lilly and Company⁶</td>
<td>33, 36, 56, 77</td>
</tr>
<tr>
<td>Leslie H. Gise, M.D.</td>
<td>Medco Health¹</td>
<td>14, 30</td>
</tr>
<tr>
<td>Alexander H. Glassman, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca Pharmaceuticals¹,³; Oto Pharma¹</td>
<td>20</td>
</tr>
<tr>
<td>Ira D. Glick, M.D.</td>
<td>Janssen Pharmaceutica Products, LP¹,³; Lilly Research Laboratories, a division of Eli Lilly and Company³; Pfizer Inc.; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals¹,³</td>
<td>15, 33, 59, 82</td>
</tr>
<tr>
<td>Donald C. Goff, M.D.</td>
<td>Cortex Pharmaceuticals³; Eli Lilly and Company³; Janssen Pharmaceutica Products, LP¹,³; AstraZeneca Pharmaceuticals¹,³; Pfizer Inc.¹; Bristol-Myers Squibb¹; Cephalon Inc.; GlaxoSmithKline; Organon Pharmaceuticals Inc.³</td>
<td>7</td>
</tr>
<tr>
<td>Robert M. Goisman, M.D.</td>
<td>Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Pfizer Inc.⁴</td>
<td>64</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals¹; Bristol-Myers Squibb³,⁴; Eli Lilly and Company³; GlaxoSmithKline³,⁴; Johnson and Johnson PRD³; Novartis Pharmaceuticals Corporation; Ortho McNeil Pharmaceutical Inc.¹; Organon Pharmaceuticals Inc.; Pfizer Inc.; UCB Pharmaceuticals¹</td>
<td>23, 77</td>
</tr>
<tr>
<td>Robert N. Golden, M.D.</td>
<td>Bristol-Myers Squibb; Duke Clinical Research Institute (DCRI); Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP¹; National Institute of Mental Health; Organon Pharmaceuticals Inc.; Ovation Pharmaceuticals; Pfizer Inc.; Wyeth Pharmaceuticals¹</td>
<td>69</td>
</tr>
<tr>
<td>Stephen M. Goldfinger, M.D.</td>
<td>Bristol-Myers Squibb; Mallinckrodt Pharmaceuticals¹,³; AstraZeneca Pharmaceuticals¹,³; Pfizer Inc.; Janssen Pharmaceutica Products, LP¹; IVAX Pharmaceuticals, Inc.¹,³</td>
<td>45, 68, 74, 92</td>
</tr>
<tr>
<td>Morris B. Goldman, M.D.</td>
<td>Bristol-Myers Squibb³</td>
<td>27</td>
</tr>
<tr>
<td>Andres Gomez-Caminero, Ph.D.</td>
<td>GlaxoSmithKline³; Bristol-Myers Squibb³</td>
<td>54</td>
</tr>
<tr>
<td>Karl Goodkin, M.D.</td>
<td>GlaxoSmithKline¹; Merck &amp; Co., Inc.; BI¹,²; Advance ImmvriT, Inc.; American Society for Microbiology⁶</td>
<td>43</td>
</tr>
<tr>
<td>David Goodman, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Shire Ridgewood Pharmaceuticals; Ortho McNeil Pharmaceutical Inc.; GlaxoSmithKline¹; Pfizer Inc.; Eli Lilly and Company; Wyeth Pharmaceuticals¹</td>
<td>32</td>
</tr>
<tr>
<td>Marianne Goodman, M.D.</td>
<td>Forest Pharmaceuticals, Inc.³</td>
<td>33</td>
</tr>
<tr>
<td>Frederick K. Goodwin, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; GlaxoSmithKline¹,³; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company³; Bristol-Myers Squibb³; Abbott Laboratories, Inc.; Forest Pharmaceuticals, Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.; Janssen Pharmaceutica Products, LP³</td>
<td>36, 56</td>
</tr>
<tr>
<td>Kevin F. Gray, M.D.</td>
<td>Novartis Pharmaceuticals Corporation¹; Lilly Research Laboratories, a division of Eli Lilly and Company¹; Pfizer Inc.; Janssen Pharmaceutica Products, LP³; Bristol-Myers Squibb³</td>
<td>1</td>
</tr>
<tr>
<td>John F. Greden, M.D.</td>
<td>Eli Lilly and Company³; Wyeth Pharmaceuticals; Merck &amp; Co., Inc.; Cyberonics, Inc.; Neurocrine Biosciences Inc.; GlaxoSmithKline¹; 49, 84</td>
<td>11, 20, 37, 41,</td>
</tr>
<tr>
<td>Alan I. Green, M.D.</td>
<td>Bristol-Myers Squibb³; Otsuka America Pharmaceutical, Inc.; Eli Lilly and Company³; Janssen Pharmaceutica Products, LP³; AstraZeneca Pharmaceuticals³; Forest Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation³</td>
<td>29, 36, 50</td>
</tr>
<tr>
<td>Melva I. Green, M.D.</td>
<td>Pfizer Inc.³</td>
<td>43</td>
</tr>
<tr>
<td>Benjamin D. Greenberg, M.D.</td>
<td>Medtronic, Inc.; Aspect Medical Systems, Inc.¹; GlaxoSmithKline¹,³; Eli Lilly and Company³; Celltech Pharmaceuticals, Ltd.; Ortho McNeil Pharmaceutical Inc.; Janssen Pharmaceutica Products, LP³</td>
<td>6, 90</td>
</tr>
<tr>
<td>Laurence L. Greenhill, M.D.</td>
<td>Novartis Pharmaceuticals Corporation¹; Eli Lilly and Company³; Celltech Pharmaceuticals, Ltd.; Ortho McNeil Pharmaceutical Inc.; Janssen Pharmaceutica Products, LP³</td>
<td>23</td>
</tr>
<tr>
<td>Carl B. Greiner, M.D.</td>
<td>Janssen Pharmaceutica Products, LP³</td>
<td>43, 64</td>
</tr>
<tr>
<td>Dimitri E. Grigoriadis, Ph.D.</td>
<td>Neurocrine Biosciences Inc.³</td>
<td>32</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>George T. Grossberg, M.D.</td>
<td>Abbott Laboratories, Inc.; Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.; Pfizer Inc.; Janssen Pharmaceutica Products, LP; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Pharmaceuticals Inc.; Omnican Inc.; Wellcome; Euno; Boehringer-Ingelheim Pharmaceuticals; Sanofi-Synthelabo Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation</td>
<td>9, 13</td>
</tr>
<tr>
<td>Raquel E. Gur, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals</td>
<td>30</td>
</tr>
<tr>
<td>Robert E. Hales, M.D.</td>
<td>Bristol-Myers Squibb; Pfizer Inc.; AstraZeneca Pharmaceuticals</td>
<td>13, 24, 39</td>
</tr>
<tr>
<td>Thomas E. Hansen, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Pfizer Inc.; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>19</td>
</tr>
<tr>
<td>Cynthia L. Harden, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline; UCB Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>95</td>
</tr>
<tr>
<td>Patrice A. Harris, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.</td>
<td>85</td>
</tr>
<tr>
<td>David G. Harrison, M.D.</td>
<td>Janssen Pharmaceutica Products, LP; Aventis Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals</td>
<td>12</td>
</tr>
<tr>
<td>Daniel W. Haupt, M.D.</td>
<td>Janssen Pharmaceutica Products, LP; Abbott Laboratories, Inc.; Pfizer Inc.; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals</td>
<td>7</td>
</tr>
<tr>
<td>David T. Healy, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Vicker and Waldner, Baum Hedlund</td>
<td>56</td>
</tr>
<tr>
<td>David C. Henderson, M.D.</td>
<td>Janssen Pharmaceutica Products, LP; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Pfizer Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc.; Pfizer Inc.; Shire Ridgewood Pharmaceuticals; UCB Pharmaceuticals; Wyeth Pharmaceuticals; Abbott Laboratories, Inc.</td>
<td>31</td>
</tr>
<tr>
<td>Paula L. Hensley, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Pfizer Inc.; Janssen Pharmaceutica Products, LP; Eli Lilly and Company; Hoffman La Roche Ltd.</td>
<td>45</td>
</tr>
<tr>
<td>Barry Herman, M.D.</td>
<td>Pfizer Inc.</td>
<td>87</td>
</tr>
<tr>
<td>Alan R. Hirsch, M.D.</td>
<td>Ayers; GlaxoSmithKline; Eli Lilly and Company; UpJohn; Ciba-Geigy; Johnson and Johnson PRD; Parke Davis; Abbott Laboratories, Inc.; Proctor &amp; Gamble; Pharmacia</td>
<td>40</td>
</tr>
<tr>
<td>Robert A. Hirschfeld, M.D.</td>
<td>Ayers; GlaxoSmithKline; Eli Lilly and Company; UpJohn; Ciba-Geigy; Johnson and Johnson PRD; Parke Davis; Abbott Laboratories, Inc.; Proctor &amp; Gamble; Pharmacia</td>
<td>33, 61, 79</td>
</tr>
<tr>
<td>Max Hirshkowitz, Ph.D.</td>
<td>Cephalon Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.; Aventis Pharmaceuticals; Pfizer Inc.; Merck &amp; Co., Inc.; Orphan; Takeda Pharmaceuticals; NBI, Inc.</td>
<td>98</td>
</tr>
<tr>
<td>Eric Hollander, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Ortho McNeil Pharmaceutical Inc.; Pfizer Inc.; Wyeth Pharmaceuticals; Solvay Pharmaceuticals, Inc.; UCB Pharmaceuticals; Abbott Laboratories, Inc.</td>
<td>40, 63</td>
</tr>
<tr>
<td>Robert C. Hsiang, M.D.</td>
<td>W.W. Norton &amp; Company</td>
<td>40</td>
</tr>
<tr>
<td>Rona Hu, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.; Janssen Pharmaceutica Products, LP; Abbott Laboratories, Inc.; Eli Lilly and Company; Pfizer Inc.; GlaxoSmithKline; Cephalon Inc.</td>
<td>11</td>
</tr>
<tr>
<td>James I. Hudson, M.D.</td>
<td>Eli Lilly and Company; Ortho McNeil Pharmaceutical Inc.</td>
<td>6</td>
</tr>
<tr>
<td>Dan V. Iosifescu, M.D.</td>
<td>Pfizer Inc.; Aspect Medical Systems, Inc.; Janssen Pharmaceutica Products, LP; Forest Pharmaceuticals, Inc.; Eli Lilly and Company</td>
<td>48</td>
</tr>
<tr>
<td>Waguil W. Ishak, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb</td>
<td>69, 73, 75</td>
</tr>
<tr>
<td>Saleem Ismail, M.D.</td>
<td>National Institute of Mental Health; Janssen Pharmaceutica Products, LP; AstraZeneca Pharmaceuticals; Forest Pharmaceuticals, Inc.</td>
<td>77</td>
</tr>
<tr>
<td>Jeanne Jackson-Siegel, M.D.</td>
<td>Abbott Laboratories, Inc.; Janssen Pharmaceutica Products, LP; Eli Lilly and Company; Pfizer Inc.; Organon Pharmaceuticals Corporation; Forest Pharmaceuticals, Inc.</td>
<td>39</td>
</tr>
<tr>
<td>Kay Redfield Jamison, Ph.D.</td>
<td>GlaxoSmithKline; Eli Lilly and Company; AstraZeneca Pharmaceuticals</td>
<td>36</td>
</tr>
<tr>
<td>Philip G. Janicak, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Janssen Pharmaceutica Products, LP; Abbott Laboratories, Inc.; Neurocrine Biosciences Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.</td>
<td>27</td>
</tr>
<tr>
<td>Geetha Jayaram, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline; Cephalon Inc.; Janssen Pharmaceutica Products, LP</td>
<td>23, 43, 52, 75</td>
</tr>
<tr>
<td>Dilip V. Jeste, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca Pharmaceuticals; Pfizer Inc.; Janssen Pharmaceutica Products, LP</td>
<td>30, 77</td>
</tr>
<tr>
<td>Wei Jiang, M.D.</td>
<td>Pfizer Inc.</td>
<td>81</td>
</tr>
<tr>
<td>Hadine Joffe, M.D.</td>
<td>Abbott Laboratories, Inc.; Eli Lilly and Company; Berlex Laboratories, Inc.; Wyeth Pharmaceuticals; Sanofi-Synthelabo Pharmaceuticals, Inc.</td>
<td>3, 9</td>
</tr>
</tbody>
</table>

XXV
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey P. Kahn, M.D.</td>
<td>Work Psych Association, Inc.; AstraZeneca Pharmaceuticals; Shire Ridgedwood Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; GlaxoSmithKline; Neurocrine Biosciences Inc.; Abbott Laboratories, Inc.; Organon Pharmaceuticals Inc.; Pfizer Inc.; Wyeth Pharmaceuticals; GlaxoSmithKline</td>
<td>72</td>
</tr>
<tr>
<td>Bankole A. Johnson, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.; Forest Pharmaceuticals, Inc.</td>
<td>31, 56</td>
</tr>
<tr>
<td>Amir H. Kalal, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Shire Ridgedwood Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly Pharmaceuticals; GlaxoSmithKline; Neuroscience Advisory Board; Neuroscience Advisory Board; Wyeth Pharmaceuticals; Janssen Pharmaceutica Products, LP; GlaxoSmithKline; Neurocrine Biosciences Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Janssen Pharmaceutica Products, LP; Corcept Therapeutics; Cypress Bioscience, Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Eli Lilly and Company; Petent Pharmaceuticals; Tularik; Neurotechnics; Neurocrine Biosciences Inc.; Promoter Neurosciences, LLC; Pfizer Inc.</td>
<td>56</td>
</tr>
<tr>
<td>Ned H. Kalin, M.D.</td>
<td>National Institute of Health; Dana Foundation; Wyeth Pharmaceuticals; Janssen Pharmaceutica Products, LP; GlaxoSmithKline; Neuroscience Advisory Board; Neuroscience Advisory Board; Wyeth Pharmaceuticals; Janssen Pharmaceutica Products, LP; GlaxoSmithKline; Neurocrine Biosciences Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Janssen Pharmaceutica Products, LP; Corcept Therapeutics; Cypress Bioscience, Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Eli Lilly and Company; Petent Pharmaceuticals; Tularik; Neurotechnics; Neurocrine Biosciences Inc.; Promoter Neurosciences, LLC; Pfizer Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Eric R. Kandel, M.D.</td>
<td>Memory Pharmaceuticals</td>
<td>16</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer Inc.</td>
<td>10, 82</td>
</tr>
<tr>
<td>Jordan F. Karp, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Pfizer Inc.</td>
<td>94</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer Inc.</td>
<td>23</td>
</tr>
<tr>
<td>David J. Katzelnick, M.D.</td>
<td>Healthcare Technology Systems, Inc.</td>
<td>84</td>
</tr>
<tr>
<td>Jerald Kay, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Pfizer Inc.</td>
<td>68, 79</td>
</tr>
<tr>
<td>Paul E. Keck, Jr., M.D.</td>
<td>Corcept Therapeutics; Novartis Pharmaceuticals Corporation; Shire Ridgedwood Pharmaceuticals; Wyeth Pharmaceuticals; Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Eli Lilly and Company; Ortho McNeil Pharmaceutical Inc.; Pfizer Inc.; American Diabetes Association; Merck &amp; Co., Inc.; National Institute of Mental Health; National Institute of Drug Abuse (NIDA); Organon Pharmaceuticals Inc.; Stanley Medical Research Institute (SMRI); Eli Lilly and Company; Johnson and Johnson PRD; Pfizer Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Abbott Laboratories, Inc.; Organon Pharmaceuticals Inc.; Aventis Pharmaceuticals; Lundbeck; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Repligen; Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.</td>
<td>3, 4, 39</td>
</tr>
<tr>
<td>Richard S.E. Keefe, Ph.D.</td>
<td>Eli Lilly and Company; Johnson and Johnson PRD; Pfizer Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Abbott Laboratories, Inc.; Organon Pharmaceuticals Inc.; Aventis Pharmaceuticals; Lundbeck; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Repligen; Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.</td>
<td>4</td>
</tr>
<tr>
<td>Martin B. Keller, M.D.</td>
<td>Bristol-Myers Squibb; Collegium; Cypress Bioscience, Inc.; Abbott Laboratories, Inc.; Cyberonics, Inc.; Cephalon Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; Janssen Pharmaceutica Products, LP; Merck &amp; Co., Inc.; Organon Pharmaceuticals Inc.; Otsuka America Pharmaceutical; Pfizer Inc.; Pharmacia; Pharmastar; Sepacor Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Somerst Pharmaceuticals Inc.; Vela Pharmaceuticals; Scirex</td>
<td>2, 11</td>
</tr>
<tr>
<td>Charles H. Kellner, M.D.</td>
<td>Somaties, LLC</td>
<td>26</td>
</tr>
<tr>
<td>Douglas K. Kelsey, M.D.</td>
<td>Eli Lilly and Company</td>
<td>34</td>
</tr>
<tr>
<td>Sidney H. Kennedy, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Organon Pharmaceuticals Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Lundbeck; Wyeth Pharmaceuticals; Biovail Laboratories, Inc.; Merck &amp; Co., Inc.; Boehringer-Ingelheim; Ortho McNeil Pharmaceutical Inc.; Servier; Janssen Pharmaceutica Products, LP</td>
<td>32</td>
</tr>
<tr>
<td>Justine M. Kent, M.D.</td>
<td>Pfizer Inc.</td>
<td>6</td>
</tr>
<tr>
<td>Terence A. Ketter, M.D.</td>
<td>Cephalon Inc.; Pfizer Inc.; Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly Pharmaceuticals; Elan Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Shire Ridgedwood Pharmaceuticals</td>
<td>13, 36, 76</td>
</tr>
<tr>
<td>Bryan H. King, M.D.</td>
<td>Janssen Pharmaceutica Products, LP</td>
<td>66</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>David G. Kingdon, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Products, LP; Pfizer Inc.</td>
<td>8, 92</td>
</tr>
<tr>
<td>Joel I. Kirson, M.D.</td>
<td>GlaxoSmithKline; Reckitt Benckiser Pharmaceuticals; Purdue Pharma L.P.</td>
<td>23, 71</td>
</tr>
<tr>
<td>Herbert D. Kleber, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.; Shire Ridgewood Pharmaceuticals; Celltech Pharmaceuticals, Ltd.; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>15, 60, 80</td>
</tr>
<tr>
<td>Scott Kollins, Ph.D.</td>
<td>Merck &amp; Co., Inc.; Lipha; Titan Pharmaceuticals; Addex Pharmaceuticals; Forest Pharmaceuticals, Inc.</td>
<td>56, 62, 96</td>
</tr>
<tr>
<td>George F. Koob, Ph.D.</td>
<td>David G. Kingdon, M.D.</td>
<td>6</td>
</tr>
<tr>
<td>Lorrin M. Koran, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Pfizer Inc.; AstraZeneca Pharmaceuticals</td>
<td>79</td>
</tr>
<tr>
<td>Susan G. Kornstein, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Merck &amp; Co., Inc.; Forest Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Berlex Laboratories, Inc.; Serpraco Inc.; Novartis Pharmaceuticals Corporation; Warner-Chilcott; Biovail Laboratories Inc.</td>
<td>13, 39, 66</td>
</tr>
<tr>
<td>Diana M. Koziupa, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb; Otsuka America Pharmaceutical; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Sanofi-Synthelabo Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
<td>60</td>
</tr>
<tr>
<td>Henry R. Kranzler, M.A.</td>
<td>Alkermes Pharmaceuticals; Forest Pharmaceuticals, Inc.; Bristol-Myers Squibb; Ortho McNeil Pharmaceutical Inc.; Drug Abuse Sciences</td>
<td>31</td>
</tr>
<tr>
<td>Christopher J. Kratochvil, M.D.</td>
<td>Eli Lilly and Company; Forest Pharmaceuticals, Inc.; Cephalon Inc.; GlaxoSmithKline; Ortho McNeil Pharmaceutical Inc.</td>
<td>34, 62</td>
</tr>
<tr>
<td>John E. Kraus, Jr., M.D.</td>
<td>Bristol-Myers Squibb; Pfizer Inc.; Eli Lilly and Company; AstraZeneca Pharmaceuticals</td>
<td>4</td>
</tr>
<tr>
<td>K. Ranga R. Krishnan, M.D.</td>
<td>GlaxoSmithKline; Pfizer Inc.; Eli Lilly and Company; Vela Pharmaceuticals; Lundbeck; Abbott Laboratories, Inc.; Amgen; Johnson and Johnson PRD; Merck &amp; Co., Inc.; NPS Pharmaceuticals; Organon Pharmaceuticals Inc.; Otsuka America Pharmaceutical; Pfizer Inc.; Somerest Pharmaceuticals Inc.; Wyeth Pharmaceuticals; Synaptic</td>
<td>2, 41, 62, 81</td>
</tr>
<tr>
<td>Kurt Kroenke, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Wyeth Pharmaceuticals; Eli Lilly and Company; Pfizer Inc.</td>
<td>25</td>
</tr>
<tr>
<td>John H. Krystal, M.D.</td>
<td>Eli Lilly and Company</td>
<td>90</td>
</tr>
<tr>
<td>Elisabeth J.S. Kunzel, M.D.</td>
<td>Pfizer Inc.; Intramed; Forest Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
<td>40, 91, 96</td>
</tr>
<tr>
<td>David J. Kupfer, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; F. Hoffmann-La Roche, LTD.; Servier Ameurique</td>
<td>9, 20, 30</td>
</tr>
<tr>
<td>Raymond W. Lam, M.D.</td>
<td>Biovail Laboratories Inc.; Canadian Network for Mood and Anxiety Treatments; Eli Lilly and Company; GlaxoSmithKline; Lifebook Company, Inc.; Lundbeck; Shire Ridgewood Pharmaceuticals; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Canadian Institutes of Health Research; Janssen Pharmaceutica Products, LP; Merck &amp; Co., Inc.; Roche Laboratories, a member of the Roche Group; Servier Canada; Vancouver Hospital Foundation</td>
<td>61</td>
</tr>
<tr>
<td>Jeanne Landgraf, M.A.</td>
<td>Shire Ridgewood Pharmaceuticals</td>
<td>32</td>
</tr>
<tr>
<td>Edward C. Lauterbach, M.D.</td>
<td>Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.</td>
<td>5, 48, 71, 89</td>
</tr>
<tr>
<td>Helen Lavretsky, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Janssen Pharmaceutica Products, LP; Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb</td>
<td>62, 64</td>
</tr>
<tr>
<td>William Lawson, M.D.</td>
<td>Abbott Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.</td>
<td>25, 56</td>
</tr>
<tr>
<td>Arthur L. Lazarus, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>22</td>
</tr>
<tr>
<td>Eric J. Lentze, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Janssen Pharmaceutica Products, LP</td>
<td>6</td>
</tr>
<tr>
<td>Stefan M. Leucht, M.D.</td>
<td>Johnson and Johnson PRD; Eli Lilly and Company; Sanofi-Synthelabo Pharmaceuticals, Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Alan I. Levenson, M.D.</td>
<td>Psychiatrists' Purchasing Group, Inc.</td>
<td>19</td>
</tr>
<tr>
<td>James L. Levenson, M.D.</td>
<td>Eli Lilly and Company</td>
<td>40, 67, 91</td>
</tr>
<tr>
<td>Frances R. Levin, M.D.</td>
<td>Eli Lilly and Company; Ortho McNeil Pharmaceutical Inc.; UCB Pharmaceuticals</td>
<td>50, 81</td>
</tr>
<tr>
<td>Ronald W. Levin, M.D.</td>
<td>Pfizer Inc.; Amgen; Cetacean; Icos</td>
<td>78</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Aventis Pharmaceuticals; Bristol-Myers Squibb; Cybereonics, Inc.; Cypress Bioscience, Inc.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutical Products, LP; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc.; Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>4, 12, 31, 51</td>
</tr>
<tr>
<td>Michael R. Liebowitz, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline.</td>
<td>3, 6</td>
</tr>
<tr>
<td>Kevin O. Lim</td>
<td>Eli Lilly and Company; Aventis</td>
<td>80</td>
</tr>
<tr>
<td>Jean-Pierre Lindenmayer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Janssen Pharmaceutical Products, LP; Bristol-Myers Squibb; Pfizer Inc.; AstraZeneca Pharmaceuticals</td>
<td>68</td>
</tr>
<tr>
<td>Marsha Lineham, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>7</td>
</tr>
<tr>
<td>Sarah H. Lisanby, M.D.</td>
<td>National Institute of Mental Health; National Alliance for Research in Schizophrenia and Depression; Stanley Foundation; American Federation for Aging Research (AFAR); The Defense Advances Research Project Agency (DARPA); Magstim Company; Cyberonics, Inc.</td>
<td>6, 37, 47, 51, 69</td>
</tr>
<tr>
<td>Sheila M. Loboprabhu, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>25, 45</td>
</tr>
<tr>
<td>Eric B. London, M.D.</td>
<td>Wyeth Pharmaceuticals; Pfizer Inc.; GlaxoSmithKline; Eli Lilly and Company; Cephalon, Inc.</td>
<td>61</td>
</tr>
<tr>
<td>Shari I. Lusskin, M.D.</td>
<td>Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Pfizer Inc.; GlaxoSmithKline</td>
<td>63</td>
</tr>
<tr>
<td>R. Bruce Lydiard, M.D.</td>
<td>Pfizer Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Contantine Lyketsos, M.D.</td>
<td>Eisai; Forest Laboratories; DuPont; Janssen Pharmaceutical Products, LP; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; NeuroLogics; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Organon Pharmaceuticals Inc.; GlaxoSmithKline; Novartis; Park Davis (Warner-Lambert); Abbott Laboratories, Inc.; Bayer; Pfizer, Inc.; Eisai; Lundbeck; National Institute of Mental Health; National Institute on Aging; Cover White Foundation; Helen Bader Foundation; Alzheimer Association</td>
<td>28, 67, 76</td>
</tr>
<tr>
<td>JoAnn E. Macbeth, J.D.</td>
<td>American Psychiatric Association</td>
<td>18</td>
</tr>
<tr>
<td>Wayne Macfadden, M.D.</td>
<td>AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA</td>
<td>48</td>
</tr>
<tr>
<td>Jose R. Maldonado, M.D.</td>
<td>Hospira/Abbott Laboratories, Inc.; Forest Pharmaceuticals, Inc.; Eli Lilly and Company; Pfizer Inc.</td>
<td>1, 8, 15, 90</td>
</tr>
<tr>
<td>Catherine L. Mancini, M.D.</td>
<td>Lundbeck; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutical Products, LP; Solvay Pharmaceuticals, Inc.; Pfizer Inc.</td>
<td>89</td>
</tr>
<tr>
<td>Lauren B. Marangell, M.D.</td>
<td>National Institute of Health; Stanley Foundation; Cyberonics, Inc.; Eli Lilly and Company; Abbott Laboratories, Inc.; Pfizer Inc.; GlaxoSmithKline; Medtronic; Forest Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
<td>6</td>
</tr>
<tr>
<td>John S. March, M.D.</td>
<td>Pfizer Inc.; Wyeth Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Pharmaceuticals Inc.; AstraZeneca Pharmaceuticals</td>
<td>31, 42, 66, 92</td>
</tr>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td>Janssen Pharmaceutical Products, LP; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Pfizer Inc.</td>
<td>27, 55, 93</td>
</tr>
<tr>
<td>John C. Markowitz, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Basic Books; American Psychiatric Publishing</td>
<td>5, 57</td>
</tr>
<tr>
<td>Randall D. Marshall, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals</td>
<td>31, 58, 71</td>
</tr>
<tr>
<td>James M. Martinez, M.D.</td>
<td>UCB Pharmaceuticals; Cyberonics, Inc.; Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Wyeth Pharmaceuticals; Janssen Pharmaceutical Products, LP; AstraZeneca Pharmaceuticals; Forest Pharmaceuticals, Inc.</td>
<td>4</td>
</tr>
<tr>
<td>Prakash S. Masand, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Janssen Pharmaceutical Products, LP; Bristol-Myers Squibb; GlaxoSmithKline; Ortho McNeil Pharmaceutical Inc.; Wyeth Pharmaceuticals; Health Care Technology; Organon Pharmaceuticals Inc.; Pfizer Inc.; Abbott Laboratories, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; PsychCME Inc.</td>
<td>3, 21, 70</td>
</tr>
<tr>
<td>Barbara J. Mason, Ph.D.</td>
<td>Sanofi-Synthelabo Pharmaceuticals; Somaxon Pharmaceuticals; Titan Pharmaceuticals; Pfizer Inc.; Merck &amp; Co., Inc.; Forest Pharmaceuticals, Inc.</td>
<td>56</td>
</tr>
<tr>
<td>Annette M. Matthews, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>54</td>
</tr>
<tr>
<td>Helen S. Mayberg, M.D.</td>
<td>GlaxoSmithKline; Cyberonics, Inc.; Advanced Neuromodulation Systems</td>
<td>12, 27, 46, 54</td>
</tr>
<tr>
<td>W. Vaughn McCall, M.S.</td>
<td>Sepracor Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.; Takeda Pharmaceuticals</td>
<td>26, 47</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>William M. McDonald, M.D.</td>
<td>American Foundation for Suicide Prevention; National Alliance for Research in</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>Schizophrenia and Depression; American Foundation for Suicide Prevention; Fuqua</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foundation; National Institute of Mental Health; National Institute of Neurological</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disease and Stroke; Neuretics Inc.; Janssen Pharmaceuticals Products, LP;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organon Pharmaceuticals Inc.; Forest Pharmaceuticals, Inc.; GlaxoSmithKline;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AstraZeneca Pharmaceuticals; Wyeth Pharmaceuticals; Amgen; Teva; Millenium;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer Inc.; Abbott Laboratories, Inc.; Neurobiological Tech.</td>
<td></td>
</tr>
<tr>
<td>Christopher J. McDougle, M.D.</td>
<td>Janssen Pharmaceuticals Products, LP; Pfizer Inc.; Eli Lilly and Company;</td>
<td>2, 87</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Repligen Corp.</td>
<td></td>
</tr>
<tr>
<td>David M. McDowell, M.D.</td>
<td>Wyeth Pharmaceuticals; Bristol-Myers Squibb; Mallinckrodt; Recked-Benheisey;</td>
<td>80, 81, 92</td>
</tr>
<tr>
<td>Susan L. McElroy, M.D.</td>
<td>Abbott Laboratories, Inc.; Bristol-Myers Squibb; GlaxoSmithKline; Janssen</td>
<td>3, 6</td>
</tr>
<tr>
<td></td>
<td>Pharmaeutica Products, LP; Eli Lilly and Company; Novartis Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corporation; Ortho McNeil Pharmaceutical Inc.; Wyeth Pharmaceuticals; Forest</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals, Inc.; Eisai Inc.; Merck &amp; Co., Inc.; Pfizer Inc.; Sanofi-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synthelabo Pharmaceuticals, Inc.; UCB Pharmaceuticals; AstraZeneca Pharmaceutical</td>
<td></td>
</tr>
<tr>
<td>Joseph P. McEvoy, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Janssen</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Pharmaceutical Products, LP; Eli Lilly and Company; Pfizer Inc.; Sanofi-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synthelabo Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td>William R. McFarlane, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company;</td>
<td>30</td>
</tr>
<tr>
<td>Thomas H. McGlashan, M.D.</td>
<td></td>
<td>30, 77</td>
</tr>
<tr>
<td>Jack S. McIntyre, M.D.</td>
<td>Janssen Pharmaceuticals Products, LP; GlaxoSmithKline; Eli Lilly and Company;</td>
<td>17, 25, 51, 67</td>
</tr>
<tr>
<td>Jacqueline M. Melonas, J.D.</td>
<td>Professional Risk Management Services, Inc.</td>
<td>19, 44, 63</td>
</tr>
<tr>
<td>Herbert M. Metzler, M.D.</td>
<td>ACADIA; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Company; Janssen Pharmaceutical Products, LP; Novartis Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corporation; Organon Pharmaceuticals Inc.; Pfizer Inc.; Solvay Pharmaceuticals,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td>Ricardo P. Mendoza, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>25</td>
</tr>
<tr>
<td>Jeffrey L. Metzner, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals</td>
<td>67, 72</td>
</tr>
<tr>
<td>Richard J. Metzner, M.D.</td>
<td>GlaxoSmithKline; Forest Pharmaceuticals, Inc.</td>
<td>90</td>
</tr>
<tr>
<td>Eric Mick, Sc.D.</td>
<td>McNeil Consumer Healthcare; Janssen Pharmaceuticals Products, LP</td>
<td>80</td>
</tr>
<tr>
<td>David J. Miklowitz, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>5</td>
</tr>
<tr>
<td>Alexander L. Miller, M.D.</td>
<td>Abbott Laboratories, Inc.; Almirall; AstraZeneca Pharmaceuticals; Bristol-</td>
<td>33, 51</td>
</tr>
<tr>
<td></td>
<td>Myers Squibb; Lilly Research Laboratories, a division of Eli Lilly and Company;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen Pharmaceutical Products, LP; Pfizer Inc.; Informevid</td>
<td></td>
</tr>
<tr>
<td>Andrew H. Miller, M.D.</td>
<td>Schering-Plough Corporation; GlaxoSmithKline; Janssen Pharmaceutical Products,</td>
<td>20</td>
</tr>
<tr>
<td>Del D. Miller, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutical Products, LP</td>
<td>33</td>
</tr>
<tr>
<td>Mark A. Mintun, M.D.</td>
<td>Molecular Imaging Corp.</td>
<td>9</td>
</tr>
<tr>
<td>Jacobo E. Mintzer, M.D.</td>
<td>Voyager Pharmaceutical; Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals</td>
<td>55, 64</td>
</tr>
<tr>
<td></td>
<td>Boehringer-Ingelheim Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Company; Forest Pharmaceuticals, Inc.; Janssen Pharmaceutical Products, LP;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Johnson and Johnson PRD; Mitsubishi Pharma Corporation; Novartis Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corporation; Pfizer Inc.; Predix; Targacept; Gerson Lehrman GRP; Deutsche</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bank; Capital Research; Parlex International Corp.; American Association of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Geriatric Psychiatry; American Psychiatric Association; Alzheimer's</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organization (local and national); Eisai Inc.</td>
<td></td>
</tr>
<tr>
<td>Karen Miotto, M.D.</td>
<td>Rickett Benckiser</td>
<td>2</td>
</tr>
<tr>
<td>Shaila Misri, M.D.</td>
<td>GlaxoSmithKline; Lundbeck; Wyeth Pharmaceuticals; Biovail Laboratories Inc.;</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Lisa A. Mistler, M.D.</td>
<td>Schering-Plough Corporation</td>
<td>29</td>
</tr>
<tr>
<td>James E. Mitchell, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott</td>
<td>1, 97</td>
</tr>
<tr>
<td></td>
<td>Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Frederick G. Moeller, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.; National Institute on Drug Abuse</td>
<td>97</td>
</tr>
<tr>
<td>Rodrigo A. Munoz, M.D.</td>
<td>Eli Lilly and Company</td>
<td>18, 33, 61, 67</td>
</tr>
<tr>
<td></td>
<td></td>
<td>82, 87, 93</td>
</tr>
<tr>
<td>Philip R. Muskin, M.D.</td>
<td>Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Cephalon</td>
<td>22, 28, 51, 67</td>
</tr>
<tr>
<td></td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals; Janssen Pharmaceutical Products</td>
<td></td>
</tr>
<tr>
<td>Hugh Myrick, M.D.</td>
<td>Abbott Laboratories, Inc.; Forest Pharmaceuticals, Inc.; Ortho McNeil</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td>Pharmaceutical Inc.; Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>David Nace, M.D.</td>
<td>Wyeth Pharmaceuticals; Bristol-Myers Squibb; United Health Group</td>
<td>17</td>
</tr>
<tr>
<td>Ziad H. Nahas, M.D.</td>
<td>Neuretics, Inc.; Cyberonics, Inc.</td>
<td>51</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Joseph C. Napoli, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.¹; Wyeth Pharmaceuticals, Inc.¹; Bristol-Myers Squibb²; Eli Lilly and Company²; Forest Pharmaceuticals, Inc.¹; Janssen Pharmaceutical Products, LP³; Neurontics, Inc.¹; AstraZeneca Pharmaceuticals, Inc.¹; Pfizer Inc.¹; GlaxoSmithKline¹; Janssen Pharmaceutical Products, LP³</td>
<td>14</td>
</tr>
<tr>
<td>Jeffrey A. Naser, M.D.</td>
<td>Wyeth Pharmaceuticals, Inc.¹; Novartis Pharmaceuticals Corporation²; Forest Pharmaceuticals, Inc.¹</td>
<td>94</td>
</tr>
<tr>
<td>George S. Nasra, M.D.</td>
<td>Forest Pharmaceuticals, Inc.¹; GlaxoSmithKline¹; Wyeth Pharmaceuticals, Inc.¹; Pfizer Inc.¹; Organon Pharmaceuticals Inc.²</td>
<td>92</td>
</tr>
<tr>
<td>J. Craig Nelson, M.D.</td>
<td>Abbott Laboratories, Inc.¹; Eli Lilly and Company²; Forest Pharmaceuticals, Inc.¹; GlaxoSmithKline¹; Janssen Pharmaceutical Products, LP³; Organon Pharmaceuticals Inc.²; Pfizer Inc.¹; Wyeth Pharmaceuticals, Inc.¹; Bristol-Myers Squibb²; Orexigen¹; Shire Ridgewood Pharmaceuticals¹</td>
<td>55</td>
</tr>
<tr>
<td>Charles B. Nemeroff, M.D.</td>
<td>Abbott Laboratories, Inc.¹; American Foundation for Suicide Prevention (AFSP)¹; Acadia Pharmaceuticals¹; AstraZeneca Pharmaceuticals¹; Bristol-Myers Squibb¹; Eli Lilly and Company¹; Corcept¹; Cypress Bioscience, Inc.¹; Cyberonics, Inc.¹; Forest Pharmaceuticals, Inc.¹; GlaxoSmithKline¹; Janssen Pharmaceutical Products, LP³; National Alliance for Research in Schizophrenia and Depression¹; National Institute of Mental Health¹; Jazz Pharmaceuticals¹; Neurocrine Biosciences Inc.¹; Otsuka America Pharmaceutical Corp.¹; Quintiles¹; Pfizer Inc.¹; Somerset Pharmaceuticals Inc.¹; Sanofi-Synthelabo Pharmaceuticals, Inc.¹; Stanley Foundation/NAMI¹; Wyeth Pharmaceuticals¹; American Psychiatric Institute for Research and Education (APIRE)¹; George West Health Foundation¹; Novadel Pharma¹; Organon Pharmaceuticals Inc.¹</td>
<td>42</td>
</tr>
<tr>
<td>David N. Neubauer, M.D.</td>
<td>Neurocrine Biosciences Inc./Pfizer Inc.¹; Takeda Pharmaceuticals¹; Sanofi-Synthelabo Pharmaceuticals, Inc.¹</td>
<td>62</td>
</tr>
<tr>
<td>Antonia S. New, M.D.</td>
<td>Eli Lilly and Company²</td>
<td>7, 98</td>
</tr>
<tr>
<td>John W. Newcomer, M.D.</td>
<td>Bristol-Myers Squibb³; Otsuka America Pharmaceutical Corp.³; National Institute of Mental Health³; National Alliance for Research in Schizophrenia and Depression³; Sidney Baer Foundation³; Pfizer Inc.³; Janssen Pharmaceutical Products, LP³; AstraZeneca Pharmaceuticals³; Wyeth Pharmaceuticals³; GlaxoSmithKline³; Eli Lilly and Company³</td>
<td>37</td>
</tr>
<tr>
<td>Cassandra F. Newkirk, M.D.</td>
<td>Pfizer Inc.¹; Abbott Laboratories, Inc.¹</td>
<td>43, 49, 66</td>
</tr>
<tr>
<td>Anthony T. Ng, M.D.</td>
<td>Pfizer Inc.¹</td>
<td>2, 19, 43, 61</td>
</tr>
<tr>
<td>Andrew A. Nierenberg, M.D.</td>
<td>Cyberonics, Inc.¹; Innapharma¹; Neurontics, Inc.¹; Shire Ridgewood Pharmaceuticals¹; Eli Lilly and Company²; GlaxoSmithKline²; National Institute of Mental Health²; Bristol-Myers Squibb²; Cederroth²; National Alliance for Research in Schizophrenia and Depression²; Stanley Foundation²; Organon Pharmaceuticals Inc.²; Janssen Pharmaceutical Products²; LP²; Wyeth Pharmaceuticals²; Lichtwer²</td>
<td>5, 70, 84</td>
</tr>
<tr>
<td>Philip T. Ninan, M.D.</td>
<td>Bristol-Myers Squibb³; Cephalon Inc.¹; Cybonics, Inc.¹; Eli Lilly and Company³; Forest Pharmaceuticals, Inc.¹; GlaxoSmithKline¹; Janssen Pharmaceutical Products, LP³; Solvay Pharmaceuticals, Inc.¹; UCB Pharmaceuticals¹; Wyeth Pharmaceuticals¹; National Institute of Mental Health²; Pfizer Inc.³</td>
<td>3, 11</td>
</tr>
<tr>
<td>Ruta M. Nonacs, M.D.</td>
<td>GlaxoSmithKline¹</td>
<td>2, 66</td>
</tr>
<tr>
<td>Carol S. North, M.D.</td>
<td>UCB Pharmaceuticals¹; GlaxoSmithKline¹; King Pharmaceuticals¹</td>
<td>19</td>
</tr>
<tr>
<td>Andrei Novac, M.D.</td>
<td>GlaxoSmithKline¹; Pfizer Inc.¹; Forest Pharmaceuticals, Inc.¹</td>
<td>91</td>
</tr>
<tr>
<td>Douglas K. Novins, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.³</td>
<td>50</td>
</tr>
<tr>
<td>H. George Nurnberg, M.D.</td>
<td>R.W. Johnson Pharmaceuticals¹; LIPHA Pharmaceuticals³; Parke-Davis Pharmaceuticals³; Wyeth Pharmaceuticals³; Abbott Laboratories, Inc.³; Pfizer Inc.¹; Eli Lilly and Company³; GlaxoSmithKline¹; Bristol-Myers Squibb³</td>
<td>70</td>
</tr>
<tr>
<td>R. Michael O'Bannon, Ph.D.</td>
<td>EEG Spectrum International³; Alkermes Pharmaceuticals¹; Drug Abuse Sciences¹; UCB Pharmaceuticals¹; Merck &amp; Co., Inc.³; Schering-Plough Corporation³</td>
<td>63, 74</td>
</tr>
<tr>
<td>Charles P. O'Brien, M.D.</td>
<td>Novartis Pharmaceuticals Corporation¹; Sanofi-Synthelabo Pharmaceuticals, Inc.¹; Merck &amp; Co., Inc.³; Schering-Plough Corporation³</td>
<td>62</td>
</tr>
<tr>
<td>Elizabeth Ofili, M.D.</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Mark Olsson, M.D.</td>
<td>Bristol-Myers Squibb³; Eli Lilly and Company³; Ortho McNeil Pharmaceutical Inc.³; Janssen Pharmaceutical Products, LP³</td>
<td>51</td>
</tr>
<tr>
<td>Mary B. O'Malley, M.D.</td>
<td>Cephalon Inc.¹</td>
<td>73</td>
</tr>
<tr>
<td>Lewis A. Opler, M.D.</td>
<td>Multi-Health Systems, Inc.¹</td>
<td>8, 18, 92</td>
</tr>
<tr>
<td>Patricia J. Ordorica, M.D.</td>
<td>Pfizer Inc.¹</td>
<td>52</td>
</tr>
<tr>
<td>Urban P. Oxbey, M.D.</td>
<td>Bristol-Myers Squibb³</td>
<td>23</td>
</tr>
<tr>
<td>Michael J. Ostacher, M.D.</td>
<td>AstraZeneca Pharmaceuticals¹; Forest Pharmaceuticals, Inc.¹; GlaxoSmithKline¹</td>
<td>5</td>
</tr>
<tr>
<td>Michael W. Otto, Ph.D.</td>
<td>GlaxoSmithKline¹; Pfizer Inc.¹; Lilly Research Laboratories, a division of Eli Lilly and Company²</td>
<td>2</td>
</tr>
<tr>
<td>Elizabeth Pappadopulos, Ph.D.</td>
<td>Bristol-Myers Squibb³; Janssen Pharmaceutical Products, LP³</td>
<td>2</td>
</tr>
<tr>
<td>XXX</td>
<td>XXX</td>
<td>XXX</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Sagar Parikh, M.D.</td>
<td>Wyeth Pharmaceuticals, AstraZeneca Pharmaceuticals, Eli Lilly and Company, Biovail Laboratories, Ortho McNeil Pharmaceutical Inc.</td>
<td>74</td>
</tr>
<tr>
<td>Joseph J. Parks III, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company, Bristol-Myers Squibb</td>
<td>15</td>
</tr>
<tr>
<td>Joseph V. Penn, M.D.</td>
<td>Celltech Pharmaceuticals, Ltd., Ortho McNeil Pharmaceutical Inc.</td>
<td>78</td>
</tr>
<tr>
<td>Jennifer K. Pennell, M.D.</td>
<td>Wyeth Pharmaceuticals</td>
<td>61</td>
</tr>
<tr>
<td>Diana O. Perkins, M.D.</td>
<td>Bristol-Myers Squibb, Lilly Research Laboratories, a division of Eli Lilly and Company, Pfizer Inc., AstraZeneca Pharmaceuticals</td>
<td>30, 52</td>
</tr>
<tr>
<td>Roy H. Perlis, M.D.</td>
<td>Eisai Inc., Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca Pharmaceuticals, Elan Pharmaceuticals</td>
<td>3, 47</td>
</tr>
<tr>
<td>Eric D. Pescow, M.D.</td>
<td>Pfizer Inc., GlaxoSmithKline, Pfizer Inc., Elan Pharmaceuticals, GE Global Research</td>
<td>19, 48</td>
</tr>
<tr>
<td>Ronald C. Petersen, M.D.</td>
<td>Pfizer Inc., Eisai Inc., Elan Pharmaceuticals, Ortho McNeil Pharmaceutical Inc.</td>
<td>62</td>
</tr>
<tr>
<td>Christopher B. Peterson, M.D.</td>
<td>Bristol-Myers Squibb, Janssen Pharmaceutical Products, Lilly Research Laboratories, Janssen Pharmaceuticals, Pfizer Inc.</td>
<td>17</td>
</tr>
<tr>
<td>Francois C. Petitjean, M.D.</td>
<td>Alkermes Pharmaceuticals, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Ortho McNeil Pharmaceutical Inc.</td>
<td>55</td>
</tr>
<tr>
<td>Helen M. Pettinati, Ph.D.</td>
<td>Eli Lilly and Company, UCB Pharmaceuticals, Pfizer Inc., Forest Pharmaceuticals, UCB Pharmaceuticals, Eli Lilly and Company</td>
<td>24, 30</td>
</tr>
<tr>
<td>Katharine A. Phillips, M.D.</td>
<td>Novartis, Pfizer Inc., Novo Nordisk, Sankyo, Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>42</td>
</tr>
<tr>
<td>Lawrence S. Phillips, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc.</td>
<td>13</td>
</tr>
<tr>
<td>Teresa A. Pigott, M.D.</td>
<td>Janssen Pharmaceutical Products, Bristol-Myers Squibb, Cephalon, Forest Pharmaceuticals, Janssen Pharmaceutical Products, Bristol-Myers Squibb, Lilly Research Laboratories, GlaxoSmithKline, Shire Ridgewood Pharmaceuticals, UCB Pharmaceuticals</td>
<td>68</td>
</tr>
<tr>
<td>Harold Alan Pincus, M.D.</td>
<td>UPMC Health Plan, Pfizer Inc.</td>
<td>52</td>
</tr>
<tr>
<td>Marie France Poirier, M.D.</td>
<td>Janssen Pharmaceutical Products, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical Products, Bristol-Myers Squibb</td>
<td>55</td>
</tr>
<tr>
<td>Mark H. Pollack, M.D.</td>
<td>AstraZeneca Pharmaceuticals, Eli Lilly and Company, AstraZeneca Pharmaceuticals, Pfizer Inc.</td>
<td>6, 84</td>
</tr>
<tr>
<td>Robert Popozian, Ph.D.</td>
<td>Pfizer Inc.</td>
<td>67</td>
</tr>
<tr>
<td>David J. Posey, M.D.</td>
<td>Janssen Pharmaceutical Products, Eli Lilly and Company, AstraZeneca Pharmaceuticals</td>
<td>2</td>
</tr>
<tr>
<td>Robert M. Post, M.D.</td>
<td>Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Elan Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutical Products, Shire Ridgewood Pharmaceuticals, UCB Pharmaceuticals</td>
<td>56, 77</td>
</tr>
<tr>
<td>William Potter, M.D.</td>
<td>Eli Lilly and Company, Merck &amp; Co., Inc.</td>
<td>84</td>
</tr>
<tr>
<td>Ulrich Preuss, M.D.</td>
<td>Eli Lilly and Company</td>
<td>34</td>
</tr>
<tr>
<td>Annel B. Primm, M.D.</td>
<td>Pfizer Inc., Eli Lilly and Company, Janssen Pharmaceutical Products, Bristol-Myers Squibb, Elan Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutical Products, Pfizer Inc.</td>
<td>76, 82, 92</td>
</tr>
<tr>
<td>India Primn-SPencer</td>
<td>Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutical Products, Bristol-Myers Squibb, Shire Ridgewood Pharmaceuticals, Novartis Pharmaceuticals Corporation</td>
<td>43</td>
</tr>
<tr>
<td>Peter V. Rabins, M.D.</td>
<td>Pfizer Inc., Eli Lilly and Company, Janssen Pharmaceutical Products, Wyeth Pharmaceuticals</td>
<td>17, 77</td>
</tr>
<tr>
<td>Charles Raison, M.D.</td>
<td>Wyeth Pharmaceuticals, Eli Lilly and Company, Schering-Plough Corporation</td>
<td>51</td>
</tr>
<tr>
<td>Luis F. Ramirez, M.D.</td>
<td>Bristol-Myers Squibb, Organon Pharmaceuticals Inc., Pfizer Inc., Janssen Pharmaceutical Products, AstraZeneca Pharmaceuticals, Janssen Pharmaceutical Products, Pfizer Inc.</td>
<td>39</td>
</tr>
<tr>
<td>Paul M. Ramirez, Ph.D.</td>
<td>Multi-Health Systems Publishers</td>
<td>8</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Mark H. Rapaport, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Organon Pharmaceuticals Inc.; Roche Laboratories, a member of the Roche Group; Sumitomo; AstaZeneca Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories, Inc.; Solvay Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica Products, LP; Sanofi-Synthelabo Pharmaceuticals, Inc.; Stanley Foundation; UCB Pharmaceuticals; National Institute of Mental Health; Cyberonics, Inc.; Pharmacia Upjohn; Neurorine Biosciences Inc.; National Institute on Drug Abuse (NIDA)</td>
<td>9, 16, 20, 27</td>
</tr>
<tr>
<td>Natalie L. Rasgon, M.D.</td>
<td>Wyeth Pharmaceuticals; Forest Pharmaceuticals, Inc.; Abbott Laboratories, Inc.; GlaxoSmithKline; UCLA General Clinical Research Center Medical Advisory Committee; National Institute on Aging; National Institute of Mental Health; Eli Lilly and Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation</td>
<td>37, 63</td>
</tr>
<tr>
<td>Shanaya Rathod, M.D.</td>
<td>Janssen Glax Pharmaceuticals Inc.</td>
<td>92</td>
</tr>
<tr>
<td>Norman Relkin, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>62</td>
</tr>
<tr>
<td>Roy O. Resnikoff, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Lilly Research Laboratories</td>
<td>5</td>
</tr>
<tr>
<td>Charles F. Reynolds III, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Pfizer Inc.</td>
<td>30, 94</td>
</tr>
<tr>
<td>Michelle B. Riba, M.D.</td>
<td>Eli Lilly and Company</td>
<td>8, 10, 13, 17, 28, 35, 43, 49, 53, 67, 83, 92, 93</td>
</tr>
<tr>
<td>Gary S. Richardson, M.D.</td>
<td>King Pharmaceutical; Neurocrine Biosciences Inc./Pfizer Inc.; Sepracor Inc.; Takeda Pharmaceuticals; Sanofi-Synthelabo Pharmaceuticals, Inc.</td>
<td>62</td>
</tr>
<tr>
<td>Michael J. Robinson, M.D.</td>
<td>Eli Lilly and Company</td>
<td>40</td>
</tr>
<tr>
<td>Rebecca L. Robinson, M.S.</td>
<td>Eli Lilly and Company</td>
<td>89</td>
</tr>
<tr>
<td>Robert G. Robinson, M.D.</td>
<td>Forest Pharmaceuticals, Inc.</td>
<td>32</td>
</tr>
<tr>
<td>Steven P. Roose, M.D.</td>
<td>Wyeth Pharmaceuticals; Forest Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Organon Pharmaceuticals Inc.</td>
<td>2, 6, 94</td>
</tr>
<tr>
<td>Jerrold F. Rosenbaum, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Cyberonics, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Organon Pharmaceuticals Inc.; Somerset Pharmaceuticals Inc.; Wyeth Pharmaceuticals</td>
<td>1</td>
</tr>
<tr>
<td>Michael B. Rosenbluth, M.D.</td>
<td>Wyeth Pharmaceuticals; Organon Pharmaceuticals Inc.; Eli Lilly and Company; Johnson and Johnson PRD</td>
<td>32</td>
</tr>
<tr>
<td>Miriam Rosenthal, M.D.</td>
<td>Pfizer Inc.; Forest Pharmaceuticals, Inc.</td>
<td>69</td>
</tr>
<tr>
<td>Norman E. Rosenthal, M.D.</td>
<td>GlaxoSmithKline; Forest Pharmaceuticals, Inc.</td>
<td>31, 61</td>
</tr>
<tr>
<td>Richard N. Rosenthal, M.D.</td>
<td>Alkermes Pharmaceuticals; Forest Pharmaceuticals, Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Thomas J. Rosko, M.D.</td>
<td>Pfizer Inc.</td>
<td>87</td>
</tr>
<tr>
<td>Anthony L. Rostain, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.; Eli Lilly and Company</td>
<td>22, 68, 85</td>
</tr>
<tr>
<td>Anthony J. Rothschild, M.D.</td>
<td>Cephalon Inc.; Wyeth Pharmaceuticals; Forest Pharmaceuticals, Inc.; Pfizer Inc.; Eli Lilly and Company; Bristol-Myers Squibb; Abbott Laboratories, Inc.</td>
<td>16, 41, 55</td>
</tr>
<tr>
<td>Peter P. Roy-Byrne, M.D.</td>
<td>GlaxoSmithKline; Pfizer Inc.; Forest Pharmaceuticals, Inc.; Alza/McNeil Pharmaceuticals; Cephalon Inc.; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Pharmacia; Roche Laboratories, a member of the Roche Group; Wyeth Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>1, 3</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>GlaxoSmithKline; Robert Wood Johnson Foundation; National Institute of Mental Health; Cyberonics, Inc.; Stanford Foundation; Bristol-Myers Squibb; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; Organon Pharmaceuticals Inc.; Urban Institute</td>
<td>6, 31</td>
</tr>
<tr>
<td>Leo J. Russo, Ph.D.</td>
<td>Johnson &amp; Johnson PRD</td>
<td>54</td>
</tr>
<tr>
<td>Gary S. Sachs, M.D.</td>
<td>Abbott Laboratories, Inc.; GlaxoSmithKline; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Elan Pharmaceuticals; Sanofi-Synthelabo Pharmaceuticals, Inc.; Sigma-Tau; AstraZeneca Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Pfizer Inc.</td>
<td>5, 11, 23, 31, 55, 76</td>
</tr>
<tr>
<td>Harold A. Sackeim, Ph.D.</td>
<td>MECTA Corp.; Neurocrine Biosciences Inc.; Cyberonics, Inc.; Magrini Corp.</td>
<td>6, 47</td>
</tr>
<tr>
<td>Martha Sajatovic, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories, Inc.; Pfizer Inc.; Janssen Pharmaceutica Products, LP</td>
<td>64</td>
</tr>
<tr>
<td>David Satcher, M.D.</td>
<td>Johnson &amp; Johnson PRD</td>
<td>30</td>
</tr>
<tr>
<td>Lawrence Scalihi, Ph.D.</td>
<td>Janssen Pharmaceutica Products, LP; Pfizer Inc.; Bristol-Myers Squibb</td>
<td>61</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Alan F. Schatzberg, M.D.</td>
<td>Abbott Laboratories, Inc.; Aventis Pharmaceuticals; Bristol-Myers Squibb; Corcept Therapeutics; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Innapharma; Janssen Pharmaceutica Products, LP; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc.</td>
<td>9, 16, 33, 45</td>
</tr>
<tr>
<td>Randolph B. Schiffer, M.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceutica Products, LP.</td>
<td>1</td>
</tr>
<tr>
<td>Christian Schmahl, M.D.</td>
<td>Eli Lilly and Company.</td>
<td>7, 97, 98</td>
</tr>
<tr>
<td>Christopher D. Schneck, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; UCB Pharmaceuticals.</td>
<td>5</td>
</tr>
<tr>
<td>Lon Schneider, M.D.</td>
<td>Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.; Janssen Pharmaceutica Products, LP; AstraZeneca Pharmaceuticals.</td>
<td>76</td>
</tr>
<tr>
<td>Franklin R. Schneier, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Pfizer Inc.; UCB Pharmaceuticals.</td>
<td>3</td>
</tr>
<tr>
<td>Nina R. Schooler, Ph.D.</td>
<td>Janssen Pharmaceutica Products, LP; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Pfizer Inc.; Johnson and Johnson PRD; Organon Pharmaceuticals Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Marc A. Schuckit, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.; Forest Pharmaceuticals, Inc.</td>
<td>56</td>
</tr>
<tr>
<td>S. Charles Schulz, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories, Inc.; Janssen Pharmaceutica Products, LP.</td>
<td>7, 80</td>
</tr>
<tr>
<td>Thomas L. Schwartz, M.D.</td>
<td>Wyeth Pharmaceuticals; Cephalon Inc.; Bristol-Myers Squibb.</td>
<td>37, 70</td>
</tr>
<tr>
<td>Larry J. Seidman, Ph.D.</td>
<td>Shire Ridgewood Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica Products, LP.</td>
<td>57</td>
</tr>
<tr>
<td>Michael J. Sernyak, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceutica Products, LP; Eli Lilly and Company; Pfizer Inc.</td>
<td>55</td>
</tr>
<tr>
<td>David D. Servan-Schreiber, M.D.</td>
<td>Institute Francais d'EMDR</td>
<td>94</td>
</tr>
<tr>
<td>Peter A. Shapiro, M.D.</td>
<td>Pfizer Inc.</td>
<td>40, 67</td>
</tr>
<tr>
<td>Tonmoy Sharma, M.D.</td>
<td>Pfizer Inc.</td>
<td>23, 89</td>
</tr>
<tr>
<td>Shawn C. Sheu, M.D.</td>
<td>GlaxoSmithKline</td>
<td>64</td>
</tr>
<tr>
<td>M. Katherine Shear, M.D.</td>
<td>Eli Lilly and Company; Forest Pharmaceuticals, Inc.; Pfizer Inc.</td>
<td>6, 31, 41</td>
</tr>
<tr>
<td>David S. Sheps, M.D.</td>
<td>Pfizer Inc.</td>
<td>53</td>
</tr>
<tr>
<td>Larry J. Siever, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company.</td>
<td>3, 7, 22, 33, 57, 80, 97, 98</td>
</tr>
<tr>
<td>Joel M. Silberberg, M.D.</td>
<td>Abbott Laboratories, Inc.; Pfizer Inc.; Eli Lilly and Company.</td>
<td>26</td>
</tr>
<tr>
<td>Samuel M. Silverman, M.D.</td>
<td>Reckitt Benckiser Pharmaceuticals</td>
<td>73</td>
</tr>
<tr>
<td>Gregory E. Simon, M.D.</td>
<td>Pfizer Inc.; Wyeth Pharmaceuticals; Eli Lilly and Company.</td>
<td>98</td>
</tr>
<tr>
<td>Naomi M. Simon, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Cephalon Inc.; Forest Pharmaceuticals, Inc.; Janssen Pharmaceutica Products, LP; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; UCB Pharmaceuticals; Wyeth Pharmaceuticals</td>
<td>1, 11, 41</td>
</tr>
<tr>
<td>Samuel G. Siris, M.D.</td>
<td>Eli Lilly and Company; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Proctor &amp; Gamble Pharmaceuticals; Aventis Pharmaceuticals</td>
<td>33</td>
</tr>
<tr>
<td>Christine Skotzko, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Wyeth Pharmaceuticals; Forest Pharmaceuticals, Inc.</td>
<td>44</td>
</tr>
<tr>
<td>Claudio N. Soares, M.D.</td>
<td>Pfizer Inc.; Sepracor Inc.; Wyeth Pharmaceuticals; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Elli Lilly and Company; Pfizer Inc.</td>
<td>36, 37, 39</td>
</tr>
<tr>
<td>H. Brent Solvason, M.D.</td>
<td>Forest Pharmaceuticals, Inc.; Eli Lilly and Company; Pfizer Inc.; Cephalon Inc.</td>
<td>37</td>
</tr>
<tr>
<td>Shamshah B. Sonawalla, M.D.</td>
<td>Forest Pharmaceuticals, Inc.</td>
<td>32</td>
</tr>
<tr>
<td>Thomas J. Spencer, M.D.</td>
<td>Abbott Laboratories, Inc.; Alza/McNeil Pharmaceuticals; Boston Life Sciences; Cephalon Inc.; Bristol-Myers Squibb; Celltech Pharmaceuticals, Ltd.; Eisai Inc.; GlaxoSmithKline; Gliatech; Lilly Research Laboratories, a division of Eli Lilly and Company; Ortho McNeil Pharmaceutical Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Shire Ridgewood Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
<td>11, 12, 32, 57</td>
</tr>
<tr>
<td>Margaret G. Spinelli, M.D.</td>
<td>Pfizer Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Murray B. Stein, M.D.</td>
<td>Eli Lilly and Company; Forest Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; GlaxoSmithKline; UCB Pharmaceuticals; Wyeth Pharmaceuticals; Alza/McNeil Pharmaceuticals; Allergan; Alexza Molecular Delivery; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Cephalon Inc.; Janssen Pharmaceutica Products, LP; Hoffmann-La Roche Pharmaceuticals; Johnson and Johnson PRD; Vela Pharmaceuticals</td>
<td>3, 84</td>
</tr>
<tr>
<td>Donna L. Stotland, M.D.</td>
<td>Eli Lilly and Company; Wyeth Pharmaceuticals.</td>
<td>24, 33, 40, 93</td>
</tr>
<tr>
<td>Nada L. Stotland, M.D.</td>
<td>GlaxoSmithKline</td>
<td>8, 15, 49, 83, 85</td>
</tr>
</tbody>
</table>

**DISCLOSURE INDEX**
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zachary N. Stowe, M.D.</td>
<td>GlaxoSmithKline, Pfizer Inc., Wyeth Pharmaceuticals, Eli Lilly and Company</td>
<td>63, 85, 99</td>
</tr>
<tr>
<td>Eric C. Strain, M.D.</td>
<td>Reckitt Benckiser Pharmaceuticals</td>
<td>14</td>
</tr>
<tr>
<td>Joshua Straus, M.D.</td>
<td>Pfizer Inc.</td>
<td>12</td>
</tr>
<tr>
<td>Joel Streim, M.D.</td>
<td>AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Forest Pharmaceuticals, Inc.</td>
<td>1, 64</td>
</tr>
<tr>
<td>Thomas S. Stroup, M.D.</td>
<td>Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>Scott Stuart, M.D.</td>
<td>Pfizer Inc., Wyeth Pharmaceuticals</td>
<td>19, 54, 64</td>
</tr>
<tr>
<td>Donna M. Sudak, M.D.</td>
<td>GlaxoSmithKline</td>
<td>98</td>
</tr>
<tr>
<td>David L. Sultz, M.D.</td>
<td>Pfizer Inc., Forest Pharmaceuticals, Janssen Pharmaceutica Products, LP</td>
<td>4, 13</td>
</tr>
<tr>
<td>Calvin R. Sumner, M.D.</td>
<td>Abbott Laboratories, Inc., Bristol-Myers Squibb, AstraZeneca Pharmaceuticals</td>
<td>34</td>
</tr>
<tr>
<td>Trisha Suppes, M.D.</td>
<td>GlaxoSmithKline, Janssen Pharmaceutica Products, LP, National Institute of</td>
<td>4, 11</td>
</tr>
<tr>
<td>James M. Swanson, M.D.</td>
<td>Celgene, Novartis Pharmaceuticals Corporation, Celltech Pharmaceuticals, Ltd.</td>
<td>48</td>
</tr>
<tr>
<td>Marvin S. Swartz, M.D.</td>
<td>Eli Lilly and Company</td>
<td>28, 81</td>
</tr>
<tr>
<td>Rajiv Tandon, M.D.</td>
<td>AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer Inc., Janssen Pharmaceutica Products, LP</td>
<td>15, 27</td>
</tr>
<tr>
<td>Andre Tapp, M.D.</td>
<td>AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceutica Products</td>
<td>33</td>
</tr>
<tr>
<td>Pierre N. Tariot, M.D.</td>
<td>Novartis Pharmaceuticals Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceutica Products</td>
<td>39, 47, 62, 77</td>
</tr>
<tr>
<td>Humberto Temporini, M.D.</td>
<td>Pfizer Inc., AstraZeneca Pharmaceuticals</td>
<td>26</td>
</tr>
<tr>
<td>Michael E. Thase, M.D.</td>
<td>Bristol-Myers Squibb, Cephalon Inc., Cyberonics, Forest Pharmaceuticals, Janssen Pharmaceutica Products, Pfizer Inc., AstraZeneca Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Organon Pharmaceuticals Inc., Wyeth Pharmaceuticals</td>
<td>26, 70</td>
</tr>
<tr>
<td>Timothy L. Thistlethwaite, M.D.</td>
<td>Eli Lilly and Company, GlaxoSmithKline</td>
<td>19, 44</td>
</tr>
<tr>
<td>Maria L.A. Tiamson, M.D.</td>
<td>Janssen Pharmaceutica Products, LP</td>
<td>88</td>
</tr>
<tr>
<td>Martin G. Tracy, J.D.</td>
<td>Professional Risk Management Services, Inc.</td>
<td></td>
</tr>
<tr>
<td>Robert L. Trestman, M.D.</td>
<td>Abbott Laboratories, Inc.</td>
<td>34</td>
</tr>
<tr>
<td>Paula T. Trzepacz, M.D.</td>
<td>Eli Lilly and Company, GlaxoSmithKline</td>
<td>12, 76</td>
</tr>
<tr>
<td>John W. Tsuang, M.D.</td>
<td>Abbott Laboratories, Inc., Janssen Pharmaceutica Products, LP, Eli Lilly and Company</td>
<td>2</td>
</tr>
<tr>
<td>Phebe M. Tucker, M.D.</td>
<td>GlaxoSmithKline, Bristol-Myers Squibb, Ortho McNeil Pharmaceutical Inc., Pfizer Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Tim Tully, Ph.D.</td>
<td>Helicon Therapeutics, Inc.</td>
<td>81</td>
</tr>
<tr>
<td>Sandra L. Tunis, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>25</td>
</tr>
<tr>
<td>Robert J. Ursano, M.D.</td>
<td>Abbott Laboratories, Inc.</td>
<td>19, 95</td>
</tr>
<tr>
<td>Donna Vanderpool, J.D.</td>
<td>Professional Risk Management Services, Inc.</td>
<td>19</td>
</tr>
<tr>
<td>Kayta L. Vansickle, M.D.</td>
<td>Pfizer Inc., AstraZeneca Pharmaceuticals, Wyeth Pharmaceuticals</td>
<td>64</td>
</tr>
<tr>
<td>Dawn I. Velligan, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company</td>
<td>87</td>
</tr>
<tr>
<td>George I. Viamontes, M.D.</td>
<td>Johnson and Johnson PRD, Pfizer Inc., GlaxoSmithKline, Janssen Pharmaceutica Products, Pfizer Inc.</td>
<td>27, 68</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Adele C. Viguela, M.D.</td>
<td>GlaxoSmithKline4</td>
<td>66, 99</td>
</tr>
<tr>
<td>Albert V. Vogel, M.D.</td>
<td>Joint Commission on Accreditation of Healthcare Organization6</td>
<td>72</td>
</tr>
<tr>
<td>Karen D. Wagner, M.D.</td>
<td>Abbott Laboratories, Inc.1,2,3; Eli Lilly and Company1,3,4; Forest Pharmaceuticals, Inc.1,2,3; GlaxoSmithKline1,2,3; Janssen Pharmaceutical Company1,2,3; Pfizer Inc.1,2,3; Bristol-Myers Squibb1,2,3; National Institute of Mental Health1,2,3; Otsuka America Pharmaceutical1; UCB Pharmaceuticals1; Wyeth Pharmaceuticals1,2,3; Organon Pharmaceuticals Inc.1; Ortho McNeil Pharmaceutical Inc.6</td>
<td>4, 63</td>
</tr>
<tr>
<td>John T. Walkup, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company1,2,3; Pfizer Inc.1,2,3; Abbott Laboratories, Inc.3; Janssen Pharmaceutical Products, LP6</td>
<td>42, 68, 93</td>
</tr>
<tr>
<td>B. Timothy Walsh, M.D.</td>
<td>Eli Lilly and Company3; Ortho McNeil Pharmaceutical Inc.3</td>
<td>59, 71</td>
</tr>
<tr>
<td>G. Scott Waterman, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company1,3; Bristol-Myers Squibb1</td>
<td>33</td>
</tr>
<tr>
<td>Peter J. Weiden, M.D.</td>
<td>Bristol-Myers Squibb1,3,4; Otsuka America Pharmaceutical1; AstraZeneca Pharmaceuticals1,2,3; Pfizer Inc.1,2,3; Janssen Pharmaceutical Products, LP1,2,3</td>
<td>51, 87</td>
</tr>
<tr>
<td>Daniel R. Weinberger, M.D.</td>
<td>Bristol-Myers Squibb1; AstraZeneca Pharmaceuticals1; Janssen Pharmaceutical Products, LP1; Eli Lilly and Company1; Otsuka America Pharmaceutical1; Pfizer Inc.1</td>
<td>11, 52</td>
</tr>
<tr>
<td>Richard D. Weiner, M.D.</td>
<td>Mecta Corp.4</td>
<td>26</td>
</tr>
<tr>
<td>Margaret D. Weiss, M.D.</td>
<td>Johnson and Johnson PRD1; Pharmacia &amp; Upjohn Company, Inc.1; Purdue Pharma L.P.1; Eli Lilly and Company1,2,3; Novartis Pharmaceuticals Corporation1,2,3; Shire Ridgewood Pharmaceuticals1,2,3; GlaxoSmithKline1; Circa Dia1</td>
<td>23, 32</td>
</tr>
<tr>
<td>Steven Wengel, M.D.</td>
<td>Pfizer Inc.4; Forest Pharmaceuticals, Inc.4</td>
<td>64</td>
</tr>
<tr>
<td>Sharon B. Wigal, Ph.D.</td>
<td>Alza/McNeil Pharmaceuticals1,2,3; McNeil Consumer &amp; Specialty Pharmaceuticals1,2,3; Celltech Pharmaceuticals, Ltd.1,2,3; Novartis Pharmaceuticals Corporation1,2,3; Shire Ridgewood Pharmaceuticals1,2,3; Celgene1,2,3; Cephalon Inc.1,2,3; Eli Lilly and Company1,2,3; Janssen Pharmaceutical Products, LP3</td>
<td>62</td>
</tr>
<tr>
<td>Timothy E. Wilens, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company1,2,3,4; Abbott Laboratories, Inc.1,2,3,4; Alza/McNeil Pharmaceuticals1,2,3; Celltech Pharmaceuticals, Ltd.1,2,3; GlaxoSmithKline1,2,3; National Institute on Drug Abuse1,2,3; National Institute of Mental Health1,2,3; NICHB1,2,3; Neurosearch1,2,3; Pfizer Inc.1,2,3,4; Shire Ridgewood Pharmaceuticals1,2,3,4</td>
<td>12, 22, 62, 80</td>
</tr>
<tr>
<td>Jill Williams, M.D.</td>
<td>Pfizer Inc.3</td>
<td>26</td>
</tr>
<tr>
<td>John W. Winkelman, M.D.</td>
<td>Cephalon Inc.1,2,3; GlaxoSmithKline1,2,3; Pfizer Inc.1,2; UCB Pharmaceuticals1; Sanofi-Synthelabo Pharmaceuticals, Inc.1,2; Eli Lilly and Company1; Elan Pharmaceuticals1; King Pharmaceuticals1; Sepacor Inc.1; Boehringer-Ingelheim Pharmaceuticals1; Novartis Pharmaceuticals Corporation1; Schwarz1</td>
<td>9, 26, 37, 53</td>
</tr>
<tr>
<td>Katherine L. Wisner, M.D.</td>
<td>Pfizer Inc.4; GlaxoSmithKline4</td>
<td>2, 23, 30, 41, 58</td>
</tr>
<tr>
<td>Madelaine M. Wohlrach, M.D.</td>
<td>Eli Lilly and Company2</td>
<td>90</td>
</tr>
<tr>
<td>William C. Wood, M.D.</td>
<td>Aventis1; Genomic Health1</td>
<td>49</td>
</tr>
<tr>
<td>Scott W. Woods, M.D.</td>
<td>Bristol-Myers Squibb2; UCB Pharmaceuticals1</td>
<td>30</td>
</tr>
<tr>
<td>Janet Wozniak, M.D.</td>
<td>Janssen Pharmaceutical Products, LP1; Eli Lilly and Company1,2,3,4; Shire Ridgewood Pharmaceuticals1</td>
<td>35</td>
</tr>
<tr>
<td>Jesse H. Wright, M.D.</td>
<td>Mindstreet1,2; Eli Lilly and Company6</td>
<td>8, 26, 50</td>
</tr>
<tr>
<td>Joel Yager, M.D.</td>
<td>Ortho McNeil Pharmaceutical Inc.1,2; Janssen Pharmaceutical Products, LP6</td>
<td>1, 6, 17, 25, 45, 68, 83, 97</td>
</tr>
<tr>
<td>Kimberly A. Yonkers, M.D.</td>
<td>Berlex Laboratories, Inc.1,2; GlaxoSmithKline1,2; Wyeth Pharmaceuticals1; Pfizer Inc.1; National Institute on Drug Abuse1; National Institute of Mental Health1; HRSA1</td>
<td>13, 30</td>
</tr>
<tr>
<td>Mary Zanarini, Ed.D.</td>
<td>Eli Lilly and Company3</td>
<td>7</td>
</tr>
<tr>
<td>Phyllis C. Zee, M.D.</td>
<td>Sanofi-Synthelabo Pharmaceuticals, Inc.4; Takeda Pharmaceuticals1,2,3</td>
<td>9, 53</td>
</tr>
<tr>
<td>Douglas M. Ziedonis, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company1,2,3,4; Janssen Pharmaceutical Products, LP1,2,3; Bristol-Myers Squibb1,2,3,4</td>
<td>26</td>
</tr>
<tr>
<td>Robert B. Zipursky, M.D.</td>
<td>Eli Lilly and Company1,2,3; Novartis Pharmaceuticals Corporation3,4; AstraZeneca Pharmaceuticals1,2,3; Pfizer Inc.5</td>
<td>10, 12</td>
</tr>
<tr>
<td>Sidney Zisook, M.D.</td>
<td>GlaxoSmithKline1,2,3,4; AstraZeneca Pharmaceuticals4; Janssen Pharmaceutical Products, Lp4; Pfizer Inc.4; Eli Lilly and Company4; Wyeth Pharmaceuticals4; Forest Pharmaceuticals, Inc.4</td>
<td>31, 82</td>
</tr>
<tr>
<td>Joseph Zohar, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Eli Lilly and Company1</td>
<td>79</td>
</tr>
</tbody>
</table>

XXXV
DISCLOSURE INDEX

The following presenters indicated neither they nor an immediate member of their family have any significant relationship to disclose.

Ronald D. Abramson, M.D.
A. Reese Abright, M.D.
Curtis N. Adams, Jr., M.D.
Babatunde A. Adetunji, M.D.
Davin A. Agustines, M.D.
Hafiz Al Alawi, M.D.
Jeffrey Aku, M.D.
Mayada Akil, M.D.
Antti Alaristinen, M.D.
Renato D. Alarcon, M.D.
David B. Albert, Ph.D.
Ian E. Alger, M.D.
David M. Allen, M.D.
Mona I. Al-Sawaf, M.D.
Steven I. Altsheuler, M.D.
Margaret Alterman, M.D.
Carol L. Alter, M.D.
Lori L. Altshuler, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Antoinette Ambrosino-Wyeyniks, M.D.
Abdel Amin, M.D.
Hany Ammar, M.D.
Shahrad R. Amiri, M.D.
AbdelF. Amin, M.D.
Antoinette Ambrosino-Wyeyniks, M.D.
Lori L. Altshuler, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Antoinette Ambrosino-Wyeyniks, M.D.
Lori L. Altshuler, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Antoinette Ambrosino-Wyeyniks, M.D.
Lori L. Altshuler, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Antoinette Ambrosino-Wyeyniks, M.D.
Lori L. Altshuler, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Antoinette Ambrosino-Wyeyniks, M.D.
Lori L. Altshuler, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Antoinette Ambrosino-Wyeyniks, M.D.
Lori L. Altshuler, M.D.
DISCLOSURE INDEX
This page intentionally left blank
SATURDAY, MAY 21, 2005

158TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 1-3

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12 noon
Room B301, Level 3, Georgia World Congress Center

DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY

Director: Russell F. Lim, M.D.
Faculty: Frank N. Brown, M.D., David C. Henderson, M.D., Renato D. Alarcon, M.D., Francis G. Lu, M.D., J. Charles Ndlela, M.D.

COURSE 2 8:00 a.m.-12 noon
Room B308, Level 3, Georgia World Congress Center

THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.
Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

COURSE 3 8:00 a.m.-12 noon
Room B314, Level 3, Georgia World Congress Center

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

9:00 a.m. Sessions

COURSES 4-7

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 4 9:00 a.m.-4:00 p.m.
Room B304, Level 3, Georgia World Congress Center

ESSENTIALS OF GERIATRIC PSYCHIATRY

Director: Joel Streim, M.D.

COURSE 5 9:00 a.m.-4:00 p.m.
Room B310, Level 3, Georgia World Congress Center

TRANSPERSONAL PSYCHIATRY: CLINICAL APPLICATIONS

Co-Directors: John F. Hiatt, M.D., William W. Foote, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Room B311, Level 3, Georgia World Congress Center

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.
Faculty: Michael Devin, M.D., Katherine A. Halmi, M.D., James E. Mitchell, M.D., Joel Yager, M.D.

COURSE 7 9:00 a.m.-4:00 p.m.
Room B316, Level 3, Georgia World Congress Center

UPDATES IN NEUROPSYCHIATRY: DELIRIUM, TRAUMATIC BRAIN INJURY, AND POST-STROKE AND POST-MI DEPRESSION

Director: Jose R. Maldonado, M.D.

12:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-3

INDUSTRY-SUPPORTED SYMPOSIUM 1
12:30 p.m.-3:30 p.m.
Grand Ballroom, Second Floor, Hilton Atlanta

ANXIETY: DIVERSE POPULATIONS AND PRESENTATIONS, UNIQUE INDIVIDUALS AND TREATMENTS
Supported by UCB Pharma, Inc.

Chp.: Naomi M. Simon, M.D.

A Untangling the Role of Gender: The Course and Treatment of Anxiety Disorders in Women
Naomi M. Simon, M.D.

B Evaluation and Treatment of Anxiety in Patients With Comorbid Mental Illness
Peter P. Roy-Byrne, M.D.

C Improving the Treatment of Anxiety, One Individual at a Time
Jerrold F. Rosenbaum, M.D.  
(Continued on next page)
D Bridging Cultures and Languages: Modifying Therapy for Refugees With PTSD
   Michael W. Otto, Ph.D.

E Anxiety and Substance Abuse: Complexities and Solutions
   Kathleen T. Brady, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2
12:30 p.m.-3:30 p.m.
Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

THE IMPACT OF DEPRESSION AND ANXIETY ON WELL-BEING ACROSS THE LIFE CYCLE
Supported by Pfizer Inc.

Chp.: Steven P. Roose, M.D.

A Comorbid Depression and Anxiety: When to Start and Continue With Psychotherapy and Pharmacotherapy
   Martin B. Keller, M.D.

B Comorbid Depression and Anxiety in Youth With Asthma
   Marcia J. Slattery, M.D.

C Depression and Anxiety in Elderly Patients With Dementia
   Davangere P. Devanand, M.D., Gregory H. Pelton, M.D.

D Depression and Anxiety as They Relate to Cardiovascular Illness
   K. Ranga R. Krishnan, M.D.

E Impact of Depression and Anxiety in Women of Reproductive Age
   Ruti M. Nonacs, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3
12:30 p.m.-3:30 p.m.
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

MANAGEMENT OF DISRUPTIVE BEHAVIORAL AND PERVERSIVE DEVELOPMENTAL DISORDERS
Supported by Janssen Pharmaceuticals and Research Foundation

Chp.: Christopher J. McDougle, M.D.

A The Unmet Treatment Needs of Youth With Severe Behavioral Problems
   David J. Posey, M.D., Kimberly A. Stigler, M.D., Christopher J. McDougle, M.D.

B Pharmacological Management of Aggression in Disruptive Behavioral Disorders
   Robert L. Findling, M.D.

C Pharmacotherapy of Behavioral Symptoms in Pervasive Developmental Disorders
   Christopher J. McDougle, M.D., David J. Posey, M.D., Kimberly A. Stigler, M.D.

D Nonpharmacologic Approaches to the Management of Behavioral Symptoms
   Elizabeth Pappadopulos, Ph.D.

1:00 p.m. Sessions

COURSES 8-12

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 8 1:00 p.m.-5:00 p.m.
Room B301, Level 3, Georgia World Congress Center

INFANTICIDE: A DIALOGUE BETWEEN ATTORNEY AND PSYCHIATRIST

Director: Margaret G. Spinelli, M.D.
Faculty: Katherine L. Wisner, M.D., Deborah Denno, J.D.

COURSE 9 1:00 p.m.-5:00 p.m.
Room B305, Level 3, Georgia World Congress Center

PSYCHIATRIC INTERVENTIONS IN DISASTERS AND PUBLIC HEALTH EMERGENCIES: THEORY TO PRACTICE
APA Committee on Psychiatric Dimensions of Disasters

Director: Anthony T. Ng, M.D.
Faculty: Molly J. Hall, M.D., Judith A. Cohen, M.D., Phebe M. Tucker, M.D.

COURSE 10 1:00 p.m.-5:00 p.m.
Room B306, Level 3, Georgia World Congress Center

STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT

Director: John W. Tsuang, M.D.
Faculty: Timothy W. Fong, M.D., Karen A. Miotto, M.D.

COURSE 11 1:00 p.m.-5:00 p.m.
Room B308, Level 3, Georgia World Congress Center

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.
COURSE 12 1:00 p.m.-5:00 p.m.
Room B315, Level 3, Georgia World Congress Center

DOING RESEARCH ON A SHOESTRING BUDGET

Director: Manish J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Edward K. Silberman, M.D.

6:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 4-10

INDUSTRY-SUPPORTED SYMPOSIUM 4 6:00 p.m.-9:00 p.m.
Grand Ballroom, Second Floor, Hilton Atlanta

PSYCHOSOMATIC ILLNESS: A 21ST-CENTURY PERSPECTIVE
Supported by GlaxoSmithKline

Chp.: Murray B. Stein, M.D.
Co-Chp.: Prakash S. Masand, M.D.

A Impact of Anxiety and Mood Disorders on Physical Disease: The Worried Not-So-Well
Murray B. Stein, M.D.

B Facilitating Treatment for Anxious Patients With Comorbid Medical Illness
Peter P. Roy-Byrne, M.D.

C Chronic Pain Syndromes: A Psychiatric Perspective
Prakash S. Masand, M.D.

D Interface of Women's Mental and Reproductive Health
Hadine Joffe, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5 6:00 p.m.-9:00 p.m.
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

THE DEVELOPMENTAL TRAJECTORY OF IMPULSIVITY
Supported by Ortho-McNeil Pharmaceuticals

Chp.: Eric Hollander, M.D.

A Comorbidities of Impulse Control Disorders Across the Lifespan
Eric Hollander, M.D.

B The Relationship of Trauma and Impulsivity in Posttraumatic Stress Disorder
Lori L. Davis, M.D.

C Adolescent Substance Abuse and Impulse Dyscontrol
Deborah Deas, M.D.

D Bipolar Disorder From Adolescence to Adulthood
Melissa P. DelBello, M.D.

E Potential Treatment for Impulsivity: Drive Versus Brake
Larry J. Siever, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6 6:00 p.m.-9:00 p.m.
Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

INTEGRATING NEUROBIOLOGY AND PSYCHOPATHOLOGY INTO EVIDENCE-BASED TREATMENT OF SOCIAL ANXIETY DISORDER
Supported by Forest Laboratories, Inc.

Chp.: Michael R. Liebowitz, M.D.

A Social Anxiety Disorder: Epidemiology, Diagnosis, and Comorbidities
Michael R. Liebowitz, M.D.

B Recent Advances in the Cognitive Neurosciences of Social Behavior
Philip T. Ninan, M.D.

C Neurobiological Mechanisms of Social Anxiety Disorder
Franklin R. Schneier, M.D.

D Evidence-Based Pharmacotherapy of Social Anxiety Disorder
Carlos Blanco-Jerez, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7 6:00 p.m.-9:00 p.m.
Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

BIPOLAR DISORDER: PSYCHIATRIC AND MEDICAL IMPLICATIONS FOR OPTIMAL PATIENT MANAGEMENT
Supported by Pfizer Inc.

Chp.: Paul E. Keck, Jr., M.D.

A Psychiatric Comorbidity in Bipolar Disorder
Susan L. McElroy, M.D.

B Treatment and Monitoring Guidelines for the Patient With Bipolar Disorder
Trisha Suppes, M.D.

(Contd next page)
C Bipolar Disorder Complicated by Medical Comorbidity
Roy H. Perlis, M.D.

D Management of the Complicated Bipolar Patient
Paul E. Keck, Jr., M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8
6:00 p.m.-9:00 p.m.
International Ballroom, North Tower, Ballroom Level, Omni Hotel

EXPANDING USES OF ATYPICAL ANTIPSYCHOTICS: ADDRESSING REAL-WORLD CHALLENGES
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Karen D. Wagner, M.D.

A Differential Pharmacology of Antipsychotic Agents: Clinical Implications
Jeffrey A. Lieberman, M.D.

B Use of Atypical Antipsychotic Medications in Children
Karen D. Wagner, M.D.

C Comparative Effectiveness of Antipsychotic Medications for Optimizing the Management of Psychosis in Geriatric Patients
David L. Sultzer, M.D.

D Managing Psychosis in the Acute Care Setting
John E. Kraus, Jr., M.D.

E Improving Neurocognition With Atypical Antipsychotics
Richard S.E. Keefe, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9
6:00 p.m.-9:00 p.m.
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

ACHIEVING REMISSION IN DEPRESSION: IS THE BAR SET TOO HIGH OR TOO LOW?
Supported by Cephalon, Inc.

Chp.: Jonathan E. Alpert, M.D.

A Remission in Depression: Definition and Treatment Approaches
Joshua A. Israel, M.D.

B Augmentation and Combination Strategies in Partial and Nonresponders to Antidepressants
Charles DeBattista, M.D.

C The Role of Psychotherapy to Enhance the Efficacy of Antidepressants
Timothy J. Petersen, Ph.D.

D Pharmacological Approaches to the Treatment of Residual Symptoms
Maurizio Fava, M.D.

E Neurotherapeutics in Resistant Depression
Linda L. Carpenter, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10
6:00 p.m.-9:00 p.m.
Peachtree Ballroom, Level 8, Westin Peachtree Plaza

DEALING WITH DEPRESSION: THE ADDDED BURDEN TO MEDICAL PATIENTS
Supported by Eli Lilly and Company

Chp.: Madhukar H. Trivedi, M.D.

A General Medical Comorbidities Associated With Depression
Wayne J. Katon, M.D.

B The Impact of Psychosomatic Symptoms on Depression and Its Treatment
David A. Fishbain, M.D.

C Strategies and Tactics of Treatment for Complicated Depression: An Algorithmic Approach
Madhukar H. Trivedi, M.D.

D The Role of Psychotherapy in the Treatment of Complicated Depression
Ellen Frank, Ph.D.

E Maintaining Remission in Depression
James M. Martinez, M.D.
SUNDAY, MAY 22, 2005

158TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 13-19

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 13 8:00 a.m.-12 noon
Room B301, Level 3, Georgia World Congress Center
SHORT-TERM PSYCHODYNAMIC SUPPORTIVE PSYCHOTHERAPY TREATMENT OF DEPRESSION
Co-Directors: Simone Kool, M.D., Jack J. Dekker, Ph.D.
Faculty: Robert A. Schoevers, M.D., Marielle Hendriksen, M.A., Gerda van Aalst, M.D., Henricus L. Van, M.D.

COURSE 14 8:00 a.m.-12 noon
Room B306, Level 3, Georgia World Congress Center
USING BOUNDARY CROSSINGS AS CREATIVE THERAPY INSTEAD OF SLIPPERY SLOPES
Director: Gail E. Robinson, M.D.
Faculty: Gary R. Schoener, Psy.D., Howard E. Book, M.D., Linda M. Jorgenson, J.D.

COURSE 15 8:00 a.m.-12 noon
Room B308, Level 3, Georgia World Congress Center
RISK ASSESSMENT FOR VIOLENCE
Director: Phillip J. Resnick, M.D.

COURSE 16 8:00 a.m.-12 noon
Room B310, Level 3, Georgia World Congress Center
BEHAVIORAL NEUROANATOMY: AN INTRODUCTION
Director: Nashaat N. Boutros, M.D.
Faculty: Edward C. Lauterbach, M.D., David L. Clark, Ph.D.

COURSE 17 8:00 a.m.-12 noon
Room B311, Level 3, Georgia World Congress Center
INTERPERSONAL PSYCHOTHERAPY
Director: John C. Markowitz, M.D.

COURSE 18 8:00 a.m.-12 noon
Room B314, Level 3, Georgia World Congress Center
ADD IN ADULTS
Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 19 8:00 a.m.-12 noon
Room B315, Level 3, Georgia World Congress Center
PERSONALITY DISORDERS: COMBINING RELATIONAL THERAPY AND PSYCHOPHARMACOLOGY
Director: Roy O. Resnikoff, M.D.

INDUSTRY-SUPPORTED SYMPOSIA 11-17

INDUSTRY-SUPPORTED SYMPOSIUM 11
8:00 a.m.-11:00 a.m.
Grand Ballroom, Second Floor, Hilton Atlanta
SYSTEMATIC TREATMENT OF BIPOLAR DISORDER: BRINGING EVIDENCE INTO PRACTICE
Supported by GlaxoSmithKline
Chp.: Gary S. Sachs, M.D.
A Approach to Treatment: Integration of Measurement and Management
Andrew A. Nierenberg, M.D.
B View of the Illness: Course and Comorbidity Findings
Claudia F. Baldassano, M.D.
C What Is the Best Treatment for Manic and Mixed Episodes?
Gary S. Sachs, M.D.
D What Is the Best Treatment for Bipolar Depression?
Michael J. Ostacher, M.D.
E What Is the Best Treatment for Rapid Cycling?
Christopher D. Schneck, M.D.
F Managing Comorbidity
Michael J. Ostacher, M.D.
G Psychosocial Interventions
David J. Miklowitz, Ph.D.
H Multiphase Suicide Prevention Strategies in Bipolar Disorder
Ellen B. Dennehy, Ph.D.
INDUSTRY-SUPPORTED SYMPOSIUM 12
8:00 a.m.-11:00 a.m.
Imperial Ballroom, Convention Level, Marriott Marquis
Atlanta

TOO LITTLE, TOO MUCH: WHAT IS DISORDERED EATING?
Supported by Ortho-McNeil Pharmaceuticals

Chp.: Joel Yager, M.D.

A Medical Morbidity of Eating Disorders
Laurel Mayer, M.D.

B Genetic Epidemiology of Eating Disorders
James I. Hudson, M.D.

C Psychiatric Comorbidity of Eating Disorders:
Understanding the Contribution of Impulsivity
Susan L. McElroy, M.D.

D Psychotherapy for Eating Disorders: When Yes, When No
Cynthia M. Bulik, Ph.D.

E Pharmacotherapy Trends in the Eating Disorder Spectrum
Scott J. Crow, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
8:00 a.m.-11:00 a.m.
Marquis Ballrooms I & II, Convention Level, Marriott
Marquis Atlanta

SPOTLIGHT ON THE UNIQUENESS OF DEPRESSION AND ANXIETY IN THE ELDERLY
Supported by Forest Laboratories, Inc.

Chp.: M. Katherine Shear, M.D.

A Late-Onset Depression: A Distinctive Disease Associated With the Elderly
Steven P. Roose, M.D.

B Recognizing Depressive Disorders Comorbid With Medical Illnesses in the Elderly
Eric J. Lenze, M.D.

C Bereavement-Related Depression and Anxiety
M. Katherine Shear, M.D.

D Antidepressants and Anxiolytics in the Elderly: A Focus on Safety
George S. Alexopoulos, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14
8:00 a.m.-11:00 a.m.
Marquis Ballrooms III & IV, Convention Level, Marriott
Marquis Atlanta

BRAIN STIMULATION: NEW TREATMENTS FOR MOOD DISORDERS
Supported by Cyberonics, Inc.

Chp.: A. John Rush, M.D.

A Optimization of the Therapeutic Elements of ECT
Harold A. Sackeim, Ph.D.

B Current Status of Repeated Transcranial Magnetic Stimulation
Mark S. George, M.D.

C Current Status of Magnetic Stimulation Therapy (MST)
Sarah H. Lisanby, M.D.

D Current Status of Vagus Nerve Stimulation (VNS)
Lauren B. Marangell, M.D.

E Current Status of Deep Brain Stimulation
Benjamin D. Greenberg, M.D., Gerhard Friesel, M.D.,
David Marlowe, M.D., Ali Rezaei, M.D., Scott L. Rauch, M.D., Lawrence H. Price, M.D., Steven A.
Rasmussen, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15
8:00 a.m.-11:00 a.m.
International Ballroom, North Tower, Ballroom Level,
Omni Hotel

PANIC DISORDER: CURRENT CONCEPTS AND FUTURE DIRECTIONS
Supported by Wyeth Pharmaceuticals

Chp.: Mark H. Pollack, M.D.

A Window Into the Brain: Imaging Panic Disorder and the Neurocircuitry of Fear
Justine M. Kent, M.D.

B Genetics of Panic Disorder: What Have We Learned?
Jordan W. Smoller, M.D.

C Cross-Cultural Aspects of Panic and Other Anxiety Disorders
Michael R. Liebowitz, M.D., Randall D. Marshall, M.D.,
Roberto Lewis-Fernandez, M.D., Carlos Blanco-Jerez, M.D.

D Panic Symptoms and the Interface of Mind and Body
Karleyton C. Evans, M.D.

E Treating Panic Disorder: Acute Therapy and Beyond
Mark H. Pollack, M.D.
SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 16
8:00 a.m.-11:00 a.m.
Grand Ballroom, North Tower, Grand Ballroom Level,
Omni Hotel

ANTIPSYCHOTIC DRUGS, MOOD STABILIZERS,
AND THE METABOLIC SYNDROME
Supported by jarssen Pharmaceutica Products

Chp.: Herbert Y. Meltzer, M.D.
Co-Chp.: Donald C. Goff, M.D.

A Effects of Atypical Antipsychotics on Weight,
Glucose Metabolism, and Diabetes Mellitus
Daniel W. Haupt, M.D.

B The Effect of Antipsychotic Drugs on Lipids and
Other Elements of the Metabolic Syndrome
Herbert Y. Meltzer, M.D., John H. Gilliam, M.D., Tianlai
Tang, M.D.

C Insulin Resistance, Dyslipidemia, and Cardiovascular
Disease
Gerald Reaven, M.D.

D Metabolic Sequelae of Atypical Antipsychotics:
Obesity and Type II Diabetes
Marilyn Ader, Ph.D.

E A Clinician's Guide to Managing Cardiac Risk Factors
Donald C. Goff, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17
8:00 a.m.-11:00 a.m.
Peachtree Ballroom, Level 8, Westin Peachtree Plaza

BORDERLINE PERSONALITY DISORDER:
PATHOPHYSIOLOGY, TREATMENT, AND COURSE
Supported by Eli Lilly and Company

Chp.: Mary Zanarini, Ed.D.

A Ten-Year Course of Borderline Personality Disorder
Mary Zanarini, Ed.D.

B Neurobiology of Borderline Personality Disorder: An
Update
Christian Schmahl, M.D.

C Borderline Personality Disorder: Pharmacotherapy
Steps Up
S. Charles Schulz, M.D., A. Adityarjee, M.D.,
Eric Brown, M.D.

D Neural Circuitry Dysfunction in Borderline Personality
Disorder
Antonia S. New, M.D., Marianne Goodman, M.D., Monte
Buchsbaum, M.D., Erin Hazlett, Ph.D., Harold W.
Koenigsberg, M.D., Janine Flory, Ph.D., Larry J.
Siever, M.D.

9:00 a.m. Sessions

COURSES 20-25

Course descriptions are available in the CME
Course Brochure included in your registration
packet. Admission by ticket only.

COURSE 20 9:00 a.m.-4:00 p.m.
Room B302, Level 3, Georgia World Congress Center

LIMBIC BRAIN: ANATOMIC THEORIES OF
EMOTIONAL DISTURBANCE: THE BASICS

Co-Directors: Andrew L. Lautin, M.D., Jack Davis, M.S.
Faculty: Adam Wolkin, M.D., Hamada Hamid, M.D.

COURSE 21 9:00 a.m.-4:00 p.m.
Room B303, Level 3, Georgia World Congress Center

KUNDALINI YOGA MEDITATION TECHNIQUES
FOR PSYCHIATRIC DISORDERS

Director: David Shannahoff-Khalsa, B.A.

COURSE 22 9:00 a.m.-4:00 p.m.
Room B304, Level 3, Georgia World Congress Center

REBUILDING SHATTERED LIVES: TREATING
COMPLEX POST-TRAUMATIC STRESS DISORDER

Director: James A. Chu, M.D.

COURSE 23 9:00 a.m.-4:00 p.m.
Room B305, Level 3, Georgia World Congress Center

PSYCHOTHERAPY OF BORDERLINE
PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E.
Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

COURSE 24 9:00 a.m.-4:00 p.m.
Room B309, Level 3, Georgia World Congress Center

UNDERSTANDING THE PERSON BEHIND THE
ILLNESS: AN APPROACH TO PSYCHODYNAMIC
FORMULATION

Director: William H. Campbell, M.D.
12:30 p.m. Session

BUSINESS MEETING
(Voting Members Only*)

12:30 p.m.–1:30 p.m.
Thomas Murphy Ballroom 1–3, Level 5, Georgia World Congress Center

CALL TO ORDER
Michelle B. Riba, M.D., President

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS
Liza H. Gold, M.D., Chairperson, Committee of Tellers

REPORTS TO THE MEMBERSHIP
Secretary: Nada L. Storland, M.D.
Treasurer: Carolyn B. Robinowitz, M.D.
Speaker: Assembly: James E. Nininger, M.D.
Speaker-Elect: Assembly Joevche E. V. Rubin, M.D.
Chairperson, By-Laws Committee: Derek Puddester, M.D.
Chairperson, Election Committee: Yvonne B. Ferguson, M.D.
Chairperson, Membership Committee: Mary K. Marrocco, M.D.
Medical Director: James H. Seuliy, Jr., M.D.

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions

COURSES 26-32
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.
1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 18-23

INDUSTRY-SUPPORTED SYMPOSIUM 18
1:30 p.m.-4:30 p.m.
Grand Ballroom, Second Floor, Hilton Atlanta

JOINING NIGHT AND DAY: INSOMNIA AND THE SLEEP/WAKE CYCLE
Supported by Takeda Pharmaceuticals North America, Inc.

Chp.: Karl Doghramji, M.D.

A Insomnia: Prevalence, Impact, and Current Approaches to Evaluation and Management
Karl Doghramji, M.D.

B Medical Causes of Insomnia
Gerald A. Maguire, M.D.

C The Sleep/Wake Cycle and Circadian Phase in Psychiatric Disorders
Alfred J. Lewy, M.D.

D Current and Emerging Treatments for Insomnia
Milton K. Erman, M.D.

E Special Concerns in Aging
Sonia Ancoli-Israel, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 19
1:30 p.m.-4:30 p.m.
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

CLINICAL INTERVENTIONS FOR THE TREATMENT OF INSOMNIA ASSOCIATED WITH PSYCHIATRIC AND COMORBID MEDICAL ILLNESSES
Supported by Novartis Pharmaceuticals, Inc.

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Ned H. Kalin, M.D.

A Clinical Approaches to Insomnia
David J. Kupfer, M.D.

B Interrelationship of Insomnia to Medical Illnesses and Neurological Disorders
Phyllis C. Zee, M.D.

C Effect of Chronic Pain Syndromes on Sleep
Raymond R. Gaeta, M.D.

D Gender-Specific Sleep Considerations in Women
Hadin Joffe, M.D.

E New Pharmacologic Approaches for the Treatment of Insomnia
John W. Winkelmann, M.D.

Discussant: Ned F. Kalin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 20
1:30 p.m.-4:30 p.m.
Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

ALZHEIMER'S DISEASE PATHWAYS TO PRACTICE: ASSESSING DIAGNOSIS AND OUTCOME MEASURES
Supported by Forest Laboratories, Inc.

Chp.: George T. Grossberg, M.D.

A The Interplay of Neurotransmitters in Alzheimer's Disease
Paul T. Francis, Ph.D.

B Formulating a Clinical Practice Care Plan for the Diagnosis and Assessment of Alzheimer's Disease
Warachal E. Faison, M.D.

C Utilizing Advanced Imaging and Surrogate Markers Across the Spectrum of Alzheimer's Disease
Mark A. Mintun, M.D.

D Rationalizing Therapeutic Approaches in Alzheimer's Disease
George T. Grossberg, M.D.

E Behavioral Neuropsychiatric Outcomes in Alzheimer's Disease
Jeffrey L. Cummings, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21
1:30 p.m.-4:30 p.m.
International Ballroom, North Tower, Ballroom Level, Omni Hotel

ANXIETY DISORDERS: UNDERSTANDING THE INTERCONNECTION BETWEEN EMOTIONAL AND PHYSICAL SYMPTOMS
Supported by Wyeth Pharmaceuticals

Chp.: Mark H. Rapaport, M.D.

A Worried Sick: How Patients Experience GAD
R. Bruce Lydiard, M.D.

B Addressing the Full Spectrum of Symptoms of Social Anxiety Disorder
Nathalie Mauclin, M.D.

C Pharmacotherapy and Psychotherapy in the Treatment of PTSD
Barbara Rothbaum, Ph.D.

D Panic Disorder: The Interconnection Between Emotional and Physical Symptoms
Mark H. Rapaport, M.D.
2:30 p.m. Session

LECTURE 1

2:30 p.m.-4:00 p.m.
Rooms B312/313, Level 3
Georgia World Congress Center

AAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE

Robert I. Simon, M.D.

Suicide Risk Assessment: Evidence-Based Psychiatry

Chp.: Michael A. Norko, M.D.

Robert I. Simon, M.D., is Clinical Professor of Psychiatry and
Director of the Program in Psychiatry and Law at Georgetown
University School of Medicine in Washington, D.C. He is also
Adjunct Professor of Psychiatry at the F. Edward Hébert School
of Medicine of the Uniformed Services University of the Health
Sciences in Bethesda, Maryland, and Chairman of the
Department of Psychiatry at Suburban Hospital in Bethesda. In
addition, he maintains a private practice in Potomac, Maryland.
Dr. Simon is President-Elect of the American Academy of
Psychiatry and the Law. He has received several awards for his
contributions to forensic psychiatry, including the Isaac Ray
Award (2004), Golden Apple Award (1995), Seymour Pollack
Award (1994), and the Manfred S. Guttmacher Award (1993).
Dr. Simon is the author and editor of more than 20 books and
numerous book chapters and articles in the fields of clinical and
forensic psychiatry. His most recent publications include The
American Psychiatric Publishing Textbook of Forensic Psychiatry
and Assessing and Managing Suicide Risk: Guidelines for Clinically Based
Risk Management. A graduate of Tufts University School of
Medicine, Dr. Simon completed his residency in psychiatry at
Jackson Memorial Hospital and the University of Miami, School
of Medicine in Miami, Florida.

5:00 p.m. Session

OFFICIAL OPENING

5:00 p.m.-6:30 p.m.
Sydney B. Marcus Auditorium, Level 4, Georgia
World Congress Center

CALL TO ORDER
Michelle B. Riba, M.D., President

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF CHAIRPERSON OF
THE SCIENTIFIC PROGRAM COMMITTEE
Manan I. Butterfield, M.D.

Chairperson, Annual Meeting Scientific Program Committee
INTRODUCTION OF VISITING DIGNITARIES

PRESIDENTIAL ADDRESS
Michelle B. Riba, M.D.
To be introduced by John F. Greden, M.D.

RESPONSE OF THE PRESIDENT-ELECT
Steven S. Sharfstein, M.D.
To be introduced by Lawrence Hartmann, M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 24-30

INDUSTRY-SUPPORTED SYMPOSIUM 24
7:00 p.m.-10:00 p.m.
Grand Ballroom, Second Floor, Hilton Atlanta

EXPLORING COGNITIVE FUNCTION: FROM BRAIN TO BEDSIDE
Supported by Cephalon, Inc.
Chp.: Philip T. Ninan, M.D.

A The Neurology of Cognition: A Glimpse Into the Brain
Daniel R. Weinberger, M.D.

B Remission in Major Depression: The Vitality of Cognition
Philip T. Ninan, M.D.

C Can Clinicians Impact Cognition in Schizophrenia?
Rona Hu, M.D.

D The Complexities of Cognitive Dysfunction in Late-Life Depression
George S. Alexopoulos, M.D.

E The Evidence and Relevance of Cognitive Dysfunction in ADHD
Scott Kollins, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25
7:00 p.m.-10:00 p.m.
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

BIPOLAR DISORDER: TREATING THROUGH THE ENTIRE SPECTRUM
Supported by AstraZeneca Pharmaceuticals
Chp.: Trisha Suppes, M.D.

A The Neuroscience of Bipolar Disorder Across the Age Spectrum
Kuki D. Chang, M.D.

B Issues in Treating Bipolar Depression
Joseph R. Calabrese, M.D.

C The Acute Setting: Achieving Stabilization
Trisha Suppes, M.D.

D From Acute to Maintenance Therapy
Gary S. Sachs, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26
7:00 p.m.-10:00 p.m.
Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

UNTANGLING DEPRESSION AND ANXIETY: A CHALLENGE FOR SCIENTISTS AND CLINICIANS
Supported by Forest Laboratories, Inc.
Chp.: Martin B. Keller, M.D.

A Genetic Models of Depression and Anxiety
Rene Hen, Ph.D.

B Serotonergic Targets as Mediators of Anxiety
Alexander Neumeister, M.D.

C Neuroanatomical Pathways Underlying Major Depression and Anxiety Disorders
John H. Krystal, M.D.

D Presentation and Diagnosis of Comorbid MDD and Anxiety Disorders
Naomi M. Simon, M.D.

E Making Treatment Decisions for Comorbid MDD and Anxiety Disorders
Martin B. Keller, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27
7:00 p.m.-10:00 p.m.
Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

ADHD THROUGH THE LIFECYCLE: NEW FINDINGS AND CLINICAL IMPLICATIONS
Supported by Shire US, Inc.
Chp.: Thomas J. Spencer, M.D.

A Adult ADHD Diagnostic and Self-Report Symptom Scales: Assessment Methodology for Diagnosing and Monitoring Treatment of Adults With ADHD
Craig B. Surman, M.D.

(Continued on next page)
B Functional Impairments in Adult ADHD: Implications for Diagnosis  
Stephen V. Faraone, Ph.D., Joseph Biederman, M.D.  

C New Research on ADHD and Substance Use Disorders  
Timothy E. Wilens, M.D.  

D Long-Term Tolerability and Effectiveness of Once-Daily Mixed Amphetamine Salts in Children With ADHD  
Thomas J. Spencer, M.D.  

E Long-Term Outcome of Adults Treated With Extended Release Mixed Amphetamine Salts  
Joseph Biederman, M.D., Thomas J. Spencer, M.D.  

INDUSTRY-SUPPORTED SYMPOSIUM 28  
7:00 p.m.-10:00 p.m.  
International Ballroom, North Tower, Ballroom Level, Omni Hotel  

EMERGING BEST PRACTICES IN THE MANAGEMENT OF BEHAVIORAL EMERGENCIES  
Supported by Bristol-Myers Squibb Company and Otsuka Pharmaceutical, Inc.  
Chp.: Peter F. Buckley, M.D.  

A Is Agitation Inevitably a Precursor to Aggression?  
Rosalind A. Spells, M.D.  

B Assessment of the Acutely Agitated Patient With Psychosis  
Joseph P. McEvoy, M.D.  

C Considering Consumer Choice During the Management of Behavioral Emergencies  
Michael H. Allen, M.D.  

D Do Atypical Antipsychotics Work Fast Enough in Behavioral Emergencies?  
Robert B. Zasypsky, M.D.  

E Acute Stabilization With Atypical Antipsychotics: New Therapeutic Options  
Peter F. Buckley, M.D.  

INDUSTRY-SUPPORTED SYMPOSIUM 29  
7:00 p.m.-10:00 p.m.  
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel  

BEYOND NEUROCHEMISTRY: THE IMPLICATIONS OF NEUROCIRCUITRY FOR UNDERSTANDING AND MANAGING PSYCHIATRIC DISORDERS  
Supported by Eli Lilly and Company  
Chp.: Paula T. Trzepacz, M.D.  
Co-Chp.: Stuart C. Yudofsky, M.D.  

A Neuroanatomy of Behavior 101  
Paula T. Trzepacz, M.D.  

B Neurocircuitry of Schizophrenia  
David A. Lewis, M.D.  

C Neurobiological Substrates of ADHD  
George Bush, M.D.  

D In Search of Depression Circuits  
Helen S. Mayberg, M.D.  

E Neural Pathways and Behavior in Anorexia Nervosa  
Walter H. Kaye, M.D.  

INDUSTRY-SUPPORTED SYMPOSIUM 30  
7:00 p.m.-10:00 p.m.  
Peachtree Ballroom, Level 8, Westin Peachtree Plaza  

FROM MOLECULAR INSIGHT TO CLINICAL OUTCOMES: RECENT ADVANCES IN SCHIZOPHRENIA TREATMENT  
Supported by Pfizer Inc.  
Chp.: Jeffrey A. Lieberman, M.D.  

A How Antipsychotics Work: From Receptors to Reality  
Shitij Kapur, M.D.  

B Clinical Effectiveness of Atypical Antipsychotic Therapy  
Thomas S. Stroup, M.D.  

C Cognitive Effectiveness of Atypical Antipsychotic Therapy  
Philip D. Harvey, Ph.D.  

D Enhancing Clinical Care in Schizophrenia: Primary Health Care Needs  
Gail L. Daumit, M.D.  

E Translating Scientific Research Into Clinical Practice  
Jeffrey A. Lieberman, M.D.
MONDAY, MAY 23, 2005

158TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 31-33

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 1
7:00 a.m.-8:30 a.m.
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

AGITATION AND PSYCHOSIS IN ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE
Supported by AstraZeneca Pharmaceuticals

Chp.: Jeffrey L. Cummings, M.D.

A Diagnosis and Assessment of Parkinson’s Disease and Alzheimer’s Disease
Daniel Weintraub, M.D.

B Imaging and Neurobiological Underpinnings: Psychosis and Agitation
David L. Sultzer, M.D.

C Treatment of Psychosis in Parkinson’s Disease
Jeffrey L. Cummings, M.D., Daniel Weintraub, M.D., Jeanne Jackson-Siegel, M.D., Pierre N. Tarlow, M.D., David L. Sultzer, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 1
7:00 a.m.-8:30 a.m.
International Ballroom, North Tower, Ballroom Level, Omni Hotel

MANAGING THE SPECTRUM OF BIPOLAR DISORDER: MINIMIZING THE BURDEN OF DISEASE
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Practical Approaches to the Diagnosis of Bipolar Disorders
Claudia F. Baldassano, M.D.

B Optimizing Pharmacotherapy in the Treatment of Acute Mania
Terence A. Ketter, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom, North, Grand Ballroom Level, Omni Hotel

ADVANCES IN THE TREATMENT OF MOOD AND ANXIETY DISORDERS IN WOMEN
Supported by Wyeth Pharmaceuticals

Chp.: Susan G. Kornstein, M.D.

A Anxiety Disorders in Women
Teresa A. Pigott, M.D.

B Antidepressant Treatment of PMS and PMDD
Susan G. Kornstein, M.D.

C Perinatal Consequences of Mood and Anxiety Disorders
Kimberly A. Yonkers, M.D.

RESIDENTS’ SESSION
7:00 a.m.-8:30 a.m.
International Rooms 4/5/6, International Level, Marriott Marquis Atlanta

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Michelle B. Riba, M.D.
Co-Chp.: Steven S. Sharfstein, M.D.

At this breakfast, nationally recognized “experts” will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Addiction/Substance Abuse, AIDS/HIV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence, Forensic, Law and Ethics in Psychiatry, Geriatric, Medical Student Issues, Public and Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in Psychiatry.

8:00 a.m. Sessions

COURSES 33-41
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 33
8:00 a.m.-12 noon
Newton Room, Second Floor, Hilton Atlanta

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE

Director: George T. Grossberg, M.D.
Faculty: Judith H. W. Grossberg, M.D., Abhilash K. Desai, M.D.
COURSE 34  8:00 a.m.-12 noon  
Rockdale Room, Second Floor, Hilton Atlanta  
ENGAGING RESISTANT AND DIFFICULT-TO-TREAT PATIENTS  
Director: David Mee-Lee, M.D.

COURSE 35  8:00 a.m.-12 noon  
Forsythe Room, Second Floor, Hilton Atlanta  
CURRENT CPT CODING AND DOCUMENTATION REQUIREMENTS  
Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.

COURSE 36  8:00 a.m.-12 noon  
Paulding Room, Second Floor, Hilton Atlanta  
TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!  
Director: Steven E. Hyler, M.D.  
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D., Jeremy R. Butler, M.D.

COURSE 37  8:00 a.m.-12 noon  
Jackson Room, Third Floor, Hilton Atlanta  
DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO  
Director: Joseph C. Napoli, M.D.  
Faculty: Michael Blumenfield, M.D., V. Alex Kehayan, Ed.D.

COURSE 38  8:00 a.m.-12 noon  
Madison Room, Third Floor, Hilton Atlanta  
FAMILIES COPING WITH MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH  
Director: John S. Rolland, M.D.

COURSE 39  8:00 a.m.-12 noon  
Monroe/Roosevelt Room, Third Floor, Hilton Atlanta  
THE PSYCHIATRIST AS EXPERT WITNESS  
Director: Phillip J. Resnick, M.D.

COURSE 40  8:00 a.m.-12 noon  
Cabinet/Council Rooms, Fourth Floor, Hilton Atlanta  
PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE  
Director: David A. Mrazek, M.D.  
Faculty: John L. Black, M.D., Brett A. Koplin, M.D.

COURSE 41  8:00 a.m.-5:00 p.m.  
Grand Salon A, Second Floor, Hilton Atlanta  
OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS  
Co-Directors: Gerardo Gonzalez, M.D., Eric C. Strain, M.D.  
Faculty: Laura F. McNicholas, M.D.
MONDAY

COURSES 42-48

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 42  9:00 a.m.-4:00 p.m.
Cherokee Room, Second Floor, Hilton Atlanta

A PSYCHODYNAMIC APPROACH TO TREATMENT REFRAC'TORY MOOD DISORDERS

Director: Eric M. Plakun, M.D.
Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.

COURSE 43  9:00 a.m.-4:00 p.m.
Fulton Room, Second Floor, Hilton Atlanta

PERSONNEL MANAGEMENT FOR CLINICIAN-ADMINISTRATORS

Director: Stephen M. Solis, M.D.
Faculty: Joseph J. Parks III, M.D., Kay Titchenal

COURSE 44  9:00 a.m.-4:00 p.m.
Cobb Room, Second Floor, Hilton Atlanta

MONEY MATTERS I: USING THEORY IN CLINICAL PRACTICE

Director: Cecilia M. Mkalac, M.D.

COURSE 45  9:00 a.m.-4:00 p.m.
Clayton Room, Second Floor, Hilton Atlanta

ADVANCED HYPNOSIS: APPLICATIONS IN PSYCHIATRY

Director: Jose R. Maldonado, M.D.
Faculty: David M. Spiegel, M.D., Matthew May, M.D.

COURSE 46  9:00 a.m.-4:00 p.m.
Grand Salon B, Second Floor, Hilton Atlanta

TREATING THE SELF AND INTERPERSONAL PROBLEMS OF PERSONALITY DISORDER

Director: John Livesley, Ph.D.

COURSE 47  9:00 a.m.-4:00 p.m.
Grand Salon D, Second Floor, Hilton Atlanta

ADVANCES IN NEUROPSYCHIATRY

Director: C. Edward Coffey, M.D.
Faculty: Mark S. George, M.D., Michael R. Trimble, M.D.

COURSE 48  9:00 a.m.-4:00 p.m.
Club/State Rooms, Fourth Floor, Hilton Atlanta

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE

Director: James Q. Schubmehl, M.D.
Faculty: Alan R. Beeber, M.D., Tewfik Said, M.D.

DEBATE

9:00 a.m.-10:30 a.m.
Room A404, Level 4, Georgia World Congress Center

RESOLVED: SECOND GENERATION ANTIPSYCHOTICS ARE UNIFORMLY SUPERIOR IN SAFETY AND EFFICIENCY TO FIRST-GENERATION ANTIPSYCHOTICS

Moderator: Richard E. D'Alli, M.D.
Affirmative: Ira D. Glick, M.D., John M. Davis, M.D.
Negative: Rajiv Tandon, M.D., William T. Carpenter, Jr., M.D.
THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-5

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1 Antoinette Ambrosino-Wyszynski, M.D., on Medically Cleared for Transfer to Psychiatry: How to Evaluate the Medical Patient With Changed Mental Status (Meet the Authors for Residents Only)
International Rooms 2-3, International Level, Marriot Marquis Atlanta

2 Herbert D. Kleber, M.D., on Prescription Drug Abuse: The Psychiatrist's Role in Recognition, Prevention, and Management
Cedar Room, South Tower, Lobby Level, Omni Hotel

3 Maria A. Oquendo, M.D., on Suicidal Behavior in Major Mood Disorders
Collaborative Session With the National Institute of Mental Health
Chesnut Room, North Tower, Meeting Level, Omni Hotel

4 Nada L. Stotland, M.D., on Practical Psychosomatics: Treating Women Patients
Hazelnut Room, North Tower, Meeting Level, Omni Hotel

5 Jon E. Grant, M.D., on Pathological Gambling and Its Clinical Management (Meet the Author)
Pecan Room, North Tower, Meeting Level, Omni Hotel
FOCUS LIVE SESSION 1
9:00 a.m.-10:30 a.m.
Room A405, Level 4, Georgia World Congress Center

MAJOR DEPRESSIVE DISORDER

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: Alan F. Schatzberg, M.D.

Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based discussions. This session covers Major Depressive Disorder, the second session at 11:00 a.m. covers Psychosomatic Medicine, and the third session at 2:00 p.m. covers Child and Adolescent Psychiatry. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 2-4

LECTURE 2
9:00 a.m.-10:30 a.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

Eric R. Kandel, M.D.

Human Psychiatric Disorders: Genetic Models in Mice
Collaborative Session With the National Institute of Mental Health

Chp.: Anthony J. Rothschild, M.D.
Co-Chp.: Daniel P. Dickstein, M.D.

Eric R. Kandel, M.D., is University Professor of Physiology and Psychiatry at Columbia University College of Physicians and Surgeons in New York City, Fred Kavli Professor and Director of the Kavli Institute for Brain Sciences at Columbia University, and a Senior Investigator at the Howard Hughes Medical Institute. He joined the faculty at Columbia University in 1974 as the founding director of the Center for Neurobiology and Behavior. Dr. Kandel's research has been concerned with the molecular mechanisms of memory storage in Aplysia and mice. Dr. Kandel received the Nobel Prize for Physiology or Medicine in 2000 and has been recognized with the Albert Lasker Award for Basic Medical Research, the Dr. A. H. Heineken Prize for Medicine from the Royal Netherlands Academy of Arts and Sciences, the Gairdner Foundation International Award for Excellence in Medical Science, the Wolf Prize in Medicine, and the United States National Medal of Science. He is a member of the U.S. National Academy of Sciences, as well as the national science academies of Germany and France. A graduate of New York University School of Medicine, Dr. Kandel trained in neurobiology at the National Institutes of Health and in psychiatry at Harvard Medical School.

Distinguished Psychiatrist Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3
9:00 a.m.-10:30 a.m.
Room A411, Level 4
Georgia World Congress Center

Beverley Raphael, M.D.

Terrorism and Disaster Population Mental Health Approaches

Chp.: Carol C. Nadelson, M.D.
Co-Chp.: Harold Kuider, M.D.

Beverley Raphael, M.D., is Director of the Centre for Mental Health in North Sydney, Australia, and Emeritus Professor of Psychiatry at the University of Queensland in Brisbane. She has a long-term interest in trauma, grief, disasters, and, more recently, mental health consequences of responses to terrorism. She has been a leader in the development of prevention and public health approaches to mental health in Australia and is responsible for coordinating the national mental health service response to disasters and terrorism. In that role, she was involved in preparation for potential terrorism for the 2000 Sydney Olympics and in the response to the 2002 Bali bombing. Dr. Raphael is the author of numerous scientific articles and the author or editor of several books, including Anatomy of Bereavement: When Disaster Strikes: How Individuals and Communities Cope With Disaster: The International Handbook of Traumatic Stress Syndromes; Handbook of Studies of Preventive Psychiatry, and Psychological Debriefing: Theory, Practice, and Evidence.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.
LECTURE 4
9:00 a.m.-10:30 a.m.
Room A412, Level 4
Georgia World Congress Center

APA's ADMINISTRATIVE PSYCHIATRY AWARD LECTURE

Gabriel Koz, M.D.

Administrative Adventures in Public Psychiatry: 1967-2005
Chp.: Beth Ann Brooks, M.D.

Gabriel Koz, M.D., is Professor of Psychiatry, NYU School of Medicine and Professor of Clinical Psychiatry, Eastern Virginia Medical School. Dr. Koz was born in Johannesburg, South Africa, on December 2, 1933, to a calm English postal worker and a wild Russian typist and homemaker. He is their middle child and only son. Although sport (rugby, cricket, and soccer) was his “religion,” his academics were good enough to admit him to Witwatersrand Medical School. After completing the six-year program, two-and-a-half years of rotation half-year internships followed in medicine, surgery, pediatrics, ObGyn, and neurosurgery. Then his first love, psychiatry, returned to the fore. One year of psychiatry in England was more revealing than he had expected; so he accepted a Fulbright scholarship to Harvard and Boston City Hospital with high hopes. According to Dr. Koz, the following years did not disappoint, professionally or personally. Married with three children, he began professionally with ten years at Albert Einstein College of Medicine, which included seven tumultuous years as Psychiatry Director at Lincoln Hospital in the South Bronx, (a.k.a. Fort Apache), during the Vietnam War era. After Lincoln, a search committee tapped Dr. Koz to unify three state hospitals into Manhattan Psychiatric Center. In 1982, he founded the Psychiatry Departments at Woodhull Hospital, Brooklyn, serving a multicultural population. Finally, in 1999, John Favret invited him to Williamsburg, Virginia, as the Medical Director of Eastern State Hospital—the nation’s first public psychiatric institution (1773).

THIS SESSION WILL BE AUDIOTAPE D.

MASTER EDUCATOR CLINICAL CONSULTATIONS 1-2
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1 Kenneth Silk, M.D., on Clinical and Pharmacologic Management of BPD
   Collaborative Session With the National Institute of Mental Health
   Room B317, Level 3, Georgia World Congress Center

2 Michelle B. Riba, M.D., on Split and Integrated Treatment: Pharmacotherapy and Psychotherapy
   Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

NEW RESEARCH YOUNG INVESTIGATORS’ POSTER SESSION 1
9:00 a.m.-10:30 a.m.
Room B302/303/304/305, Level 3, Georgia World Congress Center

For further information on new Research Sessions, please refer to the New Research Program Book included in your registration packet.

WORKSHOPS

COMPONENTS 1-12

COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room A412, Level 4, Georgia World Congress Center

MANAGED CARE: PAST, PRESENT, AND FUTURE
APA Committee on Managed Care
Chp.: Lawrence B. Lurie, M.D.
Participants: Kevin L. Smith, M.D., Raphael A. Rovere, M.D., Jonathan L. Weker, M.D., Jennifer R. Lee, M.D., Alan A. Axelson, M.D., David Nace, M.D.

COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room B301, Level 3, Georgia World Congress Center

KEEPING APA PRACTICE GUIDELINES CURRENT:
ALZHEIMER’S, DELIRIUM, AND EATING DISORDERS
APA Steering Committee on Practice Guidelines
Chp.: Jack S. McIntyre, M.D.
Participants: Ian A. Cook, M.D., Laura J. Fochtmann, M.D., Joel Yager, M.D., Peter V. Rabins, M.D.

COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room B306, Level 3, Georgia World Congress Center

WHAT NOT TO DO: THE MEDIA TALKS BACK ABOUT PUBLIC AFFAIRS
APA Committee on Public Affairs
Co-Chps.: Marc Graff, M.D., Lydia Sermons-Ward
Participants: Robert S. Benson, M.D., Christopher B. Peterson, M.D.
MONDAY

COMPONENT WORKSHOP 4  9:00 a.m.-10:30 a.m.
Room B307, Level 3, Georgia World Congress Center

PSYCHIATRIC LEADERSHIP: PUTTING OUT FIRES AND BEYOND!
APA Committee on Psychiatric Administration and Management
Chp.: Stuart B. Silver, M.D.
Participants: Christopher G. Fichtner, M.D., Sy Ateaz Saeed, M.D., Nalini Juthani, M.D.

COMPONENT WORKSHOP 5  9:00 a.m.-10:30 a.m.
Room B308, Level 3, Georgia World Congress Center

EARLY CAREER PSYCHIATRISTS AS LEADERS
APA Assembly Committee of Early Career Psychiatrists
Chp.: Adam R. Chester, D.O.
Participants: Benedicto R. Borja, M.D., Matthew W. Norman, M.D., John R. Chamberlain, M.D.

COMPONENT WORKSHOP 6  9:00 a.m.-10:30 a.m.
Room B309, Level 3, Georgia World Congress Center

CHILDREN UNDER FIRE: ENHANCING PSYCHIATRY'S GLOBAL RESPONSE
APA Corresponding Committee on Juvenile Justice Issues
Chp.: Niranjan S. Karnik, M.D.
Participants: Shanta P. Henderson, M.D., Roxanne Dryden-Edwards, M.D., Janet A. Martin, M.D., Sandra J. Kaplan, M.D.

COMPONENT WORKSHOP 7  9:00 a.m.-10:30 a.m.
Room B310, Level 3, Georgia World Congress Center

SERODISCORDANT COUPLES: ISSUES AND PSYCHODYNAMICS IN THE THIRD DECADE OF AIDS
APA New York County District Board's AIDS Committee
Chp.: Elizabeth V. Getter, M.D.
Participants: Kenneth Ashley, M.D., Mary Ann Cohen, M.D., John A.R. Grimaldi, Jr., M.D.

COMPONENT WORKSHOP 8  9:00 a.m.-10:30 a.m.
Room B314, Level 3, Georgia World Congress Center

TEN WAYS TO STAY OUT OF TROUBLE: ETHICS AND ETIQUETTE
APA Ethics Appeal Board
Chp.: Spencer Eth, M.D.
Participants: Wade C. Myers, M.D., William Arroyo, M.D., Harriet C. Stern, M.D., Scott Y. Kim, M.D., Richard D. Milone, M.D., JoAnn Macbeth, J.D., Philip T. Merideth, M.D.

COMPONENT WORKSHOP 9  9:00 a.m.-10:30 a.m.
Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

U.S. RESEARCH AND SERVICES BRIDGE WITH LATIN AMERICA
APA Council on Global Psychiatry
Co-Chps.: Rodrigo A. Munoz, M.D., Pedro Ruiz, M.D.
Participants: Jose M. Caldas de Almeida, M.D., Javier I. Escobar, M.D., Gerardo Heinze, M.D.

COMPONENT WORKSHOP 10  9:00 a.m.-10:30 a.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

FUNDING FOR PSYCHIATRY: FROM THE IRRATIONAL AND RATIONAL
APA Council on Healthcare Systems and Financing
Chp.: Selby C. Jacobs, M.D.
Participants: Mantosh J. Dewan, M.D., Anita S. Everett, M.D., Edward J. Maxwell, M.D.

COMPONENT WORKSHOP 11  9:00 a.m.-10:30 a.m.
Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

SOMATIZATION AND STIGMA IN ASIANS:
CULTURAL CHALLENGES IN PRACTICE
APA Committee of Asian American Psychiatrists
Chp.: John Luo, M.D.
Participants: Mona H. Gill, M.D., Sabina Lim, M.D., Nang Du, M.D.

COMPONENT WORKSHOP 12  9:00 a.m.-10:30 a.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

BEHIND CLOSED DOORS: THE HIDDEN FAMILY:
DOMESTIC VIOLENCE, CROSS-CULTURAL, AND ETHNIC INFLUENCES
APA Alliance
Co-Chps.: Carole L. Warshaw, M.D., Cathy Tasman
Participants: Julia L. Perilla, Ph.D., Surinder S. Nand, M.D.

ISSUES 1-13

ISSUE WORKSHOP 1  9:00 a.m.-10:30 a.m.
Room B311, Level 3, Georgia World Congress Center

TREATING PTSD: COMBINING PSYCHOTHERAPY AND PHARMACOTHERAPY
Co-Chps.: Lewis A. Opler, M.D., Kristina H. Muenzenmaier, M.D.
Participants: David B. Albert, Ph.D., Michaela Mendelsohn, Ph.D.
ISSUE WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room B315, Level 3, Georgia World Congress Center

ORAL BOARDS BOOT CAMP UPDATED
Co-Chps.: Elyse D. Weiner, M.D., Eric D. Peselow, M.D.

ISSUE WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room B316, Level 3, Georgia World Congress Center

COGNITIVE THERAPY FOR PERSONALITY DISORDERS
Chp.: Judith S. Beck, Ph.D.

ISSUE WORKSHOP 4 9:00 a.m.-10:30 a.m.
Room B401, Level 4, Georgia World Congress Center

DOCTOR, WHY DO I STILL HAVE THIS PAIN? THE PHYSICIAN'S PSYCHOSOMATIC DILEMMA
Co-Chps.: Don R. Lipsitt, M.D., Malkah T. Notman, M.D.
Participants: Donald Jay Meyer, M.D., Robert C. Joseph, M.D.

ISSUE WORKSHOP 5 9:00 a.m.-10:30 a.m.
Room B402, Level 4, Georgia World Congress Center

RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE
Chp.: Alan I. Levenson, M.D.
Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D., Donna Vanderpool, J.D.

ISSUE WORKSHOP 6 9:00 a.m.-10:30 a.m.
Room B403, Level 4, Georgia World Congress Center

MANAGING DISTRESS AND PSYCHIATRIC DISORDER AFTER TERRORISM
Collaborative Session With the National Institute of Mental Health
Co-Chps.: Farris Tuma, Sc.D., Anthony T. Ng, M.D.
Participants: Carol S. North, M.D., Sandro Galea, M.D., Matthew Friedman, M.D., Robert J. Ursano, M.D.

ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.
Room B404, Level 4, Georgia World Congress Center

THE PSYCHIATRIC CONSEQUENCES OF THE WORLD TRADE CENTER ATTACK IN DISASTER RELIEF WORKERS
Collaborative Session With the National Institute of Mental Health
Chp.: JoAnn Difede, Ph.D.
Participants: Jennifer Roberts, Ph.D., Pamela Leck, Ph.D., Margaret Altemus, M.D.
MEDIA 1-3

11:00 a.m. Sessions

DISCUSSION GROUPS 6-8

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

6 Carl C. Bell, M.D., on Tips on How to Be an Effective Psychiatrist (For Residents Only)
   International Rooms 2-3, International Level, Marriott Marquis Atlanta

7 Mary Jane Massie, M.D., on Breast Cancer: Issues in Psychotherapy
   Hazelnut Room, North Tower, Meeting Level, Omni Hotel

8 Jon G. Allen, Ph.D., on Coping With Trauma (Meet the Authors)
   Pecan Room, North Tower, Meeting Level, Omni Hotel

FOCUS LIVE SESSION 2

11:00 a.m.-12:30 p.m.
Room A405, Level 4, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: CONSULTATION-LIAISON PSYCHIATRY AND BEYOND

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: Jennifer G. Gotto, M.D., Francisco Fernandez, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Psychosomatic Medicine, the first session at 9:00 a.m. covers Major Depressive Disorder, and the third session at 2:00 p.m. covers Child and Adolescent Psychiatry. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.
LECTURE 5
11:00 a.m.-12:30 p.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

Bruce S. McEwen, Ph.D.

Stress and the Mind-Body Connection: Lessons From Neuroendocrinology
Co-Chip.: Sanjay Mathew, M.D.

Chip.: Jack M. Gorman, M.D.
Co-Chip.: Sanjay Mathew, M.D.

Bruce S. McEwen, Ph.D., discusses a new model of the adaptive and damaging effects of the mediators of the physiological stress response. The model focuses on the pivotal role of brain areas involved in memory and emotion and provides a basis for understanding the comorbidity of mental disorders with systemic disorders such as cardiovascular disease, obesity, and diabetes. Dr. McEwen is Alfred E. Mirsky Professor and Head of the Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology at Rockefeller University in New York City. His research examines environmentally-regulated, variable gene expression in the brain that is mediated by circulating steroid hormones and endogenous neurotransmitters in relation to brain sexual differentiation and the actions of sex, stress, and thyroid hormones on the adult brain. He is a member of the MacArthur Foundation Research Network on Socioeconomic Status and Health, in which he is helping to reformulate concepts and measurements related to stress and stress hormones in the context of human societies. A Past President of the Society for Neuroscience, Dr. McEwen is a member of the U.S. National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He received his doctoral degree in cell biology from Rockefeller University and completed postdoctoral studies in neurobiology at the Institute of Neurobiology in Goteborg, Sweden.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPE.
MEDICAL UPDATE 1
11:00 a.m.-12:30 p.m.
Room B403, Level 4, Georgia World Congress Center

GET SMART NATURALLY

Presenter: Richard P. Brown, M.D.
Chp.: Philip R. Muskin, M.D.
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

1 Larry J. Siever, M.D., on Biological Studies in Personality Disorders
Collaborative Session With the National Institute of Mental Health
Chestnut Room, North Tower, Meeting Level, Omni Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-9

SCIENTIFIC AND CLINICAL REPORT SESSION 1
11:00 a.m.-12:30 p.m.
Room A402, Level 4, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: INTEGRATING PSYCHIATRY AND MEDICINE

Chp.: Arthur L. Lazarus, M.D.
Co-Chp.: Carrie L. Ernst, M.D.

11:00 a.m.
2 Teaching Psychosomatic Medicine in Primary Care Residencies: Current Status
Hoyle Leigh, M.D., Deborah C. Stewart, M.D., Ronna Mallios, M.P.H.

11:30 a.m.
3 Use of Simulated Patients to Assess Primary Care Physicians' Treatment of Depression
Collaborative Session With the National Institute of Mental Health
Steven A. Epstein, M.D., Lisa M. Hooper, Ph.D., Kevin P. Weinfurt, Ph.D., William Hahless, Ph.D., Lisa A.
Cooper, M.D.

12 noon
4 Psychosocial Aspects of Automatic Internal Cardioverter Defibrillator Use
Maryam Razavi, M.D., Vicentio Holder-Perkins, M.D., Mehdi Razavi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 2
11:00 a.m.-12:30 p.m.
Room A404, Level 4, Georgia World Congress Center

SUICIDE

Chp.: David C. Purcell, M.D.
Co-Chp.: Steven J. Garlow, M.D.

11:00 a.m.
5 Exposure to SSRIs Reduces Suicidality in Elderly Patients With Depression
Yoram Barak, M.D., Ahiam Olmer, M.D., Dov Alzenberg, M.D.

11:30 a.m.
6 Suicidality in Youth With Bipolar Disorder: An Ecological, Multisite Investigation
Ruby C. Castilla-Puentes, M.D., Sandra R. Castilla-Puentes, M.D., Ivan S. Gomez, M.D., Wilma L.
Castilla-Puentes, M.D., Sandra Lopez, M.D., Maria Teresa Alvarado, Ph.D., Carlos A. Sanchez-Russi, Ph.D.

12 noon
7 Peripheral Benzodiazepine Receptors in Suicide
Donatella Marazziti, M.D., Bernardo Dell'Oso, M.D., Luciano Conti, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 3
11:00 a.m.-12:30 p.m.
Room B301, Level 3, Georgia World Congress Center

ISSUES IN PHARMACOTHERAPY AND PSYCHOTHERAPY

Chp.: Alan J. Gelenberg, M.D.
Co-Chp.: Allan M. Josephson, M.D.

11:00 a.m.
8 A Combined Treatment Approach for Adults With ADHD: Results of a Pilot Study of 45 Patients
Anthony L. Rostain, M.D., J. Russell Ramsay, Ph.D.

11:30 a.m.
9 Characteristics of Diversion and Misuse of ADHD Medications
Timothy E. Wilens, M.D., Martin Gignac, M.D., Joseph Biederman, M.D.

12 noon
10 Combined Treatment of Venlafaxin and ECT in Treatment-Resistant Depressive Patients
Nesrin Dilbaz, M.D., Cem Sengul, M.D., Tuncer Okay, M.D., Goksel Bayam, M.D., Ali Turkoglu, M.D.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room B306, Level 3, Georgia World Congress Center

ADHD
Chp.: Nashaat N. Boutros, M.D.
Co-Chp.: Joel Kirson, M.D.

11:00 a.m.
11 Sleep Hygiene and Melatonin Treatment for ADHD
Margaret D. Weiss, M.D., Melissa Bomben, M.S., Michael
Wasdell, M.A.

11:30 a.m.
12 Comorbidity Differences in ADHD Throughout the
Life Cycle
Atilla Turgay, M.D., Rubaba Ansari, M.A., Michael
Schwartz, Ph.D., David Ng, M.D., Llewelyn W.
Joseph, M.D., Joanna Blanchard, M.A., Nadeem
Chaudhry, M.D.

12 noon
13 ADHD Symptoms and Behavior Improved With
Modafinil Pediatric Formulation
Laurence L. Greenhill, M.D., Sharon B. Wigal, Ph.D.,
Christopher J. Kratochvil, M.D., Samuel Boellner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Room B408, Level 4, Georgia World Congress Center

ISSUES IN BIPOLAR DISORDER
Chp.: Katherine L. Wisner, M.D.
Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
14 Excess Mortality in Bipolar and Unipolar Disorder
Urban P. Osby, M.D., Lena Brandt, B.S.C., Nestor
Correa, Ph.D., Anders Ekbom, M.D., Par Sparen, Ph.D.

11:30 a.m.
15 Do Antidepressants Help or Hinder Recovery From
Mixed Mania?
Joseph F. Goldberg, M.D., Christine J. Truman, M.D.,
Charles L. Bowden, M.D., John Fordis, B.A., Stephen R.
Wäinölä, Ph.D., Michael E. Thase, M.D., Gary S.
Sachs, M.D.

12 noon
16 Mixed Episodes: Illness Characteristics
Gary S. Sachs, M.D., Megan F. Joseph, B.A., Cindy H.
Hwang, B.A., Gianna Marzilli, B.A., Tanya B. Tran, B.A.,
David J. Borrelli, M.D., Andrew A. Nierenberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

PSYCHOTHERAPY
Chp.: T. Byram Karasu, M.D.
Co-Chp.: Everett R. Siegel, M.D.

11:00 a.m.
17 Affect Change in Dreams in Psychotherapy
Milton Kramer, M.D., Myron L. Glucksman, M.D.

11:30 a.m.
18 The Empathic Stance
Steven H. Lipsius, M.D.

12 noon
19 Creative Thinking: A Door to the Interior Life That
Enhances the Psychotherapeutic Process
Rosa A. Chavez-Eakle, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m.-12:30 p.m.
Room B429, Level 4, Georgia World Congress Center

PSYCHOTHERAPY
Chp.: T. Byram Karasu, M.D.
Co-Chp.: Everett R. Siegel, M.D.

11:00 a.m.
17 Affect Change in Dreams in Psychotherapy
Milton Kramer, M.D., Myron L. Glucksman, M.D.

11:30 a.m.
18 The Empathic Stance
Steven H. Lipsius, M.D.

12 noon
19 Creative Thinking: A Door to the Interior Life That
Enhances the Psychotherapeutic Process
Rosa A. Chavez-Eakle, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m.-12:30 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni
Hotel

SAFETY AND EFFICACY IN ANTIPSYCHOTIC
THERAPIES
Chp.: Geetha Jayaram, M.D.
Co-Chp.: John M. Rowles, M.D.

11:00 a.m.
20 Efficacy and Safety of Ziprasidone in First-Episode
Psychosis
Tonmoy Sharma, M.D., Veena Kumari, Ph.D., Ravi
Mehrotra, Ph.D., Anil Kumar

11:30 a.m.
21 Atypical Antipsychotics and Falls in the Elderly
Ira R. Katz, M.D.

12 noon
22 Metabolic Syndrome in Schizophrenia
Hannu J. Koponen, M.D., Kaisa Saari, M.D., Sari
Lindeman, M.D., Markku Savolainen, M.D., Matti K.
Isohanni, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m.-12:30 p.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

CROSS-CULTURAL AND MINORITY ISSUES
Chp.: Leslie A. Horton, M.D.
Co-Chp.: Francis G. Lu, M.D.

11:00 a.m.
23 Ethnicity and the Prediction of Substance Abuse in Hospitalized Adolescents
Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D.

11:30 a.m.
24 Stigmatization of Mental Illnesses Among Chinese Psychiatric Patients in China and the U.S.
Collaborative Session With the National Institute of Mental Health
Albert Yeung, M.D., Yong Xu, M.D., Wendy Hu, B.S., Raymond Kam, M.D., Paul Yin, M.D., Maurizio Fava, M.D.

12 noon
25 Use of the PHQ-9 for Screening and Treatment of Major Depressive Disorders in Chinese Americans
Frederick Y. Huang, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m.-12:30 p.m.
Dogwood B, North Tower, Street Level, Omni Hotel

PERSONALITY DISORDERS
Chp.: Ossama T. Osman, M.D.
Co-Chp.: Robert Kelly, M.D.

11:00 a.m.
26 Emotion Processing in BPD: An fMRI Perspective
Harold W. Koenigsberg, M.D., Larry J. Siever, M.D., Xiaodong Guo, Ph.D., Antonia S. New, M.D., Marianne Goodman, M.D., Hu Cheng, Ph.D., Isak Prohovnik, Ph.D.

11:30 a.m.
27 Personality Traits in Patients With Panic Disorder
Mary Anne Pressman, M.D., Eric D. Peselow, M.D., Caroline B. Williams, M.D.

12 noon
28 Is Peripartum Depression a Borderline Condition?
Gisèle Apter-Danon, Ph.D., Rozenn Graougn-Philippe, M.A., Marina Gianoli-Valente, Psy.D., Emmanuel Devouche, Ph.D., Annick Le Nestour, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENT WORKSHOPS 13-17

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.
Room B307, Level 3, Georgia World Congress Center

PRACTICAL TIPS ON HOW TO BE A SUCCESSFUL AUTHOR
American Psychiatric Publishing Inc. Editorial Board

Chp.: Robert E. Hales, M.D.
Participants: Glen O. Gabbard, M.D., Katharine A. Phillips, M.D., John M. Oldham, M.D., Donna E. Stewart, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Room B308, Level 3, Georgia World Congress Center

PSYCHIATRIC ETHICS IN THE U.S. AND THROUGHOUT THE WORLD
APA Ethics Committee

Co-Chps.: Spencer Eth, M.D., Driss Moussaoui, M.D.
Participants: Wade G. Myers, M.D., Philip T. Merideth, M.D., Ahmed M.F. Okasha, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

THE MULTICULTURAL DIMENSION OF DEPRESSION: A CLINICAL APPROACH
APA/AstraZeneca Minority Fellows

Chp.: Gonzalo E. Laje, M.D.
Participants: Angel A. Caballos, M.D., Yolanda R. Coleman, M.D., Daniel Dickerson, D.O., Luisa S. Gonzalez, M.D., Jennifer R. Lee, M.D., Aditi M. Shrikhande, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.
Oak Room, South Tower, Lobby Level, Omni Hotel

EARLY DIAGNOSIS IN SPECIFIC MENTAL DISORDERS IN TODDLERS AND PRESCHOOLERS
APA Corresponding Committee on Infancy and Early Childhood

Co-Chps.: Judy S. McKay, M.D., Harry H. Wright, M.D.
Participants: Jean M. Thomas, M.D., Joan L. Luby, M.D.
MONDAY

COMPONENT WORKSHOP 17  11:00 a.m.-12:30 p.m.
Juniper Room, North Tower, Ballroom Level, Omni Hotel

GENDER BENDERS: PSYCHIATRIC ASPECTS OF
TRANSGENDER CARE
APA New York County District Branch's Committee on Gay, Lesbian,
Bisexual, and Transgender Issues

Chp.: Serena Yuan Volpp, M.D.
Participants: Steven J. Lee, M.D., Khakasa H. Wapenyi, M.D.,
Daniel Garza, M.D., Ubaldo Leli, M.D.

ISSUES 14-26

ISSUE WORKSHOP 14  11:00 a.m.-12:30 p.m.
Room B309, Level 3, Georgia World Congress Center

ETHNICITY AND PSYCHOPHARMACOLOGY:
RESEARCH AND CLINICAL IMPLICATIONS

Co-Chps.: Pedro Ruiz, M.D., Key-Ming Lim, M.D.
Participants: William Lawson, M.D., Edmond H.T. Pi, M.D.,
Ricardo P. Mendoza, M.D., Tarek A. Ohasha, M.D.

ISSUE WORKSHOP 15  11:00 a.m.-12:30 p.m.
Room B310, Level 3, Georgia World Congress Center

MAKING IT HAPPEN: IMPLEMENTING PRACTICE
GUIDELINES IN EVERYDAY PRACTICE

Chp.: Rory P. Houghtalen, M.D.
Participants: Jack S. McMyre, M.D., Jeffrey Mothersell, C.S.W.,
Joel Yager, M.D.

ISSUE WORKSHOP 16  11:00 a.m.-12:30 p.m.
Room B311, Level 3, Georgia World Congress Center

PRACTICAL CLINICAL TRIALS COMPARING
PSYCHOPHARMACOLOGICAL TREATMENTS

Co-Chps.: Sandra L. Tunis, Ph.D., Don Buesching, Ph.D.
Participants: Douglas E. Faries, Ph.D., Kurt Kroenke, M.D.,
Wayne J. Katon, M.D.

ISSUE WORKSHOP 17  11:00 a.m.-12:30 p.m.
Room B315, Level 3, Georgia World Congress Center

SPLIT THERAPY: PSYCHOTHERAPY AND
PHARMACOTHERAPY PROCEDURES AND
STRATEGIES

Chp.: Malkah T. Norman, M.D.
Participants: Carl P. Malmoquist, M.D., Brenda C.
Solomon, M.D., Amit D. Raparia, M.D.

ISSUE WORKSHOP 18  11:00 a.m.-12:30 p.m.
Room B316, Level 3, Georgia World Congress Center

TREATMENT OF DEPRESSION DURING
PREGNANCY

Co-Chps.: Janet A. Martin, M.D., Neil Silverman, M.D.
Participants: Leo L. Gallofin, M.D., Syed S.A. Naqvi, M.D.

ISSUE WORKSHOP 19  11:00 a.m.-12:30 p.m.
Room B401, Level 4, Georgia World Congress Center

BINGE-EATING DISORDER IN OBESITY AND
IMPLICATIONS FOR BARIATRIC SURGERY

Co-Chps.: Jennifer L. McLain, M.D., Edi Cooke, Psy.D.
Participant: Alexander H. Fan, M.D.

ISSUE WORKSHOP 20  11:00 a.m.-12:30 p.m.
Room B402, Level 4, Georgia World Congress Center

DUAL-CAREER COUPLES: MULTIPLE ROLES,
INNOVATIVE SOLUTIONS

Association of Women Psychiatrists

Chp.: Silvia W. Olarte, M.D.
Participants: Linda H. Chaudron, M.D., Ana E. Campo, M.D.,
Mary Kay Smith, M.D.

ISSUE WORKSHOP 21  11:00 a.m.-12:03 p.m.
Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

PRACTICE RESTRICTIONS ON PHYSICIANS:
DISABILITY, ADA, AND FUTURE EMPLOYMENT

Co-Chps.: Andrea G. Stolar, M.D., Marilyn Price, M.D.
Participant: Marcia A. Scott, M.D.

ISSUE WORKSHOP 22  11:00 a.m.-12:30 p.m.
Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

RESEARCH TRAINING AND CAREER
DEVELOPMENT: NIMH OPPORTUNITIES
Collaborative Session With the National Institute of Mental Health

Co-Chps.: Della M. Hann, Ph.D., Joseph R. Calabrese, M.D.
Participants: Mark Chavez, Robert L. Findling, M.D., Omar
Eliaz, M.D.

ISSUE WORKSHOP 23  11:00 a.m.-12:30 p.m.
Dogwood A, North Tower, Street Level, Omni Hotel

COLLABORATIVE CARE MODELS FOR
DEPRESSION IN PRIMARY CARE

ISSUE WORKSHOP 24  11:00 a.m.-12:30 p.m.
Magnolia Room, North Tower, Ballroom Level, Omni Hotel

COMPARING CAREGIVING ISSUES OF AGING
PATIENTS WITH SCHIZOPHRENIA AND
DEMENTIA

Co-Chps.: Sheila M. Loboprabhu, M.D., Michael D.
Jibson, M.D.
Participant: Theron C. Bowers, Jr., M.D.
MONDAY

ISSUE WORKSHOP 25  
11:00 a.m.-12:30 p.m. 
Hickory Room, North Tower, Meeting Level, Omni Hotel

THE PSYCHIATRY RESIDENT AS EDUCATOR: IMPLEMENTATION OF A CURRICULUM
Co-Chps.: Ruth M. Lamdan, M.D., Autumn Ming, M.D.
Participants: Roya Lewis, M.D., Diane B. Gottlieb, M.D.,
Edward A. Volkman, M.D., Robert L. Boyd, M.D., Elton Smith, M.D.

ISSUE WORKSHOP 26  
11:00 a.m.-12:30 p.m. 
Walnut Room, North Tower, Meeting Level, Omni Hotel

MEETING THE CHALLENGES OF CORRECTIONAL MENTAL HEALTH RESEARCH
Collaborative Session With the National Institute of Mental Health
Chp.: Robert L. Trestman, M.D.
Participants: Humberto Temporini, M.D., Philip Candilis, M.D., Joel M. Silberberg, M.D.

12 noon Sessions

FORUMS 1-3

FORUM 1  
12 noon-1:30 p.m. 
Room A112, Level 4, Georgia World Congress Center

RESEARCH PLANNING FOR DSM-V
APA Committee on Psychiatric Diagnosis and Assessment in Collaboration With the National Institute of Mental Health
Chp.: Darrel A. Regier, M.D.
Participants: Wilson M. Compton III, M.D., Bruce Cuthbert, Ph.D., Michael B. First, M.D., William E.
Narrow, M.D., Maritza Rubio-Steele, Sc.D., Norman Sartorius, M.D.

FORUM 2  
12 noon-1:30 p.m. 
Room B314, Level 3, Georgia World Congress Center

SHOULD PSYCHIATRISTS AND OTHER MENTAL HEALTH PROFESSIONALS TAKE A LEAD IN TOBACCO DEPENDENCE TREATMENT?
Co-Chps.: Jill Williams, M.D., Douglas M. Ziedonis, M.D.
Participants: Nora D. Volkow, M.D.

FORUM 3  
12 noon-1:30 p.m. 
Room B454, Level 4, Georgia World Congress Center

GETTING INTO RESEARCH WITH AFRICAN-AMERICAN PATIENTS
Chp.: Mindy J. Fullilove, M.D.
Participants: Vivian Pinn, M.D., Ronald O. Valdiserri, M.D.,
Benedict I. Truman, M.D., Carl C. Bell, M.D.

1:00 p.m. Sessions

COURSES 49-57

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 49  
1:00 p.m.-5:00 p.m. 
Henry Room, Second Floor, Hilton Atlanta

THE ADVANCED PRACTICE OF PSYCHOTHERAPY
Director: T. Byram Karasu, M.D.

COURSE 50  
1:00 p.m.-5:00 p.m. 
Newton Room, Second Floor, Hilton Atlanta

ASSESSMENT AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS
Director: Anton J.M. Loonen, M.D.

COURSE 51  
1:00 p.m.-5:00 p.m. 
Paulding Room, Second Floor, Hilton Atlanta

COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS
Director: Jesse H. Wright, M.D.
Faculty: Michael E. Thase, M.D., Monica Basco, Ph.D.

COURSE 52  
1:00 p.m.-5:00 p.m. 
Gwinnett Room, Second Floor, Hilton Atlanta

ECT PRACTICE UPDATE
Director: Charles H. Kellner, M.D.
Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.S.,
Richard D. Weiner, M.D.

COURSE 53  
1:00 p.m.-5:00 p.m. 
Grand Salon C, Second Floor, Hilton Atlanta

OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE
Director: Karl Doghramji, M.D.
Faculty: John W. Winkelman, M.D., Thomas D. Hurwitz, M.D.
COURSE 55
1:00 p.m.-5:00 p.m.
Jackson Room, Third Floor, Hilton Atlanta
TREATING MEDICAL STUDENTS AND PHYSICIANS
Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

COURSE 56
1:00 p.m.-5:00 p.m.
Monroe/Roosevelt Room, Third Floor, Hilton Atlanta
CHILD MURDER BY PARENTS
Director: Phillip J. Resnick, M.D.

COURSE 57
1:00 p.m.-5:00 p.m.
Cabinet/Council Rooms, Fourth Floor, Hilton Atlanta
DRUG TREATMENT OF SCHIZOPHRENIA
Director: Philip G. Janicak, M.D.
Faculty: Morris B. Goldman, M.D., Stephen R. Marder, M.D., Rajiv Tandon, M.D.

NEW RESEARCH YOUNG INVESTIGATORS’ ORAL/SLIDE SESSION 2-4
1:00 p.m.-2:30 p.m.
2 The Mind and Body
   Room B301, Level 3, Georgia World Congress Center
3 Surprising Influences
   Room B306, Level 3, Georgia World Congress Center
4 Child/Adolescent and Other Topics
   Room B438, Level 4, Georgia World Congress Center

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

LECTURES 7-8

LECTURE 7
2:00 p.m.-3:30 p.m.
Room A411, Level 4
Georgia World Congress Center
Michael Meaney, Ph.D.

Epigenetic Programming of Stress Responses Through Variations in Maternal Care: The Nurture of Nature
Collaborative Session With the National Institute of Mental Health

Chp.: Michelle T. Pato, M.D.
Co-Chp.: Olivera J. Bogunovic, M.D.

Michael Meaney, Ph.D., is James McGill Professor of Medicine and Professor of Psychiatry at McGill University, Director of the McGill Program for the Study of Behaviour, Genes and Environment, and Associate Director of the Douglas Hospital Research Centre in Montreal. He is also a Canadian Institutes of Health Research (CIHR) Investigator and has received numerous awards and recognitions for his contributions to the field of epigenetics and psychiatric research.
Health Research Senior Scientist. His research interests include early environmental regulation of gene expression and brain development, development of individual differences in behavioral and endocrine responses to stress, and environmental and neuroendocrine mechanisms influencing maternal behavior. His research honors include the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression and the Patricia R. Barchas Award in Sociophysiology from the American Psychosomatic Society. Dr. Meaney is the author of more than 200 scientific papers and a member of the Editorial Board of the Journal of Neuroendocrinology, Hormones and Behavior, Journal of Endocrinology, Biological Psychiatry, and Stress. He received his doctorate in psychobiology at Concordia University in Montreal and completed a Natural Sciences and Engineering Research Council (NSERC) of Canada postdoctoral fellowship in neuroendocrinology at Rockefeller University in New York City and an NSERC University Research Fellowship at Concordia University.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 8
2:00 p.m.-3:30 p.m.
Room A412, Level 4
Georgia World Congress Center

APA'S GEORGE TARJAN AWARD LECTURE

Hagop S. Akiskal, M.D.

Temperament, Mood Disorder, and Human Nature

Chp.: Sanjay Dube, M.D.

Hagop S. Akiskal, M.D., is Professor of Psychiatry and Director of the International Mood Center at the University of California, San Diego. Dr. Akiskal's research and clinical work address the range of mood disorders from dysthymia to bipolar spectrum disorders, and his mood clinics are distinguished by their integration of service, training, and research. The author of numerous scientific papers and several books, Dr. Akiskal is Editor-in-Chief of Journal of Affective Disorders. He currently chairs the Private Practice section of the World Psychiatric Association. A Distinguished Fellow of the American Psychiatric Association (APA), Dr. Akiskal has received the Clinical Research Award from the American Academy of Clinical Psychiatrists for his work on dysthymia, the Gold Medal for Pioneer Work in Biological Psychiatry from the Society of Biological Psychiatry, the Anna-Monika Foundation Prize for his work on depression, a Presidential Commendation from the APA, and the Jean Delay Prize for international collaborative research from the World Psychiatric Association. In 2003, he was awarded the Ellis Island Medal of Honor for exceptional humanitarian national service. Dr. Akiskal received his medical degree from the American University of Beirut and his psychiatric training at the University of Tennessee in Memphis and the University of Wisconsin in Madison.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 1-2

PRESIDENTIAL SYMPOSIUM 1
2:00 p.m.-5:00 p.m.
Room A325, Level 3, Georgia World Congress Center

ADVANCES IN PSYCHOSOMATIC MEDICINE
International College of Psychosomatic Medicine in Collaboration With the National Institute of Mental Health

Chp.: Michelle B. Riba, M.D.

A A Model for Psychosomatic Medicine: Care in a U.S. Cancer Center
Michelle B. Riba, M.D.

B Ethical Issues in Psychosomatics
George Christodoulou, M.D.

C Recent Advances in Depression and Cardiovascular Disease Research
Constantine Lyketsos, M.D.

D Suffering: Another Frontier in Psychosomatic Medicine
Tom Sensky, M.B.

Discussant: Philip R. Muskin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 2
2:00 p.m.-5:00 p.m.
Room B401, Level 4, Georgia World Congress Center

ADDRESSING HEPATITIS C AND RELATED DISEASES IN PERSONS WITH SEVERE MENTAL ILLNESS

Chp.: Marvin S. Swartz, M.D.

A Hepatitis C and Other Blood-Borne Infections in the Severely Mentally Ill
Stanley Rosenberg, Ph.D.

B Access to Medical Care for Persons With Severe Mental Illness, Hepatitis C and Related Disorders
Marvin S. Swartz, M.D.

C Gender Differences in HCV and Associated Risks With Severe Mental Illnesses
Marian I. Butterfield, M.D.
D A Public Approach to Blood-Borne Infection With Severe Mental Illness: The STIRR Intervention
Mary F. Brunette, M.D.

E Antiviral Treatment of Hepatitis C in Persons With Severe Mental Illnesses
Lisa A. Mistrer, M.D.

F Integrating Care for Persons With Severe Mental Illness
Lisa B. Dixon, M.D.

Discussant: Lisa B. Dixon, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIA 1-26

SYMPOSIUM 1 2:00 p.m.-5:00 p.m.
Room A302, Level 3, Georgia World Congress Center

STEPPS TREATMENT MODEL FOR BPD
Collaborative Session With the National Institute of Mental Health
Chp.: Donald W. Black, M.D.

A Stepps: A New Cognitive Skills Treatment for Borderline Personality
Nancee Blum, M.S.W., Donald W. Black, M.D., Bruce M. Pfohl, M.D., Don St. John, M.D.

B Randomized Clinical Trial of Stepps Versus Treatment as Usual
Donald W. Black, M.D., Nancee Blum, M.S.W., Bruce M. Pfohl, M.D., Don St. John, M.D.

C Can Staff Attitudes Regarding BPD Be Changed?
Bruce M. Pfohl, M.D., Connie Shanks, B.A., Nancee Blum, M.S.W.

D Introduction of Stepps in the Netherlands
Roelof J. A. Ten Doesschate, M.D., E. Bass Van Wel, M.D., W.M.J. Kockmann
Discussants: Robert L. Spitzer, M.D., Roger Blashfield, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2 2:00 p.m.-5:00 p.m.
Room A402, Level 4, Georgia World Congress Center

9/11 IN NEW YORK CITY: LEARNING FROM THE PAST AND LOOKING TO THE FUTURE
Chp.: Joseph T. English, M.D.

A Lessons From 9/11: Psychiatric Care of Victims
Scot G. McAfee, M.D.

B Children and Schools in the Years After a Terror Attack
A. Reese Abright, M.D.
SYMPOSIUM 5  2:00 p.m.-5:00 p.m.
Room A406, Level 4, Georgia World Congress Center

A SEX/GENDER RESEARCH AGENDA FOR DSM-V
Chp.: Katharine A. Phillips, M.D.

A Opportunities for Advancement in Psychiatric Science: Sex and Gender-Specific Analyses
Katherine L. Wisner, M.D.

B Gender Differences in Rates of Psychiatric Disorders: An Update
Myrna M. Weissman, Ph.D., Bridget F. Grant, Ph.D.

C Sex Differences in Neurobiology
Margaret Altemus, M.D.

D Gender Issues in the DSM
Kimberly A. Yonkers, M.D., Katherine A. Halmi, M.D., William E. Narrow, M.D.

E Gender in the History and Future of the DSM
Thomas A. Widiger, Ph.D.

Discussant: David J. Kupfer, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 6  2:00 p.m.-5:00 p.m.
Room A407, Level 4, Georgia World Congress Center

RESEARCH ADVANCES IN LATE-LIFE MENTAL DISORDERS: TOWARD DSM-V
Collaborative Session With the National Institute of Mental Health
Chp.: Dilip V. Jeste, M.D.

A Age-Related Diagnostic Variations: Presentations, Course, and Outcome
Dilip V. Jeste, M.D., Dan G. Blazer II, M.D.

B The Use of Biomarkers in the Elderly: Current and Future Challenges
Raquel E. Gur, M.D., Steven E. Arnold, M.D., Trey Sunderland, M.D.

C Biology and Pathophysiology: Psychosocial and Behavioral Correlates
Charles F. Reynolds III, M.D., Patricia Aarean, Ph.D.

D Comorbidity: Medical and CNS Factors in Late-Life Disorders
Susan K. Schultz, M.D., George S. Alexopoulos, M.D., Linda K. Ganzini, M.D., Ira R. Kaz, M.D., Barry D. Lebowitz, Ph.D.

Discussants: Barry D. Lebowitz, Ph.D., Darrel A. Regier, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 7  2:00 p.m.-5:00 p.m.
Room A408, Level 4, Georgia World Congress Center

HEALTH CARE MELTDOWN: WHAT CAN WE DO?
Chp.: Leslie H. Gise, M.D.

A Evaluating One State’s Single-Payer Health Care Proposal: Georgia
Henry S. Kahn, M.D.

B How Would a Canadian-Style Single-Payer Health System Impact the Practice of Community Psychiatry in America?
Karen M. Hochman, M.D.

C Working Under a Universal Health Care Plan
Jonathan S. Davine, M.D.

D Fiscal Federalism and Mental Health Care for Homeless Persons
Raymond J. Kotwicki, M.D.

Discussants: Steven S. Sharfstein, M.D., David Satcher, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 8  2:00 p.m.-5:00 p.m.
Room A410, Level 4, Georgia World Congress Center

CLINICAL ADVANCES IN EARLY DETECTION, PREVENTION, AND TREATMENT OF PSYCHOSIS
Collaborative Session With the National Institute of Mental Health
Chp.: Robert K. Heinssen, Ph.D.
Co-Chp.: Thomas H. McGlashan, M.D.

A Accurate Prediction of At-Risk Patients
Diana O. Perkins, M.D.

B Family Intervention in the Prodrome of Psychosis
William R. McFarlane, M.D., William L. Cook

C Pharmacological Intervention During the Prodromal Phase
Scott W. Woods, M.D.

D Nonadherence: A Major Risk Factor for Psychosis in Prodromal Adolescents
Barbara A. Cornblatt, Ph.D., Christopher Smith, M.A., Andrea Aheur, Ph.D., Todd Lencz, Ph.D., Christoph Currell, M.D., Ruth Olsen, B.S., Emilie Nakayana, Ph.D.

E Reducing Duration of Untreated First-Episode Psychosis
Thomas H. McGlashan, M.D., Ingrid Melle, M.D., Svein Friis, M.D., Tor K. Larsen, M.D., Jan O. Johannessen, M.D., Ulrik Haahr, M.D., Per Vaglum, M.D.

Discussant: Crystal R. Blyler, Ph.D.
THIS SESSION WILL BE AUDIOTAPEd.
SYMPOSIUM 9 2:00 p.m.-5:00 p.m.
Room B307, Level 3, Georgia World Congress Center

CLINICAL EFFECTIVENESS TRIALS IN THE REAL WORLD: STATUS AND FINDINGS OF THE NIMH TREATMENT TRIALS
Collaborative Session With the National Institute of Mental Health

Chp.: Grayson S. Norquist, M.D.

A Current Status and Controversies in Antipsychotic Drug Effectiveness: Update From the CATIE Study
Jeffrey A. Lieberman, M.D.

B Treatment for Adolescents With Depression Study (TADS)
John S. March, M.D.

C An Update on the STAR*D Trial
A. John Rush, M.D., Madhukar H. Trivedi, M.D., Stephen R. Wisniewski, Ph.D., Maurizio Fava, M.D.

D Treatment of Bipolar Depression: Effectiveness of Antidepressants' Observational Outcomes in STEP-BD
Gary S. Sachs, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 10 2:00 p.m.-5:00 p.m.
Room B308, Level 3, Georgia World Congress Center

NEW PHARMACOLOGIC APPROACHES TO ALCOHOLISM
American Academy of Addiction Psychiatry

Chp.: Marc Galanter, M.D.

A Neurochemical Basis for Alcohol Pharmacotherapy
Raymond F. Anton, Jr., M.D.

B Matching Serotonergic Medications to Alcoholism Subtypes
Henry R. Kranzler, M.D.

C Combination Medication Strategies for Alcoholism
Bankole A. Johnson, M.D.

D Relationship Between 5HT Transporter Function and Craving Among Hispanic Patients With Alcoholism
Nassima Ait-Daoud, M.D.

Discussants: Kathleen T. Brady, M.D., Michael H. Gendel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.
Room B309, Level 3, Georgia World Congress Center

CARBOHYDRATE CRAVING AND MOOD DISORDERS: NEW AND COMPLEMENTARY TREATMENTS

Chp.: John P. Docherty, M.D.

A Mediators of Carbohydrate Craving in Depression May Also Shorten Lifespan
Philip W. Gold, M.D.

B An Animal Model of Addiction to Sugar
Barley G. Hoebel, Ph.D.

C Implications of Carbohydrate Craving in SAD
Norman E. Rosenthal, M.D.

D Atypical Depression, Carbohydrate Craving, and Clinical Response
David A. Sack, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.
Room B310, Level 3, Georgia World Congress Center

BEREAVEMENT, DEPRESSION, AND PTSD: BOUNDARY AND TREATMENT ISSUES

Chp.: Sidney Zisook, M.D.
Co-Chp.: M. Katherine Shear, M.D.

A Grief: Myths, Evidence, and Unresolved Questions
George A. Bonanno, Ph.D.

B Bereavement-Related Depression: Diagnostic and Treatment Guidelines
Sidney Zisook, M.D., M. Katherine Shear, M.D.

C Distinguishing Trauma and Traumatic Loss: PTSD Versus Traumatic Grief
Randall D. Marshall, M.D.

D Depression Following Bereavement and the Occurrence of Comorbid PTSD
Paula L. Hensley, M.D., Paula Clayton, M.D.

E Traumatic Grief and Its Treatment
M. Katherine Shear, M.D.

Discussant: Paula Clayton, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 13 2:00 p.m.-5:00 p.m.  
Room B311, Level 3, Georgia World Congress Center  

UNDERSTANDING COMPLEX MOOD DISORDERS:  
THE ROLE OF PERSONALITY VARIABLES  

Chp.: Sidney H. Kennedy, M.D.  
Co-Chp.: R. Michael Bagby, Ph.D.  

A Personality Dimensions and Disorders: A  
Psychobiology Update  
Emil F. Coccaro, M.D.  

B Optimizing Outcome in Patients With Bipolar  
Disorder and Personality Psychopathology  
Glenda M. MacQueen, M.D.  

C Key Psychotherapy Issues in Patients With Major  
Depression and Personality Psychopathology  
Michael B. Rosenbluth, M.D.  

D The Influence of Personality Variables on  
Pharmacotherapy Outcomes in Major Depression  
Sidney H. Kennedy, M.D., R. Michael Bagby, Ph.D.  

Discussant: Paul T. Costa, Jr., Ph.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.  
Room B314, Level 3, Georgia World Congress Center  

DIAGNOSIS, ASSESSMENT, MANAGEMENT, AND  
QUALITY-OF-LIFE ISSUES IN ADULT ADHD  

Chp.: Thomas J. Spencer, M.D.  

A Diagnosing Adult ADHD  
Thomas J. Spencer, M.D.  

B Functional Impairment in Adults With ADHD  
Margaret D. Weiss, M.D.  

C Pharmacologic Treatment of Adults With ADHD  
David Goodman, M.D.  

D Measuring Quality of Life in Adults With ADHD  
Jeanne Landgraf, M.A.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.  
Room B315, Level 3, Georgia World Congress Center  

ETHNOPSYCHOPHARMACOLOGY: AN UPDATE ON  
CROSS-CULTURAL ASPECTS OF MOOD AND  
ANXIETY DISORDERS  

Chp.: Shamsah B. Sonawalla, M.D.  
Co-Chp.: Gregory L. Fricchione, M.D.  

A Ethnopsychopharmacology Update  
David C. Henderson, M.D.  

B Psychiatric Management of Hispanic Patients: Cross- 
Cultural Issues and Ethnopsychopharmacology  
David Mischoulon, M.D.  

C Impact of Cultural Beliefs on the Treatment of  
Depressed Chinese Americans  
Albert Yeung, M.D.  

D Mood and Anxiety Disorder Diagnosis and Treatment  
in the Asian-Indian Population  
Rajesh M. Parikh, M.D.  

Discussant: Gregory L. Fricchione, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.  
Room B316, Level 3, Georgia World Congress Center  

PSYCHOSOMATIC MEDICINE: MANAGING THE  
HIGH RATES OF MORTALITY AND MORBIDITY  

Chp.: Robert G. Robinson, M.D.  

A Poststroke Depression and Mortality  
Robert G. Robinson, M.D.  

B Heart Failure and Major Depression  
Carolyn L. Turvey, Ph.D.  

C Mortality and CHD: New Targets for Treatment  
Studies  
Francois Lesperance, M.D.  

D The Effect of Antidepressants on Mortality After  
Stroke  
Ricardo Jorge, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.  
Room B402, Level 4, Georgia World Congress Center  

NOVEL TARGETS FOR NOVEL  
NEUROPSYCHIATRIC DRUGS  

Chp.: Elliott Richelson, M.D.  

A Neurokinin Receptor Antagonists as Antidepressants  
and Anxiolytics  
Klaus Lieb, M.D.  

B Inhibitors of Enkephalin-Degrading Enzymes and  
Delta Opioid Responses  
Florence Noble, Ph.D.  

C Discovery of Nonpeptide CRF1 Receptor Antagonists  
as Novel Psychotherapeutic Agents  
Dimtri E. Grigoriadis, Ph.D.  

D Neurotensin Agonist NT69L: A Drug for  
Neuropsychiatric Diseases  
Elliott Richelson, M.D.
E Antidepressant-Elicited Changes in Gene Expression
Mitsuhiko Yamada, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Room B403, Level 4, Georgia World Congress Center

USE OF CONCOMITANT OR ADJUNCTIVE MEDICATIONS IN SCHIZOPHRENIA

Chp.: Ira D. Glick, M.D.
Co-Chp.: Alexander L. Miller, M.D.

A Use of Combination Antipsychotics
Alexander L. Miller, M.D.

B Utilization of Combinations of Antipsychotics in the Department of Veterans Affairs
Andre Tapp, M.D.

C The Use of Antidepressants in Chronic Schizophrenia
Samuel G. Siris, M.D., Paul C. Bermanzohn, M.D.

D Use of Adjunctive Medications for Anxiety, Agitation, and Sleep in Schizophrenia
Del D. Miller, M.D.

E Efficacy of Concomitant Medications for Stabilized Patients With Schizophrenia
Ira D. Glick, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Room B404, Level 4, Georgia World Congress Center

MALADAPTIVE PERSONALITY TRAITS: DRUG TREATMENT, GENETICS, AND BIOLOGY

Chp.: James H. Reich, M.D.

A General Approach to Drug Treatment of Maladaptive Personality Traits
James H. Reich, M.D.

B Antipsychotic and Antidepressant Use in Personality Traits Treatment
Alan F. Schatzberg, M.D.

C Mood Stabilizers in Personality Disorder Treatment
Eric Hollander, M.D., Daphne Simeon, M.D., Brynn Baker, M.D.

D New Research Perspectives on the Neurobiology of Personality Disorders
Larry J. Siever, M.D.

E The Neurobiology of Social and Emotional Dysfunction in BPD
Michael J. Minzenberg, M.D., Antonia S. New, M.D., Harold W. Koenigsberg, M.D., Jin Fan, Erin Hazlett, Ph.D., Larry J. Siever, M.D.

F Psychotherapy and Combined Treatment in BPD: Possible Effects
Marianne Goodman, M.D., Antonia S. New, M.D., Harold W. Koenigsberg, M.D., Erin Hazlett, Ph.D., Janine Flory, Ph.D., Larry J. Siever, M.D.

SYMPOSIUM 20 2:00 p.m.-5:00 p.m.
Room B409, Level 4, Georgia World Congress Center

THE END OF THE BIOPSYCHOSOCIAL MODEL? AN ASSESSMENT AND ALTERNATIVES

Chp.: S. Nassir Ghaemi, M.D.
Co-Chp.: Rodrigo A. Munoz, M.D.

A The Limitations of the Biopsychosocial Model in Psychiatry
G. Scott Waterman, M.D.

B The Biopsychosocial Model: Strengths Versus Weaknesses Related to Assumptions About Good Scientific Categories
Peter Zachar, Ph.D.

C Karl Jaspers and a Pluralist Model of Psychiatry
S. Nassir Ghaemi, M.D.

D Healing Psychiatry: The Need for Pragmatism
David H. Brendel, M.D.

E Six Questions for Clinical Models
John Sadler, M.D.

Discussant: Paul R. McHugh, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.
Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

BEHIND CLOSED DOORS: THE HIDDEN FAMILY: VIOLENCE AND ABUSE ISSUES WORLDWIDE

APA Alliance

Chp.: Helen Herrman, M.D.
Co-Chp.: Marianne C. Kastrup, M.D.

A Human Trafficking in Women: Behind Closed Doors
Donna E. Stewart, M.D., Olga Gajic-Veljanoski

B Domestic Abuse in the Land of the Devis
Surinder S. Nand, M.D.

C Behind Closed Doors in Africa: The Case of Women and Children
Frank G. Njenga, M.D.

(Continued next page)
D Specific Aspects Related to Traumatized Women and Their Children
Marianne C. Kastrup, M.D.

E Clinical and Public Health Aspects of Intimate Partner Violence
Helen Herman, M.D.

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.
Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

LARGE OBSERVATIONAL STUDIES OF ADHD: METHODOLOGY AND RESULTS
Chp.: Calvin R. Sumner, M.D.

A Effect of Atomoxetine in a Naturalistic Pediatric ADHD Treatment Setting
Douglas K. Kelsey, M.D., S. Malcolm, B.S., Rosalie Bakken, Ph.D., M. Paczkowski, M.P.H, Virginia Sutton, Ph.D., Calvin R. Sumner, M.D.

B A Two-Year, Pan-European, Observational Study of ADHD: Overview and Baseline
Ulrich Preuss, M.D., Airbert Rothenberger, Lauren Vlasveld, Stephen J. Ralston, Maria J. Lorenzo

C A Factorial and Graphical Multidimensional Analysis of Patients in ADORE
Bruno Falissard, M.D., Anne W. Riley, Ph.D., Hans-Christoph Steinhausen, Stephen J. Ralston, Maria J. Lorenzo

D Outcomes and Regression Analysis: ADHD Observational Research in Europe
Manfred Doepfner, M.D., Torunn S. Novick, Rob R. Pereira, Stephen J. Ralston, Maria J. Lorenzo

Discussant: Christopher J. Kratochvil, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

IMPROVING CARE FOR TRAUMA-RELATED PSYCHIATRIC DISORDERS IN GENERAL MEDICAL SETTINGS
Chp.: Charles C. Engel, M.D.

A Barriers to Care and Psychiatric Disorders Among Iraq and Afghanistan Veterans
Charles W. Hoge, M.D., Carl A. Castro, Ph.D., Stephen C. Messer, Ph.D.

B Improving Primary Care for PTSD: Lessons From the RESPECT-Depression Project
Allen J. Dietrich, M.D.

C Early PTSD and Risk Behavior Intervention After Admission for Acute Surgical Trauma
Douglas F. Zatzick, M.D.

Discussant: Matthew Friedman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

THE PSYCHIATRIC EFFECTS OF THE WORLD TRADE CENTER ATTACK IN DISASTER RELIEF WORKERS
Collaborative Session With the National Institute of Mental Health
Chp.: JoAnn Difede, Ph.D.

A Prevalence and Predictors of PTSD in 2,960 Male Disaster Relief Workers Following the World Trade Center Attack
JoAnn Difede, Ph.D.

B Childhood Sexual Abuse as a Predictor of Psychiatric Symptoms in a Sample of Disaster Relief Workers Following a Terrorist Attack
Pamela Leek, Ph.D.

C Treatment-Readiness in World Trade Center Attack Disaster Workers
Nimali Jayasinghe, Ph.D.

D Self-Report Versus Clinical Assessment of World Trade Center Disaster Workers With PTSD
Frank W. Weathers, Ph.D.

Discussant: Charles R. Marmar, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Dogwood A, North Tower, Street Level, Omni Hotel

RESEARCH UPDATE ON PEDIATRIC BIPOLAR DISORDER
Chp.: Daniel P. Dickstein, M.D.

A Course and Outcome of Bipolar Youth
Boris Birmaher, M.D., Martin Retter, M.D., Michael Strober, Ph.D., David A. Axelson, M.D., Neal D. Ryan, M.D., Henrietta L. Leonard, M.D., Mary K. Gill, R.N., Sylvia Valeri, Ph.D.

B Prepubertal Mania: Diagnosis, Prognosis, Family, and Molecular Genetics
Barbara G. Geller, M.D.
Pharmacological Treatment Options for Children and Adolescents With Bipolar Disorder
Melissa P. DelBello, M.D.

Pediatric Bipolar Disorder and the Utility of Cardinal Symptoms
Janet Wozniak, M.D., Joseph Biederman, M.D., Anne Kwon, M.S., Eric Milk, Ph.D.

Neurobiological Evidence of Pediatric Phenotypes
Daniel P. Dickstein, M.D., Brendan Rich, Ph.D., Michael Milham, M.D., Erin McGue, Ph.D., Daniel S. Pine, M.D.,
Ellen Leibenluft, M.D.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.
Dogwood B, North Tower, Street Level, Omni Hotel

THE BIOETHICS OF TREATING PSYCHOSES
Chp.: Edmund G. Howe, M.D.

A Influence of Mood State on Capacity to Consent to Research in Bipolar Patients
Sahana Misra, M.D., Linda K. Ganzini, M.D.

B The Unintended Consequences of Antipsychotic Therapy for Schizophrenia
Michael R. Arambula, M.D.

C The Unique Case of Psychotic Criminal Defendants
Paul S. Appelbaum, M.D.

THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5
3:00 p.m.-5:00 p.m.
Room B302/303/304/305, Level 3, Georgia World Congress Center

PSYCHOSIS AND ADDICTION

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

5:30 p.m. Session

CONVOCATION OF DISTINGUISHED FELLOWS
5:30 p.m.-6:30 p.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center
LECTURE 9
5:30 p.m.-6:30 p.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

WILLIAM C. MENNINGER MEMORIAL
LECTURE

Trisha Meili

I Am the Central Park Jogger:
A Story of Hope and Possibility

On April 19, 1989, a young woman went for a run in New York's Central Park shortly after 9:00 p.m. Hours later, she was found near death—in a coma, with 75% blood loss, a fierce blow to the head, and severe exposure—after a brutal beating and rape. The story seized the headlines, as people contemplated what the savagery of the attack said about our society. Fourteen years later, Trisha Meili, known to the world as the Central Park Jogger, revealed her story of survival and recovery in her memoir, I Am the Central Park Jogger: A Story of Hope and Possibility. In this lecture, Ms. Meili shares how her journey of healing clearly linked the mind, body, and spirit and allowed her to move beyond being a victim and reclaim her life. Born in Paramus, New Jersey, Ms. Meili attended Wellesley College and was a double graduate degree recipient (M.B.A. and M.A.) at Yale University. After graduation, she worked at the investment bank Salomon Brothers until her life was violently interrupted. Ms. Meili now speaks to groups about her recovery and gives her time to the organizations vital to her healing, including the Sexual Assault and Violence Intervention Program at Mount Sinai Hospital; Gaylord Hospital, where she did much of her rehabilitation; and the Achilles Track Club, which helped her run the New York City Marathon in 1995.

This session will be audiotaped.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 34-38

INDUSTRY-SUPPORTED SYMPOSIUM 34
7:00 p.m.-10:00 p.m.
Grand Ballroom, Second Floor, Hilton Atlanta

BIPOLAR DISORDER MANAGEMENT: A NEW EDITION
Supported by GlaxoSmithKline

Chp.: Frederick K. Goodwin, M.D.

A When and How to Use Antidepressants for Bipolar Depression
S. Nassir Ghaemi, M.D.

B Clinical Strategies for Bipolar Depression
Terence A. Ketter, M.D.

C How to Combine Medications for Long-Term Stabilization
Frederick K. Goodwin, M.D.

D Recognizing and Treating Bipolar Disorder in Children
Gabrielle A. Carlson, M.D.

E New Understanding of Psychological Issues and of Effective Psychotherapy
Kay Redfield Jamison, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 35
7:00 p.m.-10:00 p.m.
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

DUAL DIAGNOSIS: THE SCOPE OF THE PROBLEM
Supported by AstraZeneca Pharmaceuticals

Chp.: Alan I. Green, M.D.

A Prevalence and Consequences of Dual Diagnosis
Peter F. Buckley, M.D.

B Adolescent Substance Abuse and Psychiatric Comorbidities
Deborah Deas, MD.

C Psychosocial Intervention for Dual Diagnosis
Mary F. Brunette, M.D., Robert Drake, M.D., Kim T. Mueser, Ph.D., Greg McHugo, Ph.D.

D Treatment of Bipolar Disorder and Substance Abuse
E. Sherwood Brown, M.D.

E Treatment of Schizophrenia and Substance Abuse
Alan I. Green, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36
7:00 p.m.-10:00 p.m.
Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

INSOMNIA IN SPECIAL POPULATIONS: IS THIS INSOMNIA OR SOMETHING ELSE?
Supported by Sepracor, Inc.

Chp.: Ruth M. Benca, M.D.
Co-Chp.: Claudio N. Soares, M.D.

A Insomnia in the Elderly
Sonia Ancoli-Israel, Ph.D.

B Insomnia in Depressed Patients
Ruth M. Benca, M.D.
MONDAY

C Insomnia in Women: An Overlooked Epidemic?
Claudio N. Soares, M.D.

D Novel Strategies to Treat Insomnia
John W. Winkelman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37
7:00 p.m.-10:00 p.m.
International Ballroom, North Tower, Ballroom Level,
Omni Hotel

INSULIN RESISTANCE AND METABOLIC SYNDROME IN NEUROPSYCHIATRY
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Natalie L. Rasgon, M.D.

A The Insulin Resistance Syndrome: What Is It? Why Is It Important?
Gerald Reaven, M.D.

B Insulin Resistance and Metabolic Risk During Antipsychotic Treatment
John W. Newcomer, M.D.

C Risk, Assessment, and Management of Insulin Resistance in Affective Disorders
H. Brent Solvason, M.D.

D Insulin Resistance and Cognitive Disorders
Suzanne Craft, Ph.D.

E Insulin Resistance: The Link Between Affective Disorders and Alzheimer's Disease
Natalie L. Rasgon, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38
7:00 p.m.-10:00 p.m.
Grand Ballroom, North Tower, Grand Ballroom Level,
Omni Hotel

OVERCOMING TRADITIONAL DILEMMAS IN TREATING DEPRESSIVE ILLNESSES: EVIDENCE-BASED UPDATES
Supported by Wyeth Pharmaceuticals

Chp.: John F. Greden, M.D.

A Improved Remission Rates: Do Any Antidepressants Stand Out?
Linda L. Carpenter, M.D.

B Influence of Comorbidity on the Treatment of Depression
David L. Dunner, M.D.

C Combining Antidepressant Treatments for Better Efficacy: What Does the Literature Say?
Thomas L. Schwartz, M.D.

D Brain Stimulation in Psychiatric Treatment: State of the Evidence
Sarah H. Lisanby, M.D.

E Effectiveness of Antidepressant Treatments for Preventing Recurrences: Several Decades of Evidence
John F. Greden, M.D.
Audiotapes and CDs
Recorded Live!

Live recordings will be available for most of the following:

- Lectures • Advances in Research
- Advances in Psychotherapy • Advances in Psychosomatic Medicine
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Roundtable Discussion
- Research Advances in Medicine

Tapes may be purchased on site at Mobiltape’s booth at the Georgia World Congress Center.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 □ (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
TUESDAY, MAY 24, 2005

158TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 31-33

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 2
7:00 a.m.-8:30 a.m.
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

AGITATION AND PSYCHOSIS IN ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE
Supported by AstraZeneca Pharmaceuticals

Chp.: Jeffrey L. Cummings, M.D.

A Efficacy and Tolerability of Atypical Antipsychotics in Agitation and Psychosis: Research Results
Pierre N. Tarion, M.D.

B Efficacy and Tolerability of Atypical Antipsychotics in Agitation and Psychosis: Clinical Applications
Jeanne Jackson-Siegel, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 2
7:00 a.m.-8:30 a.m.
International Ballroom, North Tower, Ballroom Level, Omni Hotel

MANAGING THE SPECTRUM OF BIPOLAR DISORDER: MINIMIZING THE BURDEN OF DISEASE
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A The Impact of Safety and Tolerability on Patient Satisfaction With Therapy
Paul E. Keck, Jr., M.D.

B The Impact of Bipolar Maintenance Therapy on Patient Outcomes
Lori L. Altshuler, M.D.

8:00 a.m. Sessions

COURSES 58-65
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 58 - WITHDRAWN

COURSE 59 8:00 a.m.-12 noon
Newton Room, Second Floor, Hilton Atlanta

IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH

Director: Luis F. Ramirez, M.D.

COURSE 60 8:00 a.m.-12 noon
Rockdale Room, Second Floor, Hilton Atlanta

DYNAMIC PSYCHOTHERAPY FOR CANCER PATIENTS AND THEIR SPOUSES

Director: Norman L. Straker, M.D.
TUESDAY

COURSE 61 8:00 a.m.-12 noon
Gwinnett Room, Second Floor, Hilton Atlanta

EXPANDING HEALTH CARE DELIVERY? LET TELEPSYCHIATRY HELP!

Director: Steven E. Hyler, M.D.
Faculty: William M. Tucker, M.D., Gerald Segal, M.S., Scott I. Bienenfeld, M.D.

COURSE 62 8:00 a.m.-12 noon
Grand Salon A, Second Floor, Hilton Atlanta

THE WAY OF YOGA AND HERBS IN THE TREATMENT OF STRESS, DEPRESSION, AND AGGRESSION

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

COURSE 63 8:00 a.m.-12 noon
Grand Salon B, Second Floor, Hilton Atlanta

SLEEP MEDICINE UPDATE: ADVANCED TOPICS

Director: Thomas D. Hurwitz, M.D.
Faculty: Max Hirschowitz, Ph.D., Lois Krahn, M.D.

COURSE 64 8:00 a.m.-12 noon
Monroe/Roosevelt Room, Third Floor, Hilton Atlanta

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 65 8:00 a.m.-12 noon
Board/Directors Rooms, Fourth Floor, Hilton Atlanta

HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: BASIC

Co-Directors: John Luo, M.D., Richard Montgomery, M.D.
Faculty: Umar Latif, M.D., Robert J. Boland, M.D., Carlyle H. Chan, M.D., Robert C. Hsiung, M.D., Charles J. Rainey, M.D.

9:00 a.m. Sessions

ADVANCES IN PSYCHOSOMATIC MEDICINE
9:00 a.m.-12:30 p.m.
Rooms B405/406/407, Level 4, Georgia World Congress Center

ADVANCES IN PSYCHOSOMATIC MEDICINE:
PSYCHIATRIC CARE OF THE MEDITICALLY ILL
American Psychiatric Publishing Inc. Editorial Board
COURSES 66-72

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 66 9:00 a.m.-4:00 p.m.
Fulton Room, Second Floor, Hilton Atlanta

THE ASSESSMENT AND TREATMENT OF CHILD SEXUAL ABUSERS

Co-Directors: Gene G. Abel, M.D., John M. Bradford, M.B.
Faculty: Tracey L. Irvin, M.D.

COURSE 67 9:00 a.m.-4:00 p.m.
Cobb Room, Second Floor, Hilton Atlanta

MONEY MATTERS II: ADVANCED AD HOC CLINICAL SEMINAR

Director: Cecilia M. Mikalac, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.
Clayton Room, Second Floor, Hilton Atlanta

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT

Director: Robert P. Granacher, Jr., M.D.

COURSE 69 9:00 a.m.-4:00 p.m.
Grand Salon D, Second Floor, Hilton Atlanta

MED-PSYCH DRUG-DRUG INTERACTIONS

Co-Directors: Neil B. Sandson, M.D., Scott C. Armstrong, M.D.
Faculty: David M. Benedek, M.D., Gabriel Eckermann, M.D., Jessica R. Oesterheld, M.D.

COURSE 70 9:00 a.m.-4:00 p.m.
Jackson Room, Third Floor, Hilton Atlanta

PERSONALITY AND POLITICAL BEHAVIOR

APA Council on Global Psychiatry

Director: Jerrold M. Post, M.D.

COURSE 71 9:00 a.m.-4:00 p.m.
Madison Room, Third Floor, Hilton Atlanta

RECOGNITION AND TREATMENT OF COMPLICATED GRIEF

Director: M. Katherine Shear, M.D.
Faculty: Bonnie Gorscak, Ph.D., Allan Zuckoff, Ph.D., Naomi M. Simon, M.D.

COURSE 72 9:00 a.m.-4:00 p.m.
Club/State Rooms, Fourth Floor, Hilton Atlanta

PROVIDER PROTECT THYSELF: MANAGED CARE CONTRACTING FOR MENTAL HEALTH PROVIDERS

Director: William H. Campbell, M.D.

DISCUSSION GROUPS 9-12

9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

9 Pedro Ruiz, M.D., on the Role of Culture in Psychiatric Practice (For Residents Only)
International Rooms 2-3, International Level, Marriott Marquis Atlanta

10 K. Ranga R. Krishnan, M.D., on Psychiatric Diagnosis: Approaches in the Post-Genomic Era
Collaborative Session With the National Institute of Mental Health
Chestnut Room, North Tower, Meeting Level, Omni Hotel

11 Katherine L. Wisner, M.D., on Postpartum Mood Disorders
Hazelnut Room, North Tower, Meeting Level, Omni Hotel

12 Ronald W. Pies, M.D., on the Great Bipolar Depression Controversy: A Pragmatic Approach (Meet the Authors)
Pecan Room, North Tower, Meeting Level, Omni Hotel

LECTURES 10-11

LECTURE 10

9:00 a.m.-10:30 a.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

Robert Freedman, M.D.

From Genes to Therapeutics: New Approaches to Schizophrenia
Collaborative Session With the National Institute of Mental Health

Chp.: John F. Greden, M.D.
Co-Chp.: Anthony J. Rothschild, M.D.
Robert Freedman, M.D., is Chairman of the Department of Psychiatry, Professor of Psychiatry and Pharmacology, and Director of the Schizophrenia Research Center at the University of Colorado Health Sciences Center in Denver and the Denver Veterans Affairs Mental Illness Research, Education and Clinical Center. His research interest is in the application of basic findings in neurobiology and molecular biology to the treatment of psychoses. The author of more than 200 scientific articles, Dr. Freedman has received the A.E. Bennett Research Award of the Society of Biological Psychiatry, the William K. Warren Award of the International Congress of Schizophrenia Research, the Stanley R. Dean Award of the American College of Psychiatrists, and the Distinguished Investigator Award of the National Alliance for Research on Schizophrenia and Depression. He is a Distinguished Fellow of the American Psychiatric Association and a member of the Institute of Medicine, the Board of Scientific Counselors of the National Institute on Drug Abuse, and the National Advisory Council of the National Institutes of Health. Dr. Freedman received his medical degree from Harvard Medical School in Boston and trained in psychiatry at the National Institute of Mental Health in Bethesda, Maryland, and the University of Chicago Hospital and Clinics.

Distinguished Psychiatrist Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 11
9:00 a.m.-10:30 a.m.
Room A412, Level 4
Georgia World Congress Center

APA'S KUN-PO SOO AWARD LECTURE
K. Patrick Okura, Ph.D. (Posthumously)

Leadership Through Example:
Mentorship and Networking
Chp.: John Luo, M.D.
Co-Chp.: Russell F. Lim, M.D.

This lecture will be an open discussion focusing on K. Patrick Okura's life as a dynamic example of leadership through example. He served as the unofficial mayor of the Santa Anita Assembly Center (a Japanese American Internment Camp) in 1941, the National President for the Japanese American Citizen's League from 1962-64, where he led the effort to join Martin Luther King Jr. in his march on Washington, D.C., and as the Director of the Okura Mental Health Foundation, in addition to other leadership positions. THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 5-6
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

5 Harold Kudler, M.D., on PTSD and Deployment Mental Health
Room B317, Level 3, Georgia World Congress Center

6 John D. Wynn, M.D., on Psychosomatics and the Medically Complex Patient: Sorting Out Axis I, II, and III
Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

RESEARCH ADVANCES IN MEDICINE
9:00 a.m.-11:00 a.m.
Room A302, Level 3, Georgia World Congress Center

EXPLORING NEW FRONTIERS AND CLINICAL APPLICATIONS
Chp: Charles B. Nemeroff, M.D.
Co-Chp.: Marian I. Butterfield, M.D.

Participants: Cornelia M. Weyand, M.D., on Immunosenescence and Rheumatoid Arthritis
Elizabeth Ofili, M.D., on Research Advances in Cardiovascular Diseases
Lawrence S. Phillips, M.D., on Diabetes Update 2005
David G. Harrison, M.D., on Vascular Diseases, Oxidative Stress, and Depression
Viola Vaccarino, M.D., on Stress, Depression, and the Metabolic Syndrome

ROUND TABLE DISCUSSION
9:00 a.m.-10:30 a.m.
Room A404, Level 4, Georgia World Congress Center

SAFETY AND EFFICACY OF SSRI ANTIDEPRESSANTS IN CHILDREN AND ADOLESCENTS: WHAT DO WE KNOW AND WHEN DID WE KNOW IT?
Moderator: Richard E. D'Alli, M.D.
Participants: Graham J. Emslie, M.D., John S. March, M.D., John T. Walkup, M.D., Benedetto Vitiello, M.D.

WORKSHOPS
COMPONENTS 18-26

COMPONENT WORKSHOP 18
9:00 a.m.-10:30 a.m.
Room A304, Level 3, Georgia World Congress Center

"Y" PSYCHOTHERAPY: AN INTEGRATED, EVIDENCE-BASED PSYCHOTHERAPY COMPETENCY MODEL
APA Committee on Psychotherapy by Psychiatrists

Co-Chps.: Eric M. Plakun, M.D., Lisa A. Mellman, M.D.
Participants: Daniel T. Chrzanowski, M.D., Allison V. Downer, M.D., Asher B. Simon, M.D.
COMPONENT WORKSHOP 19  9:00 a.m.-10:30 a.m.
Room A405, Level 4, Georgia World Congress Center

PATIENT SAFETY: EVALUATING AN ADVERSE EVENT AND IMPLEMENTING SAFEGUARDS
APA Committee on Patient Safety

Chp.: Paul R. McHugh, M.D.
Participants: Alfred Herzog, M.D., Geetha Jayaram, M.D.,
Robert A. Wise, M.D., Kathryn J. Ednie, M.D., Bruce W. Hinrichs, M.D., Carl B. Greiner, M.D., Carol B. Perez, M.D.

COMPONENT WORKSHOP 20  9:00 a.m.-10:30 a.m.
Room A405, Level 4, Georgia World Congress Center

CLOSING PRACTICE: WHAT EVERY PSYCHIATRIST'S OFFICE AND HIS/HER FAMILY SHOULD KNOW
APA Corresponding Committee on Physician Health, Illness, and Impairment

Chp.: John A. Fromson, M.D.
Participants: Michael F. Myers, M.D., Cheryl Davenport

COMPONENT WORKSHOP 21  9:00 a.m.-10:30 a.m.
Room B307, Level 3, Georgia World Congress Center

NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO HAVE MADE THEIR OWN WAY
APA Committee on Women

Co-Chps.: Melva I. Green, M.D., Carrie L. Ernst, M.D.
Participants: Catherine A. Roca, M.D., Francine Cournos, M.D.,
Cassandra F. Newkirk, M.D., Mary Jane England, M.D.

COMPONENT WORKSHOP 22  9:00 a.m.-10:30 a.m.
Room B311, Level 3, Georgia World Congress Center

REVERSING THE CRIMINALIZATION OF THE SERIOUSLY MENTALLY ILL
APA Corresponding Committee on Jails and Prisons

Chp.: Henry C. Weinstein, M.D.
Participants: Tom Hamilton, H. Richard Lamb, M.D., Erik Roskes, M.D.

COMPONENT WORKSHOP 23  9:00 a.m.-10:30 a.m.
Room B408, Level 4, Georgia World Congress Center

DISASTER PSYCHIATRY: CHALLENGES AND NOVEL STRATEGIES FOR RESIDENCY TRAINING
APA Committee on Psychiatric Disasters/Disasters

Co-Chps.: Diane E. McLean, M.D., Anthony T. Ng, M.D.
Participants: Davin A. Agustines, M.D., Holly V. MacKenna, M.D., Roman R. Snihurowych, M.D., Molly J. Haal, M.D.

COMPONENT WORKSHOP 24  9:00 a.m.-10:30 a.m.
Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

ETHNICITY, CULTURE, AND RESPONSE TO DISASTER AMONG HISPANICS
APA Committee of Hispanic Psychiatrists

Chp.: Eugenio M. Rothe, M.D.
Participants: Daniel Castellanos, M.D.

COMPONENT WORKSHOP 25  9:00 a.m.-10:30 a.m.
Oak Room, South Tower, Lobby Level, Omni Hotel

SUICIDE AMONG ETHNIC ELDERS
APA Committee on Ethnic Minority Elderly

Co-Chps.: Iqbal Ahmed, M.D., Warachal E. Faison, M.D.
Participants: Carl I. Cohen, M.D., Mia J. Robinson, M.D.,
Yolonda R. Coleman, M.D., Cynthia L. Resendez, M.D.,
Nhi-Ha T. Trinh, M.D., Ronald Brenner, M.D.

COMPONENT WORKSHOP 26  9:00 a.m.-10:30 a.m.
Dogwood B, North Tower, Street Level, Omni Hotel

USING THE HIV DEMENTIA SCALE IN THE CLINICAL SETTING
APA Committee on AIDS

Chp.: Karl Goodkin, M.D.
Participants: Francisco Fernandez, M.D., Stephen J. Ferrado, M.D.,
Giovanni Caracci, M.D., Marshall Forstein, M.D.

ISSUES 27-43

ISSUE WORKSHOP 27  9:00 a.m.-10:30 a.m.
Room A410, Level 4, Georgia World Congress Center

ARE THERE LIMITS TO BOUNDARY LIMITS?

Chp.: Malkah T. Notman, M.D.
Participants: Carl P. Malmquist, M.D., Linda M. Jorgenson, J.D.,
Elissa P. Benedek, M.D., Lawrence B. Inderbitzin, M.D.

ISSUE WORKSHOP 28  9:00 a.m.-10:30 a.m.
Room B301, Level 3, Georgia World Congress Center

CHILDREN OF PSYCHIATRISTS: LISTEN AND LEARN

Co-Chps.: Leah J. Dickstein, M.D., Michelle B. Riba, M.D.
Participants: Sarah Sharfstein, Cory Butterfield, India Primm-Spencer, Sudepta Varma, M.D.
ISSUE WORKSHOP 29 9:00 a.m.-10:30 a.m.
Room B306, Level 3, Georgia World Congress Center

ABPN AND APA PERSPECTIVES ON MAINTENANCE OF CERTIFICATION

Chp.: Stephen C. Scheiber, M.D.
Participants: Victor I. Reus, M.D., Deborah J. Hales, M.D.,
David B. Mallon, M.D.

ISSUE WORKSHOP 30 9:00 a.m.-10:30 a.m.
Room B308, Level 3, Georgia World Congress Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 1

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.

ISSUE WORKSHOP 31 9:00 a.m.-10:30 a.m.
Room B309, Level 3, Georgia World Congress Center

PAIN MANAGEMENT OF THE CHEMICALLY-DEPENDENT PATIENT

Chp.: Jeffrey A. Berman, M.D.
Participants: Christine Skotzko, M.D., Elena Wolfson, M.D.

ISSUE WORKSHOP 32 9:00 a.m.-10:30 a.m.
Room B310, Level 3, Georgia World Congress Center

STRATEGIES FOR SUCCESS FOR EARLY CAREER ACADEMIC PSYCHIATRISTS, PART 1: WRITING FOR PUBLICATION
Collaborative Session With the National Institute of Mental Health

Chp.: Laura W. Roberts, M.D.

ISSUE WORKSHOP 33 9:00 a.m.-10:30 a.m.
Room B314, Level 3, Georgia World Congress Center

DECISIONAL CAPACITY IN THE CONSULTATION/LIAISON SETTING: CONTROVERSIES AND DIFFICULTIES

Chp.: Ramaswamy Viswanathan, M.D.
Participants: Paul S. Appelbaum, M.D., Barbara K.
Schindler, M.D., Scott Y. Kim, M.D., Laura B. Dunn, M.D.

ISSUE WORKSHOP 34 9:00 a.m.-10:30 a.m.
Room B316, Level 3, Georgia World Congress Center

PSYCHIATRIC HOSPICE ON AN ACT TEAM: WHEN MENTAL ILLNESS IS TERMINAL

Chp.: Curtis N. Adams, Jr., M.D., Ann L. Hackman, M.D.
TUESDAY

ISSUE WORKSHOP 40  9:00 a.m.-10:30 a.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

DRIVING MISS DAISY
Co-Chps.: Theron C. Bowers, Jr., M.D., Sheila M. Loboprabhu, M.D.
Participants: Jeffrey Lindeman, Psy.D., Kelly C. Anderson

ISSUE WORKSHOP 41  9:00 a.m.-10:30 a.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

PSYCHIATRISTS INTERVENING UPSTREAM: GOOD PRACTICES FOR PREVENTING VIOLENCE IN CHILDREN, YOUTH, AND FAMILIES
Collaborative Session With the National Institute of Mental Health
Chp.: Giuseppe Raviola, M.D.
Participants: Carl C. Bell, M.D., W. Rodney Hammond, Ph.D.,
Fran Henry, M.B.A., Mark L. Rosenberg, M.D.

ISSUE WORKSHOP 42  9:00 a.m.-10:30 a.m.
Redwood Room, North Tower, Street Level, Omni Hotel

CULTURAL COMPETENCE IN THE CLINICAL ENCOUNTER: IRMA BLAND AND EVELYN LEE
Chp.: Francis G. Lu, M.D.
Participant: Harriet Koskoff

ISSUE WORKSHOP 43  9:00 a.m.-10:30 a.m.
Juniper Room, North Tower, Ballroom Level, Omni Hotel

A NEW MODEL FOR THE TREATMENT OF RELATIONAL DISORDERS
Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S.

MEDIA 4-6

MEDIA WORKSHOP 4  9:00 a.m.-12 noon
Room A406, Level 4, Georgia World Congress Center

Jim in Bold: Gay, Lesbian, and Transgender Teens on Film
American Academy of Child and Adolescent Psychiatry's Sexual Orientation Committee
Co-Chps.: Richard R. Pleak, M.D., Sarah E. Herbert, M.D.
Participants: Malcolm Lazar, Susan Wheeler

MEDIA WORKSHOP 5  9:00 a.m.-12 noon
Room A407, Level 4, Georgia World Congress Center

Long-Term Management of Schizophrenia in the Film Out of the Shadow
Co-Chps.: Stephen M. Goldfinger, M.D., Susan E. Smiley, B.S.
Participant: Kenneth S. Duckworth, M.D.

MEDIA WORKSHOP 6  9:00 a.m.-12 noon
Room A408, Level 4, Georgia World Congress Center

Intergenerational Family Abuse: A Documentary Film
Chp.: Barry Herman, M.D.
Participants: Patti Obrow White, Manuel Garcia, M.D., Harold I. Eist, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 13-15
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

13 Joel Yager, M.D., on Career Building in Academic and Nonacademic Psychiatry (For Residents Only)
International Rooms 2-3, International Level, Marriott Marquis Atlanta

14 Tana A. Grady-Weliky, M.D., on Effective Teaching: What Psychiatry Residents Need to Know
Hazelnut Room, North Tower, Meeting Level, Omni Hotel

15 John A. Chiles, M.D., on Assessment and Treatment of Suicidal Patients (Meet the Authors)
Pecan Room, North Tower, Meeting Level, Omni Hotel

LECTURE 12
11:50 a.m.-12:30 p.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

APA'S JUDD MARMOR AWARD LECTURE
Thomas R. Insel, M.D.
Psychiatry in the Genomic Era
Collaborative Session With the National Institute of Mental Health
Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: David M. Spiegel, M.D.
(Continued next page)
Thomas R. Insel, M.D., is the Director of the National Institute of Mental Health in Bethesda, Maryland. He formerly was the W.E. Timmie Professor of Psychiatry and Behavioral Sciences and Director of the Center for Behavioral Neuroscience at Emory University in Atlanta. In his research, Dr. Insel has used molecular, cellular, and pharmacological approaches to explore the neurobiology of complex social behaviors, including maternal behavior, pairbond formation, and aggression, and examine the role of the neuropeptides oxytocin and vasopressin in these behaviors. Dr. Insel serves on the editorial boards of *Current Reviews in Neurobiology*, *Psychoneuroendocrinology*, and *Biological Psychiatry*. A Fellow of the American College of Neuropsychopharmacology, Dr. Insel has received the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression, the A.E. Bennett Research Award from the Society of Biological Psychiatry, and the Outstanding Service Award from the U.S. Public Health Service. He is the author of more than 200 scientific articles and book chapters and the author or editor of four books, including *The Psychobiology of Obsessive Compulsive Disorder* and *Oxytocin in Maternal, Sexual and Social Behaviors*. Dr. Insel received his medical degree from Boston University Medical School and completed his residency in psychiatry at Langley Porter Neuropsychiatric Institute, University of California, San Francisco.

**MASTER EDUCATOR CLINICAL CONSULTATIONS 7-8**

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

7 Josepha A. Cheong, M.D., on Geriatric Psychiatry
   Room B317, Level 3, Georgia World Congress Center

8 Silvia W. Olarte, M.D., on Psychodynamics in the Era of Psychopharmacology
   Room B318, Level 3, Georgia World Congress Center

**MEDICAL UPDATE 2**

11:00 a.m.-12:30 p.m.

Room B403, Level 4, Georgia World Congress Center

**STRESS-INDUCED ANOVULATION: MIND OVER MATTER**

Presenter: Sara Berga, M.D.
Chp.: Jennifer I. Downey, M.D.

**RESEARCH CONSULTATION WITH**

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

2 Helen S. Mayberg, M.D., on Functional Neuroimaging Strategies in Affective Disorders Research
   Collaborative Session with the National Institute of Mental Health
   Chestnut Room, North Tower, Meeting Level, Omni Hotel

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 10-18**

**SCIENTIFIC AND CLINICAL REPORT SESSION 10**

11:00 a.m.-12:30 p.m.

Room A402, Level 4, Georgia World Congress Center

**EPIDEMIOLOGY AND OTHER ISSUES IN PSYCHIATRY**

Chp.: Steven A. Epstein, M.D.
Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.

29 Parental Separation at Birth and Schizophrenia and Depression
   Pirjo H. Maki, M.D., Juha M. Veijola, Ph.D., Matti Joukamaa, M.D., Helinä Häkko, Ph.D., Matti K. Isohanni, Ph.D.

11:30 a.m.

30 Parental Separation at Birth and Substance-Use Disorder
   Juha M. Veijola, Ph.D., Pirjo H. Maki, M.D., Matti Joukamaa, M.D., Marianne Haapea, M.B., Matti K. Isohanni, Ph.D.

12 noon

31 Pica Syndrome: Review and Relevance
   Jambur V. Ananth, M.D., Virginia Corpuz, M.D., Belinda A. Hara, M.D., Sharath Parameswaran, B.S., Sarah Gunatilake, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**
TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Room A404, Level 4, Georgia World Congress Center

SOMATIC THERAPIES
Chp.: C. Edward Coffey, M.D.
Co-Chp.: Carrie L. Ernst, M.D.

11:00 a.m.
32 The Impact of Electroconvulsive Therapy on Quality of Life and Function
W. Vaughn McCall, M.S.

11:30 a.m.
33 Seizures Targeted to Circuitry: New Forms of Convulsive Therapy
Collaborative Session With the National Institute of Mental Health
Sarah H. Lisanby, M.D.

12 noon
34 Ethical and Legal Implications of Psychiatric Evaluation of Pediatric Gastric Bypass
Gagan Dhaliwal, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.
Room B301, Level 3, Georgia World Congress Center

COGNITIVE DISORDERS
Chp.: Frank N. Brown, M.D.
Co-Chp.: Warachal E. Faison, M.D.

11:00 a.m.
35 Is Depression a Risk Factor for Cognitive Impairment? A Meta-Analysis of 20 Cohort Studies
Alex J. Mitchell, M.D.

11:30 a.m.
36 Treatment of Agitation and Psychosis in Elderly Patients With Dementia
Pierre N. Tariot, M.D.

12 noon
37 Prevalence of Dementia in a Southern European Population in Two Different Time Periods
Pedro Saz, M.D., Antonio Lobo, M.D., Guillermo Marcos, M.D., José-Luis Día, M.D., Concepción De-la-Cámara, M.D., Turso Ventura, M.D., José-Ángel Montañés, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Room B306, Level 3, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE
Chp.: David A. Casey, M.D.
Co-Chp.: Catherine C. Greene, M.D.

11:00 a.m.
38 Somatization Increases Medical Care Utilization and Costs
Arthur J. Barsky, M.D., E. John Orav, Ph.D., David Bates, M.D.

11:30 a.m.
39 The Integrated Management of Medically Unexplained Symptoms
Donald Bakal, Ph.D., Patrick Coll, M.D., Jeffrey Schaefer, M.D.

12 noon
40 Medical and Psychiatric Comorbidities of a Substance Abusing Public Assistance Population
Bruce J. Schwartz, M.D., Scott Wetzler, Ph.D., Tami Videon, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m.-12:30 p.m.
Room B408, Level 4, Georgia World Congress Center

BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE
Chp.: Roy H. Perlis, M.D.
Co-Chp.: Wayne J. Katon, M.D.

11:00 a.m.
41 Brainstem Control of Neurotic and Psychotic Processes
Jacques St. Laurent, M.D.

11:30 a.m.
42 Brain Stimulation: Why, Where, and How?
Collaborative Session With the National Institute of Mental Health
Harold A. Sackeim, Ph.D.

12 noon
43 New Findings on Daily Prefrontal Repetitive Transcranial Magnetic Stimulation for Depression
Collaborative Session With the National Institute of Mental Health
Mark S. George, M.D.
TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Room B409, Level 4, Georgia World Congress Center

ASPECTS OF BIPOLAR DISORDER

Chp.: Thomas R. Thompson, M.D.
Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
44 Negative Impact of Medical Comorbidity on the Course of Bipolar Disorder
Dan V. losifescu, M.D., Polina Eidelman, B.A., Michael J. Ostacher, M.D., Stephanie V.M. Gironde, B.A., Andrew A. Nierenberg, M.D., Gary S. Sachs, M.D.

11:30 a.m.
45 Lithium Continuation/Discontinuation After Four Years of Stability
Eric D. Peselow, M.D., Matthew G. Biel, M.D., Caroline B. Williams, M.D., Ronald R. Fieve, M.D., Mary Anne Pressman, M.D.
12 noon
46 Magnitude of the Effects of Quetiapine Treatment in Bipolar Disorder
Wayne Macfadden, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m.-12:30 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Chp.: Kiki D. Chang, M.D.
Co-Chp.: Martha J. Little M.D.

11:00 a.m.
47 Pediatric Formulation of Modafinil Effective in Children and Adolescents With ADHD
James M. Swanson, M.D., Samuel Boellner, M.D., Thomas Rugino, M.D., R. Bart Sangal, M.D., Sharon B. Wigal, Ph.D.

11:30 a.m.
48 Modafinil Pediatric Formulation Has Early and Sustained Effect in ADHD
Joseph Biederman, M.D., Timothy E. Wilens, M.D., Frank A. Lopez, M.D.
12 noon
49 Polypharmacy Among Youths: How Prevalent Is It?
Farishe F. Duffy, Ph.D., William E. Narrow, M.D., Donald S. Rae, M.A., Joyce C. West, Ph.D., Darrel A. Regier, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17
11:00 a.m.-12:30 p.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

PTSD AND ANXIETY

Chp.: Andrea Bradford, M.D.
Co-Chp.: Asher B. Simon, M.D.

11:00 a.m.
50 PTSD Depression and Anger in Patients Recovered From SARS
Rima Strya, M.D., Allison McGeer, M.D., Sonja Kasapinovic, M.S.C., Marie Louie, M.D., Wayne L. Gold, M.D.

11:30 a.m.
51 Are Anxiety Disorders Underdiagnosed and Undertreated in Psychiatry?
Joshua E. Wilk, Ph.D., Joyce C. West, Ph.D., William E. Narrow, M.D., Donald S. Rae, M.A., Darrel A. Regier, M.D.
12 noon
52 Biological Findings in PTSD: Can They Be Changed by Psychotherapy?
Friedhelm Lamprecht, M.D., Martin Sack, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Dogwood B, North Tower, Street Level, Omni Hotel

ISSUES IN BIOLOGICAL PSYCHIATRY

Chp.: Nashaat N. Boutros, M.D.
Co-Chp.: Edward C. Lauterbach, M.D.

11:00 a.m.
53 The Family Genetic Study of Pathological Gambling
Donald W. Black, M.D., Patrick Monahan, Ph.D.

11:30 a.m.
54 Metabolic Syndrome in Psychiatric Inpatients Receiving Antipsychotics
John W. Goethe, M.D., Bonnie L. Szarek, R.N., Charles F. Galey, Pharm.D.
12 noon
55 Anger Discomfort Predicts Disordered Eating Among College Students With Obesity
Alayne Yates, M.D., Jeanne L. Edman, Ph.D., Mara S. Aruguete, Ph.D., Kurt A. Debord

THIS SESSION WILL BE AUDIOTAPED.
WORKSHOPS

COMPONENTS 27-33

COMPONENT WORKSHOP 27  11:00 a.m.-12:30 p.m.
Room A304, Level 3, Georgia World Congress Center

BENZODIAZEPINES AND OPIATES IN THE ELDERLY: USE, MISUSE, AND ABUSE
*APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly*

Chp.: Allan A. Anderson, M.D.
Participants: Julian Offsay, M.D., Colleen J. Northcott, M.D., James A. Greene, M.D.

COMPONENT WORKSHOP 28  11:00 a.m.-12:30 p.m.
Room A405, Level 4, Georgia World Congress Center

RE-ENGINEERING CLINICAL RESEARCH TRAINING: THE NPTC
*APA Council on Research*

Co-Chps.: John F. Greden, M.D., James F. Leckman, M.D.
Participants: Michael H. Ebert, M.D., Joel J. Silverman, M.D., Michele T. Patu, M.D., Michelle B. Riba, M.D., Paul C. Mohl, M.D.

COMPONENT WORKSHOP 29  11:00 a.m.-12:30 p.m.
Room B309, Level 3, Georgia World Congress Center

I DO, BUT I CAN'T: MENTAL HEALTH ISSUES AROUND GAY MARRIAGE
*APA Committee on Gay, Lesbian, and Bisexual Issues*

Chp.: Serena Yuan Volpp, M.D.
Participants: Jack Drescher, M.D., Kimberly A. Arlinghaus, M.D., Kent E. Dunn, M.D., Daniel W. Hicks, M.D.

COMPONENT WORKSHOP 30  11:00 a.m.-12:30 p.m.
Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

QUOTES AND MISQUOTES: RESIDENT PHYSICIANS WORKING WITH THE MEDIA
*APA Committee of Residents and Fellows and the APA Office of Communications and Public Affairs*

Co-Chps.: William C. Wood, M.D., Hillarie Turner
Participant: Nada L. Stotland, M.D.

COMPONENT WORKSHOP 31  11:00 a.m.-12:30 p.m.
Oak Room, South Tower, Atrium Terrace Level, Omni Hotel

PRACTICING REWARDING PSYCHIATRY IN JAILS AND PRISONS: A PRACTICUM
*APA Council of Psychiatrists Working in Correctional Settings*

Chp.: Henry C. Weinstein, M.D.
Participants: Kathryn A. Burns, M.D., Kenneth G. Gilbert, M.D., Annette L. Hanson, M.D., Cassandra F. Newkirk, M.D., John S. Zil, M.D.

COMPONENT WORKSHOP 32  11:00 a.m.-12:30 p.m.
Juniper Room, North Tower, Ballroom Level, Omni Hotel

THE VOICE OF APA PAST AND PRESENT: CONSIDERATIONS FOR AN ORAL HISTORY PROJECT
*APA Corresponding Committee on History and Library*

Chp.: Avram H. Mack, M.D.
Participants: Joel T. Braslow, M.D., John A. Talbott, M.D.

COMPONENT WORKSHOP 33  11:00 a.m.-12:30 p.m.
Walnut Room, North Tower, Meeting Level, Omni Hotel

WHEN IT'S NOT ALL IN YOUR HEAD: HEALTH, MENTAL ILLNESS, ETHNICITY, AND RECOVERY
*APA Council on Social Issues and Public Psychiatry*

Co-Chps.: Robert P. Cabaj, M.D., Matthew O. Hurford, M.D.
Participants: Gloria Pitts, D.O., Joy D. McQuery, M.D., Stephen M. Thielke, M.D., Gail L. Daumit, M.D.

ISSUES 44-56

ISSUE WORKSHOP 44  11:00 a.m.-12:30 p.m.
Room B307, Level 3, Georgia World Congress Center

TOPICS IN PSYCHOSOMATIC MEDICINE: FATIGUE IN CANCER AND AIDS
*Collaborative Session with the National Institute of Mental Health*

Co-Chps.: William Breinbart, M.D., Andrew J. Roth, M.D.
Participant: William Pirl, M.D.

ISSUE WORKSHOP 45  11:00 a.m.-12:30 p.m.
Room B308, Level 3, Georgia World Congress Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 2

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.
TUESDAY

ISSUE WORKSHOP 46 11:00 a.m.-12:30 p.m.
Room B31C, Level 3, Georgia World Congress Center

STRATEGIES FOR SUCCESS FOR EARLY CAREER ACADEMIC PSYCHIATRISTS, PART 2: PROMOTION
Collaborative Session With the National Institute of Mental Health

Chp.: Laura W. Roberts, M.D.

ISSUE WORKSHOP 47 11:00 a.m.-12:30 p.m.
Room B311, Level 3, Georgia World Congress Center

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.
Participants: Jane G. Tillman, Ph.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 48 11:00 a.m.-12:30 p.m.
Room B315, Level 3, Georgia World Congress Center

CANNABIS DEPENDENCE TREATMENT: WHERE WE ARE, WHERE WE ARE GOING
National Institute on Drug Abuse

Chp.: Francis J. Vocci, Ph.D.
Participants: Carl Hart, Ph.D., Jack R. Cornelius, M.D., Frances R. Levin, M.D., Alan I. Green, M.D.

ISSUE WORKSHOP 49 11:00 a.m.-12:30 p.m.
Room B316, Level 3, Georgia World Congress Center

BOUNDARIES AND SUPERVISION: AVOIDING LEGAL RISKS AND DOING GOOD CLINICAL WORK

Chp.: Werner Tschan, M.D.
Participants: Robert I. Simon, M.D., Linda M. Jorgenson, J.D., Gary R. Schoener, Psy.D.

ISSUE WORKSHOP 50 11:00 a.m.-12:30 p.m.
Room B401, Level 4, Georgia World Congress Center

PSYCHIATRIC COMORBIDITIES IN HIV INFECTION
Collaborative Session With the National Institute of Mental Health

Chp.: David Stoff, Ph.D.
Participants: Francine Cournos, M.D., Marshall Forstein, M.D., Stanley Rosenberg, Ph.D., Larry K. Brown, M.D., Ezra S. Susser, M.D.

ISSUE WORKSHOP 51 11:00 a.m.-12:30 p.m.
Room B402, Level 4, Georgia World Congress Center

RENEWING INTEGRITY THROUGH FILM: AN ESSENTIAL VIRTUE OF PROFESSIONALISM

Chp.: Francis G. Lu, M.D.

ISSUE WORKSHOP 52 11:00 a.m.-12:30 p.m.
Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

THE LONG-TERM EFFECTS OF VIOLENCE IN SHAPING MINORITY COMMUNITIES

Co-Chps.: Napoleon B. Higgins, Jr., M.D., Aruna S. Rao, M.D.
Participants: Jean-Marie E. Alves-Bradford, M.D., Eric R. Williams, M.D.

ISSUE WORKSHOP 53 11:00 a.m.-12:30 p.m.
Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

THE MOVIES AND THE MIND

Chp.: Willem C. Tuinebreijer
Participants: Rudolf A. Feijen, M.D., Bastiaan L. Oele, M.D., Josephine Caubel, M.D.

ISSUE WORKSHOP 54 11:00 a.m.-12:30 p.m.
Dogwood A, North Tower, Street Level, Omni Hotel

AMERICAN INDIAN TELEPSYCHIATRY: BRIDGING CULTURE AND DISTANCE

Chp.: James H. Shore, M.D.
Participants: Douglas K. Novins, M.D., Gilbert Jarvis, Daniel M. Savin, M.D.

ISSUE WORKSHOP 55 11:00 a.m.-12:30 p.m.
Magnolia Room, North Tower, Ballroom Level, Omni Hotel

CHRONIC FATIGUE SYNDROME AND GULF WAR ILLNESS: PATHOLOGY OR ABNORMAL ILLNESS BEHAVIOR?

Chp.: Peter Mau, M.D.

ISSUE WORKSHOP 56 11:00 a.m.-12:30 p.m.
Hickory Room, North Tower, Meeting Level, Omni Hotel

COMPUTER-ASSISTED CBT IN EDUCATION AND TREATMENT

Chp.: Jesse H. Wright, M.D.
Participant: Douglas Turkington, M.D.
### 12 noon Sessions

**FORUMS 4-6**

**FORUM 4**
- 12 noon-1:30 p.m.
- Room A410, Level 4, Georgia World Congress Center

**PSYCHIATRIC MANAGEMENT OF TREATMENT-RESISTANT SCHIZOPHRENIA**

Chp.: Jack S. McIntyre, M.D.
Co-Chp.: Darrel A. Reigh, M.D.
Participants: Alexander L. Miller, M.D., Jeffrey A. Lieberman, M.D., Peter J. Weiden, M.D., Mark Olfson, M.D.

**FORUM 5**
- 12 noon-1:30 p.m.
- Room B314, Level 3, Georgia World Congress Center

**HOW PSYCHO-ONCOLOGY CAME TO BE**

Chp.: Philip R. Mushkin, M.D.
Participant: Jimmie C. Holland, M.D.

**FORUM 6**
- 12 noon-1:30 p.m.
- Room B404, Level 4, Georgia World Congress Center

**IDENTITY AS PSYCHIATRISTS: HERITAGE AND CREATIVITY IN THIS UNIQUE SPECIALTY**

Chp.: Carlyle H. Chan, M.D.
Co-Chp.: Charles Raison, M.D.
Participant: Thomas P. Beresford, M.D.

**NEW RESEARCH POSTER SESSION 6**
- 12 noon-2:00 p.m.
- Room B302/303/304/305, Level 3, Georgia World Congress Center

**MOOD AND GENDER ISSUES**

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

### 1:00 p.m. Sessions

**COURSES 73-79**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

<table>
<thead>
<tr>
<th>COURSE 73</th>
<th>1:00 p.m.-5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henry Room, Second Floor, Hilton Atlanta</td>
<td></td>
</tr>
</tbody>
</table>

**BASIC FAMILY SKILLS FOR AN INPATIENT PSYCHIATRIST**

Director: Alison M. Heru, M.D.
Faculty: Laura Drury, M.S.W.

**COURSE 74**
- 1:00 p.m.-5:00 p.m.
- Paulding Room, Second Floor, Hilton Atlanta

**BIOETHICS UPDATE 2005**

Director: Edmund G. Howe, M.D.

**COURSE 75**
- 1:00 p.m.-5:00 p.m.
- DeKalb Room, Second Floor, Hilton Atlanta

**MAPSS: COMPUTER-ASSISTED SCREENING OF MEDICAL PATIENTS FOR MENTAL DISORDERS**

Co-Directors: Paul R. Miller, M.D., Charles Chiu, M.D.

**COURSE 76**
- 1:00 p.m.-5:00 p.m.
- Grand Salon A, Second Floor, Hilton Atlanta

**ADVANCED ASSESSMENT AND TREATMENT OF ADD**

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

**COURSE 77**
- 1:00 p.m.-5:00 p.m.
- Grand Salon C, Second Floor, Hilton Atlanta

**PSYCHOGENIC ILLNESS: WHAT TO DO WHEN THE SYMPTOMS DON’T MAKE SENSE**

Director: Selim Benbadis, M.D.
Faculty: Francisco Fernandez, M.D., David J. Williamson

**COURSE 78**
- 1:00 p.m.-5:00 p.m.
- Board/Directors Rooms, Fourth Floor, Hilton Atlanta

**HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: ADVANCED TOPICS**

Director: John Luo, M.D.
Faculty: Charles J. Rainey, M.D., Robert J. Boland, M.D., Hendry Ton, M.D., Richard Montgomery, M.D., Umar Latif, M.D.

**COURSE 79**
- 1:00 p.m.-5:00 p.m.
- Cabinet/Council Rooms, Fourth Floor, Hilton Atlanta

**INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION (TMS)**

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.
Faculty: Sarah H. Lisanby, M.D., Ehud M. Klein, M.D.
TUESDAY

2:00 p.m. Sessions

LECTURES 13-15

LECTURE 13
2:00 p.m.-3:30 p.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

Daniel R. Weinberger, M.D.

Genes, Cognition, and Emotion
Collaborative Session With the National Institute of Mental Health

Chp.: Diana O. Perkins, M.D.
Co-Chp.: Christine E. Marx, M.D.

Daniel R. Weinberger, M.D., is Director of the Genes, Cognition, and Psychosis Program of the Intramural Research Program at the National Institute of Mental Health. Dr. Weinberger's research has focused on brain mechanisms involved in the pathogenesis and treatment of neuropsychiatric disorders, especially schizophrenia. His laboratory identified the first specific genetic mechanism of risk for schizophrenia and the first genetic effects that account for variation in specific human cognitive functions and in human temperament. He is the recipient of many awards, including the Research Prize of the World Federation of Societies of Biological Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry; the Foundation’s Fund Prize of the American Psychiatric Association, and the Lieber Prize of the National Alliance for Research on Schizophrenia and Depression. A Past President of the Society of Biological Psychiatry, Dr. Weinberger has been elected to the Institute of Medicine and is currently President of the American College of Neuropsychopharmacology. He is the author of more than 400 scientific articles and the author or editor of six books. Dr. Weinberger graduated from University of Pennsylvania School of Medicine and completed residencies in psychiatry at Harvard Medical School and in neurology at George Washington University in Washington, D.C.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPE.

LECTURE 14
2:00 p.m.-3:30 p.m.
Room A411, Level 4
Georgia World Congress Center

Robert P. Charrow, Esq.

The Federal Regulation of Biomedical Research: A Study in Quid Pro Quo

Chp.: Geetha Jayaram, M.D.
Co-Chp.: David W. Brook, M.D.

Starting in the 1980s, the impetus for government regulation of science, including regulation in the areas of scientific integrity, protection of human subjects, conflicts of interest, and access to raw data, grew as the amount of government spending on scientific research grew. Robert P. Charrow, Esq., explores the impact of government regulation on the practice and funding of research by examining the effectiveness of a variety of regulatory programs and assessing whether they are cost justified. Mr. Charrow is a shareholder in the Washington, D.C., office of Greenberg Traurig LLP, where he specializes in legal problems associated with biomedical research, health care law, food and drug law, and legal issues associated with biotechnology. He represents academic and research institutions, learned societies, pharmaceutical companies, health care providers, and insurers, with respect to a broad range of issues arising under the Medicare and Medicaid programs and federal laws affecting research and the delivery of health care. Mr. Charrow has written extensively on health care law and the effects of the legal system on scientific research and product development. He is the co-author of a leading law school textbook and the author of more than 100 articles and monographs. He received his law degree from Stanford University.

THIS SESSION WILL BE AUDIOTAPE.

LECTURE 15
2:00 p.m.-3:30 p.m.
Room A412, Level 4
Georgia World Congress Center

APA/NIMH VESTERMARK PSYCHIATRY EDUCATOR AWARD LECTURE

Harold Alan Pincus, M.D.

The Future of Psychiatric Education: Six Bridges to Cross

Chp.: Patricia I. Ordorica, M.D.

Harold Alan Pincus, M.D., is Professor and Executive Vice Chairman of the Department of Psychiatry at the University of Pittsburgh School of Medicine. He is also a Senior Scientist at RAND and directs the RAND-University of Pittsburgh Health Institute. In addition, Dr. Pincus directs the Robert Wood Johnson Foundation’s National Program on Depression in Primary Care. He also maintains a small private practice specializing in major affective disorders, attends at the emergency department of Western Psychiatric Institute and Clinic, and spends one evening a week at a public mental health clinic, caring for patients with severe mental illnesses. A former Deputy Medical Director of the American Psychiatric Association (APA) and Executive Director of the American Psychiatric Institute for Research and Education, Dr. Pincus was the founding director of APA’s Office of Research, Vice
Chair of the Task Force on DSM-IV, and Co-Chair of the Work Group to Update the Text of DSM-IV (DSM-IV-TR). He has received numerous awards for his contributions to the science of mental health, including APA's Health Services Research Senior Scholar Award and the William C. Menninger Memorial Award of the American College of Physicians. A graduate of Albert Einstein College of Medicine in New York, Dr. Pincus completed his residency in psychiatry at George Washington University Medical Center in Washington, D.C.

THIS SESSION WILL BE AUDIOTAPE.

PRESIDENTIAL SYMPOSIA 3-4

PRESIDENTIAL SYMPOSIUM 3
2:00 p.m.-5:00 p.m.
Room A305, Level 3, Georgia World Congress Center

TOWARD AN INTEGRATED SUBSPECIALTY OF PSYCHOSOMATIC MEDICINE
American Psychosomatic Society

Chp.: Richard D. Lane, M.D.

A Acute Psychological Stress and Coronary Artery Disease
   David S. Sheps, M.D.

B Biobehavioral Contributions to Cancer Risk and Disease Progression
   Susan Lutgendorf, Ph.D.

C A Biopsychosocial Approach to Irritable Bowel Syndrome
   Douglas A. Drossman, M.D.

D Positive and Negative Psychosocial Predictors of CD4 and Viral Load in HIV
   Gail Ironson, M.D.

E Depression and Diabetes: Epidemiology and Intervention
   Wayne J. Katon, M.D.

PRESIDENTIAL SYMPOSIUM 4
2:00 p.m.-5:00 p.m.
Room B401, Level 4, Georgia World Congress Center

MENTAL HEALTH AND SUB-SAHARAN AFRICA: A 21ST CENTURY PERSPECTIVE
World Psychiatric Association's Efforts

Chp.: Michelle B. Riba, M.D.
Co-Chp.: Ahmed M.F. Okasha, M.D.

A Uganda Region
   Florence Baingana, M.D.

B World Psychiatric Association's Efforts
   Ahmed M.F. Okasha, M.D.

C Kenya
   Frank G. Njenga, M.D.

D Eastern Africa
   Sylvia Kaaya, M.D.

E The World Health Organization's Efforts and Namibia
   Custodia Mandhlate, M.D.

THIS SESSION WILL BE AUDIOTAPE.

REVIEW OF PSYCHIATRY: SECTION 1
2:00 p.m.-5:30 p.m.
Rooms B405/406/407, Level 4, Georgia World Congress Center

SLEEP DISORDERS AND PSYCHIATRY
Chp.: Daniel J. Buysse, M.D.

1 Insomnia
   Daniel J. Buysse, M.D., Anne Germain, Ph.D., Douglas E. Moul, M.D.

2 Sleep-Related Breathing Disorders
   Patrick J. Strollo, M.D., Nilesh Dave, M.D.

3 Restless Leg Syndrome and Parasomnias
   John W. Winkelman, M.D., Lindsay Jonston, B.A.

4 Circadian Rhythm Sleep Disorders
   Phyllis C. Zee, M.D., Prasanth Manthena, Ph.D.

SYMPOSIA 27-55

SYMPOSIUM 27 2:00 p.m.-5:00 p.m.
Room A302, Level 3, Georgia World Congress Center

NEUROSCIENCE FOR THE PSYCHIATRIST, PART I: NEUROIMAGING FROM GENOMICS TO THERAPY
Collaborative Session With the National Institute of Mental Health

Chp.: Andreas Meyer-Lindenberg, M.D.
Co-Chp.: Mayada Akl, M.D.

A Imaging Genomics in Psychiatry
   Andreas Meyer-Lindenberg, M.D.

B FMRI: Basics and Beyond
   Peter A. Bandettini, Ph.D.

(Continued next page)
C Understanding Schizophrenia Using Functional Brain Imaging
  Cameron Carter, M.D.

D Linking Imaging and Treatment Mechanisms for Depression
  Helen S. Mayberg, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 28  2:00 p.m.-5:00 p.m.
Room A402, Level 4, Georgia World Congress Center

REAL LIFE MEDICAL MANAGEMENT OF HIV

Chp.: Francine Cournoy, M.D.

A HIV Treatment Update
  Jeff D. Lenox, M.D.

B Managing Mood Disorders
  Sanjay M. Sharma, M.D.

C Managing Hepatitis C, Syphilis, and HIV Infection
  Annette M. Matthews, M.D.

D Managing Psychosis
  Shahrad R. Amiri, M.D.

E Managing Metabolic Syndromes
  Marshall Forstein, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 29  2:00 p.m.-5:00 p.m.
Room A403, Level 4, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: INTEGRATING EPIDEMIOLOGY, PSYCHIATRY, AND MEDICINE

Chp.: Ruby C. Castilla-Puentes, M.D.
Co-Chp.: Robert C. Joseph, M.D.

A Risk of Myocardial Infarction Associated With Panic Disorder
  Andres Gomez-Caminero, Ph.D., William Blumentals, Ph.D., Leo Russo, Ph.D., Ruby C. Castilla-Puentes, M.D.

B The Prevalence of Depressive Disorders in Patients With Dementia in IHCIS
  Dimitri Bennett, M.D., Tim Sampson, B.S.

C Diabetes and Lipid Profile Risks With Neuroleptics: Two- to Five-Year Outcome
  Robert C. Joseph, M.D., Nicole Danforth, M.D., Gayle Goren, M.D., Marianne Kardos, M.D., Tamar B. Pardo, B.A., Grace Wyshak, Ph.D., S. Nassir Ghaemi, M.D.

D Somatic Complaints in Traumatized Children
  Ruby C. Castilla-Puentes, M.D., Ivan S. Gomez, M.D., Sandra R. Castilla-Puentes, M.D., Wilma I. Castilla-Puentes, M.D., Gilma R. De Contreras, M.S.W., Maria C. Caballero, R.N., Miguel Habeych, M.D.

E A Case-Control Study of Erectile Dysfunction Among Men Diagnosed With Panic Disorder
  William Blumentals, Ph.D., Andres Gomez-Caminero, Ph.D., Leo Russo, Ph.D., Regina Brown, M.S., Vanni Jannappagari, M.S.

Discussants: Leo Russo, Ph.D., Carlos A. Sanchez-Russi, Ph.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 30  2:00 p.m.-5:00 p.m.
Room A405, Level 4, Georgia World Congress Center

THE ART AND SCIENCE OF BRIEF THERAPIES

Chp.: Mantosh J. Dewan, M.D.

A Expectancy, the Ignored Common Factor: Creating Hope in Psychotherapy
  Roger P. Greenberg, Ph.D.

B Solution-Focused Brief Therapy: Doing What Works
  Brett Steenbarger, Ph.D.

C Brief Interpersonal Therapy
  Scott Stuart, M.D.

D Cognitive Therapy: Practice and Training
  Judith S. Beck, Ph.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 31  2:00 p.m.-5:00 p.m.
Room A406, Level 4, Georgia World Congress Center

POSTTRAUMATIC STRESS AND MEDICAL ILLNESS: INTERDISCIPLINARY PERSPECTIVES

Chp.: Eyal Shemesh, M.D.
Co-Chp.: Margaret L. Stuber, M.D.

A PTSD in Medically Ill Adults and Children: A Review
  Eyal Shemesh, M.D.

B PTSD Symptoms in Children Who Had Transplants: One Center's Experience
  Sukru Emre, M.D.

C The Study of PTSD in the Medically Ill: Choice of Outcome Measures
  Gad Cotter, M.D.

D The National Child Traumatic Network Medical Trauma Toolkit
  Margaret L. Stuber, M.D.

Discussant: Jack M. Gorman, M.D.
THIS SESSION WILL BE AUDIOTAPE D.
SYMPOSIUM 32
2:00 p.m.-5:00 p.m.
Room A407, Level 4, Georgia World Congress Center

MEDICAL COMORBIDITY IN THE U.S. AND FRANCE: VIVE LA DIFFERENCE!
French Federation of Psychiatry

Chp.: John A. Talbott, M.D.
Co-Chp.: Francois C Petiehean, M.D.

A Mortality in a Cohort of Patients With Schizophrenia
Frederic Limosin, M.D., Jean-Yves Lore, M.D., Alain Philippe, Frederic Rouillon, M.D., Francoise Casadebaig

B Prevalence, Treatment, and Prevention of HIV/Hepatitis in the U.S.
Lisa B. Dixon, M.D., Stanley Rosenberg, Ph.D., Richard L. Goldberg, M.D.

C Adverse Metabolic Effects of Antipsychotics in Schizophrenia
Marie France Poirier, M.D., Celine Goldberger

D Diabetes and Other Metabolic Disorders in Schizophrenia
Michael J. Sernyak, M.D.

E The Impact of Smoking in Patients With Schizophrenia
Alain Dervaux, M.D.

F Medical Comorbidities and Health Behaviors: Smoking, Exercise, and Weight
Gail L. Daumit, M.D.

Discussant: Alexandra McLean, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 33
2:00 p.m.-5:00 p.m.
Room A408, Level 4, Georgia World Congress Center

MEDICAL AND PSYCHIATRIC ISSUES IN THE MEXICAN-AMERICAN POPULATION IN THE U.S.

Chp.: Cervando Martinez, M.D.

A Health Status of Mexican Americans
Michael P. Stern, M.D.

B Depression as Comorbid Condition With Type-2 Diabetes in a U.S.-Mexico Border Community Clinic
Roberto Villareal, M.D.

C Insights on Schizophrenia in Three Countries
Rolando A. Medina, M.D.

Discussant: Charles L. Bowden, M.D.
THIS SESSION WILL BE AUDIOTAPE D.
SYMPOSIUM 36 2:00 p.m.-5:00 p.m.
Room B306, Level 3, Georgia World Congress Center

UNDERSTANDING AND TREATING ALCOHOL DEPENDENCE

Chp.: Bankole A. Johnson, M.D.

A Neuropharmacological Basis of Alcohol Dependence
George F. Koob, Ph.D.

B New Pharmacological Strategies for Treating Alcohol Dependence
Barbara J. Mason, Ph.D.

C Recent Developments in the Genetics of Alcohol Dependence
Marc A. Schuckit, M.D.

D New Medications: The Use of Anticonvulsants, Both Alone and in Combination, With Various Forms of Psychotherapy
Bankole A. Johnson, M.D.

E Differential Effects of Pharmacological Agents on Craving
Nassima Ait-Daoud, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.
Room B307, Level 3, Georgia World Congress Center

EVIDENCE-BASED PSYCHIATRY: WHAT IT IS AND WHAT IT IS NOT

Chp.: S. Nassir Ghaemi, M.D.

A Evidence-Based Medicine in Psychiatry: An Overview
Gregory E. Gray, M.D.

B Evidence-Based Approaches to Teaching and Practicing Psychopharmacology
David N. Osser, M.D.

C Uses and Abuses of EBM in Psychiatry
S. Nassir Ghaemi, M.D.

D Evidence-Based Medicine: How It Can Be Misused
David T. Healy, M.D.

E EBM and Pharmaceutical Industry-Sponsored Clinical Trials
Amir H. Kalali, M.D.

Discussant: Frederick K. Goodwin, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 38 2:00 p.m.-5:00 p.m.
Room B308, Level 3, Georgia World Congress Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 3

Chp.: William E. Callahan, Jr., M.D.
Co-Chp.: Keith W. Young, M.D.

A Personal Factors Leading to a Successful Private Practice
William E. Callahan, Jr., M.D.

B Office Location and Design for Efficiency and Success
Keith W. Young, M.D.

C Streamlining Overhead and Managing Your Business in Private Practice
Keith W. Young, M.D.

D Marketing Your Unique Private Practice
William E. Callahan, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 39 2:00 p.m.-5:00 p.m.
Room B309, Level 3, Georgia World Congress Center

COMPLEX PHARMACOTHERAPY VERSUS POLYPHARMACY

Chp.: William Lawson, M.D.
Co-Chp.: Roger Peele, M.D.

A Polypharmacy and Ethnic Minorities
William Lawson, M.D.

B Impulsive Behavior in Children and Adolescents
Janice G. Hutchinson, M.D., William Lawson, M.D.

C Polypharmacy in Depression and Anxiety: What, When, and How to Implement
Gabriela Cora-Locatelli, M.D.

D Complexities of Bipolar Illness Typically Require Complex Combination Therapy
Robert M. Post, M.D.

E Polypharmacy in Schizophrenia Treatment
David C. Henderson, M.D.

Discussant: Roger Peele, M.D.
THIS SESSION WILL BE AUDIOTAPE D.
SYMPOSIUM 40  2:00 p.m.-5:00 p.m.
Room B310, Level 3, Georgia World Congress Center

INTEGRATING AND SEQUENCING TREATMENTS FOR BORDERLINE PATIENTS

Chp.: John C. Markowitz, M.D.
Co-Chp.: Andrew E. Skodol II, M.D.

A  Phases and Stages of Change in the Treatment of Personality Disorder
   John Livesley, Ph.D.

B  Adapting Dialectical Behavior Therapy for the Psychiatric Practitioner
   Barbara H. Stanley, Ph.D.

C  Common Mechanisms in Psychological Theories: Attachment and Mentalization
   Peter Fonagy, Ph.D., Anthony Bateman, M.D.

D  Toward a Rational Pharmacotherapy of BPD
   Larry J. Siever, M.D.

E  Psychoeducation for Family Members With a Relative With BPD
   Perry D. Hoffman, Ph.D.

Discussant: Andrew E. Skodol II, M.D.
THIS SESSION WILL BE AUDIOTAPEMED.

SYMPOSIUM 41  2:00 p.m.-5:00 p.m.
Room B311, Level 3, Georgia World Congress Center

MATERNAL DEPRESSION AND COMORBIDITIES: IMPACT ON INFANTS

Chp.: Gisèle Apter-Danon, Ph.D.

A  Maternal Depression and Comorbidities: PTSD and BPD
   Marian I. Butterfield, M.D., Jennifer L. Strauss, Ph.D.

B  Perinatal Depression: Impact of Maternal Distress on Neonatal Outcomes and Attachment
   Sheila M. Marcus, M.D.

C  Impact of Maternal BPD on Infant Emotional Regulation
   Gisèle Apter-Danon, Ph.D., Rozenn Graignic-Philippe, Marina Gianoli-Valente, Psy.D., Emmanuel Devouche, Ph.D., Annick Crivile-Le-Nestour, M.D.

D  How Early Life Experience Affects the Development of Optimism's Neural Circuitry
   Susan C. Vaughan, M.D.

Discussant: Carol C. Nadelson, M.D.
THIS SESSION WILL BE AUDIOTAPEMED.

SYMPOSIUM 42  2:00 p.m.-5:00 p.m.
Room B314, Level 3, Georgia World Congress Center

ADHD: FROM NEUROSCIENCE TO PRACTICE
Collaborative Session With the National Institute of Mental Health

Chp.: Joseph Biederman, M.D.

A  Psychiatric and Functional Outcome of Adolescent Females With ADHD: A Large, Controlled, Five-Year Longitudinal Follow-Up Study
   Joseph Biederman, M.D., Stephen V. Faraone, Ph.D., Eric Mack, Sc.D.

B  Nonstimulant Treatment of Adult ADHD
   Thomas J. Spencer, M.D.

C  Neuropsychology of ADHD: Clinical and Scientific Implications of Recent Findings
   Alysa E. Doyle, Ph.D., Stephen V. Faraone, Ph.D., Larry J. Seidman, Ph.D., Joseph Biederman, M.D.

D  Heritability: New Genetic Findings in ADHD
   Pamela Sklar, M.D.

E  Looking at the ADHD Brain: Neuroimaging Studies in ADHD
   Larry J. Seidman, Ph.D., Eve M. Valera, Ph.D., Joseph Biederman, M.D., Thomas J. Spencer, M.D., Stephen V. Faraone, Ph.D., George Bush, M.D.

Discussant: Carol C. Nadelson, M.D.
THIS SESSION WILL BE AUDIOTAPEMED.

SYMPOSIUM 43  2:00 p.m.-5:00 p.m.
Room B315, Level 3, Georgia World Congress Center

ASSOCIATIONS BETWEEN STRESS/ANXIETY AND PERSONALITY STYLES AND DISORDERS
Association for Research in Personality Disorders

Chp.: James H. Reich, M.D.

A  A Selective Overview of Relationship of Anxiety and Personality Disorders
   James H. Reich, M.D.

B  Schema Therapy for Maladaptive Personality Traits Involving Anxiety
   David Bernstein

(Continued next page)
C Personality and Stress in Three Phases of the Physician's Career: A Longitudinal Nationwide Study
Per Vaglum, M.D., Reidar Tyssen, M.D., Oivind Ekeberg, M.D., Tore Gude, M.D., Erlend Hem, M.D., Jan Ole Rovik

D Panic, Rage, and Family Discord in BPD
David M. Allen, M.D.

E Is Emotional Dyscontrol and Impulsivity Related to Suicidal Ideation in BPD Patients?
Navjot Chaudhary, B.S.C., Paul S. Links, M.D., Rahel Eynan, M.A., Aiala Barr, Ph.D.

F Stress, Personality Disorders, and Opioid Receptors
Kenneth Silk, M.D., Jon-Kar Zubiena, M.D.

Discussant: Donald W. Black, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 44 2:00 p.m.-5:00 p.m.
Room B316, Level 3, Georgia World Congress Center

PERINATAL DEPRESSION: PREVALENCE, SCREENING ACCURACY, AND INTERVENTION
Chp.: Bradley N. Gaynes, M.D.

A A Systematic Review of the Evidence on the Incidence and Prevalence of Perinatal Depression
Norma I. Gavin, Ph.D.

B What Is the Accuracy of Different Screening Tools for Detecting Depression During the Perinatal Period?
Bradley N. Gaynes, M.D.

C Does Perinatal Screening for Depressive Symptoms With Subsequent Intervention Lead to Improved Outcomes? A Systematic Review of the Evidence
Samantha E. Meltzer-Brody, M.D.

Discussants: Katherine L. Wisner, M.D., Seth Brody, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.
Room B402, Level 4, Georgia World Congress Center

THE LONG-TERM PSYCHOLOGICAL AFTERMATH OF 9/11-RELATED TRAUMATIC LOSS
Chp.: Yuval Y. Neria, Ph.D.

A Traumatic Grief Among 9/11 Victims
Yuval Y. Neria, Ph.D.

B Trauma, Bereavement, and Traumatic Loss
George A. Bonanno, Ph.D.

C A Nationwide Longitudinal Study of Responses to the 9/11 Terrorist Attacks
Roxane C. Silver, Ph.D.

D Loss and Consequences After Mass Trauma: Examples From the 9/11 Terrorist Attacks in New York City
Sandor Galea, M.D.

E 9/11-Related Traumatic Loss and Its Psychopathology in Primary Care Patients in New York City
Raz Gross, M.D.

Discussant: Randall D. Marshall, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 46 2:00 p.m.-5:00 p.m.
Room B403, Level 4, Georgia World Congress Center

REHABILITATION OF THE MAD OR BAD: GLOBALLY
American Association for Psychosocial Rehabilitation and the World Psychiatric Association's Section on Rehabilitation
Chp.: Zebulon Taintor, M.D.
Co-Chp.: Robert Cancro, M.D.

A Mad or Bad? Japan
Naotaka Shinfula, M.D.

B Mad or Bad? United States
Zebulon Taintor, M.D.

C Mad or Bad? Hungary
Ida Kosza, M.D.

D Mad or Bad? Pakistan
Afzal Javed, M.D.

E Mad or Bad? International Efforts
Humberto Martinez, M.D.

Discussant: Henry C. Weinstein, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 47 2:00 p.m.-5:00 p.m.
Room B404, Level 4, Georgia World Congress Center

NEW DEVELOPMENTS IN THE TREATMENT OF SOMATOFORM DISORDERS
Chp.: Arthur J. Barsky, M.D.
Co-Chp.: Brian A. Fallon, M.D.

A Pharmacotherapy of Somatoform Disorders
Brian A. Fallon, M.D.
B Managing Common Somatic Presentations in Primary Care: Cultural Considerations
Javier I. Escobar, M.D., Michael A. Gara, Ph.D., Angelica Diaz-Martinez, Psy.D., Lesley A. Allen, Ph.D., Alex Interian, Ph.D., Melissa Warman, Ph.D.

C Cognitive-Behavior Therapy for Hypochondriasis: A Randomized, Controlled Intervention Trial
Arthur J. Barsky, M.D., David K. Ahern, Ph.D.

D Treatment of Unexplained Somatic Symptoms in Children and Adolescents
Joshua D. Lipsitz, Ph.D., Merav Gur, Ph.D., Daniel Kamins, B.A.

E Integrative Treatment for Fibromyalgia/Chronic Fatigue Syndrome
Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

SYMPOSIUM 48 2:00 p.m.-5:00 p.m.
Room B408, Level 4, Georgia World Congress Center

INPATIENT PSYCHIATRY: CRISIS AND RESPONSE
Chp.: Ira D. Glick, M.D.
Co-Chp.: Steven S. Sharfstein, M.D.

A Public Policy and Inpatient Psychiatric Care
Anita S. Everett, M.D.

B An Updated Model for Inpatient Psychiatric Care
Ira D. Glick, M.D., Grady Carter, M.D., Rajiv Tandon, M.D.

C Crisis Residential Care for Patients With Serious Mental Illness: Outcomes and Cost
Wayne S. Fenton, M.D.

D A National Referral Center for Treatment-Resistant Patients
Edward R. Shapiro, M.D.

E Trends and Characteristics of Inpatient Treatment in Routine Psychiatric Practice in the U.S.
Joshua E. Wilk, Ph.D., Joyce C. West, Ph.D., Darrel A. Regier, M.D.

Discussant: Steven S. Sharfstein, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 49 2:00 p.m.-5:00 p.m.
Room B409, Level 4, Georgia World Congress Center

ADVANCES AND INNOVATIONS IN ASSESSING DECISION-MAKING CAPACITY
Chp.: Philip Candilis, M.D.
Co-Chp.: Laura B. Dunn, M.D.
SYMPOSIUM 51
2:00 p.m.-5:00 p.m.
Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

NEUROSCIENCE AND DYNAMIC PSYCHIATRY
American Academy of Psychoanalysis and Dynamic Psychiatry

Chp.: Ann R. Turkel, M.D.

A Psychotherapy and Neurobiology
Richard M. Brockman, M.D.

B Contemporary Affect Theory and Controversies Regarding Drive Theory in Psychoanalysis
Otto F. Kernberg, M.D.

C Imaging the Mind-Brain Interface Bridging the Psychoanalysis-Neuroscience Gap
David A. Silbersweig, M.D.

D How Neuroscience Can Help the Clinician
Samuel Slipp, M.D.

Discussant: Michael H. Stone, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 52
2:00 p.m.-5:00 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

DISTURBED FRONTO-LIMBIC BRAIN CIRCUITRY: HOW SPECIFIC IS IT FOR DIFFERENT PSYCHIATRIC DISORDERS?

Chp.: Klaus Lieb, M.D.

A Fronto-Limbic Brain Pathology: Evidence From Animal Research
Gregory Quirk, Ph.D.

B Fronto-Limbic Brain Pathology in PTSD
Eric Vermetten, M.D.

C Prefrontal and Limbic Pathology in BPD
Klaus Lieb, M.D.

D Stress-Induced Brain Structural Plasticity: What Do Animal Models Tell Us?
Bruce S. McEwen, Ph.D.

E Neural Circuits in Trauma Spectrum Disorders
J. Douglas Bremner, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 53
2:00 p.m.-5:00 p.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

INCREASES IN OPIOID ANALGESIC ABUSE: CONCERNS AND STRATEGIES
National Institute on Drug Abuse

Chp.: Wilson M. Compton III, M.D.

A Increases in Opioid Analgesic Use, Misuse, and Addiction
Wilson M. Compton III, M.D.

B The Availability of Opioid Medications Over the Internet Without a Prescription
Robert F. Forman, Ph.D.

C Managing Chronic Pain in the Patient With Comorbid Substance Abuse
Nathaniel P. Katz, M.D.

D Treatment of Prescription Analgesic Abuse
Herbert D. Kleber, M.D.

Discussant: Nora D. Volkow, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 54
2:00 p.m.-5:00 p.m.
Dogwood A, North Tower, Street Level, Omni Hotel

PSYCHIATRY AND THE PHARMACEUTICAL INDUSTRY: WHERE IS THE BOUNDARY?

Chp.: Amy C. Brodkey, M.D.

A Pharmaceutical Promotions: Effects on the Practice of Psychiatry
Amy C. Brodkey, M.D.

B Academic Medicine, Medical Education, and the Pharmaceutical Industry
Frederick S. Sierles, M.D.

C The Pharmaceutical Industry, Psychiatry, and the Public Interest
Robert M. Factor, M.D.

D Dancing With Porcupines: Dilemmas Faced by Speakers for the Pharmaceutical Industry
Diana M. Kozlupa, M.D.
THIS SESSION WILL BE AUDIOTAPE.
SYMPOSIUM 55  
2:00 p.m.-5:00 p.m.  
Dogwood B, North Tower, Street Level, Omni Hotel  

AUTISM: A COMMON, SEVERE, TREATABLE, AND NEGLECTED PSYCHIATRIC ILLNESS  
Collaborative Session With the National Institute of Mental Health  

Chp.: Eric Hollander, M.D.  
Co-Chp.: Eric B. London, M.D.  

A A Comprehensive Review of Major Research Findings in Autism From the Past Decade  
Eric B. London, M.D.  

B Biology of Social Behavior From Mice to Monkeys  
James T. Winslow, Ph.D.  

C fMRI Studies of Social Perception and Social Cognition in Autistic Disorder  
Robert T. Schultz, Ph.D.  

D Targeted Treatments for the Repetitive Behavior Domain in Autism  
Eric Hollander, M.D., Stacey Wasserman, M.D., Evdokia Anagnostou, M.D., Anne Phillips, Ph.D., Karen Zagursky, B.A., Bill Chaplin, Ph.D., Sherie L. Novotny, M.D.  

E Atypical Antipsychotics in Children With Pervasive Developmental Disorders  
Lawrence Sechrest, Ph.D.  

THIS SESSION WILL BE AUDIOTAPED.  

3:00 p.m. Session  

NEW RESEARCH POSTER SESSION 7  
3:00 p.m.-5:00 p.m.  
Room B302/303/304/305, Level 3, Georgia World Congress Center  

ANXIETY AND DISORDERS OF CHILDHOOD  

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.  

6:00 p.m. Session  

SPECIAL SESSION  
6:00 p.m.-8:00 p.m.  
Cypress Room, Carter Center  

GLOBAL DISASTERS: PSYCHIATRIC MEDICINE AND PUBLIC HEALTH CHALLENGES  
American Psychiatric Association's Council on Global Psychiatry and the World Psychiatric Association's Conflict Management and Conflict Resolution Section  

Co-Chips: Rodrigo A. Munoz, M.D., Eliot Sorel, M.D.  
Participants: Srinivas Murthy, M.D., Parameshva Deva, M.D., Lennart Levi, M.D., Frank G. Njenga, M.D.  
Discussants: Mordechai Benyakar, M.D., Anthony T. Ng, M.D., Dori B. Reissman, M.D.  

7:00 p.m. Sessions  

INDUSTRY-SUPPORTED SYMPOSIUMS 39-43  

INDUSTRY-SUPPORTED SYMPOSIUM 39  
7:00 p.m.-10:00 p.m.  
Grand Ballroom, Second Floor, Hilton Atlanta  

SEASONAL AFFECTIVE DISORDER: NEW CONCEPTS, PRACTICAL STRATEGIES  
Supported by GlaxoSmithKline  

Chp.: Norman E. Rosenthal, M.D.  

A The Clinical Picture and Epidemiology of Seasonal Affective Disorder  
Norman E. Rosenthal, M.D.  

B Pathophysiology of Seasonal Affective Disorder  
Thomas A. Wehr, M.D.  

C Light Treatment for Winter Depression: Status Report  
Raymond W. Lam, M.D.  

D Medical Treatment Including Mechanism of Action, New Study Data  
Jennifer K.Pennell, M.D.  

E Integrating Cognitive-Behavioral Therapy Into Seasonal Affective Disorder Treatment  
INDUSTRY-SUPPORTED SYMPOSIUM 40
7:00 p.m.-10:00 p.m.
Imperial Ballroom, Convention Level, Marriott Marquis
Atlanta

ALCOHOLISM: TRANSLATING EMERGING SCIENCE INTO CLINICAL PRACTICE
Supported by A. Ikemts
Chp.: Raymond F. Anton, Jr., M.D.
Co-Chp.: Charles P. O'Brien, M.D.

A Animal Models Point the Way to Novel Therapies
George F. Koob, Ph.D.

B Brain Imaging of Craving and the Effects of Anticraving Medications
Charles P. O'Brien, M.D.

C Advances in the Pharmacotherapy of Alcoholism
Helen M. Pettinati, Ph.D.

D Treatment of Alcoholism Combined With Other Mental Disorders
Hugh Myrick, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 41
7:00 p.m.-10:00 p.m.
Marquis Ballrooms I & II, Convention Level, Marriott
Marquis Atlanta

ADVANCES IN CHOLINEnergIC THERAPY:
ALZHEIMER'S DISEASE AND BEYOND
Supported by Eisai, Inc. and Pfizer Inc.
Chp.: Pierre N. Tariot, M.D.

A Revisiting the Cholinergic Hypothesis: Are Cholinesterase Inhibitors More Than Symptomatic Treatments for Alzheimer's Disease?
Norman Relkin, M.D.

B The Role of Imagining in the Study and Treatment of Dementia
K. Ranga R. Krishnan, M.D.

C Clinical Trials in Mild Cognitive Impairment
Ronald C. Petersen, M.D.

D Pharmacological Treatment of Cognitive Impairments in Schizophrenia
Robert W. Buchanan, M.D.

E Behavioral Disturbances in Alzheimer's Disease: Diagnosis and Treatment
Helen Lavretsky, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 42
7:00 p.m.-10:00 p.m.
International Ballroom, North Tower, Ballroom Level, Omni Hotel

CHALLENGES AT THE INTERFACE OF PSYCHIATRIC, MEDICAL, AND SLEEP DISORDERS
Supported by Sanofi-Aventis, Inc.
Chp.: David N. Neubauer, M.D.

A Epidemiologic and Longitudinal Perspectives on Insomnia and Psychiatric Illness
Daniel E. Ford, M.D.

B Changing Women's Sleep Vulnerabilities Across the Life Cycle
Lois Krahn, M.D.

C Sleep Disturbances and Neurodegenerative Disorders
Raymond R. Auger, M.D.

D Metabolic Consequences of Insomnia: Implications for Medicine and Psychiatry
Gary S. Richardson, M.D.

E Therapeutic Challenges in Treating Insomnia With Comorbid Psychiatric and Medical Disorders
David N. Neubauer, M.D.

Discussant: William C. Dement, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 43
7:30 p.m.-10:00 p.m.
Peachtree Ballroom, Level 8, Westin Peachtree Plaza

IT'S NOT JUST FOR KIDS: ADHD IN ADOLESCENCE AND ADULTHOOD
Supported by Shire US, Inc.
Chp.: Timothy E. Wilens, M.D.

A The Course of ADHD From Adolescence Into Adulthood
Christopher J. Kratochvil, M.D.

B Neurobiological Update on ADHD in Adolescence and Adulthood
Stephen V. Faraone, Ph.D., Joseph Biederman, M.D.

C College Considerations in Young Adults With ADHD
Sharon B. Wigal, Ph.D.

D New Psychotherapies Directed at Young Adults With ADHD
Steven A. Safren, Ph.D.

E Medication Considerations in Young Adults With ADHD
Timothy E. Wilens, M.D.
### Part 1 of Industry-Supported Breakfast Symposium 44

**7:00 a.m. - 8:30 a.m.**

**Grand Ballroom, Second Floor, Hilton Atlanta**

**Bipolar Disorder Across the Life Cycle: Special Considerations**

*Supported by GlaxoSmithKline*

**Chp.: Zachary N. Stowe, M.D.**

- **A.** Bipolar Disorder in Children: Importance of Early Intervention
  - Karen D. Wagner, M.D.

- **B.** Bipolar Disorder: Impact of Reproductive Hormones
  - Natalie L. Rasgon, M.D.

### 8:00 a.m. Sessions

**COURSES 80-87**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Time</th>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>8:00 a.m.-12 noon</td>
<td>Cherokee Room, Second Floor, Hilton Atlanta</td>
<td>Drugs and Alcohol Take Two: Teaching Addiction Medicine Using Popular Films</td>
</tr>
<tr>
<td>81</td>
<td>8:00 a.m.-12 noon</td>
<td>Forsythe Room, Second Floor, Hilton Atlanta</td>
<td>Using Neurofeedback in Your Practice I: Demonstration</td>
</tr>
<tr>
<td>82</td>
<td>8:00 a.m.-12 noon</td>
<td>DeKalb Room, Second Floor, Hilton Atlanta</td>
<td>How to Use Your Pocket PC PDA in Psychiatric Practice</td>
</tr>
<tr>
<td>83</td>
<td>8:00 a.m.-12 noon</td>
<td>Fulton Room, Second Floor, Hilton Atlanta</td>
<td>Computer-Assisted Diagnostic Interview (CAD)</td>
</tr>
<tr>
<td>84</td>
<td>8:00 a.m.-12 noon</td>
<td>Gwinnet Room, Second Floor, Hilton Atlanta</td>
<td>Contemporary Malpractice Liability: A Practical Guide</td>
</tr>
<tr>
<td>85</td>
<td>8:00 a.m.-12 noon</td>
<td>Fulton Room, Second Floor, Hilton Atlanta</td>
<td>Online Communication in Mental Health: Different Contexts, Different Issues</td>
</tr>
<tr>
<td>86</td>
<td>8:00 a.m.-12 noon</td>
<td>Madison Room, Third Floor, Hilton Atlanta</td>
<td>Insanity Defense Evaluations</td>
</tr>
<tr>
<td>87</td>
<td>8:00 a.m.-12 noon</td>
<td>Monroe/Roosevelt Room, Third Floor, Hilton Atlanta</td>
<td>Management of Psychiatric Disorders in Pregnant and Postpartum Mothers</td>
</tr>
</tbody>
</table>
9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 3
9:00 a.m.-10:30 a.m.
Room A402, Level 4, Georgia World Congress Center

CROSSING THE LINE: DETERMINING YOUR PATIENT IS TOO DANGEROUS TO DRIVE
Moderator: Carl B. Greiner, M.D.
Presenters: Laura W. Roberts, M.D., Steven Wengel, M.D., Nicole Wolfe, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 1
9:00 a.m.-12 noon
Room A403, Level 4, Georgia World Congress Center

WEATHERING THE STORM: MANAGEMENT OF COMPLEX TRANSFERENCEs
Moderator: Beth J. Seelig, M.D.
Presenter: Otto F. Kernberg, M.D.
Discussants: John M. Oldham, M.D., Wendy Jacobson, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 88-95
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 88
9:00 a.m.-4:00 p.m.
Henry Room, Second Floor, Hilton Atlanta

ESSENTIALS OF GERIATRIC PSYCHOPHARMACOLOGY
Director: Helen Lavretsky, M.D.
Faculty: Joel Streim, M.D., Martha Sajatovic, M.D., David Oslin, M.D.

COURSE 89
9:00 a.m.-4:00 p.m.
Newton Room, Second Floor, Hilton Atlanta

INTERPERSONAL PSYCHOTHERAPY
Director: Scott Stuart, M.D.
Faculty: Paula Ravitz, M.D.

COURSE 90
9:00 a.m.-4:00 p.m.
Rockdale Room, Second Floor, Hilton Atlanta

PSYCHIATRY UPDATE: IN SPANISH
Co-Directors: Gabriel Kaplan, M.D., Javier I. Escobar, M.D.
Faculty: Pedro L. Delgado, M.D., Jacobo E. Mintzer, M.D., Humberto Marin, M.D.

COURSE 91
9:00 a.m.-4:00 p.m.
Clayton Room, Second Floor, Hilton Atlanta

MEN SEXUALLY ABUSED AS BOYS: MEANINGS, CONSEQUENCES, AND TREATMENTS
Director: Murray D. Schane, M.D.
Faculty: Howard Fradkin, Ph.D., Richard Gartner, Ph.D., William Holmes, M.D., Kenneth Singer, M.S.W., Bill Burmester, M.A.

COURSE 92
9:00 a.m.-4:00 p.m.
Grand Salon B, Second Floor, Hilton Atlanta

PSYCHIATRY IN CORRECTIONS
Co-Directors: Ole Thienhaus, M.D., Gail Singleterry, R.N.
Faculty: John N. Chappel, M.D., Richard Horton, M.D., Thomas M. Kim, M.D., Kaycia L. Vansicle, M.D., Fran Zito, L.C.S.W.

COURSE 93
9:00 a.m.-4:00 p.m.
Jackson Room, Third Floor, Hilton Atlanta

INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY
Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

COURSE 94
9:00 a.m.-4:00 p.m.
Board/Directors Rooms, Fourth Floor, Hilton Atlanta

ADVANCED INTERVIEWING TECHNIQUES
Director: Shawn C. Shea, M.D.
COURSE 95 9:00 a.m.-4:00 p.m.
Club/State Rooms, Fourth Floor, Hilton Atlanta

SEEING THE FOREST AND THE TREES: AN APPROACH TO BIOPSYCHOSOCIAL FORMULATION

Director: William H. Campbell, M.D.

DISCUSSION GROUPS 16-18

9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

16 Michele T. Pato, M.D. and Carlos N. Pato, M.D., on Residency to a Research Career (For Residents Only)
Collaborative Session With the National Institute of Mental Health
International Rooms 2-3, International Level, Marriott Marquis Atlanta

17 Wayne J. Katon, M.D., on Improving Outcomes of Patients With Anxiety and Depressive Disorders Within Primary Care Settings
Chestnut Room, North Tower, Meeting Level, Omni Hotel

18 Glen O. Gabbard, M.D., on Psychodynamic Psychiatry in Clinical Practice (Meet the Author)
Pecan Room, North Tower, Meeting Level, Omni Hotel

LECTURES 16-17

LECTURE 16

9:00 a.m.-10:30 a.m.
Room A412, Level 4
Georgia World Congress Center

APA'S OSKAR PFISTER AWARD LECTURE

Armand M. Nicholi, Jr., M.D.

The Conflicting Worldviews of Sigmund Freud and Oskar Pfister: Keys to Understanding Patients

Chp.: John R. Peteet, M.D.

Armand M. Nicholi, Jr., M.D. is Associate Clinical Professor of Psychiatry at Harvard Medical School and Massachusetts General Hospital. He teaches a popular course at Harvard that served as the basis for his 2002 book The Question of God: C. S. Lewis and Sigmund Freud Debate God, Love, Sex, and the Meaning of Life. The book was adapted as a PBS television series that first aired in 2004. Dr. Nicholi's research has ranged from the study of changes in the structure of the American family and their impact on the psychological development of children to the study of object relations theory and its application to the success of organizations. His investigation of college dropouts, which focuses on the causes and effects of the widespread nontherapeutic use of drugs in this population, is the first large-scale epidemiological study of that age group. Dr. Nicholi is the author of more than 120 scientific articles, chapters, and abstracts and is the editor and co-author of The Harvard Guide to Psychiatry. A Distinguished Life Fellow of the American Psychiatric Association (APA), Dr. Nicholi formerly served on the APA Committee on Health Services Research. He has been elected to the Harvard Chapter of Sigma Xi, the Scientific Research Society. THIS SESSION WILL BE AUDIOTAPE.

LECTURE 17

9:00 a.m.-12:30 p.m.
Rooms B312/313, Level 3
Georgia World Congress Center

Nancy Frasure-Smith, Ph.D.

Depression and Heart Disease: Cause, Effect, or Coincidence

Chp.: Joseph A. Cheong, M.D.
Co-Chp.: Stephen M. Saravay, M.D.

Depression may be a risk factor for the development and worsening of coronary artery disease, and depression and cardiac disease may have common causes, including inflammation, generalized atherosclerosis, and lower levels of omega-3 fatty acid. Dr. Nancy Frasure-Smith, discusses the evidence for depression as a cardiac risk factor, as well as the potential pathophysiological and behavioral mechanisms that may account for links between depression and cardiac disease. Dr. Frasure-Smith is Professor of Psychiatry and Adjunct Professor of Nursing at McGill University in Montreal. Senior Research Associate at the Montreal Heart Institute, Associate Professor of Psychiatry at the University of Montreal, and Associate Researcher at the Centre Hospitalier de l'Université de Montréal. She is also Past President of the American Psychosomatic Society. With her colleague Dr. François Lespérance, Dr. Frasure-Smith is known internationally for bringing depression to the forefront of research in behavioral cardiology. She recently received funding from the Canadian Institutes of Health Research for a multi-site, randomized trial of interpersonal psychotherapy and citalopram in patients with stable coronary artery disease. Dr. Frasure-Smith received her doctorate in social relations from Johns Hopkins University in Baltimore and completed a National Institute of Mental Health postdoctoral fellowship in psychology at McGill University. Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPE.
WEDNESDAY

MASTER EDUCATOR CLINICAL CONSULTATIONS 9-10

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

9  Diana Dell, M.D., on Managing Menopause
   Room B317, Level 3, Georgia World Congress Center

10 Susan G. Kornstein, M.D., on Premenstrual Mood Disorders
   Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

REVIEW OF PSYCHIATRY: SECTION 2

9:00 a.m.-2:30 p.m.
Rooms B405/406/407, Level 4, Georgia World Congress Center

PREGNANCY AND POSTPARTUM DEPRESSION

Chp.: Lee S. Cohen, M.D.

5 Course of Psychiatric Disorder During Pregnancy
   Laura Fagiolo-Petrillo, M.D.

6 Psychotropic Drug Use During Pregnancy
   Lee S. Cohen, M.D.

7 Diagnosis and Treatment of Postpartum Mood Disorder
   Ruta M. Nonacs, M.D.

8 Uses of Psychotropics During Lactation
   Adele C. Vigueria, M.D., Ruta M. Nonacs, M.D.

WORKSHOPS

COMPONENT WORKSHOPS 34-43

COMPONENT WORKSHOP 34 9:00 a.m.-10:30 a.m.
Room A404, Level 4, Georgia World Congress Center

A BITTER PILL? TAILORING MEDICAL TRAINING TO FIT OUR CONTEMPORARY PRACTICE
APA/GlaxoSmithKline Fellow

Co-Chps.: Steve Sugden, M.D., Lara R. Fuchs, M.D.
Participants: Tiffany R. Farchione, M.D., Marisa A. Giggie, M.D., Prakash K. Thomas, M.D.

COMPONENT WORKSHOP 35 9:00 a.m.-10:30 a.m.
Room A404, Level 4, Georgia World Congress Center

ROADMAP TO RECERTIFICATION: LIFELONG LEARNING
APA Council on Medical Education and Lifelong Learning

Co-Chps.: Richard Balon, M.D., Sheldon I. Miller, M.D.
Participants: Deborah J. Hales, M.D., Joan M. Anzia, M.D.,
Lowell D. Tong, M.D., Trish Tivnan

COMPONENT WORKSHOP 36 9:00 a.m.-10:30 a.m.
Room A405, Level 4, Georgia World Congress Center

CPT CODING AND DOCUMENTATION UPDATE
APA Council on RBRVS, Codes, and Reimbursements

Chp.: Chester W. Schmidt, Jr., M.D.
Participants: Tracy R. Gordy, M.D., Edward Gordon, M.D.,
Napoleon B. Higgins, Jr., M.D.

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room A410, Level 4, Georgia World Congress Center

SSRIS AND SUICIDE: LESSONS LEARNED AND IMPLICATIONS FOR FUTURE TREATMENT GUIDELINES
APA Council on Children, Adolescents, and Their Families

Chp.: Graham J. Emslie, M.D.
Participants: John S. March, M.D., David Fassler, M.D.,
Jennifer K. Cheng, M.D.

COMPONENT WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room B301, Level 3, Georgia World Congress Center

TO DOSE OR NOT TO DOSE: PSYCHOPHARMACOLOGY IN THE DEVELOPMENTALLY DISABLED
APA Committee on Developmental Disabilities

Chp.: Bryan H. King, M.D.
Participants: Joel D. Bregman, M.D., John DeFigueiredo, M.D.,
Lee Combrinck-Graham, M.D.

COMPONENT WORKSHOP 39 9:00 a.m.-10:30 a.m.
Room B306, Level 3, Georgia World Congress Center

FROM CRADLE TO GRAVE: THE IMPACT OF INCARCERATION ON AFRICAN-AMERICAN FAMILIES
APA Committee of Black Psychiatrists

Co-Chps.: Michelle O. Clark, M.D., N. Kalaya Okereke, M.D.
Participants: Rahn K. Bailey, M.D., Cassandra F. Newkirk, M.D.,
William M. Womack, M.D., Nancy Boyd-Franklin, Ph.D.
COMPONENT WORKSHOP 40 9:00 a.m.-10:30 a.m.
Room B307, Level 3, Georgia World Congress Center

DOCTOR, YOUR CHILD IS CALLING
APA Corresponding Committee on Psychiatry in the Workplace

Co-Chps.: Jacquelyn B. Chang, M.D., Andrea G. Stolar, M.D.
Participant: Marcia A. Scott, M.D.

COMPONENT WORKSHOP 41 9:00 a.m.-10:30 a.m.
Room B308, Level 3, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: AN UPDATE ON A NEW SUBSPECIALTY
APA Council on Psychosomatic Medicine

Co-Chps.: Philip R. Muskin, M.D., Carol L. Alter, M.D.
Participants: Peter A. Shapiro, M.D., James L. Levenson, M.D., Constantine Lyketsos, M.D., David Gitlin, M.D., Stephen C. Scheiber, M.D.

COMPONENT WORKSHOP 42 9:00 a.m.-10:30 a.m.
Room B309, Level 3, Georgia World Congress Center

IMPROVING DIAGNOSTIC AND THERAPEUTIC SKILLS: A CROSS-CULTURAL PERSPECTIVE
APA Committee on International Medical Graduates

Chp.: Sanjay Dubey, M.D.
Participants: Nalini Juthani, M.D., Francis M. Sanchez, M.D., Oscar E. Perez, M.D., Michelle B. Riba, M.D.

COMPONENT WORKSHOP 43 9:00 a.m.-10:30 a.m.
Room B310, Level 3, Georgia World Congress Center

SAME SEX MARRIAGES: MENTAL HEALTH AND PERSONAL PERSPECTIVES
APA Northern California Psychiatric Society's Committee on Lesbian, Gay, Bisexual, and Transgender Issues

Co-Chps.: Gene A. Nakajima, M.D., Ellen Haller, M.D.
Participants: Dan H. Karasic, M.D., John S. Kruse, M.D., Marshall Forstein, M.D.

ISSUES 57-77

ISSUE WORKSHOP 57 9:00 a.m.-10:30 a.m.
Room B311, Level 3, Georgia World Congress Center

IMPACT OF VIOLENCE ON PREGNANCY, BIRTH, AND PARENTHOOD: THE INTERFACE BETWEEN PSYCHIATRY AND OBSTETRICS

Chp.: Johannes Bitzer, M.D.
Participant: Werner Tschan, M.D.

ISSUE WORKSHOP 58 9:00 a.m.-10:30 a.m.
Room B314, Level 3, Georgia World Congress Center

CLINICAL DECISIONS: GUIDELINES, INDICATORS, AND ALGORITHMS

Co-Chps.: Rodrigo A. Munoz, M.D., Jack S. McIntyre, M.D.
Participants: Robert Popenoe, Ph.D., Richard Smith, M.D., Madhukar H. Trivedi, M.D., Britton A. Hill, M.D.

ISSUE WORKSHOP 59 9:00 a.m.-10:30 a.m.
Room B315, Level 3, Georgia World Congress Center

TREATMENT OF MENTAL ILLNESS IN U.S. JAILS AND PRISONS

Co-Chps.: Joseph R. Calabrese, M.D., Omar Elhaj, M.D.
Participants: Jeffrey L. Metzner, M.D., Timothy L. Thistlrethwaite, M.D.

ISSUE WORKSHOP 60 9:00 a.m.-10:30 a.m.
Room B316, Level 3, Georgia World Congress Center

IN FROM THE COLD: PERSPECTIVES ON SOCIAL SUPPORT IN PSYCHIATRY AND MEDICINE

Chp.: Jacqueline Olds, M.D.
Participants: David M. Spiegel, M.D., James S. Goodwin, M.D., Bruce S. McEwen, Ph.D., Richard S. Schwartz, M.D.

ISSUE WORKSHOP 61 9:00 a.m.-10:30 a.m.
Room B401, Level 4, Georgia World Congress Center

RELIGIOUS AND SPIRITUAL ASSESSMENT IN CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.
Participant: James L. Griffith, M.D.

ISSUE WORKSHOP 62 9:00 a.m.-10:30 a.m.
Room B402, Level 4, Georgia World Congress Center

ANGER MANAGEMENT: EVALUATION AND TREATMENT

Chp.: Eva C. Rivco, M.D.
Participants: Larry J. Harmon, Ph.D., Gonzalo F. Quesada, M.D.

ISSUE WORKSHOP 63 9:00 a.m.-10:30 a.m.
Room B403, Level 4, Georgia World Congress Center

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINE PATIENTS

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.
WEDNESDAY

ISSUE WORKSHOP 64  9:00 a.m.-10:30 a.m.
Room B404, Level 4, Georgia World Congress Center

WHEN USUAL TREATMENTS FAIL:
AUGMENTATION STRATEGIES FOR REFRACTORY
SCHIZOPHRENIA

Chp.: Jean-Pierre Lindenmayer, M.D.
Participants: Joseph I. Friedman, M.D., Guochuan Tsai, M.D.,
Richard P. Brown, M.D., Peter F. Buckley, M.D.

ISSUE WORKSHOP 65  9:00 a.m.-10:30 a.m.
Room B406, Level 4, Georgia World Congress Center

REINVENTING CAREERS: TRANSITIONS AND
LATER-LIFE STRATEGIES FOR PSYCHIATRISTS

Chp.: Carolyn B. Robitowitz, M.D.
Participants: Joel Yager, M.D., Jerald Kay, M.D., Carol C.
Nadelson, M.D.

ISSUE WORKSHOP 66  9:00 a.m.-10:30 a.m.
Room B409, Level 4, Georgia World Congress Center

PSYCHOTHERAPY TRAINING AND IMGs: THE
INFLUENCE OF CULTURAL FACTORS

Chp.: Nyapati Rao, M.D.
Participants: Michael Garrett, M.D., Stephen M.
Goldfinger, M.D., Damir Huremovic, M.D.

ISSUE WORKSHOP 67  9:00 a.m.-10:30 a.m.
Birch Room, South Tower, Atrium Terrace Level, Omni
Hotel

CARDIOVASCULAR COMPLICATIONS OF
PSYCHIATRIC TREATMENTS

Chp.: Peter Manu, M.D.

ISSUE WORKSHOP 68  9:00 a.m.-10:30 a.m.
Maple Room, South Tower, Atrium Terrace Level, Omni
Hotel

THE MARKETING OF PSYCHIATRIC MEDICATIONS
TO PATIENTS: WHERE DO WE STAND?

Chp.: Patrick Ying, M.D.
Participant: Marshal Folstein, M.D.

ISSUE WORKSHOP 69  9:00 a.m.-10:30 a.m.
Spruce Room, South Tower, Atrium Terrace Level, Omni
Hotel

SELF-AWARENESS DEFFICITS IN SCHIZOPHRENIA
AND COCAINE ABUSE

Chp.: Bernard D. Beitman, M.D.
Participants: Laura A. Flashman, Ph.D., George I.
Viamonte, M.D.

ISSUE WORKSHOP 70  9:00 a.m.-10:30 a.m.
Oak Room, South Tower, Lobby Level, Omni Hotel

RECOGNIZING AND MANAGING OPIOID-INDUCED
HYPERALGESIA IN CHRONIC PAIN PATIENTS

Chp.: Jon M. Strelitzer, M.D.
Participants: Carl R. Sullivan, M.D., L. Kenison Roy III, M.D.

ISSUE WORKSHOP 71  9:00 a.m.-10:30 a.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

FAST TRACKING INTO CHILD PSYCHIATRY: WHO
BENEFITS? WHO SUFFERS?

Co-Chps.: Kareem D. Ghalib, M.D., Lisa A. Mellman, M.D.
Participants: Eugene V. Beresin, M.D., Jed G. Magen, D.O.,
David L. Kaye, M.D., Marc E. Dalton, M.D.

ISSUE WORKSHOP 72  9:00 a.m.-10:30 a.m.
Dogwood B, North Tower, Street Level, Omni Hotel

THE REACH OF MENTAL ILLNESS STIGMA
Collaborative Session With the National Institute of Mental Health

Chp.: Bernice A. Pescosolido, Ph.D.
Participants: Patrick W. Corrigan, Psy.D., Cathy
Sherbourne, Ph.D., Jo C Phelan, Ph.D.

ISSUE WORKSHOP 73  9:00 a.m.-10:30 a.m.
Redwood Room, North Tower, Street Level, Omni Hotel

BENEATH THE SWORD OF DAMOCLES: LIVING IN
THE LIMBO OF REMISSION FROM CANCER

Chp.: Fredric J. Van Rheenen, M.D.

ISSUE WORKSHOP 74  9:00 a.m.-10:30 a.m.
Juniper Room, North Tower, Ballroom Level, Omni Hotel

BECOME A DELIRIUM DETECTIVE

Chp.: Arthur M. Freeman III, M.D.
Participants: Kristin S. Beitzai, M.D., Marie B. Tobin, M.D.,
Robert Koress, Ph.D.

ISSUE WORKSHOP 75  9:00 a.m.-10:30 a.m.
Magnolia Room, North Tower, Ballroom Level, Omni Hotel

TREATMENT OF TOURETTE'S SYNDROME
THROUGH THE LIFE CYCLE
National Tourette's Syndrome Association

Chp.: Cathy L. Budman, M.D.
Participants: John T. Walkup, M.D., Anthony L. Rostain, M.D.


**WEDNESDAY**

**ISSUE WORKSHOP 76**  
9:00 a.m. - 10:30 a.m.  
Hickory Room, North Tower, Meeting Level, Omni Hotel

**ACCEPTANCE VERSUS CHANGE: DIALECTICS OF IMPLEMENTING DBT IN RESIDENCY TRAINING**

**Co-Chairs:** Maribel Rivera, M.D., Lisa Lyons, Ph.D.  
**Participants:** Brad Foote, M.D., Kara L. McCunn, M.D.

**ISSUE WORKSHOP 77**  
9:00 a.m. - 10:30 a.m.  
Walnut Room, North Tower, Meeting Level, Omni Hotel

**SEXUAL HISTORY: THE ART AND THE SCIENCE**

**Chair:** Waguih W. Ishak, M.D.  
**Participants:** Shahrad R. Amiri, M.D., Danni Michaeli, M.D.

**11:00 a.m. Sessions**

**DISCUSSION GROUPS 19-21**  
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

19  
**Richard Balon, M.D. and Carol A. Bernstein, M.D., on Core Competencies (For Residents Only)**  
International Rooms 2-3, International Level, Marriott Marquis Atlanta

20  
**Laura W. Roberts, M.D., on Ethics Evidence and Ethical Skills in Psychiatry (Meet the Author)**  
Hazelnut Room, North Tower, Meeting Level, Omni Hotel

21  
**Sarah H. Lisanby, M.D., on Emerging Brain Stimulation Techniques in Psychiatry (Meet the Author)**  
Collaborative Session With the National Institute of Mental Health  
Pecan Room, North Tower, Meeting Level, Omni Hotel

**LECTURE 18**  
11:00 a.m.-12:30 p.m.  
Room A411, Level 4  
Georgia World Congress Center

**Stuart C. Yudofsky, M.D.,** Neuropsychiatry and the Future of Psychiatry and Neurology

**Chp.:** David A. Casey, M.D.  
**Co-Chp.:** Nicole Wolfe, M.D.

**MASTER EDUCATOR CLINICAL CONSULTATIONS 11-12**

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

11  
**Miriam Rosenthal, M.D., on Psychiatric Aspects of Reproduction in Chronically Mentally Ill Women**  
Room B317, Level 3, Georgia World Congress Center

12  
**Robert N. Golden, M.D., on the Approaches to Treatment-Refractory Depression**  
Room B318, Level 3, Georgia World Congress Center

**THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ENTRANCE.**

**MEDICAL UPDATE 3**  
11:00 a.m.-12:30 p.m.  
Room B403, Level 4, Georgia World Congress Center

**OKAY INSIDE THEIR HEAD, BUT WHAT'S UNDER THEIR NOSE?**

**Presenter:** Claudia Miller, M.D.  
**Chp.:** Joan A. Lang, M.D.
RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

Michael E. Thase, M.D., on Evaluating the Effects of Treatment for Depression
Chestnut Room, North Tower, Meeting Level, Omni Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 19-27

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Room A402, Level 4, Georgia World Congress Center

ADDITIONAL PSYCHIATRY

Chp.: Shelly F. Greenfield, M.D.
Co-Chp.: Kenneth Stoller, M.D.

11:00 a.m.
56 Virtual Reality Cue Exposure for Crack Cocaine Dependence
Barbara Rothbaum, Ph.D., Michael Saladin, Ph.D., Ken Graap, M.A., Kathleen T. Brady, M.D.

11:30 a.m.
57 Low-Dose Naltrexone for Opioid Dependence
Paolo Mannelli, M.D., Charles Thornton, Ph.D., Heather Murray, Ashwin A. Patkar, M.D.

12 noon
58 Buprenorphine Versus Methadone Treatments in Addicted Opioid Patients: A Two-Year Observational Study
Paolo Marzorati, M.D., Livia Guglielmino, M.D., Pierluigi Vigezzi, M.D., Rosella Silenzio, M.D., Margherita de Chiara, M.D., Filomena Corrado, M.D., Edoardo Cozzolino, M.D.

12 noon
59 Last Observation Carried Forward Use in Antidepressant Efficacy Trials: Review of 260 Studies
Alex A. Cardoni, MS., Stephen B. Woolley, M.P.H., John W. Goethe, M.D.

11:30 a.m.
60 Sildenafil Treatment of SSRI-Associated Sexual Dysfunction in Nonresponders of a Double-Blind, Placebo-Controlled Study: Single-Blind, Open-Label Results
H. George Numberg, M.D., Paula L. Hensley, M.D., Maurizio Fava, Ph.D., Alan J. Gelbein, M.D., John Lauriello, M.D., Susan Paine, M.P.H.

12 noon
61 Association Between SSRI Side Effects and Adherence to Modern SSRIs
Stephen B. Woolley, M.P.H., John W. Goethe, M.D.

THIS SESSION WILL BE AUDIOTAPED.

DEPRESSION

Chp.: Thomas L. Schwartz, M.D.
Co-Chp.: Glenn J. Treisman, M.D.

11:00 a.m.
62 The Effect of Chromium Picolinate on Carbohydrate Craving in Atypical Depression
John P. Docherty, M.D., James Komorowski, M.S., David A. Sack, M.D., Mark Roffman, Ph.D., Manley Finch

12 noon
63 Does Remission of Acute Depression Predict Long-Term Efficacy
Caroline B. Williams, M.D., Eric D. Peselow, M.D., Mary Anne Pressman, M.D., Gonzalo E. Laje, M.D.

THIS SESSION WILL BE AUDIOTAPED.

EATING DISORDERS

Chp.: Regina Dolan-Sewell, Ph.D.
Co-Chp.: Theodore E. Weltzin, M.D.

11:00 a.m.
64 Anorexia Nervosa and Bulimia Nervosa: From Culture to Genes
Pamela K. Keel, Ph.D.
11:30 a.m. 66 Psychosocial Treatment of Eating Disorders
Cynthia M. Bulik, Ph.D.

12 noon
67 Psychopharmacology of Eating Disorders
B. Timothy Walsh, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Room B408, Level 4, Georgia World Congress Center

VIOLENCE AND TRAUMA
Chp.: Randall D. Marshall, M.D.
Co-Chp.: Barbara D’Orio, M.D.

11:00 a.m.
68 Effects of Terrorism on Psychopathology: Two Years After 9/11
Judith A. Richman, Ph.D., Kenneth W. Zlatoper, MS., Joseph A. Flaherty, M.D., Kathleen Rospenda, Ph.D.

11:30 a.m.
69 9/11: Terrorism, Psychiatric Symptoms, Service Utilization, and Alcohol Intake
Linda S. Grossman, Ph.D., Judith A. Richman, Ph.D., Kenneth W. Zlatoper, MS., Cherise Rosen, M.A.

12 noon
70 Clozapine, Olanzapine, and Haloperidol Treatment of Violent Patients With Schizophrenia
Menahem I. Krakowski, M.D., Pal Czobor, Ph.D., Leslie L. Cérome, M.D., Fabien Tremante, M.D., Biman Roy, M.D., Linda Kline, R.N.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m.-12:30 p.m.
Room B409, Level 4, Georgia World Congress Center

SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS
Chp.: David Walker, M.D.
Co-Chp.: Mark Hurto, M.D.

11:00 a.m.
71 Premorbid Developmental Achievements and Later Recovery in Schizophrenia
Martin Harrow, Thomas H. Jobe, M.D., Linda S. Grossman, Ph.D., Joseph F. Goldberg, M.D., Robert Faull, B.S.

11:30 a.m.
72 Pain Insensitivity in Schizophrenia: State or Trait Marker?
Lisa L. Gies, M.D., Manpreet Singh, M.D., Henry A. Nasrallah, M.D.

12 noon
73 Effectiveness of an Early Psychosis Treatment Service
Donald E. Addington, M.D., Jean M. Addington, Ph.D., Scott B. Patten, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:30 a.m.-12:30 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

TREATMENT TECHNIQUES
Chp.: Joel Kirson, M.D.
Co-Chp.: Jennifer Heath, M.D.

11:00 a.m.
74 Does Exercise Have a Place in Psychiatry?
James Annesi, Ph.D., Sheldon B. Cohen, M.D.

11:30 a.m.
75 Restraint Stress Elevates Plasma Icytokines Levels in Superoxide Dependent Manner
Atsuo Sekiyama, Ph.D., Haruyasu Ueda, Ph.D., Shinichiro Kashiwamura, Ph.D., Masatoshi Takeda, M.D., Haruki Okamura, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

MEDICAL ILLNESS AND PSYCHIATRIC DISORDERS
Chp.: Michael Burke, M.D.
Co-Chp.: Jeffrey Lee Erickson, M.D.

11:00 a.m.
77 Depression Correlates With Left Nigrostriatopallidal Circuit Focal Lesions
Edward C. Lauterbach, M.D., Julia B. Tolley, M.Ed., William F. Bina, M.D., Thomas D. Hope, M.D.

11:30 a.m.
78 Depression-Related Impairment of Barorreflex in Heart Failure
Salvador M. Guinjoan, M.D., Carlos Berbara, M.D., Maria Gabrielli, B.A., Daniel E. Vigo, M.D., Ricardo Perez-De-La-Hoz, M.D., Alfredo Ortiz-Fragola, Daniel P. Cardinali, M.D., Rodolfo D. Falhrr, M.D.

12 noon
79 Respiratory Panic Disorder in a Long-Term Clonazepam Follow-Up
Antonio E. Nardi, M.D., Alexandre M. Valenca, M.D., Fabiana L. Lopes, M.D., Isabella Nascimento, M.D., Marco A. Mezzzasima, M.D., Rafael C. Freire, M.D., Walter A. Zin, M.D.
THIS SESSION WILL BE AUDIOTAPED.
WEDNESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Redwood Room, North Tower, Street Level, Omni Hotel

PSYCHIATRIC ADMINISTRATION AND SERVICES
Chp.: Ossama T. Osman, M.D.
Co-Chp.: Amie D. Rajparia, M.D.

11:00 a.m.
80 Changing Trends in Psychiatric Emergency Room Patients in Large Urban Hospitals
Christopher K. Chung, M.D., Davin A. Agustines, M.D.,
Steve Brown, Ph.D., Jambur V. Ananth, M.D.

11:30 a.m.
81 Data From a Psychiatric Emergency Service Using an Electronic Medical Record
Jennifer S. Brasch, M.D., Rolf Sebalt, M.D., Christopher Webster, Ph.D., Marilyn Craven, M.D.

12 noon
82 Implementing a Mixed Psychiatric and Somatic Care Unit in a General Hospital
Ariel Eytan, M.D., Christel Alberque, M.D., Marianne Geex-Fabry, M.S.C.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 44-51

COMPONENT WORKSHOP 44 11:00 a.m.-12:30 p.m.
Room A304, Level 3, Georgia World Congress Center

MENTAL STATUS AFTER CABG: IMPLICATIONS FOR PSYCHIATRISTS' COMPETENCE
APA Council
Co-Chps.: Abram M. Hosseter, M.D., Sheila Hafer Gray, M.D.
Participants: Margaret O'Connor, Ph.D., Alberto M. Goldwasser, M.D.

COMPONENT WORKSHOP 45 11:00 a.m.-12:30 p.m.
Room B308, Level 3, Georgia World Congress Center

CURRENT ISSUES IN PSYCHIATRY AND LAW AT APA
APA Council on Psychiatry and Law
Chp.: Paul S. Appelbaum, M.D.
Participants: Richard Bonnie, J.D., Howard V. Zonana, M.D.,
Jeffrey L. Metzner, M.D., Patricia R. Recupero, M.D.

COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m.
Room B401, Level 4, Georgia World Congress Center

THE CONFLICTING WORLDVIEWS OF SIGMUND FREUD AND C.S. LEWIS
APA Corresponding Committee on Religion, Spirituality, and Psychiatry
Chp.: John R. Petreet, M.D.
Participants: Dan G. Blazer II, M.D., Armand M. Nicholi, Jr., M.D.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m.
Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

HOW TO LEAD AN EFFECTIVE TREATMENT TEAM
APA Caucus of State Hospital Psychiatrists
Chp.: Beatrice Kovasznay, M.D.
Participants: Joel S. Feiner, M.D., Pamela A. Weinberg, M.D.,
Yad Jabbarpour, M.D.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m.
Juniper Room, North Tower, Ballroom Level, Omni Hotel

WHY BUSINESS NEEDS QUALITY CARE FOR DEPRESSION, ANXIETY, AND SUBSTANCE-USE DISORDERS
APA Committee on APA/Business Relationships
Chp.: Norman A. Clemens, M.D.
Participants: Jeffrey P. Kahn, M.D., Alan Langlieb, M.D.,
Herbert S. Peyser, M.D.

COMPONENT WORKSHOP 49 11:00 a.m.-12:30 p.m.
Magnolia Room, North Tower, Ballroom Level, Omni Hotel

COME AND COMPLAIN: DO PSYCHIATRISTS HAVE A ROLE IN ACCREDITATION? A DEBATE
APA Committee on Standards and Survey Procedures
Chp.: Steven I. Altchuler, M.D.
Participants: Marlin R.A. Mattson, M.D., Dennis J. Milke, M.D.,
Albert V. Vogel, M.D.

COMPONENT WORKSHOP 50 11:00 a.m.-12:30 p.m.
Hickory Room, North Tower, Meeting Level, Omni Hotel

INDIAN HEALTH SERVICE MENTAL HEALTH UPDATE AND PLANNING FOR THE FUTURE
APA Committee of American Indians, Alaska Natives, and Native Hawaiian Psychiatrists
Chp.: Frank Brown, M.D.
Participants: Jon Perez, Ph.D., Brian T. Benton, M.D.
COMPONENT WORKSHOP 51  11:00 a.m.-12:30 p.m.
Walnut Room, North Tower, Meeting Level, Omni Hotel

NEED AN OXYCONTIN FIX? THE ROLE OF BUPRENORPHINE IN THE OUTPATIENT TREATMENT OF PRESCRIPTION NARCOTIC PROBLEMS
Consortium Committee on Treatment Services for Patients with Addictive Disorders

Chp.: George F. Kolodner, M.D.
Participants: Marianne T. Guschwan, M.D., John Renner, M.D., Samuel M. Silverman, M.D.

ISSUES 78-89

ISSUE WORKSHOP 78  11:00 a.m.-12:30 p.m.
Room A405, Level 4, Georgia World Congress Center
SLEEP DISORDERS IN PATIENTS WITH MEDICAL AND PSYCHIATRIC ILLNESS

Chp.: Dimitri D. Markov, M.D.
Participants: Karl Doghramji, M.D., Mary B. O'Malley, M.D.

ISSUE WORKSHOP 79  11:00 a.m.-12:30 p.m.
Room B307, Level 3, Georgia World Congress Center
FEMALE KNOCKOUTS: WOMEN PERPETRATORS AND VICTIMS OF PARTNER VIOLENCE

Chp.: Susan J. Hatters-Friedman, M.D.
Participants: Joy E. Stankowski, M.D., Renee M. Sorrentino, M.D.

ISSUE WORKSHOP 80  11:00 a.m.-12:30 p.m.
Room B309, Level 3, Georgia World Congress Center
POLYPHARMACY: NEW ADVANCES IN SUPPORTING PSYCHIATRIC PRACTICE
Collaborative Session With the National Institute of Mental Health

Co-Chps.: Jurius J. Gonzales, M.D., Graca Cardoso, M.D.
Participants: Madhukar H. Trivedi, M.D., Robert L. Trestman, M.D.

ISSUE WORKSHOP 81  11:00 a.m.-12:30 p.m.
Room B310, Level 3, Georgia World Congress Center
PHILIP PULLMAN'S THE GOLDEN COMPASS: COMING OF AGE IN A FRACUTRED WORLD

Chp.: JoAnne Isbey, A.B.D.
Participants: Theresa A. Yuschok, M.D., Eva M. Szigethy, M.D., Leah J. Dickstein, M.D., Cheryl Munday, Ph.D.

ISSUE WORKSHOP 82  11:00 a.m.-12:30 p.m.
Room B311, Level 3, Georgia World Congress Center
THE DIFFICULT-TO-TREAT BULIMIA NERVOsa PATIENT

Chp.: Wagih W. Ishak, M.D.
Participants: Jennifer L. McLain, M.D., Antonia Ludwig-Noble, M.F.T., Marlene Clark

ISSUE WORKSHOP 83  11:00 a.m.-12:30 p.m.
Room B315, Level 3, Georgia World Congress Center
PSYCHOSOMATIC MEDICINE WITH A DEVELOPMENTAL TWIST: CHILD CONSULTATION/LIAISON FOR ADULT PSYCHIATRISTS

Chp.: Maryland Pao, M.D.
Participant: Susan B. Turkel, M.D.

ISSUE WORKSHOP 84  11:00 a.m.-12:30 p.m.
Room B316, Level 3, Georgia World Congress Center
VIRTUAL REALITY AND OTHER FORMS OF CYBERTHERAPY: AN EVIDENCE-BASED REVIEW

Chp.: Jack Kuo, M.D.
Participants: William Huang, M.D., Carson Reynolds, M.S., Jeffery Wilkins, M.D.

ISSUE WORKSHOP 85  11:00 a.m.-12:30 p.m.
Birch Room, South Tower, Atrium Terrace Level, Omni Hotel
THERAPEUTIC USE OF MOVIE CLIPS IN OUTPATIENT AND INPATIENT GROUP TREATMENT

Chp.: Michael A. Kalm, M.D.

ISSUE WORKSHOP 86  11:00 a.m.-12:30 p.m.
Maple Room, South Tower, Atrium Terrace Level, Omni Hotel
INDIVIDUALS AND CONJOINT APPROACHES TO COUPLES THERAPY

Chp.: Eva C. Ritvo, M.D.
Participants: Michael C. Hughes, M.D., Jon A. Shaw, M.D.
WEDNESDAY

ISSUE WORKSHOP 87 11:00 a.m.-12:30 p.m.
Oak Room, South Tower, Lobby Level, Omni Hotel

RESIDENTS IN THE TRENCHES, BUT NOT OUT IN THE COLD: INTEGRATING SHELTER-BASED OUTPATIENT ROTATIONS WITH ONLINE EDUCATIONAL TOOLS
American Association of Community Psychiatrists

Chp.: Stephen M. Goldfinger, M.D.
Participants: Ellen Berkowitz, M.D., Eric Weitzner, M.D., Van Yu, M.D., Ramose Saunders, M.D., Damir Huremovic, M.D.

ISSUE WORKSHOP 88 11:00 a.m.-12:30 p.m.
Dogwood A, North Tower, Street Level, Omni Hotel

GRANDPARENTS AND GRANDCHILDREN: CHILD PSYCHIATRIC AND FAMILY PERSPECTIVES
Co-Chps.: G. Pirooz Sholevar, M.D., Ellen Harris Sholevar, M.D.

ISSUE WORKSHOP 89 11:00 a.m.-12:30 p.m.
Dogwood B, North Tower, Street Level, Omni Hotel

UNEXPLAINED MEDICAL SYMPTOMS IN A PEDIATRIC POPULATION
Chp.: Rose Geist, M.D.
Participants: Gillian Kirsh, M.A., Rachel Gropper

12 noon Sessions

FORUMS 7-9

FORUM 7 12 noon-1:30 p.m.
Room A410, Level 4, Georgia World Congress Center
ABPN UPDATE: CERTIFICATION IN PSYCHIATRY AND ITS SUBSPECIALTIES
Chp.: Stephen C. Scheiber, M.D.
Participants: Naline N. Andrade, M.D., Michael H. Ebert, M.D., David A. Mrazek, M.D., Burton V. Reifler, M.D., Victor I. Reus, M.D., James H. Scully, Jr., M.D.

FORUM 8 12 noon-1:30 p.m.
Room B314, Level 3, Georgia World Congress Center
CULTURE, SPIRITUALITY, AND FOLK BELIEF
Chp.: Edward F. Foulks, M.D.
Participants: Pedro Ruiz, M.D.

FORUM 9 12 noon-1:30 p.m.
Room B404, Level 4, Georgia World Congress Center

CDC MENTAL HEALTH AND ILLNESSES
Chp.: Marc A. Safran, M.D.
Participants: Alex Crosby, M.D., Pamela G. Tucker, M.D., Daniel P. Chapman, Ph.D., Barbara Lopes-Cardozo, M.D.

NEW RESEARCH POSTER SESSION 8
12 noon-2:00 p.m.
Room B322/303/304/305, Level 3, Georgia World Congress Center

OTHER TOPICS
For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

1:00 p.m. Sessions

COURSES 96-100
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 96 1:00-5:00 p.m.
Forsythe Room, Second Floor, Hilton Atlanta
USING NEUROFEEDBACK IN YOUR PRACTICE II: APPLICATIONS
Co-Directors: Thomas M. Brod, M.D., Michael Cohen, B.S.
Faculty: Sebern F. Fisher, M.A., Angelo S. Bolea, Ph.D., Stephen E. Buie, M.D., Emily Stevens, Ph.D., R. Michael O'Bannon, Ph.D., William C. Scott, B.S.W.

COURSE 97 1:00-5:00 p.m.
DeKalb Room, Second Floor, Hilton Atlanta
RECOVERY FROM MENTAL ILLNESS AND STIGMA: INTEGRATING MEDICINE AND REHABILITATION
Co-Directors: Eugene A. Oulvey, Ph.D., Karen L. Lee, M.A.
Faculty: Vivek Jain, M.D., Connie Clark, M.A., Michael J. Martin, M.D.

COURSE 98 1:00-5:00 p.m.
Gwinnett Room, Second Floor, Hilton Atlanta
RATING SCALES IN PSYCHIATRY
Co-Directors: Sagar Parikh, M.D., Vyta S. Velyvis, M.D.
WEDNESDAY

COURSE 99
1:00 p.m.-5:00 p.m.
Madison Room, Third Floor, Hilton Atlanta

SEXUAL MEDICINE

Director: Waguih W. Ishak, M.D.
Faculty: Shahrad R. Amiri, M.D., Laura A.C. Berman, Ph.D., Albert A. Mikhail, M.D.

COURSE 100
1:00 p.m.-5:00 p.m.
Monroe/Roosevelt Room, Third Floor, Hilton Atlanta

MOOD DISORDERS IN LATER LIFE: AN INTERDISCIPLINARY APPROACH

Director: James M. Ellison, M.D.
Faculty: Francesca Antognini, Ph.D., Donald A. Davidoff, Ph.D., Brent P. Forester, M.D., E. Yusuf Sivrioglu, M.D.

2:00 p.m. Sessions

LECTURES 19-20

LECTURE 19
2:00 p.m.-3:30 p.m.
Room A411, Level 4
Georgia World Congress Center

Randolph M. Nesse, M.D.
Evolution: The Missing Basic Science That Brings Psychiatry Coherence and Deeper Empathy

Chp.: Francine Cournos, M.D.
Co-Chp.: Stephen Hersh, M.D.

Randolph M. Nesse, M.D., is Professor of Psychiatry and Professor of Psychology at the University of Michigan in Ann Arbor, where he is also Research Professor in the Research Center for Group Dynamics at the Institute for Social Research. He directs the Evolution and Human Adaptation Program at the University of Michigan and was a founder of the Human Behavior and Evolution Society. Dr. Nesse is the editor of the book Evolution and the Capacity for Commitment, which explores the question of whether the capacities for making, assessing, and keeping commitments have been shaped by natural selection. His book, coauthored with George Williams, Why We Get Sick: The New Science of Darwinian Medicine, explains why natural selection has left humans with bodies that are vulnerable to so many diseases. In his current work, he applies these same principles to the questions of why humans are so vulnerable to depression and how this knowledge can foster more effective research and treatment. Dr. Nesse received his medical degree from the University of Michigan Medical School.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPE D.

LECTURE 20
2:00 p.m.-3:30 p.m.
Room A412, Level 4
Georgia World Congress Center

Gerald F.M. Russell, M.D.
The 25th Anniversary of Bulimia Nervosa: A New Disorder

Chp.: Geetha Jayaram, M.D.
Co-Chp.: Kathryn J. Zerbe, M.D.

Gerald F.M. Russell, M.D., is Emeritus Professor of Psychiatry at the University of London and Consultant Psychiatrist at Priory Hospital Hayes Grove in Kent, U.K. Dr. Russell’s research has been in the investigation and treatment of human disorders of eating. This work has spanned some 45 years and led to the elucidation of the nutritional and endocrine aspects of anorexia nervosa and a measurement of the disturbance of body image in this illness. His most influential work was the delineation of the syndrome of bulimia nervosa in 1979; the diagnostic criteria originally proposed were incorporated into the main systems of classification of psychiatric disorders. Between 1981 and 2000, his primary emphasis was on the development and evaluation of psychological treatments in eating disorders. This research resulted in demonstration of the specific value of family therapy in young patients with anorexia nervosa. Dr. Russell has received numerous awards for his contributions to eating disorders research and treatment, including the Outstanding Research Publication Award of the American Association for Marriage and Family Therapy, the Paul Hoch Award of the American Psychopathological Association, and the Eating Disorders National Award from the Eating Disorders Association of the United Kingdom. Dr. Russell was educated at George Watson’s College in Edinburgh.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPE D.

PRESIDENTIAL SYMPOSIA 5-6

PRESIDENTIAL SYMPOSIUM 5
2:00 p.m.-5:00 p.m.
Room A305, Level 3, Georgia World Congress Center

THE INTERFACE OF PSYCHIATRY AND MEDICINE: DISORDERS OF AFFECT, BEHAVIOR, AND COGNITION
Academy of Psychosomatic Medicine

Chp.: Theodore A. Stern, M.D.

(Continued next page)
A Psychiatric Aspects of Dementia
Constantine Lyketsos, M.D.

B The Management of Depression and Comorbid Medical Illness
Michael K. Popkin, M.D.

C Reproductive Mood Disorders: The Brain in Context
David R. Rubinow, M.D.

D The Interface of Psychiatry and Medicine: Disorders of Affect, Behavior, and Cognition
Theodore A. Stern, M.D.

E Etiologies and Neuropathogenesis of Delirium: Management Implications
Paula T. Trzepacz, M.D.

PRESIDENTIAL SYMPOSIUM 6
2:00 p.m.-5:00 p.m.
Room B401, Level 4, Georgia World Congress Center

HEART, MIND, AND SOUL: PSYCHIATRIC ISSUES IN CARDIAC HEALTH FOR AFRICAN AMERICANS
Association of Black Cardiologists
Chp.: Michelle O. Clark, M.D.
Co-Chp.: B. Waine Kong, J.D.

A The Link Between Depression and Cardiovascular Disease
Richard Williams, M.D.

B Racial Disparities: The Metabolic Breakdown
Randall Maxey, M.D.

C Psychotropic Medication Use With the African-American Cardiology Patient
Curley L. Bonds, M.D.

D Cultural Change: A Psychosocial Adjustment for the African-American Cardiology Patient
Annette L. Prim, M.D.

Discussant: B. Waine Kong, J.D.

SYMPOSIA 56-86

SYMPOSIUM 56
2:00 p.m.-5:00 p.m.
Cypress Room, Carter Center

SOVIET/ RUSSIAN PSYCHIATRY: 15-YEAR EVOLUTION, DAVID LOZOVSKY MEMORIAL
APA Council on Global Psychiatry in Collaboration With the National Institute of Mental Health
Chp.: Darrel A. Regier, M.D.

A Ending Soviet Abuse of Psychiatry
Richard Schiffer

Loren H. Roth, M.D.

C Unraveling Soviet Psychiatry: Changes in 15 Years
Richard Bonnie, J.D.

D Reform of Russian Psychiatry: Problems and Prospects
Svetlana Polubinskaya, Ph.D.

E Disaster Psychiatry in Russia: Example of the Beslan Tragedy
Zurab Kekelidze, M.D.

F Reforming Russian Psychiatry: Role of Russian-American Collaboration
Valery N. Krasnov, M.D.

Discussants: Walder J. Reich, M.D., Thomas H. Borneman, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 57
2:00 p.m.-5:00 p.m.
Room A302, Level 3, Georgia World Congress Center

THE NIMH CLINICAL ANTIPSYCHOTIC TRIAL OF INTERVENTION EFFECTIVENESS FOR ALZHEIMER'S DISEASE (CATIE-AD): FIRST OUTCOMES
Collaborative Session With the National Institute of Mental Health
Chp.: Lon Schneider, M.D.
**WEDNESDAY**

**A** An Overview of Main Outcomes in CATIE-AD  
Pierre N. Tariot, M.D.

**B** AD: Safety and Tolerability of Antipsychotics and Citalopram  
Saleem Ismail, M.D.

**C** Quality of Life of Patient and Caregiver: Caregiver-Rated Assessments and Outcomes  
Peter V. Rabins, M.D.

**D** CATIE-AD: Economic Utilization  
Robert A. Rosenheck, M.D.

**Discussants:** Dilip V. Jeste, M.D., Barry D. Lebowitz, Ph.D.

THIS SESSION WILL BE AUDIOTAPE D.

**SYMPOSIUM 59**  
2:00 p.m.-5:00 p.m.

Room A403, Level 4, Georgia World Congress Center

**ADVERTISE IN PREVENTION: SCIENCE AND CLINICAL STRATEGIES**

Chp.: Thomas H. McGlashan, M.D.
Co-Chp.: David Reiss, M.D.

**A** Early Recognition and Treatment of Psychosis: Initial Findings and Prospects  
Thomas H. McGlashan, M.D., Per Vaglum, M.D., Ingrid Melle, M.D., Scott W. Woods, M.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Robert B. Zipursky, M.D.

**B** Need for Early Intervention Trials in Prepubertal Bipolar Disorder  
Robert M. Post, M.D.

**C** Prevention of Depression in Childhood: Review and Implications  
William R. Beardslee, M.D.

**D** Preventing Secondary Substance Use Disorders  
Wilson M. Compton III, M.D.

**E** Putting Genetics to Work for Preventive Interventions  
David Reiss, M.D.

**SYMPOSIUM 58**  
2:00 p.m.-5:00 p.m.

Room A402, Level 4, Georgia World Congress Center

**DIAGNOSTIC AND TREATMENT IMPLICATIONS OF A NEW MODEL OF PERSONALITY DISORDERS**

Collaborative Session With the National Institute of Mental Health

**Chp.:** Andrew E. Skodol II, M.D.
**Co-Chp.:** John G. Gunderson, M.D.

**A** Course of Symptoms and Impairments in Patients With Personality Disorders  
Andrew E. Skodol II, M.D., M. Tracie Shea, Ph.D., Carlos M. Grilo, Ph.D., Robert L. Stout, Ph.D., John G. Gunderson, M.D., Maria E. Pagano, Ph.D., Thomas H. McGlashan, M.D.

**B** Association of Course Changes in Personality Disorders and Axis I Disorders  
M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Carlos M. Grilo, Ph.D., John G. Gunderson, M.D., Andrew E. Skodol II, M.D., Shirley Yen, Ph.D., Leslie C. Morey, Ph.D.

**C** A Hybrid Model of Personality Disorders: Traits and Symptomatic Behaviors  
Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., John G. Gunderson, M.D., Leslie C. Morey, Ph.D., M. Tracie Shea, Ph.D., Andrew E. Skodol II, M.D., Thomas H. McGlashan, M.D.

**D** Comparative Validity of Three Alternative Personality Disorder Models  
Leslie C. Morey, Ph.D.

**E** Implications for Research on the Treatment of BPD From the CLPS  
John G. Gunderson, M.D.

**Discussant:** Thomas A. Widiger, Ph.D.

**SYMPOSIUM 60**  
2:00 p.m.-5:00 p.m.

Room A404, Level 4, Georgia World Congress Center

**BIPOLAR DISORDER: OPTIMIZING OUTCOME THROUGH EARLY RECOGNITION AND INTERVENTION**

Chp.: Joseph F. Goldberg, M.D.

**A** Screening for Bipolar Spectrum Disorders in the Community  
Robert M.A. Hirschfeld, M.D.

**B** Pediatric and Adult Bipolar Patients: Neuroimaging and Pharmacological Differences  
Melissa P. DelBello, M.D.

**C** Impact of Delayed Treatment on Illness Course and Suicide Risk in Bipolar Disorders  
Joseph F. Goldberg, M.D.

**D** Overcoming Obstacles to Medication Adherence  
Jan L. Scott, M.D.

**E** Do FDA Concerns About Antidepressant Safety Reflect Early Bipolar Risk?  
S. Nassir Ghaemi, M.D.

**Discussant:** Thomas A. Widiger, Ph.D.

**THIS SESSION WILL BE AUDIOTAPE D.**
SYMPOSIUM 61 2:00 p.m.-5:00 p.m.
Room A405, Level 4, Georgia World Congress Center
THE BIOPSYCHOSOCIAL CONSEQUENCES OF PATHOLOGICAL GAMBLING
Chp.: Timothy W. Fong, M.D.
A The Medical Consequences of Pathological Gambling
Timothy W. Fong, M.D.
B Problem Gambling: Psychosocial Problems in Special Populations and Treatments
Nancy M. Petry, Ph.D.
C The Impact of Pathological Gambling on the Family
Donald W. Black, M.D.
D Pathological Gambling and the Law
Jon E. Grant, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 62 2:00 p.m.-5:00 p.m.
Room A406, Level 4, Georgia World Congress Center
PSYCHOANALYSIS AND PSYCHOSOMATIC ILLNESS: A MODERN MIND-BODY PERSPECTIVE
Chp.: Regina Pally, M.D.
A The Therapeutic Consultation of Patients With Psychosomatic Symptoms
Milton Viederman, M.D.
B Psychoanalysis and Psychosomatic Processes in the Brain and Mind
Ronald W. Levin, M.D.
C Psychoanalytic Treatment of a Patient With Irritable Bowel Syndrome
Beth J. Seelig, M.D.
D The Developmental Line of Human Feeding: Covariant Roots of Psychopathology and Neurobiological Dysregulation in Eating Disorders
Barton J. Blinder, M.D.
Discussant: Elizabeth O. Travick, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 63 2:00 p.m.-5:00 p.m.
Room A407, Level 4, Georgia World Congress Center
THE DOCTOR’S DILEMMA: MANAGING PEDIATRIC CHRONIC UNEXPLAINED SYMPTOMS
Chp.: Rose Geist, M.D.
A Shifting the Focus: Family-Oriented Rehabilitation for Chronic Unexplained Medical Symptoms
Rose Geist, M.D., Louis Peltz, M.D., Caroline Ho, Ph.D., Hasmig Halajian, C.Y.C.
B Back to the Land of the Living: Dealing With Chronic Fatigue Syndrome/Fibromyalgia
Arlette M. LeFebvre, M.D.
C Making It Through Treatment: The Role of Medical Psychiatry in Oncology
Claire M. De Souza, M.D.
D Mastering Pain: Taking Back Your Life
Michael M. Jeavons, M.D.
THIS SESSION WILL BE AUDIOTAPE.
A Strategies for Investigating the Genetics of Psychiatric Disorders  
Margit Burmeister, Ph.D.

B Transcriptome Profiling of Brain Tissue: Implications for Schizophrenia Research  
Karyn Mirick, M.D.

C Gene Expression Abnormalities in Schizophrenia: What Do They Mean?  
David A. Lewis, M.D.

D From Phenotype to Genotype and Back: How to Put It All Together  
Mayada Akil, M.D.

THESE SESSIONS WILL BE AUDIOTAPED.

SYMPOSIUM 66 2:00 p.m.-5:00 p.m.  
Room B301, Level 3, Georgia World Congress Center

THE MAKING OF A COMPETENT PSYCHOTHERAPIST: ADDRESSING THE NEW RRC GUIDELINES

Chp.: Mantosh J. Dewan, M.D.

A The Making of a Competent Psychotherapist: Developing the Program  
Priyanthy Weerasekera, M.D.

B Combining a Common Factors Approach With Specific Psychotherapies  
Jon Manring, M.D.

C Future Directions: Simulation-Based Training and Evaluation  
Usha G. Satish, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69 2:00 p.m.-5:00 p.m.  
Room B308, Level 3, Georgia World Congress Center

VIOLENCE FROM CRADLE TO GRAVE: BATTERING, STALKING, CHILD ABUSE, AND ELDER ABUSE  
APA Committee on Family Violence and Abuse

Chp.: Deborah Spitz, M.D.

A Domestic Violence, Trauma, and Mental Health: Critical Issues for Clinical Practice  
Carole L. Warshaw, M.D.

B Stalking: Causes, Consequences, and Therapeutic Considerations  
Gail E. Robinson, M.D., Karen M. Abrams, M.D.

C Reviewing the Role of Antipsychotic Agents in OCD  
Naomi Fineberg, M.A., Tim M. Gale, Ph.D., Thanusha Sivakumarani, B.S.C.

D Long-Term Efficacy of Intravenous and Oral-Label Citalopram in Resistant OCD  
Stefano Pallanti, M.D., Leonardo Quercioli, M.D.

Discussant: Joseph Zohar, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68 2:00 p.m.-5:00 p.m.  
Room B307, Level 3, Georgia World Congress Center

SEQUENCED TREATMENT ALGORITHMS FOR RESISTANT OCD: AN INTERNATIONAL APPROACH  
Collaborative Session With the National Institute of Mental Health

Chp.: Eric Hollander, M.D.  
Co-Chp.: Joseph Zohar, M.D.

A Odds of Response in OCD to Switching SRIs, Increasing SRI Dose or Treatment Time  
Lorrin M. Koran, M.D.

B Switching From SSRIs to SNRIs in Resistant OCD  
Eric Hollander, M.D., Stacey Wasserman, M.D., Andrea Allen, Ph.D., Alicia J. Kaplan, M.D., Sallie J. Hadley, M.D., Brynn Baker, M.D., Suah Kim, B.A.

C Reviewing the Role of Antipsychotic Agents in OCD  
Naomi Fineberg, M.A., Tim M. Gale, Ph.D., Thanusha Sivakumarani, B.S.C.

D Long-Term Efficacy of Intravenous and Oral-Label Citalopram in Resistant OCD  
Stefano Pallanti, M.D., Leonardo Quercioli, M.D.

Discussant: Joseph Zohar, M.D.

THIS SESSION WILL BE AUDIOTAPED.

ADVANCES AND ISSUES IN PSYCHODYNAMIC PSYCHOTHERAPY

Chp.: Jerald Kay, M.D.

A Evidence-Based Psychodynamic Psychotherapy  
Jerald Kay, M.D.

B Dynamic Psychotherapy of Personality Disorders  
Glen O. Gabbard, M.D.

C Psychodynamic Psychotherapy in the Treatment of Panic Disorder  
Barbara L. Milrod, M.D.

(Continued next page)
WEDNESDAY

D The Role of Psychotherapeutic Techniques in Pharmacotherapy
   Allan Tasman, M.D.

E Unique Contributions of Psychodynamic Psychotherapy
to Residency Training
   David A. Goldberg, M.D.

Discussant: Joan A. Lang, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m.-5:00 p.m.
Room B309, Level 3, Georgia World Congress Center

THE USE OF NEUROSCIENCE TO UNDERSTAND MEDICATION TREATMENT
Chp.: S. Charles Schulz, M.D.

A Imaging Antipsychotics: From Bench to Bedside
   Shitij Kapur, M.D.

B MRI in Assessing Drug Response
   Kelvin Lim, M.D.

C Population Pharmacokinetic Approaches in Neuropharmacology Research
   Angela Birnbaum, M.D.

D Cognitive Neuroscience and New Schizophrenia Treatments
   Robert W. Buchanan, M.D.

E PET Imaging of Treatment-Resistant Depression
   Sohail A. Sheikh, M.D., Jose Pardo, M.D., Joseph Lee, M.S.,
   Matthew Hagen, Farouk S. Abuzzahab, Sr., M.D., David E.
   Adson, M.D., Barry Rittberg, M.D.

Discussant: Richard Brundage, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m.-5:00 p.m.
Room B310, Level 3, Georgia World Congress Center

PEDIATRIC BIPOLAR DISORDER:
PHENOMENOLOGY AND NEW TREATMENT OPTIONS
Chp.: Joseph Biederman, M.D.

A Molecular Genetics of Pediatric Bipolar Disorder
   Stephen V. Faraone, Ph.D.

B Revisiting the Diagnostic Utility of Irritability in Pediatric Bipolar Disorder
   Eric Mick, Sc.D.

C Examining the Association Between Pediatric Bipolar Disorder and Anxiety Disorders in Psychiatrically-Referred Children and Adolescents
   Theresa L. Harpold, M.D., Joseph Biederman, M.D., Anne
   Kwon, M.S., Jennifer Gilbert, M.S., Julia Wood, B.A., Laura
   Smith, B.A.

D Neuropsychological Deficits in Children With Bipolar Disorder
   Timothy E. Wilens, M.D., Alysa E. Doyle, Ph.D.

E Comparative Efficacy of Atypical Antipsychotics for Pediatric Bipolar Disorder
   Joseph Biederman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72 2:00 p.m.-5:00 p.m.
Room B311, Level 3, Georgia World Congress Center

EMOTION REGULATION IN BPD
Chp.: Ulrich W. Ebner-Priemer, Ph.D.

A Autonomic Reactivity and Borderline Features Among Intimate Partner Abusers
   Julia C. Babcock, Ph.D.

B Emotional Response to Parasuicide Imagery in BPD
   Stacy Shaw-Welch, Ph.D.

C Calculating Instability in BPD
   Ulrich W. Ebner-Priemer, Ph.D.

D Emotional Sensitivity and Reactivity in BPD: Empirical Evidence
   Thomas R. Lynch, Ph.D.

E Neurofunctional Correlates of Affective Deregulation
   and Changes Under Psychotherapy
   Sabine Herpertz, M.D.

Discussant: Larry J. Siever, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73 2:00 p.m.-5:00 p.m.
Room B314, Level 3, Georgia World Congress Center

CHOOSING THE RIGHT TREATMENT FOR SUBSTANCE ABUSE
Chp.: Herbert D. Kleber, M.D.
Co-Chp.: David M. McDowell, M.D.

A Choosing the Right Treatment for Opioid Dependence
   Herbert D. Kleber, M.D.
SYMPOSIUM 74
2:00 p.m.-5:00 p.m.
Room B315, Level 3, Georgia World Congress Center

A WORLD VIEW OF MEDICAL AND PSYCHIATRIC COMORBIDITY
Chp.: Nigel M. Bark, M.D.
Co-Chp.: A. Hamid Ghodse, Ph.D.

A Soma and Psyche in Middle Eastern Cultures: A Historical Review
Nasser F. Loza, M.B.

B An International Study of Physical and Psychiatric Comorbidity in Primary Care
Stephen R. Kisely, M.D., Gregory E. Simon, M.D.

C Psychiatry and Medicine in Pakistan
Haroon R. Chaudhry, M.D., Muhammad M. Iqbal, Fahd A. Cheema, Khalid A. Mufti, M.D.

D What Kills Our Patients: A Kenyan Perspective
Frank G. Njenga, M.D.

E Comorbidity Between Psychiatric Disorders and Substance Dependence: Results From a National Survey
Maria E. Medina-Mora, Ph.D., Guilherme Borges, Ph.D., Carmen Lara, Ph.D.

Discussant: John L. Cox, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 75
2:00 p.m.-5:00 p.m.
Room B316, Level 3, Georgia World Congress Center

RUNNING A MEDICINE/PSYCHIATRY SERVICE: THE DUKE EXPERIENCE
Chp.: K. Ranga R. Krishnan, M.D.

A Caring for Patients on a Combined Internal Medicine/Psychiatry Service: Advantages Over Consultation-Liaison Psychiatry
Y. Fritham Raj, M.D., Jane P. Gagliardi, M.D.

B Training Internist/Psychiatrists: An Overview of the Literature, Current Practice, and Future Directions
Erin Silvetooth, M.D., Jane P. Gagliardi, M.D.

C Research in Medicine/Psychiatry: Investigating Interactions Between Body and Mind
Wee Jia, M.D.

D Administrative Considerations in Operating a Medicine/Psychiatry Service
Eric J. Christopher, M.D., Jane P. Gagliardi, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 76
2:00 p.m.-5:00 p.m.
Room B402, Level 4, Georgia World Congress Center

NEW SCIENTIFIC ADVANCES IN THE NEUROBIOLOGY OF BEHAVIOR
National Institute on Drug Abuse
Chp.: David Shurtleff, Ph.D.
Co-Chp.: Jonathan Pollock, Ph.D.

A Molecular Mechanisms of Drug Addiction
Eric J. Nestler, M.D.

B Environmentally-Induced Modifications in Chromatin Structure as a Potential Mediator for the Effects of Early Experience on Later Vulnerability
Michael Meaney, Ph.D.

C Neural Substrates of Memory: From Synapse to System
Tim Tully, Ph.D.

D Neuroimaging Human Reward Circuitry and Using It for Across-Scale Systems Biology in Addiction
Hans C. Breiter, M.D.

Discussant: Nora D. Volkow, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 77
2:00 p.m.-5:00 p.m.
Room B403, Level 4, Georgia World Congress Center

PSYCHIATRIC ADVANCE DIRECTIVES: KEY ISSUES AND CLINICAL CHALLENGES
Collaborative Session With the National Institute of Mental Health
Chp.: Eric B. Elbogen, Ph.D.

A Psychiatrists' Attitudes About Psychiatric Advance Directives
Marvin S. Swartz, M.D.

B Prevalence and Demand for Psychiatric Advance Directives in the U.S.
Jeffrey W. Swanson, Ph.D.

(Continued next page)
C Psychiatric Advance Directives: Issues for Veterans With Mental Illness  
Marian I. Butterfield, M.D., Jennifer L. Strauss, Ph.D., Eugene Oddone, M.D., Morris Weinberger, Ph.D., Timothy Wompler, M.S.W., Jennifer Zervakis, Ph.D.

D Psychiatric Advance Directives: What Are Patients' Preferences?  
Eric B. Elbogen, Ph.D.

Discussant: Paul S. Appelbaum, M.D.  
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 78  
2:00 p.m.-5:00 p.m.  
Room B424, Level 4, Georgia World Congress Center  
TEACHING PSYCHOPHARMACOLOGY FOR THE 21ST CENTURY  
Ameri can Society of Clinical Psychopharmacology  
Chp.: Richard Balon, M.D.

A The Challenge of Teaching Psychopharmacology in the New Millennium: The Role of Curricula  
Ira D. Glick, M.D., Sidney Zisook, M.D.

B Alternate Teaching Venues  
Sidney Zisook, M.D., Richard Balon, M.D., Richard Benjamin, M.D., Ira D. Glick, M.D., Alan Louie, M.D., Cynthia Santos, M.D.

C Teaching Collaborative and Integrated Treatments for Psychiatrists  
Richard Balon, M.D.

D Resident as Teacher: Are We Ready for Some Changes?  
Andres Sciolla, M.D.

E Psychopharmacologic Education: Interactions With Drug Companies  
Paul C. Mohl, M.D.

Discussants: Anna M. Georgiopoulos, M.D., John M. Kane, M.D.  
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 79  
2:00 p.m.-5:00 p.m.  
Room B408, Level 4, Georgia World Congress Center  
TOXIC LOVE: CINEMA ON ROMANTIC LOVE AND ITS PATHOLOGIES  
Chp.: Anton C. Trinidad, M.D.

A Using Movies to Portray Pathologic Interpersonal Styles  
Robert J. Boland, M.D.

B Obsessive Love and Loss of the Self in Film Narratives  
Anton C. Trinidad, M.D.

C Recent Films on the Spectrum of Love From Normality to Pathology  
Anton C. Trinidad, M.D., Robert J. Boland, M.D.  
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 80  
2:00 p.m.-5:00 p.m.  
Room B409, Level 4, Georgia World Congress Center  
DEFINING MENTAL DISORDER IN DSM-V: PROBLEMS AND CHALLENGES  
Chp.: Claire L. Pouncey, M.D.

A What Can a DSM Definition of Mental Disorder Do? What Should It Do?  
John Sadler, M.D.

B Theoretical Models of Scientific Classification and the DSM-V  
Peter Zachar, Ph.D.

C Can a Family Have a Mental Disorder?  
Christian D. Perrin, Ph.D.

D The Concept of Mental Disorder: Psychiatry's Gordian Knot  
Claudio E.M. Banzato, M.D.

Discussant: Robert L. Spitzer, M.D.  
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 81  
2:00 p.m.-5:00 p.m.  
Birch Room, South Tower, Atrium Terrace Level, Omni Hotel  
CULTURAL ASPECTS OF PSYCHIATRIC DIAGNOSIS: TOWARD A NEW CLASSIFICATION  
APA Council on Global Psychiatry  
Chp.: Renato D. Alarcon, M.D.  
Co-Chp.: Rodrigo A. Munoz, M.D.

A Cultural Views From U.S. Minorities and Relevance of the Cultural Formulation  
Annelie B. Prim, M.D., Russell F. Lim, M.D.

B An Update on Race, Ethnicity, and Culture in Current Psychiatric Literature  
Roberto Lewis-Fernandez, M.D., Maria A. Oquendo, M.D., Ivan Balan, Ph.D., Dana Wachtel, Ph.D., Naelys Diaz, M.S.W., Anne O'Connell, M.D., Renato D. Alarcon, M.D.
SYMPOSIUM 83  2:00 p.m.-5:00 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

APA WOMEN PRESIDENTS: LESSONS LEARNED, ROAD AHEAD
Association of Women Psychiatrists

Chp.: Silvia W. Olarte, M.D.
Co-Chp.: Nada L. Stotland, M.D.

A How to Open Doors and Keep Them Open
Carol C. Nadelson, M.D.

B Creating Change, Evaluating Responses, and Participating in the New Course
Elissa P. Benedek, M.D.

C Beyond APA Presidency: Leadership as a Way of Life
Mary Jane England, M.D.

D Assertive or Aggressive?
Marcia K. Goin, M.D.

E Success Is a Team Effort
Michelle B. Riba, M.D.

Discussant: Leah J. Dickstein, M.D.
THIS SESSION WILL BE AUDIOTAPE.D.

SYMPOSIUM 84  2:00 p.m.-5:00 p.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

NATIONAL HEALTH INFORMATION INITIATIVE AND PSYCHIATRY
American Association for Social Psychiatry and American Association for Technology in Psychiatry

Chp.: Zebulon Taintor, M.D.
Co-Chp.: Roger Peele, M.D.

A Health Information Technology: A Framework for Strategic Action
Rex W. Cowdry, M.D.

B National Health Information: General Medicine
Zebulon Taintor, M.D.

C National Health Information: Psychiatric Treatment Systems and the APA
Steven S. Sharfstein, M.D.

D National Health Information: General Hospital and Addiction Psychiatry
Richard N. Rosenthal, M.D.

E National Health Information: Private Practice, Rural, and Academic Psychiatry
Joel Yager, M.D.

Discussant: Lawrence Hartmann, M.D.
THIS SESSION WILL BE AUDIOTAPE.D.
3:00 p.m. Session

NEW RESEARCH POSTER SESSION 9
3:00 p.m.-5:00 p.m.
Room B302/303/304/305, Level 3, Georgia World Congress Center

PSYCHOSOMATIC AND RESEARCH ISSUES

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

7:00 p.m. Session

INDUSTRY-SUPPORTED SYMPOSIUM 45
7:00 p.m.-10:00 p.m.
International Ballroom, North Tower, Ballroom Level, Omni Hotel

IMPACT OF STRESS AND ANXIETY ON BRAIN AND BODY
Supported by Cephalon, Inc.

Chp.: Samantha E. Meltzer-Brody, M.D.
Co-Chp.: Murray B. Stein, M.D.

A Sick and Tired: Anxiety, Stress, and Insomnia
Murray B. Stein, M.D.

B Impact of Anxiety on Women's Health: Focusing on the Link Between Trauma and Chronic Pain
Samantha E. Meltzer-Brody, M.D.

C Health Effects of Exposure to Violence in Women
Soraya Seedat, M.D.

D Neuroimaging and the Traumatized Brain: PTSD and Emotion
Ruth A. Lanius, M.D.

E Treatment of Anxiety: The Pharmacotherapy of Psyche and Soma
Mark H. Pollack, M.D.
THURSDAY, MAY 26, 2005
158TH ANNUAL MEETING

7:00 a.m. Session

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 44
7:00 a.m.-8:30 a.m.
Grand Ballroom, Second Floor, Hilton Atlanta

BIPOLAR DISORDER ACROSS THE LIFE CYCLE: SPECIAL CONSIDERATIONS
Supported by GlaxoSmithKline
Chp.: Zachary N. Stowe, M.D.
A Bipolar Disorder in Pregnancy: A Clinician's Dilemma
Zachary N. Stowe, M.D.
B Bipolar Disorder in the Elderly: Special Treatment Considerations
John L. Beyer, M.D.

8:00 a.m. Sessions

COURSES 101-103
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 101 8:00 a.m.-12 noon
Forsythe Room, Second Floor, Hilton Atlanta
TREATING COMORBID ADULT ADHD BY COMBINING MEDICATION AND COGNITIVE THERAPY
Co-Directors: Anthony L. Rostain, M.D., J. Russell Ramsay, Ph.D.

COURSE 102- WITHDRAWN

COURSE 103 8:00 a.m.-12 noon
Gwinnett Room, Second Floor, Hilton Atlanta
ADOLESCENT PSYCHIATRY: ENHANCING CLINICAL SKILLS
American Society for Adolescent Psychiatry
Co-Directors: Stephen B. Billick, M.D., Lois T. Flaherty, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 4
9:00 a.m.-10:30 a.m.
Room A402, Level 4, Georgia World Congress Center

COMMENDED TO KILL: APPROACHING THE TREATMENT OF A MURDEROUS GRANDMOTHER
Moderator: June A. Powell, M.D.
Presenters: Patrice A. Harris, M.D., Nada L. Stotland, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 2
9:00 a.m.-12 noon
Room A403, Level 4, Georgia World Congress Center
WEATHERING THE STORM: MANAGEMENT OF COMPLEX TRANSFE RENCES, PART 2
Moderator: Beth J. Seelig, M.D.
Presenter: Otto F. Kernberg, M.D.
Discussants: John M. Oldham, M.D., Wendy Jacobson, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

DISCUSSION GROUP 22

9:00 a.m.-10:30 a.m.
This session is limited to 25 participants on a first-come, first-served basis.

22 Richard P. Brown, M.D., on the Benefits of Yoga in Psychiatry
Chestnut Room, North Tower, Meeting Level, Omni Hotel
THURSDAY

LECTURES 21-22

LECTURE 21
9:00 a.m.-10:30 a.m.
Room A411, Level 4
Georgia World Congress Center

Laura W. Roberts, M.D.

Inspiring Ethics: Ethical Milestones and Preparation in Psychiatric Education

Chp.: Josepha A. Cheong, M.D.
Co-Chp.: Daniel K. Winslow, M.D.

Laura W. Roberts, M.D., is Professor and Chair of the Department of Psychiatry and Behavioral Medicine and Professor of Bioethics in the Health Policy Institute at the Medical College of Wisconsin in Milwaukee. She is also Founder and Director of the Empirical Ethics Group, a clinical ethics resource and research team currently based at the Medical College of Wisconsin. Dr. Roberts is Editor-in-Chief of *Academic Psychiatry* and Associate Editor of *International Review of Psychiatry*. She is Scientific Advisor to the Office of Minority Health of the Department of Health and Human Services and a member of several scientific advisory groups, including the Council for Human Subjects Research Workgroup of the National Institute of Mental Health. A Fellow of the American Psychiatric Association (APA), Dr. Roberts chairs the APA Task Force to Update the Ethics Annotations. She is the author of more than 80 peer-reviewed articles and co-author of the book *Concise Guide to Ethics in Mental Health Care*. She graduated from the University of Chicago Pritzker School of Medicine, where she also completed a fellowship in clinical ethics. She completed her residency in psychiatry and a fellowship in child and adolescent psychiatry at the University of New Mexico School of Medicine in Albuquerque. Distinguished Psychiatrist Series

WORKSHOPS

ISSUES 90-113

ISSUE WORKSHOP 90 9:00 a.m.-10:30 a.m.
Room A304, Level 3, Georgia World Congress Center

USING AUDIOVISUAL TECHNOLOGY TO TEACH BEHAVIORAL SCIENCE

Chp.: Jonathan S. Davine, M.D.

ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m.
Room A404, Level 4, Georgia World Congress Center

NEUTRALITY REVISITED: IS AUTONOMY WHAT WE MOST WANT?

Chp.: John R. Peteet, M.D.
Participants: Samuel B. Thielman, M.D., Allan M. Josephson, M.D., Leigh C. Bishop, M.D.

LECTURE 22
9:00 a.m.-10:30 a.m.
Room A412, Level 4
Georgia World Congress Center

Margaret A. Pericak-Vance, Ph.D.

Sifting Through the Haystack: Finding Genes for Complex Traits

Chp.: Stephen M. Saravay, M.D.
Co-Chp.: Michael Slifer, M.D.

Margaret A. Pericak-Vance, Ph.D., is a James B. Duke Professor of Medicine and Director of the Center for Human Genetics at Duke University Medical Center in Durham, North Carolina, where she is also Professor of Genetics, Professor of Biostatistics and Bioinformatics, and Professor in Ophthalmology. Her research focuses on the underlying causes of both single-gene disorders and more complex phenotypes where several genes as well as environmental forces act together. Her investigations have examined the genetics of autism, amyotrophic lateral sclerosis, Alzheimer disease, multiple sclerosis, primary open-angle glaucoma, age-related macular degeneration, Parkinson disease, and various muscular dystrophies. Dr. Pericak-Vance is Editor of *Genetic Epidemiology* and co-editor of the book *Approaches to Gene Mapping in Complex Human Diseases*. A Founding Fellow of the American College of Medical Genetics, she serves on the National Institute of Mental Health Board of Scientific Counselors. She is a member of the Institute of Medicine and a recipient of the Louis-D scientific award from the Institut de France for her contributions to the field of genetic research in Alzheimer disease. Dr. Pericak-Vance received her doctorate in Medical Genetics from Indiana University in Indianapolis and completed postdoctoral work in biostatistics at the University of North Carolina in Chapel Hill. Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPE.
THURSDAY

ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m.
Room A405, Level 4, Georgia World Congress Center
FIBROMYALGIA: CURRENT UNDERSTANDING AND FUTURE DIRECTIONS
Chp.: Alan Z.A. Manevitz, M.D.
Participant: James P. Halper, M.D.

ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m.
Room A408, Level 4, Georgia World Congress Center
SUBSTANCE ABUSE IN THE PRISON SETTING
Co-Chps.: Leo L. Gallofin, M.D., Jeffery Wilkins, M.D.
Participants: Thomas J. Rosko, M.D., Janet A. Martin, M.D., Katherine G. Ruiz-Mellot, M.D.

ISSUE WORKSHOP 94 9:00 a.m.-10:30 a.m.
Room A410, Level 4, Georgia World Congress Center
ASSESSMENT OF CAPACITY: LAW, ALGORITHMS, AND VIDEOTAPE
Chp.: Michael E. Wise, M.R.C.
Participant: Julian Beezhold, M.R.C.

ISSUE WORKSHOP 95 9:00 a.m.-10:30 a.m.
Room B301, Level 3, Georgia World Congress Center
AUTISM: PARENTS AS THERAPISTS
Co-Chps.: Gary Heffner, M.A., Joyce Cox

ISSUE WORKSHOP 96 9:00 a.m.-10:30 a.m.
Room B306, Level 3, Georgia World Congress Center
PENAL JUSTICE AND INJUSTICE
Chp.: Rodrigo A. Munoz, M.D.
Participants: Igor Koutsemok, M.D., David Deitch, Ph.D., Gretchen Bergman

ISSUE WORKSHOP 97 9:00 a.m.-10:30 a.m.
Room B307, Level 3, Georgia World Congress Center
GUESS WHAT’S IN YOUR GENES? TALKING ABOUT GENETIC ILLNESS IN THE FAMILY
Chp.: Arlette M. LeFebvre, M.D.

ISSUE WORKSHOP 98 9:00 a.m.-10:30 a.m.
Room B308, Level 3, Georgia World Congress Center
BARIATRIC SURGERY: PSYCHIATRIC CONSIDERATIONS
Chp.: Laura T. Safar, M.D.
Participants: Brenda Temblador, Ph.D., Wenda Restall, L.C.S.W.
THURSDAY

ISSUE WORKSHOP 125 9:00 a.m.-10:30 a.m.
Room B401, Level 4, Georgia World Congress Center

HELPING PATIENTS COPE WITH CANCER: HOW TO MAKE A DIFFERENCE

Chp.: Alex J. Mitchell, M.D.
Participants: Robert Zachariae, M.D., Manoj Kumar, M.D.

ISSUE WORKSHOP 106 9:00 a.m.-10:30 a.m.
Room B402, Level 4, Georgia World Congress Center

CHALLENGES WHEN PSYCHIATRISTS SEEK TREATMENT FOR THEMSELVES

National Alliance for the Mentally Ill

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Raymond M. Reyes, M.D., Francine Kornos, M.D., Jack Drescher, M.D., Suzanne E. Vogel-Scibilia, M.D.

ISSUE WORKSHOP 107 9:00 a.m.-10:30 a.m.
Room B403, Level 4, Georgia World Congress Center

GOT PSYCH? INCREASING STUDENT INVOLVEMENT IN PSYCHIATRY

Chp.: Paul D. Cox, M.D.
Participants: Cyndi R. Murrer, B.S., Sherry A. Nykiel, B.A., Deborah J. Hales, M.D.

ISSUE WORKSHOP 108 9:00 a.m.-10:30 a.m.
Room B404, Level 4, Georgia World Congress Center

OUTCOMES AND THERAPEUTIC PROCESSES OF ACUTE PARTIAL HOSPITALIZATION

Chp.: Paul B. Lieberman, M.D.
Participants: Mark B. Elliot, M.D., Reinales Villalba, M.D.

ISSUE WORKSHOP 109 9:00 a.m.-10:30 a.m.
Room B405, Level 4, Georgia World Congress Center

THE DOUBLE-EDGED SWORD: MENTAL HEALTH CHALLENGES IN HIV AND HEPATITIS C

Society for Liaison Psychiatry

Chp.: Maria L.A. Tiamson, M.D.
Participants: Kenneth Ashley, M.D., Silvia Hafliger, M.D.

ISSUE WORKSHOP 110 9:00 a.m.-10:30 a.m.
Room B406, Level 4, Georgia World Congress Center

EDUCATING PATIENTS AND FAMILIES ABOUT BPD

National Education Alliance for Borderline Personality Disorder in Collaboration With the National Institute of Mental Health

Chp.: Richard G. Hersh, M.D.
Participants: Kenneth Silk, M.D., Dianne Penney, Ph.D., Perry D. Hoffman, Ph.D.

ISSUE WORKSHOP 111 9:00 a.m.-10:30 a.m.
Room B407, Level 4, Georgia World Congress Center

CASE CONSULTATION IN FORENSIC PSYCHIATRY: FACTITIOUS DISORDER WITH PSYCHOLOGICAL AND PHYSICAL SYMPTOMS

Chp.: Jay Wing, M.D.
Participants: Henry C. Weinstein, M.D., Marc D. Feldman, M.D., Renee M. Sorrentino, M.D.

ISSUE WORKSHOP 112 9:00 a.m.-10:30 a.m.
Room B408, Level 4, Georgia World Congress Center

USING ADULT LEARNING PRINCIPLES IN RESIDENT PSYCHOTHERAPY EDUCATION

Chp.: Kim A. Coon, Ed.D.
Participant: Bryan K. Touchet, M.D.

ISSUE WORKSHOP 113 9:00 a.m.-10:30 a.m.
Room B409, Level 4, Georgia World Congress Center

CHALLENGES IN TEACHING CULTURAL ISSUES TO PSYCHIATRIC RESIDENTS: PERSPECTIVES FROM RESIDENTS AND FACULTY

Chp.: Francis G. Lu, M.D.
Participants: Antonio E. Bullon, M.D., Jennifer R. Lee, M.D., David J. Geltman, M.D.

11:00 a.m. Sessions

MEDICAL UPDATE 4
11:00 a.m.-12:30 p.m.
Room B403, Level 4, Georgia World Congress Center

A PRIMER OF GENETICS FOR PSYCHIATRY

Presenter: Stephen Warren, Ph.D.
Chp.: Elizabeth Binder, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 28-35

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Room A402, Level 4, Georgia World Congress Center

EPIDEMIOLOGY AND COMMUNITY ISSUES IN PSYCHIATRY

Chp.: Shivkumar Hari, M.D.
Co-Chp.: Andrea Bradford, M.D.
THURSDAY

11:00 a.m.
83 Mortality Among Psychotic Patients Within the Northern Finland 1966 Birth Cohort
Antti Alaräisänen, M.D., Jouko Miettunen, Ph.D., Erika Lauronen, B.Med., Pirkko Räsänen, Ph.D., Matti K. Isohanni, Ph.D.

11:30 a.m.
84 Outcome and Its Predictors in Schizophrenia in the Northern Finland 1966 Birth Cohort
Erika Lauronen, B.Med., Juha M. Veijola, Ph.D., Jouko Miettunen, Ph.D., Peter B. Jones, Ph.D., Wayne S. Fenton, M.D., Johanna Koskinen

12 noon
85 Psychiatric Practices and Patient Outcomes in Assertive Community Treatment
Paul R. Miller, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m.-12:30 p.m.
Room A404, Level 4, Georgia World Congress Center

TREATMENT OF SCHIZOPHRENIA
Chp.: David M. Walker, M.D.
Co-Chp.: Francine Cournos, M.D.

11:00 a.m.
86 Effectiveness and Tolerability of Antipsychotic Treatments for Schizophrenia: Two-Year Results from the Intercontinental Schizophrenia Outpatient Health Outcomes Study (IC-SOHO)
Martin Dossenbach, M.D., C.Y. Kim, M.D., W.W. Lin, M.D., S. Singh, M.D., Y. Dyachkova, M.S.C., Margaret E. McBride, Ph.D., P. Lee, M.D.

11:30 a.m.
87 An Investigation of Cognitive Effects of Rivastigmine in Schizophrenia
Collaborative Session With the National Institute of Mental Health
Tommy Sharma, M.D., Catherine Hughes, Ph.D., Ingrid Aasen, Veena Kumari, Ph.D.

12 noon
88 Rivastigmine or Galantamine for the Treatment of Schizophrenic Cognitive Impairment
Mohammad Z. Hassain, M.D., Zubaida Chaudhry, M.D., Waqar Waheed, M.D., Seema Hussain, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m.-12:30 p.m.
Room B301, Level 3, Georgia World Congress Center

ISSUES IN MOOD DISORDERS AND PSYCHIATRIC TRAINING
Chp.: Richard G. Hersh, M.D.
Co-Chp.: Edward C. Lauterbach, M.D.

11:00 a.m.
89 The Uses of Reading Poetry for General Psychiatric Education
Neil E. Scheurich, M.D.

11:30 a.m.
90 Variations in Depression Treatment Quality: Medicaid Versus Commercial Claims
Rebecca Robinson, M.S., Stephen Able, Ph.D., Stacey Long, M.S., Stella Chang, M.P.H., Omir Baser, Ph.D., Robert Obenchain, Ph.D., Ralph W. Swindle, M.D.

12 noon
91 Antidepressants for Depression in the Medically Ill: Are They Effective?
Steven A. Cole, M.D., Evan Delucia-Deranja, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m.-12:30 p.m.
Room B306, Level 3, Georgia World Congress Center

CONSULTATION-LIAISON PSYCHIATRY
Chp.: Wayne J. Katon, M.D.
Co-Chp.: Andy Casimir, M.D.

11:00 a.m.
92 The Prevalence of Migraine Headaches in an Anxiety Disorders Clinic Sample
Catherine L. Mancini, M.D., Michael A. Van Ameringen, M.D., Mark Bennett, B.A., Beth Pipe, B.S.N., Deirdre Dejean

11:30 a.m.
93 Assessing Anxiety With the Memorial Anxiety Scale for Prostate Cancer
Andrew J. Roth, M.D., Christian Nelson, Ph.D., Barry D. Rosenfeld, Ph.D., Adam Warshakowski, M.A., Noelle O'Shea, R.N., Howard Scher, M.D., William Breitbart, M.D.

12 noon
94 Modafinil Augmentation of SSRI Therapy in MDD
Maurizio Fava, M.D., Charles DeBattista, M.D., Michael E. Thase, M.D., Joseph G. Fanelli, M.D., Karl Doghrumji, M.D.

THIS SESSION WILL BE AUDIOTAPE D.
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m.-12:30 p.m.
Room B428, Level 4, Georgia World Congress Center

BIPOLAR DISORDER THROUGH THE LIFE CYCLE

Chp.: Douglas G. Jacobs, M.D.
Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
95 Bipolar Prodromal Patterns Among Amish Youth
Jon A. Shaw, M.D., Janice A. Egeland, Ph.D., Jean Endicott, Ph.D., Geona R. Allen, B.A., Abram M.
Hostetter, M.D.

11:30 a.m.
96 Typical and Atypical Antipsychotics in Bipolar Depression
Kerning Gao, M.D., Joseph R. Calabrese, M.D.

12 noon
97 Childhood Disorders in Early- Versus Late-Onset
Bipolar Disorder
Aude I. Henin, Ph.D., Eric Mick, Sc.D., Joseph
Biederman, M.D., Stephanie V.M. Girodse, B.A., Tanya B.
Tran, B.A., Megan F. Joseph, B.A., Andrew A.
Nierenberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 33
11:00 a.m.-12:30 p.m.
Room B429, Level 4, Georgia World Congress Center

MEASURING MOOD DISORDERS

Chp.: Susan Stabinsky, M.D.
Co-Chp.: Kisha James, M.D.

11:00 a.m.
98 The Targeted Treatment of Depression Inventory: New
Depression Inventory Designed to Guide
Antidepressant Selection
Richard J. Metzner, M.D.

11:30 a.m.
99 Is It Time to Replace the Hamilton Depression Rating
Scale?
Mark Zimmerman, M.D., Michael Posternak, M.D., Iwona
Chelmski, Ph.D.

12 noon
100 Daily Measurements Elucidate Effects of Initial Dosing
of Duloxetine
Madeleine M. Wohlerich, M.D., Heidi Moore, Ph.D.,
James C. Mundy, Ph.D., Craig H. Mallinckrodt, Ph.D.,
John H. Greist, M.D., Lesley M. Arnold, M.D., Maurizio
Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34
11:00 a.m.-12:30 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

OCD AND ANXIETY

Chp.: Oscar J. Bienvenu III, M.D.
Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.
101 Deep Brain Stimulation in Intractable OCD and
Intractable Depression
Benjamin D. Greenberg, M.D.

11:30 a.m.
102 Clinical Characteristics of OCD With and Without
Comorbid BDD
S. Evelyn Stewart, M.D., Sabine Wilhelm, Ph.D.

12 noon
103 The Burden Experienced by Families of Individuals
With Anxiety Disorders
Michael A. Van Ameringen, M.D., Catherine L.
Mancini, M.D., Mark Bennett, B.A., Beth Pipe, B.S.N.

SCIENTIFIC AND CLINICAL REPORT SESSION 35
11:00 a.m.-12:30 p.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

ALCOHOL AND DRUG RELATED DISORDERS

Chp.: Harvey Stabinsky, M.D.
Co-Chp.: Susan K. Blank, M.D.

11:00 a.m.
104 A Comparison of Lorazepam Versus Diazepam
Treatment of Alcohol Withdrawal
Jose R. Maldonado, M.D., John O. Brooks, M.D., Long H.
Nguyen, B.A., Merritt Schader, B.A.

11:30 a.m.
105 Suboxone in Private Practice
Ronald D. Abramson, M.D.

12 noon
106 Nonmedical Use and Diversion of Stimulants in the
U.S.: 2002
Larry A. Kroudl, M.P.H., David L. Van Brunt, Ph.D.,
Robert M. Bray, Ph.D., Mindy Herman-Stahl, Ph.D.,
David C. Heller, B.S.

THIS SESSION WILL BE AUDIOTAPED.
WORKSHOPS

ISSUES 114-129

ISSUE WORKSHOP 114 11:00 a.m.-12:30 p.m.
Room A304, Level 3, Georgia World Congress Center
GROUP THERAPY OF SUBSTANCE ABUSE
Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.

ISSUE WORKSHOP 115 11:00 a.m.-12:30 p.m.
Room A405, Level 4, Georgia World Congress Center
SCULPTING THE SCULPTURE: REDEFINING ETHICAL BOUNDARIES IN FACULTY-RESIDENT RELATIONSHIPS
Chp.: Manisha R. Punwani, M.D.
Participants: Mahmoud A. Mohamed, M.D., Paul S. Appelbaum, M.D., Eugene V. Beresin, M.D., Laura W. Roberts, M.D.

ISSUE WORKSHOP 116 11:00 a.m.-12:30 p.m.
Room A408, Level 4, Georgia World Congress Center
FELLOWSHIP TRAINING IN PSYCHOSOMATIC MEDICINE: WHAT TO EXPECT FROM ACCREDITED PROGRAMS IN A NEW SUBSPECIALTY
Chp.: Philip A. Bialer, M.D.
Participants: James L. Levenson, M.D., Vassilios Latoussakis, M.D., Susan Lee, M.D., Mark J. Ehrenreich, M.D.

ISSUE WORKSHOP 117 11:00 a.m.-12:30 p.m.
Room B307, Level 3, Georgia World Congress Center
WORLD VIEW AND SPIRITUALITY IN CLINICAL PRACTICE
Chp.: Allan M. Josephson, M.D.
Participants: John R. Petee, M.D., Mary Lynn Dell, M.D.

ISSUE WORKSHOP 118 11:00 a.m.-12:30 p.m.
Room B308, Level 3, Georgia World Congress Center
WOMEN AS LEADERS: OPPORTUNITIES AND STRATEGIES FOR SUCCESS
American Association of Psychiatric Administrators
Chp.: Jeanne L. Steiner, D.O.
Participants: Page Burkholder, M.D., Mary Ellen Foci, M.D., Elisabeth J.S. Kunzkel, M.D., June A. Powell, M.D., Rose Yu-Chin, M.D.

ISSUE WORKSHOP 119 11:00 a.m.-12:30 p.m.
Room B309, Level 3, Georgia World Congress Center
BUILDING TRAUMA RESILIENCE: THE IMPACT OF MUSIC ON THE LIFE OF HOLOCAUST SURVIVORS
Chp.: Andrei Novac, M.D.
Participant: Bonita Jaros, Ph.D.

ISSUE WORKSHOP 120 11:00 a.m.-12:30 p.m.
Room B310, Level 3, Georgia World Congress Center
HOMELESSNESS, ADDICTION, AND SEVERE MENTAL ILLNESS IN PERSONS WITH HIV/AIDS
Co-Chps.: Mary Ann Cohen, M.D., Jack M. Gorman, M.D.
Participants: Jeffrey Weiss, Ph.D., Julie D. Maggi, M.D., Rosalind G. Hoffman, M.D.

ISSUE WORKSHOP 121 11:00 a.m.-12:30 p.m.
Room B311, Level 3, Georgia World Congress Center
EFFECT OF MATERNAL DEPRESSION ON THE COGNITIVE AND EMOTIONAL DEVELOPMENT OF CHILDREN
Co-Chps.: Syed S. A. Naqvi, M.D., Heather Lin, M.D.

ISSUE WORKSHOP 122 11:00 a.m.-12:30 p.m.
Room B315, Level 3, Georgia World Congress Center
KENDRA'S LAW BECOMES REALITY: MANDATING OUTPATIENT TREATMENT IN MANHATTAN
Chp.: Andrew M. Kleiman, M.D.
Participants: Michael Magera, M.D., Gary R. Collins, M.D., Jennifer Correale, J.D.

ISSUE WORKSHOP 123 11:00 a.m.-12:30 p.m.
Room B316, Level 3, Georgia World Congress Center
PRESENTEEISM AND ABSENTEEISM: UNDERRECOGNIZED AND UNDERTREATED AT WORK
Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 124 11:00 a.m.-12:30 p.m.
Room B401, Level 4, Georgia World Congress Center
TREATING PHYSICIANS IN A CULTURAL CONTEXT: SOME UNIQUE ISSUES
Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Nyapati Rao, M.D., Renato D. Alarcon, M.D., Carmen T. Webb, M.D.
THURSDAY

ISSUE WORKSHOP 125  11:00 a.m.-12:30 p.m.
Room B402, Level 4, Georgia World Congress Center

COGNITIVE THERAPY FOR PSYCHOSIS FOR PSYCHIATRISTS: BASIC TECHNIQUE

Chp.: Shanaya Rathod, M.D.
Participants: Douglas Turkington, M.D., David G. Kingdon, M.D.

ISSUE WORKSHOP 126  11:00 a.m.-12:30 p.m.
Room B404, Level 4, Georgia World Congress Center

FINDING EFFECTIVE ADOLESCENT DRUG TREATMENT: ASSESSMENT OF 144 LEADING PROGRAMS

Chp.: Matheia Falco
Participants: Robert Millman, M.D., A. Thomas McLellan, Ph.D., David Lewis, M.D.

ISSUE WORKSHOP 127  11:00 a.m.-12:30 p.m.
Room B405, Level 4, Georgia World Congress Center

THE MARRIAGE OF PSYCHIATRY AND MEDICINE IN INTEGRATED TREATMENT FOR ANOREXIA NERVOSA

Co-Chps.: George S. Nasra, M.D., Mary Tamillo, Ph.D.
Participants: Manuel Matos, M.D., Sheri A. Faggiano, R.N.

ISSUE WORKSHOP 128  11:00 a.m.-12:30 p.m.
Room B406, Level 4, Georgia World Congress Center

THE FUTURE OF PSYCHOSOMATIC MEDICINE IN THE U.S. AND ABROAD
World Psychiatric Association's Section of Psychiatry, Medicine, and Primary Care

Co-Chps.: Michelle B. Riba, M.D., Rodolfo D. Fahrer, M.D.
Participants: Allan Tasman, M.D., Pedro Ruiz, M.D., Don R. Lipsit, M.D.

ISSUE WORKSHOP 129  11:00 a.m.-12:30 p.m.
Room B407, Level 4, Georgia World Congress Center

ADVANCES IN EARLY INTERVENTION IN THE PRODROMAL PHASE OF SCHIZOPHRENIA

Chp.: Ian E. Alger, M.D.
Participants: Lewis A. Opler, M.D., Eric R. Marcus, M.D., Clarice J. Kestenbaum, M.D.

12 noon Sessions

FORUMS 10-11

FORUM 10  12 noon-1:30 p.m.
Room A410, Level 4, Georgia World Congress Center

APA AND THE PHARMACEUTICAL INDUSTRY

Chp.: David M. McDowell, M.D.
Participants: Richard Balon, M.D., Stephen M. Goldfinger, M.D., Charles R. Goldman, M.D., Trevor R.P. Price, M.D., Anand Pandya, M.D., David B. Mallott, M.D.

FORUM 11  12 noon-1:30 p.m.
Room B314, Level 3, Georgia World Congress Center

A STITCH IN TIME: PSYCHIATRIC AND MEDICAL COMORBIDITY IN AFRICAN AMERICANS ACROSS THE LIFE CYCLE

Chp.: Annelle B. Primm, M.D.
Participants: Kenneth M. Rogers, M.D., Debbie Carter, M.D., Stephen McLeod-Bryant, M.D., F.M. Baker, M.D.

NEW RESEARCH POSTER SESSION 10
12 noon-2:00 p.m.
Room B302/303/304/305, Level 3, Georgia World Congress Center

TREATMENT ISSUES

For further information on New Research Sessions, please refer to the New Research Program and Abstract Book included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 87-113

SYMPOSIUM 87  2:00 p.m.-5:00 p.m.
Room A302, Level 3, Georgia World Congress Center

EFFICACY AND SAFETY OF SSRI MEDICATIONS IN CHILDREN AND ADOLESCENTS
Collaborative Session With the National Institute of Mental Health

Chp.: Susan E. Swedo, M.D.
A SSRI Risk and Benefits: Lessons From the Treatment for Adolescents With Depression Study (TADS)
John S. March, M.D.
B Searching for Moderators and Mediators of Treatment in Adolescent Depression
Benedetto Vitiello, M.D.
C Efficacy and Safety of SSRIs in OCD and Other Anxiety Disorders  
John T. Walkup, M.D.

D Antidepressants and Suicide-Related Events: An Analysis of Pediatric Trials  
Thomas P. Laughren, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 88 2:00 p.m.-5:00 p.m.  
Room A305, Level 3, Georgia World Congress Center

NEW DIRECTIONS IN PSYCHIATRIC ASPECTS OF TERRORISM: CAUSES, CONSEQUENCES, RESPONSES  
APA Council on Global Psychiatry

Chp.: Stevan M. Weine, M.D.  
Co-Chp.: Jerrold M. Post, M.D.

A Psychological Mechanisms Underlying Martyrdom Among Palestinian Youth  
Daphne F. Burdman, M.D.

B Dying to Kill: The Socio-Cultural Foundations of Suicide Terrorism  
Jerrold M. Post, M.D.

C Muslim Immigrant Youth in Difficult Times  
Stevan M. Weine, M.D.

D Using Psychology to Counter Terrorism at the Personal and Community Level  
Chris Stout, Psy.D.

E Thinkers and Doers: Integrating Academe Into Terrorism's Reality  
Gregory B. Saathoff, M.D.

Discussant: David Rothstein, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 89 2:00 p.m.-5:00 p.m.  
Room A402, Level 4, Georgia World Congress Center

LEADERSHIP IN PSYCHIATRY: WOMEN LEADERS IN ADVOCACY AND SERVICES

Chp.: Helen Herrman, M.D.  
Co-Chp.: Michelle B. Riba, M.D.

A Women and Leadership in Psychiatry  
Michelle B. Riba, M.D.

B The Need for Female Leadership in International Professional Organizations  
Marianne C. Kastrup, M.D.

C Aspects of Leadership Required in Developing a National Mental Health Plan  
Janice Wilson, M.D.

D Evidence and Accountability for Women's Mental Health  
Donna E. Stewart, M.D.

E The Psychiatrist as Clinical Leader  
Helen Herrman, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 90 2:00 p.m.-5:00 p.m.  
Room A403, Level 4, Georgia World Congress Center

IMPROVING MEDICAL CARE FOR PATIENTS WITH SERIOUS MENTAL DISORDERS  
Collaborative Session With the National Institute of Mental Health

Chp.: Benjamin G. Druss, M.D.  
Co-Chp.: Lisa B. Dixon, M.D.

A Co-Occurring Somatic Disorders and Quality of Care in SMI  
Lisa B. Dixon, M.D.

B Psychiatrists' Role in Addressing Cardiovascular Risk Factors in Serious Mental Disorders  
Gail L. Daumit, M.D.

C Targeted Delivery of Clinical Preventive Services to the Seriously Mentally Ill  
Caroline C. Doebbeling, M.D.

D Health Monitoring in Schizophrenia  
Stephen R. Marder, M.D.

Discussant: Benjamin G. Druss, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m.  
Room A404, Level 4, Georgia World Congress Center

PSYCHOTHERAPY IS UNIVERSALLY FUTURE ORIENTED

Chp.: Rodrigo A. Munoz, M.D.  
Co-Chp.: Carol C. Nadelson, M.D.

A Expectation Videos  
Bernard D. Beitman, M.D.

B Mentalizing's Future  
Howard E. Book, M.D.

(Continued next page)
C Using the Future in the Psychotherapeutic Treatment of Depression
Maria T. Lymberis, M.D.

D Future-Focused Brief Psychotherapy in Clinical Practice
James L. Griffith, M.D.

SYMPOSIUM 92 2:00 p.m.-5:00 p.m.
Room A455, Level 4, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE IN PSYCHIATRIC PRIVATE PRACTICE
Chp.: Thomas N. Wise, M.D.
Co-Chp.: Maryam Razavi, M.D.

A Comprehensive Psychiatry: Patients With Medical Illnesses in Child and Adolescent Psychiatry
Jeffrey A. Naser, M.D.

B Irritable Bowel, Interstitial Cystitis, and Fibromyalgia in Private Practice
Ronald D. Abramson, M.D.

C Comprehensive Psychiatry: Patients With Medically-Unexplained Physical Symptoms and PTSD
Brian Crowley, M.D.

D Comprehensive Psychiatry: Patients With Medical Illness
John C. Urbain, M.D., Roger Peele, M.D.

E Psychosomatic Aspects of the Private Practice of Psychiatry in a Geriatric Practice
Walter P. Bland, M.D.

Discussant: Donna M. Norris, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 93 2:00 p.m.-5:00 p.m.
Room A456, Level 4, Georgia World Congress Center

REVIEW AND UPDATE OF EYE MOVEMENT DESENSITIZATION AND REPROCESSING
Chp.: Enoch Callaway III, M.D.

A Eye Movement Desensitization and Reprocessing With Victims of Traffic Accidents, Suicide Bus Bombings, and Terrorist Attacks in Israel
Gary M. Quinn, M.D.

B A Pilot Blinded, Randomized Study of Alternating Stimulation in Eye Movement Desensitization and Reprocessing for PTSD
David D. Servan-Schreiber, M.D., Johnathan Schoeler, Ph.D., Mary A. Dew, Ph.D., Cameron Carter, M.D., Patricia Bartone, R.N.

C Sleep, Memory, and Trauma
Robert Stickgold, Ph.D.

Discussant: Frank B. Schoenfeld, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 94 2:00 p.m.-5:00 p.m.
Room A458, Level 4, Georgia World Congress Center

RESEARCH DURING PSYCHIATRY RESIDENCY: SHOULD IT BE REQUIRED OR BANNED?
Chp.: Bret R. Rutherford, M.D.
Co-Chp.: Steven P. Roose, M.D.

A What Should Psychiatric Residents Know About Research?
Ronald O. Rieder, M.D.

B A Resident's Perspective on Research During Psychiatry Training
Bret R. Rutherford, M.D.

C The Way to A K: A Research Fellow's Experience
Jordan F. Karp, M.D.

D Training Future Generations of Psychiatrist Researchers: The Functions of Residency Research Track
Charles F. Reynolds III, M.D.

E Research in Psychodynamics and Psychotherapy During Residency
Robert Michels, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 95 2:00 p.m.-5:00 p.m.
Room A410, Level 4, Georgia World Congress Center

THE WAR COMES HOME: PSYCHOSOCIAL AND PSYCHOSOMATIC CONSEQUENCES OF DEPLOYMENT
APA Caucus of VA Psychiatrists
Chp.: Laurent S. Lehmann, M.D.
Co-Chp.: Albert C. Gaw, M.D.

A Rehabilitation/Recovery Orientation Towards Returning Veterans
Laurent S. Lehmann, M.D.

B VA Outreach, Psychoeducation, and Care Efforts
Harold Kudler, M.D.

C Department of Defense Care for Injured Troops and Their Families
Stephen J. Cozza, M.D.
D Deployment Research Issues: Stress and Physical Disorders
Matthew Friedman, M.D.

Discussant: Robert J. Ursano, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96  2:00 p.m.-5:00 p.m.
Room B301, Level 3, Georgia World Congress Center

RESEARCH AGENDA FOR A DIMENSIONAL CLASSIFICATION OF PERSONALITY DISORDER

Chp.: John Livesley, Ph.D.
Co-Chp.: Thomas A. Widiger, Ph.D.

A Alternative Dimensional Models: Toward Integration
Thomas A. Widiger, Ph.D.

B Is an Etiological Classification of Personality Disorder Feasible for DSM-V?
John Livesley, Ph.D.

C Personality Dimensions Integrate Axis I and Axis II Classification Systems
Lee Anna Clark, Ph.D.

D Clinical Utility of Dimensional Models of Personality Pathology
Roel Verheul, Ph.D.

Discussant: Michael B. First, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97  2:00 p.m.-5:00 p.m.
Room B306, Level 3, Georgia World Congress Center

TRANSCULTURAL ARAB PERSPECTIVE ON SUBSTANCE ABUSE AND DEPENDENCE
Arab American Psychiatric Association

Chp.: Ossama T. Osman, M.D.
Co-Chp.: Abdel F. Amin, M.D.

A Highlights on Dependence: An Egyptian Perspective
Ahmed M.F. Okasha, M.D.

B Dual Diagnosis in Substance Abuse in an Egyptian Sample
Tarek A. Okasha, M.D., Afaf Hamed Khalil, M.D., Tarek A. Asaad, M.D., Mohamed Abouzied, M.D., Fisham Hatata

C Substance Abuse and Comorbidities Among Men in Saudi Arabia
Ossama T. Osman, M.D.

(Continued next page)
D  Relationship of Childhood Sexual Abuse Histories to Adult Pedophilic Behavior
Lisa J. Cohen, Ph.D., Yakov Semenov, M.D., Mustafa Kalim, Yuli Grebchenko, M.D., Matthew Steinfeld, B.A., Lauren Kunik, B.A., Igor I. Galynker, M.D.

Discussant: Igor I. Galynker, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 101  2:00 p.m.-5:00 p.m.
Room B313, Level 3, Georgia World Congress Center

LONG-TERM CARE AND TREATMENT OF ELDERLY PATIENTS WITH SCHIZOPHRENIA
APA: Corresponding Committee on Long-Term Care and Treatment for the Elderly

Chp.: Helen H. Kyomen, M.D.

A  The Impact on the Health Care System of Elderly Patients With Schizophrenia
Helen H. Kyomen, M.D.

B  Long-Term Care, Health Management, and Rehabilitation of Elderly Patients With Schizophrenia
Stephen J. Bartels, M.D.

C  Evolution of Treatment Interventions for Elderly Patients With Schizophrenia
Susan M. Edwards-Loidl, M.D.
D Barriers to Effective Research on Treatment of Personality Disorder
Drew Westen, Ph.D.

E Stigma, Countertransference, and Personality Disorders
Glen O. Gabbard, M.D.

Discussant: John M. Oldham, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 104
2:00 p.m.-5:00 p.m.
Room B315, Georgia World Congress Center

IMPULSIVE AGGRESSION AND CRIMINAL RESPONSIBILITY
Chp.: Alan R. Felthous, M.D.

A Assessing and Treating Aggressive Behavior: The Importance of Subtyping
Matthew S. Stanford, Ph.D.

B Impulsivity Risk Factor or Symptom in Psychopathology?
Ernest S. Barratt, Ph.D.

C The Biology of Impulsive Aggression: Implications for Forensic Psychiatry
Frederick G. Moeller, M.D., Ernest S. Barratt, Ph.D., Joel L. Steinberg, M.D., Ignacio H. Valdes, M.D., Alan C. Swann, M.D.

D Impulsivity and the Criminal Law
Daniel W. Shuman, J.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 105
2:00 p.m.-5:00 p.m.
Room B316, Georgia World Congress Center

OPTIMIZING PATIENT RESPONSE THROUGH THE INTEGRATION OF PSYCHIATRY AND MEDICINE
Chp.: Gerald A. Maguire, M.D.

A Remembering the Whole Person: Providing Comprehensive Psychiatric Care of the Severely Medically Ill
Noel Gardner, M.D.

B Treating Psychiatrically Hospitalized, Agitated Children
Gabrielle A. Carlson, M.D., David Margulies, M.D., Zinoviy Gutkovich, M.D.

C Treatment of Acute Agitation in the Emergency Department
Scott Rudkin, M.D.

D Diabetes and Schizophrenia: Guidelines, Evidence, and Practical Implementation for Improved Patient Outcomes
John Buse, M.D.

E Cultural Issues in Psychopharmacologic Management
Charles Nguyen, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 106
2:00 p.m.-5:00 p.m.
Room B421, Georgia World Congress Center

EATING DISORDERS 2005: FROM SCIENCE TO PRACTICE
Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A Defining the Neuroanatomy of Anorexia and Bulimia Nervosa
Walter H. Kaye, M.D., Frank Guido, M.D., Ursula Bailer, M.D., Angela Wagner, M.D., Shannan Henry, B.S., Claire McConaha, B.S.

B The Genetics of Anorexia Nervosa and Bulimia Nervosa
Katherine A. Halmi, M.D.

C Does Participation in Osteoporosis Treatment Studies Influence Eating Disorder Symptoms in Patients With Anorexia?
David B. Herzog, M.D., Debra L. Franko, Ph.D., David J. Dorer, Ph.D., Safia C. Jackson, B.S., Mary Patricia Manzo, A.B., Karen K. Miller, M.D., Anne Klibanski, M.D.

D CBT for Bulimia Nervosa Delivered via Telemedicine Versus Face-to-Face
James E. Mitchell, M.D., Ross D. Crosby, Ph.D., Stephen A. Wonderlich, Ph.D., James Roerig, Pharm.D., Tricia Myers, Ph.D., Lorraine Swan-Kremier, Ph.D., Kathy Lancaster

E Updating APA Eating Disorders Practice Guidelines: What's New for Practice?
Joel Yager, M.D., Michael J. Devlin, M.D., James E. Mitchell, M.D., Katherine A. Halmi, M.D., Pauline Powers, M.D., David B. Herzog, M.D., Kathryn J. Zerbe, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 107 - CANCELLED

SYMPOSIUM 108
2:00 p.m.-5:00 p.m.
Room B403, Georgia World Congress Center

NEW DEVELOPMENT IN NEUROIMAGING IN BPD
Chp.: Christian Schmahl, M.D.
Co-Chp.: Larry J. Siever, M.D.

(Continued next page)
A Overview of New Neuroimaging Research Strategies for BPD
Larry J. Siever, M.D.

B MR-Morphometric and Spectroscopic Findings in Patients With BPD
Ludger Tebanz Van Elsi, M.D., Juergen Hcnnig, Ph.D., Dieter Eben, M.D., Martin Bohus, M.D., Klaus Lieb, M.D.

C Amygdala/Frontal Circuitry Dysfunction in BPD
Antonia S. New, M.D., Monte Buchsbaum, M.D., Erin Hazlett, Ph.D., Randall Newmark, B.A., Serge A. Mitelman, M.D., Marianne Goodman, M.D., Larry J. Siever, M.D.

D Neural Correlates of BPD Patients With and Without PTSD
Charles A. Sanislov, Ph.D., Nelson H. Donegan, Ph.D., Thomas H. McGlashan, M.D.

E Neural Correlates of Antinociception in BPD
Christian Schmahl, M.D., Erich Seifritz, M.D., Rolf-Detlef Treede, M.D., Martin Bohus, M.D.

Discussant: Kenneth Silk, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 109 2:00 p.m.-5:00 p.m.
Room B404, Level 4, Georgia World Congress Center
EVIDENCE-BASED PRACTICES IN SUICIDE PREVENTION
Chp.: Howard S. Sudak, M.D.

A Risk and Protective Factors in Suicide Prevention
Morton M. Silverman, M.D.

B Safety and Harm Issues in Suicide Prevention
Phillip Rodgers, Ph.D.

C Examples of Evidence-Based Practices in Suicide Prevention
Howard S. Sudak, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 110 2:00 p.m.-5:00 p.m.
Room B405, Level 4, Georgia World Congress Center
TREATMENT AND INTERVENTION FOR AUTISM SPECTRUM DISORDERS
Chp.: Craig Newschaffer, Ph.D.
Co-Chp.: Li-Ching Lee, Ph.D.

A Detecting Signs of Autism in Infancy
Rebecca Landa, Ph.D.

B Effective Early Intervention for Very Young Children With Autism Spectrum Disorders
Ilene Schwartz, Ph.D.

C Psychopharmacological Treatments for Autism Spectrum Disorders
Eric Hollander, M.D.

D Natural History, Prognosis, and Outcomes of Autism Spectrum Disorders
Li-Ching Lee, Ph.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 111 2:00 p.m.-5:00 p.m.
Room B407, Level 4, Georgia World Congress Center
HOW TO PRACTICE EVIDENCE-BASED MEDICINE
Chp.: Donna M. Sudak, M.D.

A Introduction to Evidence-Based Psychiatry
Bryce Templeton, M.D.

B Review of Basic Statistical Concepts
Maju Mathews, M.D.

C Critical Appraisal of Randomized, Controlled Trials
Adedapo B. Williams, M.D.

D Critical Appraisal of Systematic Reviews and Meta-Analysis
Babatunde A. Adetunji, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 112 2:00 p.m.-5:00 p.m.
Room B408, Level 4, Georgia World Congress Center
TRANSLATING RISK RESEARCH INTO COMORBIDITY INTERVENTION RESEARCH
APA Council on Psychosomatic Medicine
Chp.: Junius J. Gonzales, M.D.

A Early Identification and Intervention With High Risk, Low Back Pain Patients
Robert Gatchel, Ph.D.

B Depression and Diabetes
Wayne J. Katon, M.D., Michael Von Korff, Sc.D., Elizabeth H.B. Lin, M.D., Paul S. Gechawowski, M.D., Gregory E. Simon, M.D., Evette J. Ludman, Ph.D.

C Comorbidity of Obesity and Depression
Gregory E. Simon, M.D., Evette J. Ludman, Ph.D.
D Depression and Breast Cancer: Treatment Response and HPA Dysregulation
David M. Spiegel, M.D., Janine Giese-Davis, Ph.D., Lisa D. Butler, Ph.D., Catherine Classen, Ph.D., Gary Norrow, M.D.
Discussant: Theodore A. Stern, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 113  2:00 p.m.-5:00 p.m.
Room B409, Level 4, Georgia World Congress Center

POSTPARTUM MOOD DISORDERS
Collaborative Session With the National Institute of Mental Health
Chp.: Catherine A. Roca, M.D.

A Reproductive Hormones and Postpartum Depression
Catherine A. Roca, M.D., David R. Rubinow, M.D.

B Uncovering the Nature of the Puerperal Trigger: Genetic Studies of Postpartum Mood Disorders
Ian R. Jones, M.R.C.

C Bipolar Disorder and the Postpartum Period
Adele C. Viguera, M.D., Lee S. Cohen, M.D.

D Postpartum Mental Illness: Impact and Treatment
Zachary N. Stowe, M.D., Donald J. Newport, M.D., Kimberly A. Ragan, M.S.W.
2005 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS
1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
6. Eating Disorders
7. Mental Retardation (Child/Adolescent/Adult)
8. Mood Disorders
9. Personality Disorders
10. Schizophrenia and Other Psychotic Disorders
11. Sexual and Gender Identity Disorders
12. Sleep Disorders
13. Somatoform Disorders

PRACTICE AREAS/SETTINGS
14. Psychiatric Administration and Services: Public, Private, and University

SUBSPECIALTY AREAS OR SPECIAL INTERESTS
15. Addiction Psychiatry
16. Biological Psychiatry and Neuroscience
17. Brain Imaging
18. Child and Adolescent Psychiatry and Disorders
19. Consultation-Liaison and Emergency Psychiatry
20. Cross-Cultural and Minority Issues
21. Diagnostic Issues
22. Epidemiology
23. Ethics and Human Rights
24. Forensic Psychiatry
25. Genetics
26. Geriatric Psychiatry
27. Neuropsychiatry
28. Pain Management
29. Psychiatric Education
30. Psychiatric Rehabilitation
31. Psychoanalysis
32. Psychoimmunology
33. Research Issues
34. Social and Community Psychiatry
35. Stress
36. Suicide
37. Violence, Trauma, and Victimization

TREATMENTS
38. Behavior and Cognitive Therapies
39. Combined Pharmacotherapy and Psychotherapy
40. Couple and Family Therapies
41. Group Therapy
42. Individual Psychotherapies
43. Other Somatic Therapies
44. Psychopharmacology
45. Treatment Techniques and Outcome Studies

OTHER ISSUES
46. Creativity and the Arts
47. Gender Issues
48. Health Services Research
49. Historical Questions
50. Information Technology
51. Internet
52. Lesbian/Gay/Bisexual/Transgender Issues
53. Managed Care and Health Care Funding
54. National Institute of Mental Health
55. Patient Safety
56. Personal Digital Assistants (PDAs)
57. Presidential Theme: "Psychosomatic Medicine: Integrating Psychiatry & Medicine"
58. Professional and Personal Issues
59. Religion, Spirituality, and Psychiatry
60. Resident and Medical Student Concerns
61. Stigma/Advocacy
62. Telepsychiatry
63. Women's Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
## TOPIC INDEX

### DISORDERS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC 1: AIDS AND HIV-RELATED DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Real Life Medical Management of HIV</td>
</tr>
<tr>
<td>COMPONENT WORKSHOPS</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Sexodependent Couples: Issues and Psychodynamics in the Third Decade of AIDS</td>
</tr>
<tr>
<td>26</td>
<td>Using the HIV Dementia Scale in the Clinical Setting</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td></td>
</tr>
<tr>
<td>129</td>
<td>The Double-Edged Sword: Mental Health Challenges in HIV and Hepatitis C</td>
</tr>
<tr>
<td>120</td>
<td>Homelessness, Addiction, and Severe Mental Illness in Persons With HIV/AIDS</td>
</tr>
<tr>
<td><strong>TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Street Drugs and Mental Disorders: Overview and Treatment</td>
</tr>
<tr>
<td>80</td>
<td>Drugs and Alcohol Take Two: Teaching Addiction Medicine Using Popular Films</td>
</tr>
<tr>
<td>FORUM</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Should Psychiatrists and Other Mental Health Professionals Take a Lead in Tobacco Dependence Treatment</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Dual Diagnosis: The Scope of the Problem</td>
</tr>
<tr>
<td>40</td>
<td>Alcoholism: Translating Emerging Science Into Clinical Practice</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Parental Separation at Birth and Substance Use Disorder</td>
</tr>
<tr>
<td>104</td>
<td>A Comparison of Lorazepam Versus Diazepam Treatment of Alcohol Withdrawal</td>
</tr>
<tr>
<td>125</td>
<td>Suboxone in Private Practice</td>
</tr>
<tr>
<td>156</td>
<td>Nonmedical Use and Diversion of Stimulants in the US: 2002</td>
</tr>
<tr>
<td>SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Comorbid Psychosis and Substance Use: Diagnosis, Course, and Outcome</td>
</tr>
<tr>
<td>10</td>
<td>New Pharmacologic Approaches to Alcoholism</td>
</tr>
<tr>
<td>36</td>
<td>Understanding and Treating Alcohol Dependence</td>
</tr>
<tr>
<td>53</td>
<td>Increases in Opioid Analogic Abuse Concerns and Strategies</td>
</tr>
<tr>
<td>73</td>
<td>Choosing the Right Treatment for Substance Abuse</td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Need an Oxycontin Fix? The Role of Buprenorphine in the Outpatient Treatment of Prescription Narcotic Problems</td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Cannabis Dependence Treatment: Where We Are, Where We Are Going</td>
</tr>
<tr>
<td><strong>TOPIC 3: ANXIETY DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>DISCUSSION GROUP</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Improving Outcomes of Patients With Anxiety and Depressive Disorders Within Primary Care Settings</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Anxiety: Diverse Populations and Presentations, Unique Individuals and Treatments</td>
</tr>
<tr>
<td>6</td>
<td>Integrating Neurobiology and Psychopathology Into Evidence-Based Treatment of Social Anxiety Disorder</td>
</tr>
<tr>
<td>15</td>
<td>Panic Disorder: Current Concepts and Future Directions</td>
</tr>
<tr>
<td>21</td>
<td>Anxiety Disorders: Understanding the Interconnection Between Emotional and Physical Symptoms</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Personality Traits in Patients With Panic Disorder</td>
</tr>
<tr>
<td>50</td>
<td>PTSD Depression and Anger in Patients Recovered From SARS</td>
</tr>
<tr>
<td>51</td>
<td>Are Anxiety Disorders Underdiagnosed and Undertreated in Psychiatry?</td>
</tr>
<tr>
<td>52</td>
<td>Biological Findings in PTSD: Can They Be Changed by Psychotherapy?</td>
</tr>
<tr>
<td>79</td>
<td>Respiratory Panic Disorder in a Long-Term Clonazepam Follow-Up</td>
</tr>
<tr>
<td>92</td>
<td>The Prevalence of Migraine Headaches in an Anxiety Disorders Clinic Sample</td>
</tr>
<tr>
<td>102</td>
<td>Clinical Characteristics of OCD With and Without Comorbid BDD</td>
</tr>
<tr>
<td>103</td>
<td>The Burden Experienced by Families of Individuals With Anxiety Disorders</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>The Long-Term Psychological Aftermath of 9/11-Related Traumatic Loss</td>
</tr>
<tr>
<td><strong>TOPIC 4: ATTENTION SPECTRUM DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>ADD in Children and Adolescents</td>
</tr>
<tr>
<td>15</td>
<td>ADD in Adults</td>
</tr>
<tr>
<td>76</td>
<td>Advanced Assessment and Treatment of ADD</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Exploring Cognitive Function: From Brain to Bedside</td>
</tr>
<tr>
<td>27</td>
<td>ADHD Through the Lifecycle: New Findings and Clinical Implications</td>
</tr>
<tr>
<td>43</td>
<td>It's Not Just for Kids: ADHD in Adolescence and Adulthood</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Sleep Hygiene and Melatonin Treatment for ADHD Sleep-Onset Delay</td>
</tr>
<tr>
<td>12</td>
<td>Comorbidity Differences in ADHD Throughout the Life Cycle</td>
</tr>
<tr>
<td>SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Diagnosis, Assessment, Management, and Quality-of-Life Issues in Adult ADHD</td>
</tr>
<tr>
<td>22</td>
<td>Large Observational Studies of ADHD: Methodology and Results</td>
</tr>
<tr>
<td>TOPIC INDEX</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td><strong>TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
<td></td>
</tr>
<tr>
<td>2 The Evaluation and Identification of the Major Dementias</td>
<td>1</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>20 Alzheimer's Disease Pathways to Practice: Assessing Diagnosis and Outcome Measures</td>
<td>9</td>
</tr>
<tr>
<td>31 Agitation and Psychosis in Alzheimer's Disease and Parkinson's Disease, Part 1</td>
<td>13</td>
</tr>
<tr>
<td>31 Agitation and Psychosis in Alzheimer's Disease and Parkinson's Disease, Part 2</td>
<td>39</td>
</tr>
<tr>
<td>41 Advances in Cholinergic Therapy: Alzheimer's Disease and Beyond</td>
<td>62</td>
</tr>
<tr>
<td><strong>MEDICAL UPDATE</strong></td>
<td></td>
</tr>
<tr>
<td>1 Get Smart Naturally</td>
<td>22</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
<td></td>
</tr>
<tr>
<td>35 Is Depression a Risk Factor for Cognitive Impairment?</td>
<td>47</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>17 Advances and Innovations in Assessing Decision-Making Capacity</td>
<td>59</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>40 Driving Miss Daisy</td>
<td>45</td>
</tr>
<tr>
<td>74 Become a Delirium Detective</td>
<td>68</td>
</tr>
<tr>
<td><strong>TOPIC 6: EATING DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
<td></td>
</tr>
<tr>
<td>6 Therapeutic Interventions in Eating Disorders: Basic Principles</td>
<td>1</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td><strong>LECTURES</strong></td>
<td></td>
</tr>
<tr>
<td>6 Eating Disorders in Middle and Late Life: Diagnosis and Treatment of a Neglected Problem</td>
<td>21</td>
</tr>
<tr>
<td>20 The 25th Anniversary of Bulimia Nervosa: A New Disorder</td>
<td>75</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>31 Pica Syndrome: Review and Relevance</td>
<td>46</td>
</tr>
<tr>
<td>55 Impulse Disorder Predicts Disordered Eating Among College Students With Obesity</td>
<td>48</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>106 Eating Disorders 2005: From Science to Practice</td>
<td>97</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>19 Binge-Eating Disorder in Obesity and Implications for Bariatric Surgery</td>
<td>25</td>
</tr>
<tr>
<td>82 The Difficult-to-Treat Bulimia Nervosa Patient</td>
<td>73</td>
</tr>
<tr>
<td>127 The Marriage of Psychiatry and Medicine in Integrated Treatment for Anorexia Nervosa</td>
<td>92</td>
</tr>
</tbody>
</table>

**MEDIA WORKSHOP**
3 Super Size Me: Exploring Causes, Effects, and Solutions to Obesity in Children and Adolescents | 20 |

**TOPIC 7: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)**

**COMPONENT WORKSHOP**
38 To Dose or Not to Dose: Psychopharmacology in the Developmentally Disabled | 66 |

**ISSUE WORKSHOP**
38 Uncovering Medical Causes of Functional Decline in the Developmentally Disabled | 44 |

**TOPIC 8: MOOD DISORDERS**

**COURSE**
11 Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders | 2 |

**DISCUSSION GROUPS**
11 Postpartum Mood Disorders | 41 |
12 The Great Bipolar Depression Controversy: A Pragmatic Approach | 41 |

**FOCUS LIVE SESSION**
1 Major Depressive Disorder | 16 |

**FORUM**
9 CDC Mental Health and Illnesses | 74 |

**INDUSTRY-SUPPORTED SYMPOSIA**
2 The Impact of Depression and Anxiety on Well-Being Across the Life Cycle | 2 |
3 The Developmental Trajectory of Impulsivity | 3 |
7 Bipolar Disorder Psychiatric and Medical Implications for Optimal Patient Management | 3 |
9 Achieving Remission in Depression: Is the Bar Set Too High or Too Low? | 4 |
10 Dealing With Depression: The Added Burden to Medical Patients | 4 |
11 Systematic Treatment of Bipolar Disorder: Bringing Evidence Into Practice | 5 |
26 Untangling Depression and Anxiety: A Challenge for Scientists and Clinicians | 11 |
32 Managing the Spectrum of Bipolar Disorder: Maximizing the Burden of Disease, Part 1 | 13 |
32 Managing the Spectrum of Bipolar Disorder: Maximizing the Burden of Disease, Part 2 | 39 |
34 Bipolar Disorder Management: A New Edition | 36 |
38 Overcoming Traditional Dilemmas in Treating Depressive Illness: Evidence-Based Updates | 37 |
39 Seasonal Affective Disorder: New Concepts, Practicable Strategies | 61 |
44 Bipolar Disorder Across the Life Cycle: Special Considerations, Part 1 | 63 |
44 Bipolar Disorder Across the Life Cycle: Special Considerations, Part 2 | 85 |

**LECTURES**
8 Temperament, Mood Disorder, and Human Nature | 28 |
17 Depression and Heart Disease: Cause, Effect, or Coincidence | 85 |
# TOPIC INDEX

## MASTER EDUCATOR CLINICAL CONSULTATIONS
- 3 Treatment-Refractory Depression 21
- 12 The Approaches to Treatment-Refractory Depression 69

## REVIEW OF PSYCHIATRY: SECTION 2
- Pregnancy and Postpartum Depression 66

## SCIENTIFIC AND CLINICAL REPORTS
- 14 Excess Mortality in Bipolar and Unipolar Disorder 23
- 15 Do Antidepressants Help or Hinder Recovery From Mixed Mania? 23
- 16 Mixed Episodes: Illness Characteristics 23
- 28 Is Peripartum Depression a Borderline Condition? 48
- 45 Magnitude of the Effects of Quetiapine Treatment in Bipolar Disorder 48
- 46 Lithium Continuation/Discontinuation After Four Years of Stability 48
- 62 Last Observation Carried Forward Use in Antidepressant Efficacy Trials: Review of 260 Studies 70
- 63 The Effect of Chromium Picolinate on Carbohydrate Craving in Atypical Depression 70
- 64 Does Remission of Acute Depression Predict Long-Term Efficacy 70
- 77 Depression Correlates With Left Nigrostriatopallidal Circuit Focal Lesions 71
- 90 Emotion Regulation in BPD 80
- 96 Research Agenda for a Dimensional Classification of Personality Disorder 95
- 100 Barriers to the Effective Treatment of Personality Disorders 96

## ISSUE WORKSHOP
- 3 Cognitive Therapy for Personality Disorders 19

## TOPIC 10: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

### COURSE
- 29 Assessing Positive and Negative Symptoms in Psychosis With the PANSS 8

### DEBATE
- Resolved: Second Generation Antipsychotics Are Uniformly Superior in Safety and Efficacy to First-Generation Antipsychotics 15

### FORUM
- 4 Psychiatric Management of Treatment-Resistant Schizophrenia 51

## INDUSTRY-SUPPORTED SYMPOSIA
- 16 Antipsychotic Drugs, Mood Stabilizers, and the Metabolic Syndrome 7
- 22 Relapse Prevention in Schizophrenia: Defining a Path From Pharmacologic Intervention to Long-Term Functional Recovery 10
- 30 From Molecular Insight to Clinical Outcomes: Recent Advances in Schizophrenia Treatment 12

## SCIENTIFIC AND CLINICAL REPORTS
- 71 Premorbid Developmental Achievements and Later Recovery in Schizophrenia 71
- 72 Pain Insensitivity in Schizophrenia: State or Trait Marker? 71
- 73 Effectiveness of an Early Psychotic Treatment Service 71
- 86 Effectiveness and Tolerability of Antipsychotic Treatments for Schizophrenia: Two-Year Results From the Intercontinental Schizophrenia Outpatient Health Outcomes Study (IC-SOHO) 89

## ISSUE WORKSHOPS
- 64 What Usual Treatments Fail: Augmentation Strategies for Refractory Schizophrenia 68
- 129 Advances in Early Intervention in the Prodromal Phase of Schizophrenia 92

## MEDIA WORKSHOP
- 4 Long-Term Management of Schizophrenia in the Film Out of the Shadow 45

## TOPIC 11: SEXUAL AND GENDER IDENTITY DISORDERS

### COURSES
- 66 The Assessment and Treatment of Child Sexual Abusers 41
- 99 Sexual Medicine 75

---

<table>
<thead>
<tr>
<th>SYMPOSIA</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 Maladaptive Personality Traits: Drug Treatment, Genetics, and Biology</td>
<td>33</td>
</tr>
<tr>
<td>43 Associations Between Stress/Avoidance and Personality Styles and Disorders</td>
<td>57</td>
</tr>
<tr>
<td>72 Emotion Regulation in BPD</td>
<td>80</td>
</tr>
<tr>
<td>96 Research Agenda for a Dimensional Classification of Personality Disorder</td>
<td>95</td>
</tr>
<tr>
<td>103 Barriers to the Effective Treatment of Personality Disorders</td>
<td>96</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 The Multicultural Dimension of Depression: A Clinical Approach</td>
<td>24</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Cognitive Therapy for Personality Disorders</td>
<td>19</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOPIC 9: PERSONALITY DISORDERS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>19 Personality Disorders: Combining Relational Therapy and Psychopharmacology</td>
<td>5</td>
</tr>
<tr>
<td>23 Psychotherapy of Borderline Personality</td>
<td>7</td>
</tr>
<tr>
<td>46 Treating the Self and Interpersonal Problems of Personality Disorder</td>
<td>15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 BPD: Pathophysiology Treatment and Course</td>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REVIEW OF PSYCHIATRY: SECTION 3</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bipolar Disorders</td>
<td>76</td>
</tr>
</tbody>
</table>
TOPIC INDEX

TOPIC 12: SLEEP DISORDERS

COURSES
54 Overview and Update of Sleep Disorders Medicine 26
63 Sleep Medicine Update: Advanced Topics 40

INDUSTRY-SUPPORTED SYMPOSIAS
18 Joining Night and Day: Insomnia and the Sleep/Wake Cycle 9
19 Clinical Interventions for the Treatment of Insomnia Associated With Psychiatric and Comorbid Medical Illnesses 9
36 Insomnia in Special Populations: Is This Insomnia or Something Else? 36
42 Challenges at the Interface of Psychiatric, Medical, and Sleep Disorders 62

REVIEW OF PSYCHIATRY: SECTION 1
Sleep Disorders and Psychiatry 26

ISSUE WORKSHOP
78 Sleep Disorders in Patients With Medical and Psychiatric Illness 73

TOPIC 13: SOMATOFORM DISORDERS

COURSE
77 Psychogenic Illness: What to Do When the Symptoms Don’t Make Sense 51

SCIENTIFIC AND CLINICAL REPORT
38 Somatization Increases Medical Care Utilization and Cost 47

SYMPOSIAS
47 New Developments in the Treatment of Somatoform Disorders 58
63 The Doctor’s Dilemma: Managing Pediatric Chronic Unexplained Symptoms 78

ISSUE WORKSHOPS
55 Chronic Fatigue Syndrome and Gulf War Illness: Pathology or Abnormal Illness Behavior? 50
103 Conversion Disorders in Children: Diagnostic and Cultural Challenges 87

TOPIC 14: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY

COURSES
43 Personnel Management for Clinician-Administrators 15
44 Money Matters I: Using Theory in Clinical Practice 15
67 Money Matters II: Advanced Ad Hoc Clinical Seminar 41

LECTURE
4 Administrative Adventures in Public Psychiatry: 1967-2005 17

SCIENTIFIC AND CLINICAL REPORT
80 Changing Trends in Psychiatric Emergency Room Patients in Large Urban Hospitals 72

TOPIC 15: ADDICTION PSYCHIATRY

DISCUSSION GROUPS
2 Prescription Drug Abuse: The Psychiatrist’s Role in Recognition, Prevention, and Management 15
5 Pathological Gambling and Its Clinical Management (Meet the Author) 15

SCIENTIFIC AND CLINICAL REPORTS
56 Virtual Reality Cue Exposure for Crack Cocaine Dependence 70
57 Low-Dose Naltrexone for Opioid Dependence 72
58 Buprenorphine Versus Methadone Treatments in Addicted Opioid Patients: A Two-Year Observational Study 70

SYMPOSIUM
61 The Biopsychosocial Consequences of Pathological Gambling 7

ISSUE WORKSHOP
93 Substance Abuse in the Prison Setting 87

TOPIC 16: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

COURSE
16 Behavioral Neuroanatomy: An Introduction 5

INDUSTRY-SUPPORTED SYMPOSIUM
29 Beyond Neurochemistry: The Implications of Neurocircuitry for Understanding and Managing Psychiatric Disorders 12

LECTURE
19 Evolution: The Missing Basic Science That Brings Psychiatry Coherence and Deeper Empathy 75

SCIENTIFIC AND CLINICAL REPORTS
41 Brainstem Control of Neuromuscular and Psychotic Processes 47

SYMPOSIUM
51 Neuroscience and Dynamic Psychiatry 60
52 Disturbed Prefrontal Circuitry: How Specific Is It for Different Psychiatric Disorders? 60
76 New Scientific Advances in the Neurobiology of Behavior 81
102 Neurobiology of Compulsive Reward-Seeking 96

ISSUE WORKSHOP
69 Self-Awareness Deficits in Schizophrenia and Cocaine Abuse 68
## TOPIC INDEX

### TOPIC 17: BRAIN IMAGING

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>79 Introduction to Transcranial Magnetic Stimulation (TMS)</td>
<td>51</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORT</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>26 Emotion Processing in BPD: An MRI Perspective</td>
<td>24</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>108 New Developments in Neuroimaging in BPD</td>
<td>97</td>
</tr>
</tbody>
</table>

### TOPIC 18: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS

<table>
<thead>
<tr>
<th>CONTINUOUS CLINICAL CASE CONFERENCES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Control What You Can: Successful Treatment of Teenagers in Chronic Pain, Part 1</td>
<td>14</td>
</tr>
<tr>
<td>1 Control What You Can: Successful Treatment of Teenagers in Chronic Pain, Part 2</td>
<td>40</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>103 Adolescent Psychiatry: Enhancing Clinical Skills</td>
<td>85</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FOCUS LIVE SESSION</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Child and Adolescent Psychiatry</td>
<td>27</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Management of Disruptive Behavioral and Pervasive Developmental Disorders</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ROUND TABLE DISCUSSION</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety and Efficacy of SSRI Antidepressants in Children and Adolescents: What Do We Know and When Did We Know It?</td>
<td>42</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 ADHD Symptoms and Behavior Improved With Modafinil Pediatric Formulation</td>
<td>23</td>
</tr>
<tr>
<td>23 Ethnicity and the Prediction of Substance Abuse in Hospitalized Adolescents</td>
<td>24</td>
</tr>
<tr>
<td>47 Pediatric Formulation of Modafinil Effective in Children and Adolescents With ADHD</td>
<td>48</td>
</tr>
<tr>
<td>48 Modafinil Pediatric Formulation Has Early and Sustained Effect in ADHD</td>
<td>48</td>
</tr>
<tr>
<td>49 Polypharmacy Among Youth: How Prevalent Is It?</td>
<td>48</td>
</tr>
<tr>
<td>95 Bipolar Procedural Patterns Among Amish Youth</td>
<td>90</td>
</tr>
<tr>
<td>97 Childhood Disorders in Early-Versus Late-Onset Bipolar Disorder</td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>64 Emerging Frontier of Psychiatry: Juvenile Justice</td>
<td>78</td>
</tr>
<tr>
<td>71 Pediatric Bipolar Disorder: Phenomenology and New Treatment Options</td>
<td>80</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOPS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 Early Diagnosis in Specific Mental Disorders in Toddlers and Preschoolers</td>
<td>24</td>
</tr>
<tr>
<td>37 SSRI and Suicide: Lessons Learned and Implications for Future Treatment Guidelines</td>
<td>66</td>
</tr>
</tbody>
</table>

### TOPIC 19: CONSULTATION-LIAISON PSYCHIATRY

<table>
<thead>
<tr>
<th>ISSU7 WORKSHOPS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>89 Unexplained Medical Symptoms in a Pediatric Population</td>
<td>74</td>
</tr>
<tr>
<td>95 Autism: Parents as Therapists</td>
<td>87</td>
</tr>
<tr>
<td>121 Effect of Maternal Depression on the Cognitive and Emotional Development of Children</td>
<td>91</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADVANCES IN RESEARCH</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk Factors</td>
<td>20</td>
</tr>
<tr>
<td>Psycho-Oncology</td>
<td>20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLINICAL CASE CONFERENCE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Consultation/Liaison Casebook Challenge: Strategies and Limitations in Establishing Competency</td>
<td>40</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>33 Psychiatric Consultation in Long-Term Care</td>
<td>13</td>
</tr>
<tr>
<td>60 Dynamic Psychotherapy for Cancer Patients and Their Spouse</td>
<td>39</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FOCUS LIVE SESSION</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Psychosomatic Medicine: Consultation-Liaison Psychiatry and Beyond</td>
<td>20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FORUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 How Psycho-Oncology Came to Be</td>
<td>51</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 Emerging Best Practices in the Management of Behavioral Emergencies</td>
<td>12</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RESEARCH ADVANCES IN MEDICINE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immuno-senescence and Rheumatoid Arthritis</td>
<td>42</td>
</tr>
<tr>
<td>Research Advances in Cardiovascular Diseases</td>
<td>42</td>
</tr>
<tr>
<td>Diabetes Update 2005</td>
<td>42</td>
</tr>
<tr>
<td>Vascular Diseases, Oxidative Stress, and Depression</td>
<td>42</td>
</tr>
<tr>
<td>Stress, Depression, and the Metabolic Syndrome</td>
<td>42</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Teaching Psychosomatic Medicine in Primary Care Residencies: Current Status</td>
<td>22</td>
</tr>
<tr>
<td>78 Depression-Related Impairment of Baroreflex in Heart Failure</td>
<td>71</td>
</tr>
<tr>
<td>81 Data From a Psychiatric Emergency Service Using an Electronic Medical Record</td>
<td>72</td>
</tr>
<tr>
<td>82 Implementing a Mixed Psychiatric and Somatic Care Unit in a General Hospital</td>
<td>72</td>
</tr>
<tr>
<td>93 Assessing Anxiety With the Memorial Anxiety Scale for Prostate Cancer</td>
<td>89</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>112 Translating Risk Research Into Comorbidty Intervention Research</td>
<td>98</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOPS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>41 Psychosomatic Medicine: An Update on a New Subspecialty</td>
<td>67</td>
</tr>
<tr>
<td>47 How to Lead an Effective Treatment Team</td>
<td>72</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOPS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>33 Decisional Capacity in the Consultation-Liaison Setting: Controversies and Difficulties (Continued next page)</td>
<td>44</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

#### LECTURE
- **15** The Future of Psychiatric Education: Six Bridges to Cross  
- **16** The Conflicting Worldviews of Sigmund Freud and Oskar Pfister: Keys to Understanding Patients

#### SCIENTIFIC AND CLINICAL REPORT
- **89** The Uses of Reading Poetry for General Psychiatric Education

#### SYMPOSIUM
- **66** The Making of a Competent Psychotherapist: Addressing the New RRC Guidelines
- **62** Psychoanalysis and Psychosomatic Illness: A Modern Mind-Body Perspective

#### COMPONENT WORKSHOPS
- **13** Practical Tips on How to Be a Successful Author
- **23** Disaster Psychiatry: Challenges and Novel Strategies for Residency Training
- **28** Re-Engineering Clinical Research Training: The NPTC
- **34** A Bitter Pill? Tailoring Medical Training to Fit Our Contemporary Practice
- **35** Roadmap to Recertification: Lifelong Learning

#### ISSUE WORKSHOPS
- **12** Issues and Challenges in Integrating Interpersonal Psychotherapy Into Psychiatry Departments
- **25** The Psychiatry Resident as Educator: Implementation of a Curriculum
- **49** Boundaries and Supervision: Avoiding Legal Risks and Doing Good Clinical Work
- **66** Psychotherapy Training and IMGs: The Influence of Cultural Factors
- **71** Fast Tracking Into Child Psychiatry: Who Benefits? Who Suffers?
- **76** Acceptance Versus Change: Dialectics of Implementing DBT in Residency Training
- **87** Residents in the Trenches, But Not Out in the Gold: Integrating Shelter-Based Outpatient Rotations With Online Educational Tools

#### ISSUE WORKSHOPS (continued)
- **90** Using Audiovisual Technology to Teach Behavioral Science
- **107** Got Psych? Increasing Student Involvement in Psychiatry Education

#### TOPIC 30: PSYCHIATRIC REHABILITATION
- **97** Recovery From Mental Illness and Stigma: Integrating Medicine and Rehabilitation

#### SYMPOSIUM
- **46** Rehabilitation of the Mad or Bad: Globally

#### TOPIC 31: PSYCHOANALYSIS
- **16** The Future of Psychiatric Education: Six Bridges to Cross

#### LECTURE
- **16** The Conflicting Worldviews of Sigmund Freud and Oskar Pfister: Keys to Understanding Patients

#### SYMPOSIUM
- **62** Psychoanalysis and Psychosomatic Illness: A Modern Mind-Body Perspective

#### TOPIC 32: PSYCHOIMMUNOLOGY
- **3** Okay Inside Their Head, But What's Under Their Nose?

#### SCIENTIFIC AND CLINICAL REPORT
- **75** Restraint Stress Elevates Plasma Icytokines Levels in Superoxide Dependent Manner

#### TOPIC 33: RESEARCH ISSUES

#### COURSES
- **12** Doing Research on a Shoestring Budget
- **98** Rating Scales in Psychiatry

#### FORUM
- **3** Getting Into Research With African American Patients

#### LECTURE
- **13** The Federal Regulation of Biomedical Research: A Study in Quid Pro Quos

#### SYMPOSIAS
- **20** The End of the Biopsychosocial Model? An Assessment and Alternatives
- **37** Evidence-Based Psychiatry: What It Is and What It Is Not
- **94** Research During Psychiatry Residency: Should It Be Required or Banned?

#### TOPIC 34: SOCIAL AND COMMUNITY PSYCHIATRY

#### SPECIAL SESSION
- **Global Disasters: Psychiatric Medicine and Public Health Challenges**

#### CLINICAL CASE CONFERENCE
- **1** House Call: Treading on Privacy in Public Psychiatry

#### COURSE
- **92** Psychiatry in Corrections

#### SCIENTIFIC AND CLINICAL REPORT
- **85** Psychiatric Practices and Patient Outcomes in Assertive Community Treatment

#### ISSUE WORKSHOPS
- **34** Psychiatric Hospice on an ACT Team: When Mental Illness Is Terminal
- **59** Treatment of Mental Illness in U.S. Jails and Prisons

#### TOPIC 35: STRESS

#### DISCUSSION GROUP
- **8** Coping With Trauma (Meet the Authors)

#### MASTER EDUCATOR CLINICAL CONSULTATION
- **5** PTSD and Deployment Mental Health

#### SYMPOSIUM
- **95** The War Comes Home: Psychosocial and Psychosomatic Consequences of Deployment

#### ISSUE WORKSHOP
- **122** Presenteeism and Absenteeism: Underrecognized and Underaddressed at Work
TOPIC INDEX

TOPIC 36: SUICIDE

DISCUSSION GROUP
15 Assessment and Treatment of Suicidal Patients (Meet the Authors) 45

LECTURE
1 Suicide Risk Assessment: Evidence-Based Psychiatry 10

SCIENTIFIC AND CLINICAL REPORTS
5 Exposure to SSRIs Reduces Suicidality in Elderly Patients With Depression 22
6 Suicidality in Youth With Bipolar Disorder: A Community-Based, Multisite Investigation 22
7 Peripheral Benzodiazepine Receptors in Suicide 22

SYMPOSIUM
109 Evidence-Based Practices in Suicide Prevention 98

COMPONENT WORKSHOP
25 Suicide Among Ethnic Elders 43

ISSUE WORKSHOPS
9 Physician Suicide: What Can Be Done? 19
47 Responding to the Impact of Suicide on Clinicians 50

TOPIC 37: VIOLENCE, TRAUMA, AND VICTIMIZATION

CLINICAL CASE CONFERENCE
4 Commanded to Kill: Approaching the Treatment of a Murderous Grandmother 85

COURSES
9 Psychiatric Interventions in Disasters and Public Health Emergencies: Theory to Practice 2
22 Rebuilding Shattered Lives: Treating Complex Post-Traumatic Stress Disorder 7
37 Disaster Psychiatry: Terrorism, Trauma, and Things to Do 14
70 Personality and Political Behavior 41
91 Men Sexually Abused as Boys: Meanings, Consequences, and Treatments 64

LECTURES
3 Terrorism and Disaster: Population Mental Health Approaches 16
9 I Am the Central Park Jogger: A Story of Hope and Possibility 36

SCIENTIFIC AND CLINICAL REPORTS
68 Effects of Terrorism on Psychopathology Two Years After 9/11 71
69 9/11: Terrorism, Psychiatric Symptoms, Service Utilization, and Alcohol Intake 71

SYMPOSIUM
2 9/11 in New York City: Learning From the Past and Looking to the Future 29
21 Behind Closed Doors: The Hidden Family: Violence and Abuse Issues Worldwide 33
67 Violence From Cradle to Grave: Battering, Stalking, Child Abuse, and Elder Abuse 79
88 New Directions in Psychiatric Aspects of Terrorism: Causes, Consequences, Responses 93
99 Childhood Sexual Abuse: Victims and Perpetrators 95

TOPIC 38: BEHAVIOR AND COGNITIVE THERAPIES

COURSES
31 Cognitive Therapy for Schizophrenia 8
34 Engaging Resistant and Difficult-to-Treat Patients 14
51 Cognitive Therapy for Severe Mental Disorders 26
93 Introduction to Cognitive-Behavioral Therapy 64

ISSUE WORKSHOPS
56 Computer-Assisted CBT in Education and Treatment 50
62 Anger Management: Evaluation and Treatment 67
125 Cognitive Therapy for Psychosis for Psychiatrists: Basic Technique 92

TOPIC 39: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

COURSES
42 A Psychodynamic Approach to Treatment Refractory Mood Disorders 15
101 Treating Comorbid Adult ADHD by Combining Medication and Cognitive Therapy 85

MASTER EDUCATOR CLINICAL CONSULTATIONS
2 Split and Integrated Treatment: Pharmacotherapy and Psychotherapy 17
8 Psychodynamics in the Era of Psychopharmacology 46

SCIENTIFIC AND CLINICAL REPORT
8 A Combined Treatment Approach for Adults With ADHD: Results of a Pilot Study of 45 Patients 22

ISSUE WORKSHOPS
1 Treating PTSD: Combining Psychotherapy and Pharmacotherapy 18
17 Split Therapy: Psychotherapy and Pharmacotherapy Procedures and Strategies 25

TREATMENTS
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC 40: COUPLE AND FAMILY THERAPIES</strong></td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>38 Families Coping With Medical Illness: An Integrative Treatment Approach</td>
<td>14</td>
</tr>
<tr>
<td>73 Basic Family Skills for an Inpatient Psychiatrist</td>
<td>51</td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
<td></td>
</tr>
<tr>
<td>86 Individuals and Conjint Approaches to Couples Therapy</td>
<td>73</td>
</tr>
<tr>
<td><strong>TOPIC 41: GROUP THERAPY</strong></td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td></td>
</tr>
<tr>
<td>85 Therapeutic Use of Movie Clips in Outpatient and Inpatient Group Treatment</td>
<td>73</td>
</tr>
<tr>
<td>114 Group Therapy of Substance Abuse</td>
<td>91</td>
</tr>
<tr>
<td><strong>TOPIC 42: INDIVIDUAL PSYCHOTHERAPIES</strong></td>
<td></td>
</tr>
<tr>
<td>ADVANCES IN PSYCHOTHERAPY</td>
<td></td>
</tr>
<tr>
<td>Neurological Underpinnings of Psychotherapy</td>
<td>27</td>
</tr>
<tr>
<td>CONTINUOUS CLINICAL CASE CONFERENCES</td>
<td></td>
</tr>
<tr>
<td>2 Weathering the Storm: Management of Complex Transferences, Part 1</td>
<td>64</td>
</tr>
<tr>
<td>2 Weathering the Storm: Management of Complex Transferences, Part 2</td>
<td>85</td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>13 Short-Term Psychodynamic Supportive Psychotherapy: Treatment of Depression</td>
<td>5</td>
</tr>
<tr>
<td>17 Interpersonal Psychotherapy</td>
<td>5</td>
</tr>
<tr>
<td>24 Understanding the Person Behind the Illness: An Approach to Psychodynamic Formulation</td>
<td>7</td>
</tr>
<tr>
<td>25 Basic Hypnosis: Principles and Applications</td>
<td>8</td>
</tr>
<tr>
<td>26 Dream Translation: One Empirically-Based Approach</td>
<td>8</td>
</tr>
<tr>
<td>32 Brief Psychodyanaic Psychotherapy: The Core Conflicted Relationship Theme</td>
<td>8</td>
</tr>
<tr>
<td>45 Advanced Hypnosis: Applications in Psychiatry</td>
<td>15</td>
</tr>
<tr>
<td>48 Davanloo's Intensive Short-Term Dynamic Psychotherapy in Clinical Practice</td>
<td>15</td>
</tr>
<tr>
<td>49 The Advanced Practice of Psychotherapy</td>
<td>26</td>
</tr>
<tr>
<td>89 Interpersonal Psychotherapy</td>
<td>64</td>
</tr>
<tr>
<td>94 Advanced Interviewing Techniques</td>
<td>64</td>
</tr>
<tr>
<td>DISCUSSION GROUP</td>
<td></td>
</tr>
<tr>
<td>18 Psychodynamic Psychiatry in Clinical Practice (Meet the Authors)</td>
<td>65</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>17 Affect Change in Dreams in Psychotherapy</td>
<td>23</td>
</tr>
<tr>
<td>18 The Empathic Stance</td>
<td>23</td>
</tr>
<tr>
<td>SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>30 The Art and Science of Brief Therapies</td>
<td>54</td>
</tr>
<tr>
<td>69 Advances and Issues in Psychodynamic Psychotherapy</td>
<td>79</td>
</tr>
<tr>
<td>91 Psychotherapy Is Universally Future Oriented</td>
<td>93</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 &quot;Y&quot; Psychotherapy: An Integrated, Evidence-Based Psychotherapy Competency Model</td>
<td>42</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>63 Dynamic Therapy With Self-Destructive Borderline Patients</td>
<td>67</td>
</tr>
</tbody>
</table>

| TOPIC 43: OTHER SOMATIC THERAPIES | |
| COURSES | |
| 21 Kundalini Yoga Meditation Techniques for Psychiatric Disorders | 7 |
| 53 ECT Practice Update | 26 |
| 62 The Way of Yoga and Herbs in the Treatment of Stress, Depression, and Aggression | 40 |
| 81 Using Neurofeedback in Your Practice I: Demonstration | 63 |
| 96 Using Neurofeedback in Your Practice II: Applications | 74 |

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 Brain Stimulation: New Treatments for Mood Disorders</td>
<td>6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORT</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>32 The Impact of Electroconvulsive Therapy on Quality of Life and Function</td>
<td>47</td>
</tr>
</tbody>
</table>

| TOPIC 44: PSYCHOPHARMACOLOGY | |
| COURSES | |
| 57 Drug Treatment of Schizophrenia | 27 |
| 69 Med-Psych Drug-Drug Interactions | 41 |
| 90 Psychiatry Update: In Spanish | 64 |

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIAS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 Bipolar Disorder: Treating Through the Entire Spectrum</td>
<td>11</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 Characteristics of Diversion and Misuse of ADHD Medications</td>
<td>22</td>
</tr>
<tr>
<td>10 Combined Treatment of Venlafaxine and ECT in Treatment- Resistant Depressive Patients</td>
<td>22</td>
</tr>
<tr>
<td>20 Efficacy and Safety of Ziprasidone in First-Episode Psychosis</td>
<td>23</td>
</tr>
<tr>
<td>22 Metabolic Syndrome in Schizophrenia</td>
<td>23</td>
</tr>
<tr>
<td>59 Thinking About Adverse Drug Effects: Lessons From the Psychology of Risk and Decision Making for Clinical Psychopharmacology</td>
<td>70</td>
</tr>
<tr>
<td>60 Sildenafil Treatment of SSRI-Associated Sexual Dysfunction: Lessons From the Psychology of Risk and Decision Making for Clinical Psychopharmacology</td>
<td>70</td>
</tr>
<tr>
<td>61 Association Between SSRI Side Effects and Adherence to Modern SSRIs</td>
<td>70</td>
</tr>
<tr>
<td>70 Clozapine, Olanzapine, and Haloperidol Treatment of Violent Patients With Schizophrenia</td>
<td>71</td>
</tr>
<tr>
<td>87 An Investigation of Cognitive Effects of Rivastigmine in Schizophrenia</td>
<td>89</td>
</tr>
<tr>
<td>88 Rivastigmine or Galantamine for the Treatment of Schizophrenic Cognitive Impairment</td>
<td>89</td>
</tr>
<tr>
<td>91 Antidepressants for Depression in the Medically Ill: Are They Effective?</td>
<td>89</td>
</tr>
</tbody>
</table>
TOPIC INDEX

TOPIC 51: INTERNET

COURSES
52 Psychiatry and the Internet 26
45 Online Communication in Mental Health: Different Contexts, Different Issues 63

ISSUE WORKSHOP
54 Virtual Reality and Other Forms of Cybertherapy: An Evidence-Based Review 73

TOPIC 52: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES

SYMPOSIUM
3 Queer Thought for the Straight Shrink: Expert Tips 29

COMPONENT WORKSHOPS
17 Gender Benders: Psychiatric Aspects of Transgender Care 25
32 I Do, But I Can't: Mental Health Issues Around Gay Men 49
43 Same Sex Marriages: Mental Health and Personal Perspectives 67

TOPIC 53: MANAGED CARE AND HEALTH CARE FUNDING

COURSES
35 Current CPT Coding and Documentation Requirements 14
72 Provider Protect Thyself: Managed Care Contracting for Mental Health Providers 41

SYMPOSIUM
7 Health Care Meltdown: What Can We Do? 30

COMPONENT WORKSHOPS
1 Managed Care: Past, Present, and Future 17
10 Funding for Psychiatry From the Irrational and Rational 18
36 CPT Coding and Documentation Update 86

TOPIC 54: NATIONAL INSTITUTE OF MENTAL HEALTH

DISCUSSION GROUPS
3 Suicidal Behavior in Major Mood Disorders 15
10 Psychiatric Diagnosis: Approaches in the Post-Genomic Era 41
16 Residency to a Research Career (For Residents Only) 66
21 Emerging Brain Stimulation Techniques in Psychiatry (Meet the Author) 69

FORUM
1 Research Planning for DSM-V 26

LECTURES
2 Human Psychiatric Disorders: Genetic Models in Mice 16
5 Stress and the Mind-Body Connection: Lessons From Neuroendocrinology 21

7 Epigenetic Programming of Stress Responses Through Variations in Maternal Care: The Nurture of Nature 27
10 From Genes to Therapeutics: New Approaches to Schizophrenia 41
12 Psychiatry in the Genomic Era 45
13 Genes, Cognition, and Emotion 52
21 Inspiring Ethics: Ethical Milestones and Preparation in Psychiatric Education 86

MASTER EDUCATOR CLINICAL CONSULTATION
1 Clinical and Pharmacologic Management of BPD 17

PRESIDENTIAL SYMPOSIA
1 Advances in Psychosomatic Medicine 28
2 Addressing Hepatitis C-Related Diseases in Persons With Severe Mental Illness 28

RESEARCH CONSULTATIONS
1 Biological Studies in Personality Disorders 22
2 Functional Neuroimaging Strategies in Affective Disorders Research 46

SCIENTIFIC AND CLINICAL REPORTS
3 Use of Simulated Patients to Assess Primary Care Physicians' Treatment of Depression 22
24 Stigmatization of Mental Illnesses Among Chinese Psychiatric Patients in China and the U.S. 24
33 Seizures Targeted to Clock: New Forms of Convulsive Therapy 47
42 Brain Stimulation: Why, Where, and How? 47
43 New Findings in Daily Prefrontal Repetitive Transcranial Magnetic Stimulation for Depression 47
44 Negative Impact of Medical Comorbidity on the Course of Bipolar Disorder 48
65 Anorexia Nervosa and Bulimia Nervosa: From Culture to Genes 70
66 Psychosocial Treatment of Eating Disorders 71
67 Psychopharmacology of Eating Disorders 71
101 Deep Brain Stimulation in Intractable OCD and Intractable Depression 90

SYMPOSIA
5 Steps Towards a Treatment Model for BPD 29
6 Research Advances in Late-Life Mental Disorders: Toward DSM-V 30
9 Clinical Advances in Early Detection, Prevention, and Treatment of Psychosis 30
9 Clinical Effectiveness Trials in the Real World: Status and Findings of the NIMH Treatment Trials 31
24 The Psychiatric Effects of the World Trade Center Attack in Disaster Relief Workers 34
25 Research Update on Pediatric Bipolar Disorder 34
27 Neuroscience for the Psychiatrist, Part 1: Neuroimaging From Genomics To Therapy 53
42 ADHD: From Neuroscience to Practice 57
50 Novel Research Treatments for Eating Disorders 59
55 Autism: A Common, Severe, Treatable, Neglected Psychiatric Illness 61
57 The NIMH Clinical Antipsychotic Trial of Intervention Effectiveness for Alzheimer's Disease (CATIE-AD): First Outcomes 76
58 Diagnostic and Treatment Implications of a New Model of Schizophrenia 77
65 Neuroscience for the Psychiatrist, Part 2 78
68 Sequenced Treatment Algorithm for Resistant OCD: An International Approach 79
77 Psychiatric Advance Directives: Key Issues and Clinical Challenges 81
85 Dissemination of Evidence-Based Mental Health Models 84
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page #</td>
</tr>
<tr>
<td>87</td>
</tr>
<tr>
<td>90</td>
</tr>
<tr>
<td>113</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>22</td>
</tr>
<tr>
<td>26</td>
</tr>
<tr>
<td>32</td>
</tr>
<tr>
<td>41</td>
</tr>
<tr>
<td>44</td>
</tr>
<tr>
<td>50</td>
</tr>
<tr>
<td>72</td>
</tr>
<tr>
<td>80</td>
</tr>
<tr>
<td>102</td>
</tr>
<tr>
<td>104</td>
</tr>
<tr>
<td>110</td>
</tr>
<tr>
<td>TOPIC 55: PATIENT SAFETY</td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>TOPIC 56: PERSONAL DIGITAL ASSISTANTS (PDA)</td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>65</td>
</tr>
<tr>
<td>78</td>
</tr>
<tr>
<td>82</td>
</tr>
<tr>
<td>TOPIC 57: PRESIDENTIAL THEME: “PSYCHOSOMATIC MEDICINE: INTEGRATING PSYCHIATRY &amp; MEDICINE”</td>
</tr>
<tr>
<td>ADVANCES IN PSYCHOSOMATIC MEDICINE</td>
</tr>
<tr>
<td>Advances in Psychosomatic Medicine: Psychiatric Care of the Medically Ill</td>
</tr>
<tr>
<td>ADVANCES IN RESEARCH</td>
</tr>
<tr>
<td>Treating Depression After a Heart Attack Influencing Death?</td>
</tr>
<tr>
<td>COURSE</td>
</tr>
<tr>
<td>75</td>
</tr>
<tr>
<td>DISCUSSION GROUPS</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>FORUM</td>
</tr>
<tr>
<td>11</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>23</td>
</tr>
<tr>
<td>45</td>
</tr>
<tr>
<td>MASTER EDUCATOR CLINICAL CONSULTATION</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>PRESIDENTIAL SYMPOSIA</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>39</td>
</tr>
<tr>
<td>42</td>
</tr>
<tr>
<td>54</td>
</tr>
<tr>
<td>SYMPOSIA</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>16</td>
</tr>
<tr>
<td>29</td>
</tr>
<tr>
<td>31</td>
</tr>
<tr>
<td>33</td>
</tr>
<tr>
<td>74</td>
</tr>
<tr>
<td>75</td>
</tr>
<tr>
<td>92</td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
</tr>
<tr>
<td>33</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>23</td>
</tr>
<tr>
<td>57</td>
</tr>
<tr>
<td>62</td>
</tr>
<tr>
<td>67</td>
</tr>
<tr>
<td>83</td>
</tr>
</tbody>
</table>

113
# Topic Index

## Topic 58: Professional and Personal Issues

### Courses
- 59 Treating Medical Students and Physicians  
- 58 Improving Your Presentation Skills: A Coaching Approach

### Discussion Group
- 22 The Benefits of Yoga in Psychiatry

### Lecture
- 11 Leadership Through Example: Mentorship and Networking

### Symposium
- 38 How to Launch a Successful Private Practice, Part 3
- 54 Psychiatry and the Pharmaceutical Industry: Where Is the Boundary?
- 83 APA Women Presidents: Lessons Learned, Road Ahead

### Component Workshops
- 5 Early Career Psychiatrists as Leaders
- 20 Closing Practice: What Every Psychiatrist's Office and He/Her Family Should Know
- 21 Novel Careers in Psychiatry: Women Who Have Made Their Own Way
- 40 Doctor, Your Child Is Calling

### Issue Workshops
- 5 Risk Management Issues in Psychiatric Practice
- 8 Mental Health of Physicians: Whose Business Is It?
- 29 ABPN and APA Perspectives on Maintenance of Certification
- 40 How to Launch a Successful Private Practice, Part 2
- 45 How to Launch a Successful Private Practice, Part 3
- 65 Reimprinting Careers: Transitions and Later-Life Strategies for Psychiatrists
- 88 Grandparents and Grandchildren: Child Psychiatric and Family Perspectives
- 126 Challenges When Psychiatrists Seek Treatment for Themselves
- 118 Women as Leaders: Opportunities and Strategies for Success
- 124 Treating Physicians in a Cultural Context: Some Unique Issues

## Topic 59: Religion, Spirituality, and Psychiatry

### Course
- 5 Transpersonal Psychiatry: Clinical Applications

### Forum
- 8 Culture, Spirituality, and Folk Belief

### Component Workshop
- 46 The Contrasting Worldviews of Sigmund Freud and C.S. Lewis

### Issue Workshops
- 61 Religious and Spiritual Assessment in Clinical Practice
- 117 Worldview and Spirituality in Clinical Practice

## Topic 60: Resident and Medical Student Concerns

### Discussion Groups
- 5 Tips on How to Be an Effective Psychiatrist (For Residents Only)
- 13 Career Building in Academic and Nonacademic Psychiatry (For Residents Only)

### Forum
- 9 ABPN Update: Certification in Psychiatry and Its Subspecialties

### Residents' Session
- Meet the Experts: Sunny-Side Up

### Component Workshop
- 32 Quotes and Misquotes: Resident Physicians Working With the Media

### Issue Workshops
- 2 Oral Boards Boot Camp Updated
- 39 Drug Companies in Training Clinics: Economic Necessity Versus Undue Influence

## Topic 61: Stigma/Advocacy

### Component Workshop
- 3 What Not To Do: The Media Talks Back About Public Affairs

### Issue Workshop
- 67 The Marketing of Psychiatric Medications to Patients: Where Do We Stand?

## Topic 62: Telepsychiatry

### Course
- 61 Expanding Health Care Delivery? Let Telepsychiatry Help!

### Issue Workshop
- 54 American Indian Telepsychiatry: Bridging Culture and Distance

## Topic 63: Women's Health Issues

### Course
- 87 Management of Psychiatric Disorders in Pregnant and Postpartum Mothers

### Industry-Supported Symposia
- 33 Advances in the Treatment of Mood and Anxiety Disorders in Women, Part 1
- 34 Advances in the Treatment of Mood and Anxiety Disorders in Women, Part 2

### Master Educator Clinical Consultations
- 9 Managing Menopause
- 10 Premenstrual Mood Disorders
- 11 Psychiatric Aspects of Reproduction in Chronically Mentally Ill Women
# TOPIC INDEX

## MEDICAL UPDATE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Stress-Induced Anovulation: Mind Over Matter</td>
</tr>
</tbody>
</table>

## ISSUE WORKSHOP

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Treatment of Depression During Pregnancy</td>
</tr>
</tbody>
</table>

## SYMPOSIA

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>A Sex/Gender Research Agenda for DSM-V</td>
</tr>
<tr>
<td>41</td>
<td>Maternal Depression and Comorbidities: Impact on Infants</td>
</tr>
<tr>
<td>44</td>
<td>Perinatal Depression: Prevalence, Screening Accuracy, and Intervention</td>
</tr>
<tr>
<td>89</td>
<td>Leadership in Psychiatry: Women Leaders in Advocacy and Services</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

APA 158TH ANNUAL MEETING

A

Abramson, Ronald D ........................................... 90, 94
Able, Stephen .................................................. 89
Abouzied, Mohamed ........................................... 95
Abrams, Karen M ................................................ 79
Abramson, Ronald D ........................................... 90, 94
Abright, A. Reese ............................................. 29
Abuakil, Sr., Farouk S ......................................... 80
Adams, Jr., Curtis N ............................................. 71, 77
Addington, Jean M ............................................. 71, 77
Adams, Jr., Curtis N ............................................. 71, 77
Abuzzahab, Sr., Farouk S .................................... 80
Abright, A. Reese ............................................. 29
Addington, Donald E .......................................... 71
Abrams, Karen M ............................................. 79
Abouzied, Mohamed ........................................... 95
Aasen, Ingrid .................................................... 89
Ader, Marilyn .................................................... 79
Alderman, E. ..................................................... 82
Aguero, Richard ............................................... 74
Aiken, J. .......................................................... 76
Akiskal, Hagop S .............................................. 95
Alarcon, Renato D ............................................ 72
Alarcon, Renato D ............................................ 72
Alderman, E. ..................................................... 82
Alam, A. .......................................................... 82
Alvarez, J. ........................................................ 82
Al-Hallaj, M. ..................................................... 82
Ambroso, W. ..................................................... 82
Ambrosino-Wyszynski, Antoinette ..................... 15
Ambrosino-Wyszynski, Antoinette ..................... 15
Alarcon, Renato D ............................................ 72
Alarcon, Renato D ............................................ 72
Ambroso, W. ..................................................... 82
Ambrosino-Wyszynski, Antoinette ..................... 15
Ambrosino-Wyszynski, Antoinette ..................... 15
Brady, Kathleen T 2, 31, 70
Bragg, John E. 87
Brandt, Lila 23
Braich, Jennifer S. 72
Braklow, Joel T. 49
Bray, Robert M. 66
Breiman, Joel D. 66
Brecht, William 49, 89
Breiter, Hans C. 81
Bremer, J. Douglas 20, 60
Brendel, David H. 33
Brenn, Ronald 49
Bruckman, Richard M. 60
Brod, Thomas M. 63, 74
Brodky, Amy C. 60
Brody, Seth 58
Brooke, David W. 52, 91
Brooks, Beth Ann 17
Brooks, Beth E. 17
Brown, E. Sherwood 36
Brown, Frank N. 1, 47, 72
Brown, Larry R. 50
Brown, Regina Virginia 54
Brown, Richard P. 22, 40, 59, 68, 85
Brown, Steve 72
Brown, Thomas E. 1, 5, 51
Brunclak, Richard 82
Brunette, Mary F. 29, 36
Buchanan, Robert W. 52, 80
Buchman, Monte 7, 98
Buckley, Peter F. 72
Budman, Cathy L. 68
Buesching, Dan 25
Baie, Stephen E. 74
Baird, Lisa D. 99
Bairnsfather, Angela 79
Bermester, Bill 64
Bens, Kathy A. 49
Bursztajn, Harold J. 20
Bush, George 12, 57
Butler, Jeremy R. 14
Butler, Lisa D. 99
Butterfield, Cory 43
Buxbaum, Monte 7, 98
Cabrera, Angel A. 24
Caccese, Giovanni 43
Cardelli, Daniel P. 71
Carden, Alex A. 70
Cardoso, Gracia 73
Carlson, Gabrielle A. 4, 37
Carpenter, Linda L. 15
Carpenter, Jr., William T. 15
Carter, Cameron 54, 94
Carter, Debbie 92
Carter, Diana 63
Carter, Grady 59
Caradeba, Francisco 55
Casey, David A. 47, 69
Castir, Andy 89
Castellanos, Daniel 43
Castillo-Puentes, Ruby C. 22, 54
Castillo-Puentes, Sandra R. 22, 54
Castillo-Puentes, Wilma I. 22, 54
Castro, Carl A. 34
Caton, Carol L. 29
Caylor, Josephine 50
Chamberlain, John R. 18
Chan, Gail H. 26, 40, 51
Chang, Jacqueline B. 67
Chang, Kiki D. 11, 48, 76
Chang, Stella 89
Chaplin, Bill 61
Chapman, Daniel P. 46, 74, 90
Chapman, John N. 64
Chavez, Robert P. 52
Chau, Holiday 58
Chau, Harold R. 81
Chau, Nader 23
Chau, Zohaida 89
Chiappinetti, Linda H. 25
Chavez, Mark 25
Chavez-Eakle, Rosa A. 23
Chen, Fah A. 81
Chen, Paula 90
Cheng, Hua 24
Cheng, Jennifer K. 66
Cheung, Joseph A. 46, 65, 86
Chester, Adam R. 18
Chiles, John A. 45
Chinn, Lorna 40
Chu, Charles 11
Christo, George 28
Christopher, Eric J. 81
Chung, Christopher K. 72
Cicchino, Paul S. 84, 98
Cirone, Leslie L. 71
Clark, Conrie 74
Clark, David L. 15
Clark, Lee Anna 95
Clark, Michael O. 66, 76
Clarin, John F. 7
Clay, Catherine 99
Claw, Daniel J. 10
Clayton, Paula 31
Clancy, Norman A. 72
Coffman, Jeffrey L. 19
Cocito, Emil F. 32
Cocozza, Joseph J. 78
Cox, Karen 19

Coffey, C. Edward 15, 47
Cohen, Carl L. 43, 96
Cohen, Judy A. 2
Cohen, Lee S. 66, 99
Cohen, Lisa J. 95, 96
Cohen, Mary Ann 48, 91
Cohen, Michael 63, 74
Cohen, Sheldon B. 89
Cole, Steven A. 25, 89
Colemon, Yoolla R. 24, 43
Coll, Pat 47
Collins, Gary R. 91
Collins-Kennedy, Lee 66
Compton III, Wilson M. 26, 60, 77
Comolli, Luciano 22
Cook, Jan A. 17
Cook, William L. 30
Cook, Ed 70
Coon, Mark A. 88
Cooper, Lisa A. 22
Corazza-Locatelli, Gabriella 56
Corbett, Barbara A. 30
Corbett, John R. 50
Corrigan, Patrick W. 68
Costa, Robert W. 96
Costa, Jr., Paul T. 32
Cottrell, Gal 54
Couto, Patricia 43, 50, 54, 75, 88, 89
Cowley, Rex W. 83
Cox, John L. 81
Cox, Jeffrey 87
Cox, Paul D. 88
Cozza, Stephen J. 94
Cuzzolino, Edoardo 70
Craft, Suzanne 37
Craver, Marilyn 22
Gravelle-Le-Nestour, Annick 57
Crofford, Leslie J. 10
Crone, Catherine C. 47
Crosby, Alex 74
Crosby, Ross D. 97
Crossley, Judith H. W. 13
Crow, Scott J. 33
Crye, Brian 94
Curwen, Timothy 87
Cullen, Ken 95
Cumming, Jeffrey L. 9, 13, 39
Curran, Christopher 30
Cutler, Karen A. 44
Cutler, Rodney C. 44
Cuthbert, Bruce 26
Caissie, Paul 71

D'Alessio, Richard E. 15, 42
Dalton, Marc E. 68
Daly, Patricia A. 20
Daw, Anne R. 28
Dawkins, Gail M. 12, 49, 55, 93
Dave, Michael 53
Davenport, Cheryl 43
Davidoff, Donald A. 75

PARTICIPANT INDEX
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davis, Lori L</td>
<td>3</td>
</tr>
<tr>
<td>DeBattista, Charles</td>
<td>4, 89</td>
</tr>
<tr>
<td>Debord, Kurt A</td>
<td>48</td>
</tr>
<tr>
<td>DeFigueiredo, John</td>
<td>66</td>
</tr>
<tr>
<td>DeFrancisci, Leo E</td>
<td>29</td>
</tr>
<tr>
<td>Deitch, David</td>
<td>87</td>
</tr>
<tr>
<td>Dejean, Deirdre</td>
<td>89</td>
</tr>
<tr>
<td>Dekeyser, Jack J</td>
<td>5</td>
</tr>
<tr>
<td>De-la-Cámara, Concepción</td>
<td>47</td>
</tr>
<tr>
<td>DeBello, Melissa P</td>
<td>35, 77</td>
</tr>
<tr>
<td>Delgado, Pedro L</td>
<td>55, 64</td>
</tr>
<tr>
<td>Dell, Diana</td>
<td>66</td>
</tr>
<tr>
<td>Dell, Mary Lynn</td>
<td>91</td>
</tr>
<tr>
<td>DelOso, Bernardo</td>
<td>22</td>
</tr>
<tr>
<td>Delacruz-Denzau, Evan</td>
<td>89</td>
</tr>
<tr>
<td>DelMasco, David</td>
<td>14, 40</td>
</tr>
<tr>
<td>Demet, William C</td>
<td>62</td>
</tr>
<tr>
<td>Demitrack, Mark</td>
<td>84</td>
</tr>
<tr>
<td>Denny, Ellen B</td>
<td>5</td>
</tr>
<tr>
<td>Denno, Deborah</td>
<td>2</td>
</tr>
<tr>
<td>Deursus, Alan</td>
<td>55</td>
</tr>
<tr>
<td>DeSta, Abrahm K</td>
<td>13</td>
</tr>
<tr>
<td>Deve, M. Parmesheva</td>
<td>61</td>
</tr>
<tr>
<td>Devinc, Davangere P</td>
<td>2</td>
</tr>
<tr>
<td>Devlin, Michael J</td>
<td>1</td>
</tr>
<tr>
<td>Devlin, Michael J</td>
<td>59, 97</td>
</tr>
<tr>
<td>Devloche, Emmanuel</td>
<td>24, 87</td>
</tr>
<tr>
<td>Dew, Mary A</td>
<td>94</td>
</tr>
<tr>
<td>Deuwa, Marc J</td>
<td>3, 18, 54, 79</td>
</tr>
<tr>
<td>Dhaliwal, Gagan</td>
<td>47</td>
</tr>
<tr>
<td>Du, José Luis</td>
<td>47</td>
</tr>
<tr>
<td>Draz, Nadia</td>
<td>82</td>
</tr>
<tr>
<td>Dzau-Martin, Angela</td>
<td>59</td>
</tr>
<tr>
<td>Dickson, Daniel</td>
<td>24</td>
</tr>
<tr>
<td>Dickstein, Daniel P</td>
<td>16, 34, 35</td>
</tr>
<tr>
<td>Dickstein, Leah J</td>
<td>21, 27, 35, 43, 73, 83, 88, 91</td>
</tr>
<tr>
<td>Dietrich, Allen J</td>
<td>34</td>
</tr>
<tr>
<td>Dide, JeAnn</td>
<td>19, 34</td>
</tr>
<tr>
<td>Dilan, Neom</td>
<td>22</td>
</tr>
<tr>
<td>DiMartini, Andrea F</td>
<td>40</td>
</tr>
<tr>
<td>Dixon, Lisa B</td>
<td>55, 84, 93</td>
</tr>
<tr>
<td>Docherry, John P</td>
<td>31, 70</td>
</tr>
<tr>
<td>Doebelbang, Caroline C</td>
<td>93</td>
</tr>
<tr>
<td>Doepfer, Marfred</td>
<td>34</td>
</tr>
<tr>
<td>Doghramzi, Karl</td>
<td>9, 26, 73, 89</td>
</tr>
<tr>
<td>Dolan-Sewel, Regina</td>
<td>70</td>
</tr>
<tr>
<td>Donegan, Nelson H</td>
<td>98</td>
</tr>
<tr>
<td>Doren, David J</td>
<td>97</td>
</tr>
<tr>
<td>D'Ono, Barbara</td>
<td>71</td>
</tr>
<tr>
<td>Dosenbach, Martin</td>
<td>89</td>
</tr>
<tr>
<td>Downer, Allison V</td>
<td>42</td>
</tr>
<tr>
<td>Downey, Jennifer I</td>
<td>46</td>
</tr>
<tr>
<td>Doyle, Abys E</td>
<td>57, 80</td>
</tr>
<tr>
<td>Drake, Robert</td>
<td>29, 36</td>
</tr>
<tr>
<td>Drescher, Jack</td>
<td>20, 49, 88</td>
</tr>
<tr>
<td>Dressman, Douglas A</td>
<td>53</td>
</tr>
<tr>
<td>Drury, Laura</td>
<td>51</td>
</tr>
<tr>
<td>Drus, Benjamin G</td>
<td>84, 93</td>
</tr>
<tr>
<td>Dryden-Edwards, Roxanne</td>
<td>18</td>
</tr>
<tr>
<td>Du, Ning</td>
<td>18</td>
</tr>
<tr>
<td>Dube, Sarnai</td>
<td>28, 67</td>
</tr>
<tr>
<td>Duckworth, Kenneth S</td>
<td>45</td>
</tr>
<tr>
<td>Duffy, Patrick F</td>
<td>48</td>
</tr>
<tr>
<td>Dunn, David W</td>
<td>95</td>
</tr>
<tr>
<td>Dunn, Keer E</td>
<td>49</td>
</tr>
<tr>
<td>Dunn, Laura B</td>
<td>44, 59</td>
</tr>
<tr>
<td>Dupper, David L</td>
<td>37</td>
</tr>
<tr>
<td>Dyachulaya, Y</td>
<td>89</td>
</tr>
<tr>
<td>Dyck, Ingrid R</td>
<td>96</td>
</tr>
<tr>
<td>Ebert, Dieter</td>
<td>98</td>
</tr>
<tr>
<td>Ebert, Michael H</td>
<td>49, 74</td>
</tr>
<tr>
<td>Eberth-Priemert, Ulrich W</td>
<td>80</td>
</tr>
<tr>
<td>Eckermann, Gabriel</td>
<td>41</td>
</tr>
<tr>
<td>Edelenar, Judith G</td>
<td>87</td>
</tr>
<tr>
<td>Edelman, Jeanne L</td>
<td>48</td>
</tr>
<tr>
<td>Edin, Kathryn J</td>
<td>43</td>
</tr>
<tr>
<td>Edwards-Loud, Susan M</td>
<td>96</td>
</tr>
<tr>
<td>Egeland, Janice A</td>
<td>70</td>
</tr>
<tr>
<td>Eiger, Helen L</td>
<td>91</td>
</tr>
<tr>
<td>Ehrenreich, Mark J</td>
<td>55</td>
</tr>
<tr>
<td>Edelman, Polina</td>
<td>48, 70</td>
</tr>
<tr>
<td>Ein, Harold I</td>
<td>45</td>
</tr>
<tr>
<td>Eibon, Anders</td>
<td>23</td>
</tr>
<tr>
<td>Eieren, Ovid</td>
<td>58</td>
</tr>
<tr>
<td>Eiberg, Eric B</td>
<td>81, 82</td>
</tr>
<tr>
<td>Elia, Omar</td>
<td>25, 67</td>
</tr>
<tr>
<td>Ellic, Mark B</td>
<td>88</td>
</tr>
<tr>
<td>Ellison, James M</td>
<td>75</td>
</tr>
<tr>
<td>Ent, Selma</td>
<td>54</td>
</tr>
<tr>
<td>Enals, Graham J</td>
<td>42, 66</td>
</tr>
<tr>
<td>Enzler, Jean</td>
<td>90</td>
</tr>
<tr>
<td>Engel, Aram G</td>
<td>71</td>
</tr>
<tr>
<td>Engel, Charles C</td>
<td>34</td>
</tr>
<tr>
<td>England, Mary Jane</td>
<td>43, 83</td>
</tr>
<tr>
<td>English, Joseph T</td>
<td>9</td>
</tr>
<tr>
<td>Epstein, Steven A</td>
<td>22, 46</td>
</tr>
<tr>
<td>Ericksson, Jeffrey L</td>
<td>71</td>
</tr>
<tr>
<td>Ermann, Milton K</td>
<td>19</td>
</tr>
<tr>
<td>Ernst, Carle L</td>
<td>22, 43, 47</td>
</tr>
<tr>
<td>Escobar, Javier L</td>
<td>18, 59, 64</td>
</tr>
<tr>
<td>Eth, Spencer</td>
<td>18, 24, 29</td>
</tr>
<tr>
<td>Evans, Kaleym C</td>
<td>6</td>
</tr>
<tr>
<td>Everett, Anita S</td>
<td>18, 59</td>
</tr>
<tr>
<td>Eynan, Rahul</td>
<td>58</td>
</tr>
<tr>
<td>Eynan, Ariel</td>
<td>72</td>
</tr>
<tr>
<td>Faber, Raymond A</td>
<td>1</td>
</tr>
<tr>
<td>Factor, Robert M</td>
<td>60</td>
</tr>
<tr>
<td>Faggiano, Sheri A</td>
<td>92</td>
</tr>
<tr>
<td>Fagiolito-Petillo, Laura</td>
<td>66</td>
</tr>
<tr>
<td>Fansler, Rodolfo D</td>
<td>71, 92</td>
</tr>
<tr>
<td>Faust, Waranach E</td>
<td>9, 43, 47</td>
</tr>
<tr>
<td>Falco, Mathias</td>
<td>92</td>
</tr>
<tr>
<td>Falso, Bruno</td>
<td>34</td>
</tr>
<tr>
<td>Fallon, Brian A</td>
<td>58</td>
</tr>
<tr>
<td>Fan, Alexander H</td>
<td>25</td>
</tr>
<tr>
<td>Fan, Jan J</td>
<td>33</td>
</tr>
<tr>
<td>Fanelli, Joseph G</td>
<td>89</td>
</tr>
<tr>
<td>Fazzone, Stephen V</td>
<td>12, 57, 62, 82</td>
</tr>
<tr>
<td>Fazzone, Tiffany R</td>
<td>66</td>
</tr>
<tr>
<td>Faux,hone, Tiffany R</td>
<td>66</td>
</tr>
<tr>
<td>Fauxh, Douglass E</td>
<td>25</td>
</tr>
<tr>
<td>Faser, David</td>
<td>66</td>
</tr>
<tr>
<td>Faur, Robert</td>
<td>71</td>
</tr>
<tr>
<td>Fava, Maria</td>
<td>4, 24, 31, 55, 70, 89, 90</td>
</tr>
<tr>
<td>Feibelmann, Nathan D</td>
<td>35</td>
</tr>
<tr>
<td>Feigen, Rudolf A</td>
<td>50</td>
</tr>
<tr>
<td>Feinberg, David T</td>
<td>78</td>
</tr>
<tr>
<td>Feiner, Joel D</td>
<td>72</td>
</tr>
<tr>
<td>Feldman, Marc D</td>
<td>88</td>
</tr>
<tr>
<td>Felhous, Alan R</td>
<td>97</td>
</tr>
<tr>
<td>Fenton, Wayne S</td>
<td>59, 89</td>
</tr>
<tr>
<td>Ferguson, Yvonne B</td>
<td>8</td>
</tr>
<tr>
<td>Fernandes, Francisco</td>
<td>20, 43, 51</td>
</tr>
<tr>
<td>Fernandez, Stephen J</td>
<td>43</td>
</tr>
<tr>
<td>Feltner, Christopher G</td>
<td>18</td>
</tr>
<tr>
<td>Feve, Ronald R</td>
<td>48</td>
</tr>
<tr>
<td>Finch, Manley</td>
<td>70</td>
</tr>
<tr>
<td>Fidling, Robert I</td>
<td>2, 25</td>
</tr>
<tr>
<td>Fire, Carh</td>
<td>19</td>
</tr>
<tr>
<td>Fishberg, Nathani</td>
<td>79</td>
</tr>
<tr>
<td>First, Michael B</td>
<td>14, 26, 29, 95</td>
</tr>
<tr>
<td>Fachbein, Ellen R</td>
<td>19</td>
</tr>
<tr>
<td>Fabian, David A</td>
<td>4</td>
</tr>
<tr>
<td>Fisher, Sebnem F</td>
<td>74</td>
</tr>
<tr>
<td>Flash, James N</td>
<td>19</td>
</tr>
<tr>
<td>Fishery, Joseph A</td>
<td>71</td>
</tr>
<tr>
<td>Fishery, Lois T</td>
<td>20, 85</td>
</tr>
<tr>
<td>Flashman, Laura A</td>
<td>68</td>
</tr>
<tr>
<td>Flory, Jane</td>
<td>7, 33</td>
</tr>
<tr>
<td>Flynn, Heather</td>
<td>19</td>
</tr>
<tr>
<td>Fochtman, Laura J</td>
<td>17</td>
</tr>
<tr>
<td>Fosha, Yahsh</td>
<td>55</td>
</tr>
<tr>
<td>Forangy, Peter</td>
<td>57</td>
</tr>
<tr>
<td>Fong, Timothy W</td>
<td>2, 78</td>
</tr>
<tr>
<td>Ford, Brad</td>
<td>69</td>
</tr>
<tr>
<td>Ford, Willam W</td>
<td>1</td>
</tr>
<tr>
<td>Ford, Daniel F</td>
<td>23</td>
</tr>
<tr>
<td>Forrester, Brent P</td>
<td>75</td>
</tr>
<tr>
<td>Formman, Robert F</td>
<td>60</td>
</tr>
<tr>
<td>Forstein, Marshall</td>
<td>43, 50, 54, 67</td>
</tr>
<tr>
<td>Fot, Mary Ellen</td>
<td>91</td>
</tr>
<tr>
<td>Foulis, Edward F</td>
<td>14, 74</td>
</tr>
<tr>
<td>Frodkin, Howard</td>
<td>64</td>
</tr>
<tr>
<td>French, Paul T</td>
<td>9</td>
</tr>
<tr>
<td>Frank, Ellen</td>
<td>9</td>
</tr>
<tr>
<td>Franzio, Debra L</td>
<td>97</td>
</tr>
<tr>
<td>Frazier-Smith, Nancy</td>
<td>65</td>
</tr>
<tr>
<td>Freeman, Robert</td>
<td>41</td>
</tr>
<tr>
<td>Freeman III, Arthur M</td>
<td>68</td>
</tr>
<tr>
<td>Freno, Rafael C</td>
<td>71</td>
</tr>
<tr>
<td>Fricchio, Gregory L</td>
<td>32</td>
</tr>
<tr>
<td>Friedland, Joseph I</td>
<td>68</td>
</tr>
<tr>
<td>Friedman, Matthew</td>
<td>19, 34, 95</td>
</tr>
<tr>
<td>Fried, Gerhard</td>
<td>6</td>
</tr>
<tr>
<td>Friis, Steven</td>
<td>10</td>
</tr>
<tr>
<td>Fromston, John A</td>
<td>43</td>
</tr>
<tr>
<td>Fuchs, Lara R</td>
<td>66</td>
</tr>
<tr>
<td>Fallislove, Mindy J</td>
<td>26</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabbard, Glen O</td>
<td>24, 27, 65, 79, 97</td>
</tr>
<tr>
<td>Gabrilli, Maria</td>
<td>71</td>
</tr>
<tr>
<td>Gaeta, Raymond R</td>
<td>9</td>
</tr>
<tr>
<td>Gagea, Jane P</td>
<td>81</td>
</tr>
<tr>
<td>Gajic-Veljanoski, Olga</td>
<td>33</td>
</tr>
<tr>
<td>Galanter, Marc</td>
<td>31</td>
</tr>
<tr>
<td>Gale, Tim M</td>
<td>79</td>
</tr>
<tr>
<td>Gales, Sandro</td>
<td>19, 58</td>
</tr>
<tr>
<td>Gallikin, Leo L</td>
<td>23, 87</td>
</tr>
<tr>
<td>Name</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------</td>
</tr>
<tr>
<td>Hochman, Karen M</td>
<td>30</td>
</tr>
<tr>
<td>Ho, Caroline</td>
<td>78</td>
</tr>
<tr>
<td>Holland, Erci</td>
<td>51</td>
</tr>
<tr>
<td>Holmen, William</td>
<td>64</td>
</tr>
<tr>
<td>Hooper, Lisa M</td>
<td>22</td>
</tr>
<tr>
<td>Hope, Thomas D</td>
<td>71</td>
</tr>
<tr>
<td>Horton, Leslie A</td>
<td>24</td>
</tr>
<tr>
<td>Horton, Richard</td>
<td>64</td>
</tr>
<tr>
<td>Horstem, Abram M</td>
<td>29</td>
</tr>
<tr>
<td>Hoaghton, Rory P</td>
<td>25</td>
</tr>
<tr>
<td>Howe, Edmund G</td>
<td>35, 51</td>
</tr>
<tr>
<td>Hoang, Robert C</td>
<td>40, 63</td>
</tr>
<tr>
<td>Hsia, Rona</td>
<td>11</td>
</tr>
<tr>
<td>Huang, Frederick Y</td>
<td>24</td>
</tr>
<tr>
<td>Huang, Frank</td>
<td>65</td>
</tr>
<tr>
<td>Hudson, James I</td>
<td>5</td>
</tr>
<tr>
<td>Hughes, Katherine</td>
<td>89</td>
</tr>
<tr>
<td>Hughes, Michael C</td>
<td>73</td>
</tr>
<tr>
<td>Huravmova, Darrin</td>
<td>68, 74</td>
</tr>
<tr>
<td>Harford, Matthew O</td>
<td>49</td>
</tr>
<tr>
<td>Harwig, Thomas D</td>
<td>40</td>
</tr>
<tr>
<td>Hassan, Mohammad Z</td>
<td>89</td>
</tr>
<tr>
<td>Hasiuri-Neema</td>
<td>89</td>
</tr>
<tr>
<td>Hutchison, Janice G</td>
<td>56</td>
</tr>
<tr>
<td>Hutto, Mark</td>
<td>71</td>
</tr>
<tr>
<td>Hung, Cindy H</td>
<td>23</td>
</tr>
<tr>
<td>Hyler, Steven E</td>
<td>14, 40</td>
</tr>
<tr>
<td>I</td>
<td></td>
</tr>
<tr>
<td>Igbal, Muhammad M</td>
<td>81</td>
</tr>
<tr>
<td>Inderherz, Lawrence B.</td>
<td>56</td>
</tr>
<tr>
<td>Insel, Thomas R</td>
<td>45</td>
</tr>
<tr>
<td>Intriand, Alex</td>
<td>59</td>
</tr>
<tr>
<td>Ionisescu, Dan V</td>
<td>48</td>
</tr>
<tr>
<td>Ironson, Gail</td>
<td>53</td>
</tr>
<tr>
<td>Irvin, Tracey L</td>
<td>41</td>
</tr>
<tr>
<td>Issenst, Jeanne</td>
<td>73</td>
</tr>
<tr>
<td>Istaak, Waguhi W</td>
<td>69, 73, 75</td>
</tr>
<tr>
<td>Ismail, Saeem</td>
<td>77</td>
</tr>
<tr>
<td>Isobam, Matti K</td>
<td>23, 46, 89</td>
</tr>
<tr>
<td>Israel, Joshua A</td>
<td>4</td>
</tr>
<tr>
<td>J</td>
<td></td>
</tr>
<tr>
<td>Jabbarpour, Yad</td>
<td>72</td>
</tr>
<tr>
<td>Jackson, Sadi C</td>
<td>97</td>
</tr>
<tr>
<td>Jackson-Siegel, Jeanne</td>
<td>13, 39</td>
</tr>
<tr>
<td>Jacobs, Douglas G</td>
<td>90</td>
</tr>
<tr>
<td>Jacobs, Seby C</td>
<td>18</td>
</tr>
<tr>
<td>Jacobson, Wendy</td>
<td>64, 85</td>
</tr>
<tr>
<td>Jaffe, Richard I</td>
<td>26</td>
</tr>
<tr>
<td>Jain, Vivek</td>
<td>74</td>
</tr>
<tr>
<td>James, Keith</td>
<td>90</td>
</tr>
<tr>
<td>Jamison, Kay Redfield</td>
<td>39</td>
</tr>
<tr>
<td>Janicak, Philip G</td>
<td>27</td>
</tr>
<tr>
<td>Janapaguri, Vani</td>
<td>54</td>
</tr>
<tr>
<td>Jaros, Bonita</td>
<td>91</td>
</tr>
<tr>
<td>Jarv, Gilbert</td>
<td>50</td>
</tr>
<tr>
<td>Javed, Arafal</td>
<td>58</td>
</tr>
<tr>
<td>Jayram, Geetha</td>
<td>23, 43, 52, 75</td>
</tr>
<tr>
<td>Jayasinghe, Nirali</td>
<td>34</td>
</tr>
<tr>
<td>Javcek, Michael M</td>
<td>78</td>
</tr>
<tr>
<td>Jeste, Dileep V</td>
<td>30, 59, 77</td>
</tr>
<tr>
<td>Jiang, Wei</td>
<td>81</td>
</tr>
<tr>
<td>Jibson, Michael D</td>
<td>25</td>
</tr>
<tr>
<td>Jimerson, David C</td>
<td>1</td>
</tr>
<tr>
<td>Jolke, Thomas H</td>
<td>71</td>
</tr>
<tr>
<td>Joffe, Haldine</td>
<td>3, 9</td>
</tr>
<tr>
<td>Johannessen, Jan O</td>
<td>32</td>
</tr>
<tr>
<td>Johnson, Bankole A</td>
<td>56</td>
</tr>
<tr>
<td>Johnson, Bradley R</td>
<td>8</td>
</tr>
<tr>
<td>Johnson, Hillary</td>
<td>87</td>
</tr>
<tr>
<td>Johnson, Jeffrey</td>
<td>95</td>
</tr>
<tr>
<td>Johnson, Leigh G</td>
<td>4</td>
</tr>
<tr>
<td>Jones, Ian R</td>
<td>99</td>
</tr>
<tr>
<td>Jones, Peter S</td>
<td>84</td>
</tr>
<tr>
<td>Jonson, Lindsay</td>
<td>53</td>
</tr>
<tr>
<td>Jorge, Ricardo</td>
<td>32</td>
</tr>
<tr>
<td>Jorgepol, Linda M</td>
<td>5, 43, 50</td>
</tr>
<tr>
<td>Joseph, Llewelyn W</td>
<td>23</td>
</tr>
<tr>
<td>Joseph, Magor F</td>
<td>23, 90</td>
</tr>
<tr>
<td>Joseph, Robert C</td>
<td>15, 54, 87</td>
</tr>
<tr>
<td>Josephson, Allan M</td>
<td>22, 86, 91</td>
</tr>
<tr>
<td>Jouraba, Matti</td>
<td>46</td>
</tr>
<tr>
<td>Joy, Charles R</td>
<td>54</td>
</tr>
<tr>
<td>Junita, Tony</td>
<td>63</td>
</tr>
<tr>
<td>Jutulis, Naim</td>
<td>18, 67</td>
</tr>
<tr>
<td>K</td>
<td></td>
</tr>
<tr>
<td>Kaara, Sylvia</td>
<td>53</td>
</tr>
<tr>
<td>Kahn, Henry S</td>
<td>30</td>
</tr>
<tr>
<td>Kahn, Jeffrey C</td>
<td>72</td>
</tr>
<tr>
<td>Kalak, Amir H</td>
<td>56</td>
</tr>
<tr>
<td>Kalso, Mustafa</td>
<td>95</td>
</tr>
<tr>
<td>Kalim, Mustafa</td>
<td>96</td>
</tr>
<tr>
<td>Kalin, Nell H</td>
<td>9</td>
</tr>
<tr>
<td>Kaim, Michael A</td>
<td>73</td>
</tr>
<tr>
<td>Kam, Raymon D</td>
<td>24</td>
</tr>
<tr>
<td>Karns, Daniel</td>
<td>59</td>
</tr>
<tr>
<td>Kandel, Eric R</td>
<td>16</td>
</tr>
<tr>
<td>Kane, John M</td>
<td>10, 82</td>
</tr>
<tr>
<td>Kang, Shimi</td>
<td>63</td>
</tr>
<tr>
<td>Kaplan, Alex J</td>
<td>79</td>
</tr>
<tr>
<td>Kaplan, Allan S</td>
<td>59</td>
</tr>
<tr>
<td>Kaplan, Gabriel</td>
<td>64</td>
</tr>
<tr>
<td>Kaplan, Sandra J</td>
<td>18</td>
</tr>
<tr>
<td>Kapur, Shiqi</td>
<td>12, 80</td>
</tr>
<tr>
<td>Karase, Dan H</td>
<td>67</td>
</tr>
<tr>
<td>Karasu, T, Byram</td>
<td>23, 26</td>
</tr>
<tr>
<td>Kardon, Marianne</td>
<td>54</td>
</tr>
<tr>
<td>Karr, Nanjan S</td>
<td>18</td>
</tr>
<tr>
<td>Karp, Jordan F</td>
<td>94</td>
</tr>
<tr>
<td>Kasapovic, Sanja</td>
<td>48</td>
</tr>
<tr>
<td>Kasar, Connie</td>
<td>87</td>
</tr>
<tr>
<td>Kashiram, Minakuro</td>
<td>67</td>
</tr>
<tr>
<td>Kastri, Marianne C</td>
<td>33, 34, 93</td>
</tr>
<tr>
<td>Katon, Wayne J</td>
<td>4, 25, 47, 53, 65, 84, 98</td>
</tr>
<tr>
<td>Katsavaki, Koskas</td>
<td>95</td>
</tr>
<tr>
<td>Katz, Ira R</td>
<td>23, 30</td>
</tr>
<tr>
<td>Katz, Nathaniel P</td>
<td>60</td>
</tr>
<tr>
<td>Katzenich, David J</td>
<td>84</td>
</tr>
<tr>
<td>Kay, Yerald</td>
<td>68, 79</td>
</tr>
<tr>
<td>Kaye, David L</td>
<td>27, 68</td>
</tr>
<tr>
<td>Kaye, Walter H</td>
<td>12, 97</td>
</tr>
<tr>
<td>Keck, Jr., Paul E</td>
<td>3, 4, 39</td>
</tr>
<tr>
<td>Keef, Richard S.E</td>
<td>4</td>
</tr>
<tr>
<td>Keel, Pamela K</td>
<td>70</td>
</tr>
<tr>
<td>Kehayyan, V, Alex</td>
<td>14</td>
</tr>
<tr>
<td>Kedikizoo, Zuhab</td>
<td>76</td>
</tr>
<tr>
<td>Keller, Martin B</td>
<td>2, 11</td>
</tr>
<tr>
<td>Keller, Charles H</td>
<td>76</td>
</tr>
<tr>
<td>Kelly, Robert</td>
<td>24</td>
</tr>
<tr>
<td>Kelley, Douglas K</td>
<td>34</td>
</tr>
<tr>
<td>Kennedy, Robert S</td>
<td>26</td>
</tr>
<tr>
<td>Kennedy, Sidney H</td>
<td>32</td>
</tr>
<tr>
<td>Kert, Juuise M</td>
<td>6</td>
</tr>
<tr>
<td>Kernberg, Otto F</td>
<td>7, 65, 64, 85</td>
</tr>
<tr>
<td>Kestenbaum, Clarice J</td>
<td>92</td>
</tr>
<tr>
<td>Ketzer, Terence A</td>
<td>13, 36, 76</td>
</tr>
<tr>
<td>Khalil, Afaf Hamed</td>
<td>95</td>
</tr>
<tr>
<td>Kan, GY</td>
<td>89</td>
</tr>
<tr>
<td>Ken, Scott Y</td>
<td>18, 44, 59</td>
</tr>
<tr>
<td>Kesi, Sun</td>
<td>79</td>
</tr>
<tr>
<td>Kim, Thomas M</td>
<td>64</td>
</tr>
<tr>
<td>King, Bryan H</td>
<td>66</td>
</tr>
<tr>
<td>Kingdon, David G</td>
<td>8, 92</td>
</tr>
<tr>
<td>Kish, Gilin</td>
<td>74</td>
</tr>
<tr>
<td>Kisson, Joel</td>
<td>23, 71</td>
</tr>
<tr>
<td>Klein, William R</td>
<td>81</td>
</tr>
<tr>
<td>Kluber, Herbert D</td>
<td>15, 62, 80</td>
</tr>
<tr>
<td>Kleinman, Andrew M</td>
<td>91</td>
</tr>
<tr>
<td>Klein, Erd H</td>
<td>51</td>
</tr>
<tr>
<td>Kluban, Anne</td>
<td>97</td>
</tr>
<tr>
<td>Kline, Linda</td>
<td>71</td>
</tr>
<tr>
<td>Koos, Thomas W.M.</td>
<td>29</td>
</tr>
<tr>
<td>Koengsberg, Harold W.</td>
<td>7, 24, 33</td>
</tr>
<tr>
<td>Kollins, Scott</td>
<td>31</td>
</tr>
<tr>
<td>Kolodner, George F</td>
<td>73</td>
</tr>
<tr>
<td>Komorowicz, Janes</td>
<td>70</td>
</tr>
<tr>
<td>Kong, B. Waine</td>
<td>76</td>
</tr>
<tr>
<td>Koob, George F</td>
<td>56, 62, 86</td>
</tr>
<tr>
<td>Kool, Simone</td>
<td>5, 83</td>
</tr>
<tr>
<td>Kopelivation, Alex J</td>
<td>87</td>
</tr>
<tr>
<td>Koplin, Brett A</td>
<td>14</td>
</tr>
<tr>
<td>Koponen, Hamu J</td>
<td>23</td>
</tr>
<tr>
<td>Korm, John M</td>
<td>79</td>
</tr>
<tr>
<td>Kores, Robert</td>
<td>68</td>
</tr>
<tr>
<td>Kornstein, Susan G</td>
<td>13, 39, 66</td>
</tr>
<tr>
<td>Kosik, Johanna</td>
<td>89</td>
</tr>
<tr>
<td>Koseick, Harnett</td>
<td>45</td>
</tr>
<tr>
<td>Kosza, Ida</td>
<td>48</td>
</tr>
<tr>
<td>Kowic, Raymond J</td>
<td>13</td>
</tr>
<tr>
<td>Kostan, Igor</td>
<td>72</td>
</tr>
<tr>
<td>Kowacyn, Beatrice</td>
<td>72</td>
</tr>
<tr>
<td>Kox, Gabriel</td>
<td>17</td>
</tr>
<tr>
<td>Kozupa, Diana M</td>
<td>66</td>
</tr>
<tr>
<td>Kuhn, Lois</td>
<td>40, 62</td>
</tr>
<tr>
<td>Krakowicz, Menthen I</td>
<td>71</td>
</tr>
<tr>
<td>Kramer, Milton</td>
<td>8, 23</td>
</tr>
<tr>
<td>Kramer, Thomas A.M.</td>
<td>26</td>
</tr>
<tr>
<td>Kranzler, Henry R</td>
<td>31</td>
</tr>
<tr>
<td>Krlcst, Valery N</td>
<td>76</td>
</tr>
<tr>
<td>Kratochv, Christopher J</td>
<td>23, 34, 62</td>
</tr>
<tr>
<td>Krass, Jr., John E</td>
<td>4</td>
</tr>
<tr>
<td>Krishan, K Ranga R</td>
<td>2, 41, 62, 81</td>
</tr>
<tr>
<td>Kroenke, Kurt</td>
<td>25</td>
</tr>
<tr>
<td>Kronau, Larry A</td>
<td>90</td>
</tr>
<tr>
<td>Kruze, John S</td>
<td>87</td>
</tr>
<tr>
<td>Kuehle, John H</td>
<td>29</td>
</tr>
<tr>
<td>Kusler, Harold</td>
<td>62, 94</td>
</tr>
<tr>
<td>Kurnaz, Anil</td>
<td>23</td>
</tr>
<tr>
<td>Kurnaz, Manoj</td>
<td>88</td>
</tr>
<tr>
<td>Karni, Veen</td>
<td>23, 89</td>
</tr>
<tr>
<td>Karak, Lawrence</td>
<td>95, 96</td>
</tr>
</tbody>
</table>
### PARTICIPANT INDEX

<table>
<thead>
<tr>
<th>Participator Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>McLaren, Tom</td>
<td>44</td>
</tr>
<tr>
<td>McKay, Judy S</td>
<td>24</td>
</tr>
<tr>
<td>McHugo, Greg</td>
<td>23</td>
</tr>
<tr>
<td>McInroy, Jack S</td>
<td>17, 25, 51, 67</td>
</tr>
<tr>
<td>McKay, Judy S</td>
<td>24</td>
</tr>
<tr>
<td>McLean, Jennifer L</td>
<td>25, 73</td>
</tr>
<tr>
<td>McLane, Tom</td>
<td>44</td>
</tr>
<tr>
<td>McLean, Alexandra</td>
<td>35</td>
</tr>
<tr>
<td>McLean, Diane E</td>
<td>43</td>
</tr>
<tr>
<td>McLean, Sarah</td>
<td>78</td>
</tr>
<tr>
<td>McClear, A. Thomas</td>
<td>92</td>
</tr>
<tr>
<td>McLeod-Bryant, Stephen</td>
<td>92</td>
</tr>
<tr>
<td>McNicholas, Laura F.</td>
<td>14</td>
</tr>
<tr>
<td>McQuary, Joy D.</td>
<td>49</td>
</tr>
<tr>
<td>Menley, Michael</td>
<td>27, 81</td>
</tr>
<tr>
<td>Medina, Roland A.</td>
<td>55</td>
</tr>
<tr>
<td>Medina-Mora, Maria E</td>
<td>81</td>
</tr>
<tr>
<td>Meis-Lee, David</td>
<td>34</td>
</tr>
<tr>
<td>Mehrnaz, Ravi</td>
<td>23</td>
</tr>
<tr>
<td>Meil, Trisha</td>
<td>36</td>
</tr>
<tr>
<td>Meille, Edgardo J.</td>
<td>29</td>
</tr>
<tr>
<td>Meldrin, Philip T.</td>
<td>18, 24</td>
</tr>
<tr>
<td>Meister, Stephen C</td>
<td>34</td>
</tr>
<tr>
<td>Metzner, Jeffrey L</td>
<td>67, 72</td>
</tr>
<tr>
<td>Metzner, Richard J</td>
<td>70</td>
</tr>
<tr>
<td>Meyer, Donald Jay</td>
<td>19</td>
</tr>
<tr>
<td>Meyer-Ludenberg, Andreas</td>
<td>53</td>
</tr>
<tr>
<td>Mezzasalma, Marco A</td>
<td>71</td>
</tr>
<tr>
<td>Michal, Danny</td>
<td>69</td>
</tr>
<tr>
<td>Michel, Robert</td>
<td>94</td>
</tr>
<tr>
<td>Mk, Eric</td>
<td>57, 80, 92</td>
</tr>
<tr>
<td>Mertenszteyn, Yoako</td>
<td>89</td>
</tr>
<tr>
<td>Mikulasie, Cecilia M</td>
<td>15, 41</td>
</tr>
<tr>
<td>Michael, Albert A</td>
<td>75</td>
</tr>
<tr>
<td>Mialewitz, David J</td>
<td>5</td>
</tr>
<tr>
<td>Milham, Michael</td>
<td>35</td>
</tr>
<tr>
<td>Milt, Eric</td>
<td>35</td>
</tr>
<tr>
<td>Miller, Dennis J.</td>
<td>72</td>
</tr>
<tr>
<td>Miller, Alexander L</td>
<td>33, 51</td>
</tr>
<tr>
<td>Miller, Andrew H.</td>
<td>20</td>
</tr>
<tr>
<td>Miller, Claudia</td>
<td>59</td>
</tr>
<tr>
<td>Miller, Del D.</td>
<td>33</td>
</tr>
<tr>
<td>Miller, Karen H.</td>
<td>97</td>
</tr>
<tr>
<td>Miller, Paul R.</td>
<td>51, 63, 89</td>
</tr>
<tr>
<td>Miller, Sheldon I.</td>
<td>66</td>
</tr>
<tr>
<td>Millman, Robert</td>
<td>92</td>
</tr>
<tr>
<td>Milone, Richard D.</td>
<td>18</td>
</tr>
<tr>
<td>Milot, Barbara L.</td>
<td>79</td>
</tr>
<tr>
<td>Minchew, Nancy</td>
<td>87</td>
</tr>
<tr>
<td>Mintun, Mark A</td>
<td>9</td>
</tr>
<tr>
<td>Mintz, David L.</td>
<td>15</td>
</tr>
<tr>
<td>Minter, Jacob E.</td>
<td>55, 54</td>
</tr>
<tr>
<td>Minzenberg, Michael J</td>
<td>33</td>
</tr>
<tr>
<td>Moro, Karen A.</td>
<td>2</td>
</tr>
<tr>
<td>Muravchik, Karoly</td>
<td>79</td>
</tr>
<tr>
<td>Macbrun, David</td>
<td>32</td>
</tr>
<tr>
<td>Mara, Sahana</td>
<td>35</td>
</tr>
<tr>
<td>Man, Shula</td>
<td>63</td>
</tr>
<tr>
<td>Mandler, Lisa A.</td>
<td>29</td>
</tr>
<tr>
<td>Mitchell, Alex J.</td>
<td>47, 88</td>
</tr>
<tr>
<td>Mitchell, James E.</td>
<td>1, 97</td>
</tr>
<tr>
<td>Minahan, Scholar</td>
<td>98</td>
</tr>
<tr>
<td>Moeller, Frederick G.</td>
<td>97</td>
</tr>
<tr>
<td>Mole, Marshall</td>
<td>91</td>
</tr>
<tr>
<td>Mole, Paul C.</td>
<td>49, 82</td>
</tr>
<tr>
<td>Menahan, Patrick</td>
<td>48</td>
</tr>
<tr>
<td>Montahat, Jose-Angel</td>
<td>47</td>
</tr>
<tr>
<td>Montgomery, Richard</td>
<td>46, 51</td>
</tr>
<tr>
<td>Moore, Helit</td>
<td>90</td>
</tr>
<tr>
<td>Morey, Leslie C.</td>
<td>77</td>
</tr>
<tr>
<td>Moster, David J.</td>
<td>59</td>
</tr>
<tr>
<td>Mothersell, Jeffrey</td>
<td>25</td>
</tr>
<tr>
<td>Moul, Douglas E.</td>
<td>53</td>
</tr>
<tr>
<td>Moussau, Dres</td>
<td>24</td>
</tr>
<tr>
<td>Mueck, David A.</td>
<td>14, 74</td>
</tr>
<tr>
<td>Mudajan, Sander</td>
<td>59</td>
</tr>
<tr>
<td>Muenster, Krista H.</td>
<td>18</td>
</tr>
<tr>
<td>Mueser, Kim T.</td>
<td>36</td>
</tr>
<tr>
<td>Mufi, Khalid A.</td>
<td>81</td>
</tr>
<tr>
<td>Munday, Cheryl</td>
<td>73</td>
</tr>
<tr>
<td>Mundy, James C.</td>
<td>90</td>
</tr>
<tr>
<td>Muran, Rodrigo A.</td>
<td>18, 31, 61, 67, 82, 87, 93</td>
</tr>
<tr>
<td>Murray, Heather</td>
<td>70</td>
</tr>
<tr>
<td>Murray, Cyndi R.</td>
<td>88</td>
</tr>
<tr>
<td>Murthy, Srinivas</td>
<td>61</td>
</tr>
<tr>
<td>Munk, Philip R.</td>
<td>22, 28, 51, 67</td>
</tr>
<tr>
<td>Myers, Michael F.</td>
<td>19, 27, 43, 88, 91</td>
</tr>
<tr>
<td>Myers, Tricia</td>
<td>97</td>
</tr>
<tr>
<td>Myers, Wade C.</td>
<td>18, 24</td>
</tr>
<tr>
<td>Myrick-Hugh</td>
<td>62</td>
</tr>
<tr>
<td>Mace, David</td>
<td>17</td>
</tr>
<tr>
<td>Nadelson, Carol C.</td>
<td>16, 57, 68, 83, 93</td>
</tr>
<tr>
<td>Nagel, DeAnna Merz</td>
<td>63</td>
</tr>
<tr>
<td>Nahas, Ziad H</td>
<td>51</td>
</tr>
<tr>
<td>Nakajima, Gene A</td>
<td>67</td>
</tr>
<tr>
<td>Nakaya, Vivekie</td>
<td>30</td>
</tr>
<tr>
<td>Nad, Surinder S</td>
<td>18, 33</td>
</tr>
<tr>
<td>Nalopp, Joseph C.</td>
<td>14</td>
</tr>
<tr>
<td>Naqui, Syed S. A.</td>
<td>25, 91</td>
</tr>
<tr>
<td>Ward, Antonio E.</td>
<td>71</td>
</tr>
<tr>
<td>Narrow, William E.</td>
<td>19, 26, 30, 48, 83, 96</td>
</tr>
<tr>
<td>Nasovinolo, Isabella</td>
<td>71</td>
</tr>
<tr>
<td>Naser, Jeffrey A.</td>
<td>94</td>
</tr>
<tr>
<td>Nazi, George S.</td>
<td>92</td>
</tr>
<tr>
<td>Nasrallah, Henry A.</td>
<td>71</td>
</tr>
<tr>
<td>Nave, J. Richard</td>
<td>70</td>
</tr>
<tr>
<td>Nazzaro, Maier</td>
<td>63</td>
</tr>
<tr>
<td>Nieda, J. Charles</td>
<td>21</td>
</tr>
<tr>
<td>Neilson, Christian</td>
<td>89</td>
</tr>
<tr>
<td>Neilson, J. Craig</td>
<td>55</td>
</tr>
<tr>
<td>Nemero, Charles B.</td>
<td>42</td>
</tr>
<tr>
<td>Nerda, Yuval Y.</td>
<td>58</td>
</tr>
<tr>
<td>Nesse, Randolph M.</td>
<td>83</td>
</tr>
<tr>
<td>Netter, Eric J.</td>
<td>81</td>
</tr>
<tr>
<td>Neuhauser, David N.</td>
<td>62</td>
</tr>
<tr>
<td>Neumeister, Alexander</td>
<td>11</td>
</tr>
<tr>
<td>New, Antonia S.</td>
<td>7, 24, 33, 98</td>
</tr>
<tr>
<td>Newcomer, John W.</td>
<td>37</td>
</tr>
<tr>
<td>Newkirk, Cassandra D.</td>
<td>43, 49, 56</td>
</tr>
<tr>
<td>Newmark, Randall</td>
<td>98</td>
</tr>
<tr>
<td>Newport, Donald J.</td>
<td>99</td>
</tr>
<tr>
<td>Newschaffer, Craig</td>
<td>98</td>
</tr>
<tr>
<td>Ng, Anthony T.</td>
<td>2, 19, 43, 61</td>
</tr>
<tr>
<td>Ng, David</td>
<td>23</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nguyen, Long H.</td>
<td>90</td>
</tr>
<tr>
<td>Nicholl, Jr, Armand M.</td>
<td>65, 72</td>
</tr>
<tr>
<td>Nierenberg, Andrew A.</td>
<td>23, 48, 70, 84, 90</td>
</tr>
<tr>
<td>Niran, Philip T.</td>
<td>3, 11</td>
</tr>
<tr>
<td>Ning, Auranze</td>
<td>26, 44</td>
</tr>
<tr>
<td>Niranger, James E.</td>
<td>8</td>
</tr>
<tr>
<td>Nyenga, Frank G.</td>
<td>33, 53, 61, 81</td>
</tr>
<tr>
<td>Noble, Florence</td>
<td>32</td>
</tr>
<tr>
<td>Noma, Ruta M.</td>
<td>2, 56</td>
</tr>
<tr>
<td>Norko, Michael A.</td>
<td>10</td>
</tr>
<tr>
<td>Norman, Matthew W.</td>
<td>18</td>
</tr>
<tr>
<td>Norquist, Grosen S.</td>
<td>31</td>
</tr>
<tr>
<td>Noris, Donna M.</td>
<td>94</td>
</tr>
<tr>
<td>Norvik, Torun S.</td>
<td>34</td>
</tr>
<tr>
<td>Novin, Douglas K.</td>
<td>90</td>
</tr>
<tr>
<td>Novossny, Shari L.</td>
<td>61</td>
</tr>
<tr>
<td>Nucci, Edward V.</td>
<td>81</td>
</tr>
<tr>
<td>Nurnberg, H. George</td>
<td>70</td>
</tr>
<tr>
<td>Nyike, Sherry A.</td>
<td>88</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBannon, R. Michael</td>
<td>63, 74</td>
</tr>
<tr>
<td>Ochenberg, Robert</td>
<td>89</td>
</tr>
<tr>
<td>O'Brien, Charles P.</td>
<td>62</td>
</tr>
<tr>
<td>O'Connell, Anne</td>
<td>82</td>
</tr>
<tr>
<td>O'Connell, Margaret</td>
<td>72</td>
</tr>
<tr>
<td>Oddone, Eugene</td>
<td>82</td>
</tr>
<tr>
<td>Ode, Bernard L.</td>
<td>90</td>
</tr>
<tr>
<td>Oesterheld, Jessica R.</td>
<td>41</td>
</tr>
<tr>
<td>Offray, Julian</td>
<td>49</td>
</tr>
<tr>
<td>O'Flaherty, Elizabeth</td>
<td>42</td>
</tr>
<tr>
<td>Olasuru, Haruka</td>
<td>71</td>
</tr>
<tr>
<td>Oluaga, Ahmed M.F.</td>
<td>24, 53, 83, 95</td>
</tr>
<tr>
<td>Olivas, Jacqueline</td>
<td>67</td>
</tr>
<tr>
<td>Olle, Tuncer</td>
<td>22</td>
</tr>
<tr>
<td>Olarea, Kalsya</td>
<td>66</td>
</tr>
<tr>
<td>Oluara (Posthumously), R. Patrick</td>
<td>42</td>
</tr>
<tr>
<td>Oliver, Silvia W.</td>
<td>25, 46, 83</td>
</tr>
<tr>
<td>Oldham, John M.</td>
<td>24, 64, 85, 97</td>
</tr>
<tr>
<td>Olga, Jacqueline</td>
<td>67</td>
</tr>
<tr>
<td>Olsson, Mark</td>
<td>51</td>
</tr>
<tr>
<td>Olmer, Ahkwam</td>
<td>22</td>
</tr>
<tr>
<td>Olsen, Ruth</td>
<td>30</td>
</tr>
<tr>
<td>O'Malley, Mary B.</td>
<td>73</td>
</tr>
<tr>
<td>Opl, Lewis A.</td>
<td>8, 19, 92</td>
</tr>
<tr>
<td>Osseo, Maria A.</td>
<td>15, 82</td>
</tr>
<tr>
<td>Orav, E. John</td>
<td>47</td>
</tr>
<tr>
<td>Orfonde, Patricia I.</td>
<td>32</td>
</tr>
<tr>
<td>Ortiz-Fragola, Alfredo</td>
<td>71</td>
</tr>
<tr>
<td>Ostry, Urban P.</td>
<td>23</td>
</tr>
<tr>
<td>O'Sullivan, Noelie</td>
<td>89</td>
</tr>
<tr>
<td>O'Neal, David</td>
<td>84</td>
</tr>
<tr>
<td>Osem, Osmas T.</td>
<td>24, 72, 95</td>
</tr>
<tr>
<td>Oser, David N.</td>
<td>56</td>
</tr>
<tr>
<td>Otter, Michael J.</td>
<td>5, 48</td>
</tr>
<tr>
<td>Oito, Michael W.</td>
<td>74</td>
</tr>
<tr>
<td>Ouelvey, Eugene A.</td>
<td>74</td>
</tr>
<tr>
<td>Pardo, Tamara B</td>
<td>54</td>
</tr>
<tr>
<td>-----------------</td>
<td>----</td>
</tr>
<tr>
<td>Pardojose</td>
<td>80</td>
</tr>
<tr>
<td>Pardes, Herbert</td>
<td>20</td>
</tr>
<tr>
<td>Pandya, Anand</td>
<td>92</td>
</tr>
<tr>
<td>Pally, Regina</td>
<td>27,78</td>
</tr>
<tr>
<td>Pallanti, Stefano</td>
<td>79</td>
</tr>
<tr>
<td>Pagano, Maria E</td>
<td>73</td>
</tr>
<tr>
<td>Paczkowski, M</td>
<td>34</td>
</tr>
<tr>
<td>Pennell, Jennifer K</td>
<td>61</td>
</tr>
<tr>
<td>Pelton, Gregory H</td>
<td>2</td>
</tr>
<tr>
<td>Peele, Roger</td>
<td>84</td>
</tr>
<tr>
<td>Pappadopulos, Elizabeth</td>
<td>2</td>
</tr>
<tr>
<td>Paul, Robindra K</td>
<td>20</td>
</tr>
<tr>
<td>Patten, Scott B</td>
<td>71</td>
</tr>
<tr>
<td>Pato, Michele T</td>
<td>3,27,49,65</td>
</tr>
<tr>
<td>Pato, Carlos N</td>
<td>65</td>
</tr>
<tr>
<td>Pato, Michel</td>
<td>43</td>
</tr>
<tr>
<td>Patkar, Ashwin A</td>
<td>70</td>
</tr>
<tr>
<td>Pauer, Roger</td>
<td>79</td>
</tr>
<tr>
<td>Pavan, Shant K</td>
<td>46</td>
</tr>
<tr>
<td>Pave, Anand</td>
<td>92</td>
</tr>
<tr>
<td>Paw, Maryland</td>
<td>73</td>
</tr>
<tr>
<td>Pemberton, Michael</td>
<td>90</td>
</tr>
<tr>
<td>Penn, Pauline</td>
<td>97</td>
</tr>
<tr>
<td>Pericak-Vance, Margaret</td>
<td>86</td>
</tr>
<tr>
<td>Perlis, Roy</td>
<td>4,47</td>
</tr>
<tr>
<td>Pemberton, Ronald C</td>
<td>62</td>
</tr>
<tr>
<td>Perkins, Jennifer K</td>
<td>61</td>
</tr>
<tr>
<td>Perez, Carlos J</td>
<td>72</td>
</tr>
<tr>
<td>Perez, Oscar E</td>
<td>67</td>
</tr>
<tr>
<td>Perez, Paul</td>
<td>71</td>
</tr>
<tr>
<td>Perez, Roger</td>
<td>78</td>
</tr>
<tr>
<td>Pesce, Renato</td>
<td>87</td>
</tr>
<tr>
<td>Pezner, Rob B</td>
<td>54</td>
</tr>
<tr>
<td>Pezzola, Eric D H</td>
<td>70</td>
</tr>
<tr>
<td>Pezet, Jerrold M</td>
<td>93</td>
</tr>
<tr>
<td>Pfeffer, Stu</td>
<td>43</td>
</tr>
<tr>
<td>Pfeifer, John</td>
<td>72</td>
</tr>
<tr>
<td>Pfeifer, Roy</td>
<td>49</td>
</tr>
<tr>
<td>Phelan, Joan C</td>
<td>68</td>
</tr>
<tr>
<td>Petros, Christos</td>
<td>50</td>
</tr>
<tr>
<td>Petterson, Ronald C</td>
<td>62</td>
</tr>
<tr>
<td>Peterson, Jonathan</td>
<td>82</td>
</tr>
<tr>
<td>Peterson, Michael</td>
<td>49</td>
</tr>
<tr>
<td>Peterson, Christopher B</td>
<td>17</td>
</tr>
<tr>
<td>Peterson, Christopher A</td>
<td>55</td>
</tr>
<tr>
<td>Petruzielo, Ramiel</td>
<td>18</td>
</tr>
<tr>
<td>Photo, Charles A</td>
<td>44</td>
</tr>
<tr>
<td>Phelan, Ronald W</td>
<td>41,63</td>
</tr>
<tr>
<td>Phillips, Anni</td>
<td>61</td>
</tr>
<tr>
<td>Phillips, Karathine A</td>
<td>24,30</td>
</tr>
<tr>
<td>Phillips, Lawrence S</td>
<td>42</td>
</tr>
<tr>
<td>Pi, Edmond H T</td>
<td>25</td>
</tr>
<tr>
<td>Pigna, Pier P</td>
<td>96</td>
</tr>
<tr>
<td>Pineda, Ronald W</td>
<td>49</td>
</tr>
<tr>
<td>Pikett, Teresa A</td>
<td>13</td>
</tr>
<tr>
<td>Pincus, Harold A</td>
<td>52</td>
</tr>
<tr>
<td>Ponce, Daniel S</td>
<td>35</td>
</tr>
<tr>
<td>Pena, Vivian</td>
<td>26</td>
</tr>
<tr>
<td>Pepe, Beth</td>
<td>80</td>
</tr>
<tr>
<td>Per, William</td>
<td>49</td>
</tr>
<tr>
<td>Perrin, Mary</td>
<td>45</td>
</tr>
<tr>
<td>Pinto, Gloria</td>
<td>49</td>
</tr>
<tr>
<td>Pitkar, Eric M</td>
<td>15,42,50,67</td>
</tr>
<tr>
<td>Pikkar, Richard R</td>
<td>29,45</td>
</tr>
<tr>
<td>Poirier, Marie France</td>
<td>55</td>
</tr>
<tr>
<td>Pollack, Mark H</td>
<td>6,84</td>
</tr>
<tr>
<td>Pollock, Jonathan</td>
<td>81</td>
</tr>
<tr>
<td>Polonskaya, Svetlana</td>
<td>76</td>
</tr>
<tr>
<td>Poplin, Michael J</td>
<td>79</td>
</tr>
<tr>
<td>Popovian, Robert</td>
<td>67</td>
</tr>
<tr>
<td>Posey, David J</td>
<td>2</td>
</tr>
<tr>
<td>Post, Jerrold M</td>
<td>41,93</td>
</tr>
<tr>
<td>Post, Robert M</td>
<td>56,77</td>
</tr>
<tr>
<td>Postert, Michael P</td>
<td>84</td>
</tr>
<tr>
<td>Poulsen, Clare L</td>
<td>82</td>
</tr>
<tr>
<td>Pouw, Pauline</td>
<td>97</td>
</tr>
<tr>
<td>Pown, Seth M</td>
<td>44</td>
</tr>
<tr>
<td>Prass, Matthew A</td>
<td>24,48,70</td>
</tr>
<tr>
<td>Prenter, Maurice</td>
<td>20</td>
</tr>
<tr>
<td>Preus, Ulrich</td>
<td>34</td>
</tr>
<tr>
<td>Price, Lawrence H</td>
<td>6</td>
</tr>
<tr>
<td>Price, Marilyn</td>
<td>25</td>
</tr>
<tr>
<td>Price, Trevor R P</td>
<td>92</td>
</tr>
<tr>
<td>Pritman, Anne B</td>
<td>76,82,92</td>
</tr>
<tr>
<td>Prime, N.</td>
<td>43</td>
</tr>
<tr>
<td>Prince, Jefferson B</td>
<td>1,5,51</td>
</tr>
<tr>
<td>Prohovnik, Isak</td>
<td>24</td>
</tr>
<tr>
<td>Puchalski, Christine M</td>
<td>67</td>
</tr>
<tr>
<td>Puddester, Derek</td>
<td>8</td>
</tr>
<tr>
<td>Puriwari, Meenakshi R</td>
<td>91</td>
</tr>
<tr>
<td>Puselle, David C</td>
<td>22</td>
</tr>
<tr>
<td>Quercioli, Leonardo</td>
<td>79</td>
</tr>
<tr>
<td>Qureshi, raina</td>
<td>67</td>
</tr>
<tr>
<td>Quinn, Gary M</td>
<td>94</td>
</tr>
<tr>
<td>Quinn, Gregory</td>
<td>62</td>
</tr>
<tr>
<td>Rahm, Peter V</td>
<td>17,77</td>
</tr>
<tr>
<td>Rae, Donald S</td>
<td>48,96</td>
</tr>
<tr>
<td>Ragan, Kimberly A</td>
<td>99</td>
</tr>
<tr>
<td>Rainey, Charles J</td>
<td>40,51</td>
</tr>
<tr>
<td>Raisen, Charles</td>
<td>51</td>
</tr>
<tr>
<td>Raj, V. Premchand</td>
<td>81</td>
</tr>
<tr>
<td>Ramana, Anil D</td>
<td>25,72</td>
</tr>
<tr>
<td>Ralston, Stephen J</td>
<td>34</td>
</tr>
<tr>
<td>Ramchandran, Dilip</td>
<td>39</td>
</tr>
<tr>
<td>Ramirez, Luis F</td>
<td>39</td>
</tr>
<tr>
<td>Ramirez, Paul M</td>
<td>8</td>
</tr>
<tr>
<td>Ramsev, J. Russell</td>
<td>85</td>
</tr>
<tr>
<td>Rao, Aruna S</td>
<td>52</td>
</tr>
<tr>
<td>Rao, Niparni</td>
<td>68,91</td>
</tr>
<tr>
<td>Rapaport, Mark H</td>
<td>9,16,20,27</td>
</tr>
<tr>
<td>Raphael, Beverley</td>
<td>16</td>
</tr>
<tr>
<td>Rakieden, Polkdo</td>
<td>89</td>
</tr>
<tr>
<td>Rash, J. D.</td>
<td>37,63</td>
</tr>
<tr>
<td>Rathmussen, Steven A</td>
<td>6</td>
</tr>
<tr>
<td>Rathod, Sharanya</td>
<td>92</td>
</tr>
<tr>
<td>Rasa, Lawrence</td>
<td>87</td>
</tr>
<tr>
<td>Rauch, Scott L</td>
<td>6</td>
</tr>
<tr>
<td>Ravindra, Giuseppe</td>
<td>45</td>
</tr>
<tr>
<td>Ravitz, Paul J</td>
<td>64</td>
</tr>
<tr>
<td>Razavi, Maryam A</td>
<td>22,94</td>
</tr>
<tr>
<td>Razavi, Mehdi</td>
<td>22</td>
</tr>
<tr>
<td>Reaven, Gerald</td>
<td>7,37</td>
</tr>
<tr>
<td>Recupero, Patricia R</td>
<td>72</td>
</tr>
<tr>
<td>Regier, Darrel A</td>
<td>26,30,48,51,59,76</td>
</tr>
<tr>
<td>Reich, James H</td>
<td>33,57</td>
</tr>
<tr>
<td>Reich, Walter J</td>
<td>76</td>
</tr>
<tr>
<td>Reif RVodm, Burton V</td>
<td>74</td>
</tr>
<tr>
<td>Reissman, Dori B</td>
<td>93</td>
</tr>
<tr>
<td>Rejek, Norman</td>
<td>62</td>
</tr>
<tr>
<td>Renner, John</td>
<td>73</td>
</tr>
<tr>
<td>Resendez, Cynthia L</td>
<td>43</td>
</tr>
<tr>
<td>Resnick, Phillip J</td>
<td>5,8,14,27,40,63</td>
</tr>
<tr>
<td>Restall, Wenda</td>
<td>43</td>
</tr>
<tr>
<td>Retter, Martin</td>
<td>34</td>
</tr>
<tr>
<td>Reus, Victor I</td>
<td>44,74</td>
</tr>
<tr>
<td>Reyes, Raymond M</td>
<td>88</td>
</tr>
<tr>
<td>Reynolds, Canton</td>
<td>73</td>
</tr>
<tr>
<td>Reynolds III, Charles F</td>
<td>30,94</td>
</tr>
<tr>
<td>Rezaei, Ali</td>
<td>6</td>
</tr>
<tr>
<td>Ribas, Michelle B</td>
<td>8,10,13,17,28,35,43</td>
</tr>
<tr>
<td>---</td>
<td>49,53,67,83,92,93</td>
</tr>
<tr>
<td>Rich, Ronald</td>
<td>35</td>
</tr>
<tr>
<td>Richetson, Gary S</td>
<td>62</td>
</tr>
<tr>
<td>Richner, Michael A</td>
<td>32</td>
</tr>
<tr>
<td>Ried, Ronald O</td>
<td>94</td>
</tr>
<tr>
<td>Rieut, Marie-Claude</td>
<td>19</td>
</tr>
<tr>
<td>Riley, Anne W</td>
<td>34</td>
</tr>
<tr>
<td>Rittenberg, Barry</td>
<td>80</td>
</tr>
<tr>
<td>Rice, Eva C</td>
<td>67,73</td>
</tr>
<tr>
<td>Rivera, Markel</td>
<td>69</td>
</tr>
<tr>
<td>Roberts, David C S</td>
<td>96</td>
</tr>
<tr>
<td>Roberts, Jennifer</td>
<td>19</td>
</tr>
<tr>
<td>Roberts, Laura W</td>
<td>19,44,50,64,69,86,91</td>
</tr>
<tr>
<td>Robinsowicz, Carolyn B</td>
<td>8,68</td>
</tr>
<tr>
<td>Robinsowicz, Joel A</td>
<td>5,79</td>
</tr>
<tr>
<td>Robinson, Marc J</td>
<td>43</td>
</tr>
<tr>
<td>Robinson, Michael J</td>
<td>40</td>
</tr>
<tr>
<td>Robinson, Rebecca</td>
<td>89</td>
</tr>
<tr>
<td>Robinson, Robert G</td>
<td>32</td>
</tr>
<tr>
<td>Rocca, Catherine A</td>
<td>43,99</td>
</tr>
<tr>
<td>Roden, Barbara A</td>
<td>98</td>
</tr>
<tr>
<td>Roedelstein, K.A</td>
<td>61</td>
</tr>
<tr>
<td>Roed, Thomas</td>
<td>97</td>
</tr>
<tr>
<td>Rollman, Mark</td>
<td>70</td>
</tr>
<tr>
<td>Rogers, Kenneth M</td>
<td>92</td>
</tr>
<tr>
<td>Roleman, Kelly J</td>
<td>61</td>
</tr>
<tr>
<td>Rolland, John S</td>
<td>14</td>
</tr>
<tr>
<td>Roose, Steven P</td>
<td>2,6,94</td>
</tr>
<tr>
<td>Rosario, Vernona A</td>
<td>29</td>
</tr>
<tr>
<td>Rosen, Cerrine</td>
<td>71</td>
</tr>
<tr>
<td>Rosenbaum, Jerrold F</td>
<td>1</td>
</tr>
<tr>
<td>Rosenberg, Mark L</td>
<td>45</td>
</tr>
<tr>
<td>Rosenberg, Stanley</td>
<td>28,55</td>
</tr>
<tr>
<td>Rosenbluth, Michael B</td>
<td>32</td>
</tr>
<tr>
<td>Rosenfeld, Barry D</td>
<td>89</td>
</tr>
<tr>
<td>Rosenbeck, Harry A</td>
<td>77</td>
</tr>
<tr>
<td>Rosenfield, Miriam</td>
<td>69</td>
</tr>
<tr>
<td>Rosenfeld, Norman E</td>
<td>31,61</td>
</tr>
<tr>
<td>Rosenfeld, Richard N</td>
<td>43</td>
</tr>
<tr>
<td>Rosick, Erin</td>
<td>43</td>
</tr>
<tr>
<td>Roskto, Thomas J</td>
<td>87</td>
</tr>
<tr>
<td>Rossetta, Kathleen</td>
<td>71</td>
</tr>
<tr>
<td>Rossin, Anthony L</td>
<td>22,68,85</td>
</tr>
<tr>
<td>Roth, Andrew J</td>
<td>89</td>
</tr>
<tr>
<td>Roth, Loren H</td>
<td>76</td>
</tr>
<tr>
<td>Rothbaum, Barbara</td>
<td>9,70</td>
</tr>
<tr>
<td>Rotke, Eugenio M</td>
<td>43</td>
</tr>
<tr>
<td>Rothenberg, Albert</td>
<td>8</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Stein, Murray B.</td>
<td>3, 84</td>
</tr>
<tr>
<td>Steinberg, Joel L.</td>
<td>97</td>
</tr>
<tr>
<td>Stein, Leanne</td>
<td>91</td>
</tr>
<tr>
<td>Sorensen, Matthew</td>
<td>95, 96</td>
</tr>
<tr>
<td>Stringham, Joanna E.</td>
<td>59</td>
</tr>
<tr>
<td>Steichen, Hans-Christoph</td>
<td>34</td>
</tr>
<tr>
<td>Stern, Harriet C.</td>
<td>18</td>
</tr>
<tr>
<td>Stern, Michael P.</td>
<td>55</td>
</tr>
<tr>
<td>Stern, Theodore A.</td>
<td>75, 76, 99</td>
</tr>
<tr>
<td>Stewart, S. Evelyn</td>
<td>90</td>
</tr>
<tr>
<td>Stewart, Deborah C.</td>
<td>22</td>
</tr>
<tr>
<td>Stewart, Donna E.</td>
<td>24, 33, 40, 93</td>
</tr>
<tr>
<td>Stewart, S. Evelyn</td>
<td>90</td>
</tr>
<tr>
<td>Stick, Robert</td>
<td>94</td>
</tr>
<tr>
<td>Stigler, Kimberly A.</td>
<td>2</td>
</tr>
<tr>
<td>Stimmel, James L.</td>
<td>96</td>
</tr>
<tr>
<td>Stoll, David</td>
<td>52</td>
</tr>
<tr>
<td>Stolar, Andrea G.</td>
<td>25, 57</td>
</tr>
<tr>
<td>Stoller, Robert R.</td>
<td>53</td>
</tr>
<tr>
<td>Stone, Michael H.</td>
<td>60</td>
</tr>
<tr>
<td>Scotland, Nada L.</td>
<td>8, 15, 49, 83, 85</td>
</tr>
<tr>
<td>Stout, Robert L.</td>
<td>93</td>
</tr>
<tr>
<td>Stout, Robert L.</td>
<td>77</td>
</tr>
<tr>
<td>Strow, Zachary N.</td>
<td>63, 85, 99</td>
</tr>
<tr>
<td>Strain, Calvin R.</td>
<td>68</td>
</tr>
<tr>
<td>Strayer, Norman L.</td>
<td>39</td>
</tr>
<tr>
<td>Straus, Joshua</td>
<td>63</td>
</tr>
<tr>
<td>Strauss, Jennifer L.</td>
<td>57, 82</td>
</tr>
<tr>
<td>Streen, Joel</td>
<td>1, 54</td>
</tr>
<tr>
<td>Streicher, Jorja M.</td>
<td>58</td>
</tr>
<tr>
<td>Strauss, Michael</td>
<td>34, 59</td>
</tr>
<tr>
<td>Strick, Craig A.</td>
<td>87</td>
</tr>
<tr>
<td>Stryk, Robert</td>
<td>48</td>
</tr>
<tr>
<td>Sadak, Donna M.</td>
<td>98</td>
</tr>
<tr>
<td>Sadak, H.</td>
<td>98</td>
</tr>
<tr>
<td>Sugden, Steve</td>
<td>66</td>
</tr>
<tr>
<td>Sullivan, James M.</td>
<td>48</td>
</tr>
<tr>
<td>Sullivan, Donald C.</td>
<td>68</td>
</tr>
<tr>
<td>Sulzer, David L.</td>
<td>4, 13</td>
</tr>
<tr>
<td>Summer, Calvin R.</td>
<td>34</td>
</tr>
<tr>
<td>Sunderland, Terry</td>
<td>30</td>
</tr>
<tr>
<td>Suppes, Trisha</td>
<td>3, 11</td>
</tr>
<tr>
<td>Siurn, Craig B.</td>
<td>11</td>
</tr>
<tr>
<td>Sumner, Ezra S.</td>
<td>50</td>
</tr>
<tr>
<td>Sutton, Virginia</td>
<td>34</td>
</tr>
<tr>
<td>Swan-Kremier, Lorraine</td>
<td>97</td>
</tr>
<tr>
<td>Swann, Alan C.</td>
<td>97</td>
</tr>
<tr>
<td>Swanson, James M.</td>
<td>48</td>
</tr>
<tr>
<td>Swanson, Jeffrey W.</td>
<td>81</td>
</tr>
<tr>
<td>Swartz, Marvin S.</td>
<td>28, 81</td>
</tr>
<tr>
<td>Swedo, Susan E.</td>
<td>92</td>
</tr>
<tr>
<td>Swindle, Ralph W.</td>
<td>89</td>
</tr>
<tr>
<td>Sykes, Robyn</td>
<td>59</td>
</tr>
<tr>
<td>Szarek, Bonnie L.</td>
<td>48</td>
</tr>
<tr>
<td>Szigethy, Eva M.</td>
<td>14, 42, 73</td>
</tr>
<tr>
<td>Taizan, Zebalon</td>
<td>58, 83</td>
</tr>
<tr>
<td>Takeuchi, Masaru</td>
<td>71</td>
</tr>
<tr>
<td>Talbott, John A.</td>
<td>49, 55</td>
</tr>
<tr>
<td>Tandon, Rajiv</td>
<td>15, 27, 59</td>
</tr>
<tr>
<td>Tang, Tianli</td>
<td>7</td>
</tr>
<tr>
<td>Tarno, Mary</td>
<td>92</td>
</tr>
<tr>
<td>Tapp, Andre</td>
<td>33</td>
</tr>
<tr>
<td>Tan, Pierre N.</td>
<td>13, 39, 47, 62, 77</td>
</tr>
<tr>
<td>Taisnier, Allard</td>
<td>80, 92</td>
</tr>
<tr>
<td>Tait, Nathan</td>
<td>18</td>
</tr>
<tr>
<td>Tait, Van Eik, Ludger</td>
<td>98</td>
</tr>
<tr>
<td>Temblador, Brenda</td>
<td>87</td>
</tr>
<tr>
<td>Temprano, Bruce</td>
<td>98</td>
</tr>
<tr>
<td>Ten Doeschate, Roelof J A.</td>
<td>29</td>
</tr>
<tr>
<td>Thase, Michael E.</td>
<td>23, 26, 70, 89</td>
</tr>
<tr>
<td>Thelke, Stephen M.</td>
<td>49</td>
</tr>
<tr>
<td>Thelma, Suzanne B.</td>
<td>86</td>
</tr>
<tr>
<td>Thijssen, Ole</td>
<td>64</td>
</tr>
<tr>
<td>Thistedt, Timothy L.</td>
<td>67</td>
</tr>
<tr>
<td>Thomas, Christopher R.</td>
<td>78</td>
</tr>
<tr>
<td>Thomas, Jean M.</td>
<td>24</td>
</tr>
<tr>
<td>Thomas, Frank H.</td>
<td>66</td>
</tr>
<tr>
<td>Thompson, Leonti H.</td>
<td>20</td>
</tr>
<tr>
<td>Thompson, Thomas R.</td>
<td>48</td>
</tr>
<tr>
<td>Thompson, Charles</td>
<td>70</td>
</tr>
<tr>
<td>Thompson, Steven L.</td>
<td>44</td>
</tr>
<tr>
<td>Tietjen, Toi L.</td>
<td>88</td>
</tr>
<tr>
<td>Tiedeman, Kristin R.</td>
<td>61</td>
</tr>
<tr>
<td>Tenenbaum, Glen J.</td>
<td>70</td>
</tr>
<tr>
<td>Temeau, Fabien</td>
<td>71</td>
</tr>
<tr>
<td>Trestman, Robert L.</td>
<td>26, 73</td>
</tr>
<tr>
<td>Trimble, Michael T.</td>
<td>15</td>
</tr>
<tr>
<td>Trinh, Ngin H.</td>
<td>43</td>
</tr>
<tr>
<td>Trinidad, Antonio C.</td>
<td>82</td>
</tr>
<tr>
<td>Trivedi, Madhulika H.</td>
<td>4, 31, 67, 73</td>
</tr>
<tr>
<td>Truman, Benedict L.</td>
<td>26</td>
</tr>
<tr>
<td>Truman, Christian G.</td>
<td>23</td>
</tr>
<tr>
<td>Trepzan, Paula T.</td>
<td>12, 76</td>
</tr>
<tr>
<td>Tsa, Guochuan</td>
<td>68</td>
</tr>
<tr>
<td>Tichler, Werner</td>
<td>60</td>
</tr>
<tr>
<td>Ti, Wenhui</td>
<td>73</td>
</tr>
<tr>
<td>Tucker, Lawrence V.</td>
<td>72</td>
</tr>
<tr>
<td>Tucker, Pamela G.</td>
<td>74</td>
</tr>
<tr>
<td>Tucker, Peter E.</td>
<td>2</td>
</tr>
<tr>
<td>Tucker, William M.</td>
<td>40</td>
</tr>
<tr>
<td>Tzipniner, Wilhelm C.</td>
<td>50</td>
</tr>
<tr>
<td>Tull, Tim</td>
<td>81</td>
</tr>
<tr>
<td>Tuma, Farris</td>
<td>19</td>
</tr>
<tr>
<td>Tunis, Sandra L.</td>
<td>25</td>
</tr>
<tr>
<td>Tunug, Atilla</td>
<td>23</td>
</tr>
<tr>
<td>Turk, Anna K.</td>
<td>60</td>
</tr>
<tr>
<td>Turkel, Susan B.</td>
<td>73</td>
</tr>
<tr>
<td>Tuchmann, Douglas L.</td>
<td>8, 50, 92</td>
</tr>
<tr>
<td>Turin, Ali</td>
<td>22</td>
</tr>
<tr>
<td>Turner, Hillary</td>
<td>49</td>
</tr>
<tr>
<td>Turvey, Carolyn L.</td>
<td>32</td>
</tr>
<tr>
<td>Tynan, Redi</td>
<td>58</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Warshowski, Adam</td>
<td>89</td>
</tr>
<tr>
<td>Wasdell, Michael</td>
<td>23</td>
</tr>
<tr>
<td>Wasserman, Stacey</td>
<td>51, 79</td>
</tr>
<tr>
<td>Waterman, G. Scott</td>
<td>33</td>
</tr>
<tr>
<td>Weidert, Frank W.</td>
<td>24</td>
</tr>
<tr>
<td>Webb, Carmen T.</td>
<td>91</td>
</tr>
<tr>
<td>Webster, Christopher</td>
<td>72</td>
</tr>
<tr>
<td>Weiss, Stephen M.</td>
<td>43, 49, 58, 88</td>
</tr>
<tr>
<td>Weinfurt, Kevin P.</td>
<td>22</td>
</tr>
<tr>
<td>Weinstain, Henry C.</td>
<td>43, 49, 58, 88</td>
</tr>
<tr>
<td>Weinstain, Daniel</td>
<td>13</td>
</tr>
<tr>
<td>Weiss, Jeffrey</td>
<td>91</td>
</tr>
<tr>
<td>Weiss, Margaret D.</td>
<td>23, 32</td>
</tr>
<tr>
<td>Weissman, Myrna M.</td>
<td>30</td>
</tr>
<tr>
<td>Wettiner, Eric</td>
<td>74</td>
</tr>
<tr>
<td>Wexler, Jonathan L.</td>
<td>17</td>
</tr>
<tr>
<td>White, Christopher J.</td>
<td>63</td>
</tr>
<tr>
<td>Weltz, Theodore</td>
<td>70</td>
</tr>
<tr>
<td>Wengel, Steven</td>
<td>64</td>
</tr>
<tr>
<td>West, Joyce C.</td>
<td>48, 49, 96</td>
</tr>
<tr>
<td>Weintraub, David</td>
<td>13</td>
</tr>
<tr>
<td>Womack, William M.</td>
<td>29, 66</td>
</tr>
<tr>
<td>Wompler, Timothy</td>
<td>82</td>
</tr>
<tr>
<td>Wonderlich, Stephen A.</td>
<td>87</td>
</tr>
<tr>
<td>Wood, Julia</td>
<td>87</td>
</tr>
<tr>
<td>Wood, William C.</td>
<td>49</td>
</tr>
<tr>
<td>Woods, Scott W.</td>
<td>30, 77</td>
</tr>
<tr>
<td>Woodley, Stephen B.</td>
<td>86</td>
</tr>
<tr>
<td>Woodley, Linda M.</td>
<td>30, 77</td>
</tr>
<tr>
<td>Wiener, David</td>
<td>93</td>
</tr>
<tr>
<td>Wigner, Jesse H.</td>
<td>8, 26, 50</td>
</tr>
<tr>
<td>Wu, Yelena</td>
<td>70</td>
</tr>
<tr>
<td>Wung, Jay</td>
<td>88</td>
</tr>
<tr>
<td>Wynn, John D.</td>
<td>42</td>
</tr>
<tr>
<td>Wyshak, Grace</td>
<td>54</td>
</tr>
<tr>
<td>Xu, Yong</td>
<td>24</td>
</tr>
<tr>
<td>Yager, Joel</td>
<td>1, 6, 17, 25, 45, 68, 83, 97</td>
</tr>
<tr>
<td>Yamada, Matsushiro</td>
<td>33</td>
</tr>
<tr>
<td>Yates, Alayne</td>
<td>48</td>
</tr>
<tr>
<td>Yen, Shirley</td>
<td>77</td>
</tr>
<tr>
<td>Yeomans, Frank E.</td>
<td>7</td>
</tr>
<tr>
<td>Yng, Albert</td>
<td>24, 32</td>
</tr>
<tr>
<td>Ying, Patrick</td>
<td>88</td>
</tr>
<tr>
<td>Younkers, Kimberly A.</td>
<td>13, 30</td>
</tr>
<tr>
<td>Young, Kenneth W.</td>
<td>44, 49, 56</td>
</tr>
<tr>
<td>Yu, Van</td>
<td>74</td>
</tr>
<tr>
<td>Yu-Chun, Rose</td>
<td>91</td>
</tr>
<tr>
<td>Yudishoy, Stuart C.</td>
<td>12, 13, 39, 69</td>
</tr>
<tr>
<td>Yusch, Theresa A.</td>
<td>73</td>
</tr>
<tr>
<td>Yuzhar, Peter</td>
<td>33, 82</td>
</tr>
<tr>
<td>Zachariah, Robert</td>
<td>88</td>
</tr>
<tr>
<td>Zagarsky, Karen</td>
<td>61</td>
</tr>
<tr>
<td>Zanetti, Mary</td>
<td>7</td>
</tr>
<tr>
<td>Zatnick, Douglas F.</td>
<td>34</td>
</tr>
<tr>
<td>Zee, Phyllis C.</td>
<td>9, 33</td>
</tr>
<tr>
<td>Zebe, Kathryn J.</td>
<td>21, 75, 97</td>
</tr>
<tr>
<td>Zephas, Jennifer</td>
<td>82</td>
</tr>
<tr>
<td>Ziedonis, Douglas M.</td>
<td>26</td>
</tr>
<tr>
<td>Zil, John S</td>
<td>49</td>
</tr>
<tr>
<td>Zimmer, Mark</td>
<td>90</td>
</tr>
<tr>
<td>Zin, Waker A.</td>
<td>71</td>
</tr>
<tr>
<td>Zipursky, Robert B.</td>
<td>10, 12, 77</td>
</tr>
<tr>
<td>Zolotov, Sidney</td>
<td>51, 82</td>
</tr>
<tr>
<td>Zito, Fran</td>
<td>64</td>
</tr>
<tr>
<td>Zlatoper, Kenneth W.</td>
<td>71</td>
</tr>
<tr>
<td>Zehar, Joseph</td>
<td>79</td>
</tr>
<tr>
<td>Zolovski, Beata A.</td>
<td>9</td>
</tr>
<tr>
<td>Zordania, Howard V.</td>
<td>72</td>
</tr>
<tr>
<td>Zuber, Jon-Kar</td>
<td>58</td>
</tr>
<tr>
<td>Zucker-Goldstein, Marion</td>
<td>21</td>
</tr>
<tr>
<td>Zuckoff, Allan</td>
<td>41</td>
</tr>
</tbody>
</table>
CALL FOR PAPERS

PRESIDENT'S THEME:
From Science to Public Policy: Advocacy for Patients & the Profession

Steven S. Sharfstein, M.D.
President

Marian I. Butterfield, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported</td>
<td>June 1, 2005</td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
</tr>
<tr>
<td>Course</td>
<td>September 6, 2005</td>
</tr>
<tr>
<td>Reports</td>
<td>September 6, 2005</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 6, 2005</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue: September 6, 2005</td>
</tr>
<tr>
<td></td>
<td>Component: September 20, 2005</td>
</tr>
<tr>
<td>New Research</td>
<td>December 2, 2005</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

You are encouraged to complete your submissions online by visiting www.psych.org, click on the Annual Meeting logo, then click on the submission form box.

You may also fill out and download a PDF version of the forms. Feel free to contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
Recovery and Community

Save the date now to attend the 57th Institute on Psychiatric Services, APA's leading educational conference on clinical issues and community mental health to meet the service needs of people with severe mental illness.

With 100 exhibits that complement the educational program, and popular networking events, and over 175 expertly-led educational sessions on topics including:

- Recovery issues
- Social and community psychiatry
- Psychopharmacology
- Resident and medical student concerns
- Substance abuse
- Child and adolescent issues
- AIDS and HIV related disorders
- Cross-cultural and minority issues
- Psychiatric administration and services
- Treatment techniques and outcome studies
- Cognitive disorders
- Health service research
- Mood disorders
- Schizophrenia and other Psychotic disorders
- Psychopharmacology
- Violence and trauma
- And much more...

Who Should Attend?

- All APA Members
- Psychiatrists and mental health professionals in community practice or the public sector including state, community, and Veterans Affairs hospitals, community clinics, and jails and prisons.
- Psychiatric administrators
- Mental health professionals interested in social issues that have an impact on patients and their families
- Minority psychiatrists and International Medical Graduates
- Psychiatric Residents
- Medical Students
- Consumers interested in recovery issues

Why Should You Attend?

- Earn up to 48 hours of category 1 CME credit
- Receive a 40% discount on APA member registration fees
- Industry-supported lunch and dinner symposia presented each day

How Will You Benefit?

- Learn the latest knowledge and skills in clinical psychiatry, which can be utilized to improve patient care
- Acquire a deeper understanding of how the current health care system affects patient care
- Gain new knowledge and skills useful in clinical and public psychiatric settings
- Recognize and improve mental health disparities in the community
- Understand all aspects of recovery and how this affects the community

Continuing Medical Education Credit

The American Psychiatric Association is accredited by the Accreditation Council on Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 48 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.
Three Nights, Three Special Programs
Join us for three evening events at the 2005 APA Annual Meeting

Saturday, May 21, 2005
APF's 2005 Annual Benefit
"Georgia on My Mind"
The High Museum of Art
7:00 – 10:00 p.m.

Spend a wonderful evening with the foundation featuring a silent auction of artwork created by Skyland Trail clients, a tour of the High Museum's galleries, nouvelle southern cuisine and live music. Silent auction proceeds will benefit Skyland Trail, the foundation's 2005 community partner for the event. Skyland Trail is the winner of the APA 2004 Psychiatric Services Gold Achievement Award for community-based programs.

Tickets - $150 per person ($100 tax deductible)
Call 703.907.8512 or visit www.psychfoundation.org

Supported by:
Abbott Laboratories
Cyberonics
Forest Laboratories
Eli Lilly and Company
Otsuka America Pharmaceutical
Professional Risk Management Services

Monday, May 23, 2005
Psychiatry Film Fest
Sheraton Atlanta, Grand Ballroom
7:00 – 10:00 p.m.
Open to all Annual Meeting attendees

Join us for a viewing of “The Son's Room,” the Best Picture Award winner at the 2001 Cannes Film Festival. The film, presented in Italian with English subtitles, portrays a psychiatrist and his family grappling with grief. The film will be followed by a discussion of depression and culture, moderated by Steven Hyler, M.D., Clinical Professor of Psychiatry at Columbia University College of Physicians and Surgeons. Light refreshments will be served.

Supported through an unrestricted educational grant from:
Pfizer

Tuesday, May 24, 2005
“Conversations”
Sydney J. Marcus Auditorium
World Congress Center
5:30 – 6:30 p.m.
Open to all Annual Meeting attendees

Greg Louganis, Guest Speaker

Join us for our 4th annual “Conversations” event, an interactive discussion series that offers psychiatrists an opportunity to hear unique perspectives on mental illness. Greg Louganis, winner of five Olympic medals for diving, will be our guest. Louganis will share his experiences with depression, substance abuse, and an HIV-positive diagnosis.

Supported through an unrestricted educational grant from:
AstraZeneca ©
The First and Last Word in Psychiatry

APPI Bookstore at the 2005 APA Annual Meeting in Atlanta!

Psychiatry's premier publisher brings the cutting-edge titles you've been waiting for directly to you! Come check out APPI's latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions all in one stop. Don't miss the Author Book Signings. See you there!

Psychodynamic Psychiatry in Clinical Practice, Fourth Edition
Glen O. Gabbard, M.D.
2005 • 640 pages • ISBN 1-58562-185-4
Hardcover • $89.95 • Item #62185

Alan E. Schatzberg, M.D., Jonathan O. Cole, M.D., and Charles D. Harbaugh, M.D.
2005 • 672 pages • ISBN 1-58562-209-5
Paperback • $69.00 • Item #62209

APPI Bookstore Hours
Saturday, May 21 10:00am - 5:00pm
Sunday, May 22 10:00am - 4:30pm
Monday, May 23 10:00am - 5:30pm
Tuesday, May 24 10:00am - 6:00pm
Wednesday, May 25 10:00am - 3:00pm

Special Benefits for American Psychiatric Association Members!
10% Discount for All APA Members
25% Discount for Members-in-Training
Prices subject to change without notice.

Please reference priority code AP512 when ordering.

The First and Last Word in Psychiatry
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901
Phone: 703-907-7322 or 1-800-368-5777
Mon.-Fri., 9 am to 5:30 pm, ET
Fax: 703-907-1051
Email: appi@psych.org
Web: www.appi.org
## AT YOUR ANNUAL MEETING BOOKSTORE

### REVIEW OF PSYCHIATRY, VOLUME 24
- **Sleep Disorders and Psychiatry**
  - Edited by Daniel J. Buysse, M.D.
  - 2005 • pages TBA • ISBN 1-58562-229-X
  - Paperback • $34.95 • Item #62229

- **Mood Disorders During Pregnancy and the Postpartum**
  - Edited by Lee S. Cohen, M.D., and Ruta M. Nonacs, M.D., Ph.D.
  - 2005 • pages TBA • ISBN 1-58562-225-7
  - Paperback • $34.95 • Item #62225

- **Psychiatric Genetics**
  - Edited by Kenneth S. Kendler, M.D., and Lindon Eaves, Ph.D., D.Sc.
  - 2005 • pages TBA • ISBN 1-58562-228-1
  - Paperback • $34.95 • Item #62228

- **Advances in Treatment of Bipolar Disorder**
  - Edited by Terence A. Ketter, M.D.
  - 2005 • pages TBA • ISBN 1-58562-230-3
  - Paperback • $34.95 • Item #62230

### SET OF REVIEW OF PSYCHIATRY, VOLUME 24
- 2005 • $109.00 • Item #5088

### JANUARY
- **Research Advances in Genetics and Genomics Implications for Psychiatry**
  - Edited by Nancy C. Andreasen, M.D., Ph.D.
  - 2005 • 159 pages • ISBN 1-58562-200-1
  - Paperback • $24.95 • Item #62200

### FEBRUARY
- **Understanding and Treating Borderline Personality Disorder A Guide for Professionals and Families**
  - Edited by John G. Gunderson, M.D., and Perry D. Hoffman, Ph.D.
  - 2005 • 192 pages • ISBN 1-58562-135-8
  - Paperback • $29.95 • Item #62135

### MARCH
- **Menopause A Mental Health Practitioner's Guide**
  - Edited by Donna E. Stewart, M.D., F.R.C.P.C.
  - 2005 • 240 pages • ISBN 1-58562-1609
  - Paperback • $34.95 • Item #62160

### APRIL
- **What Your Patients Need to Know About Psychiatric Medications A Resource Book of Medication Information**
  - Robert E. Hales, M.D., M.B.A., Stuart C. Yudofsky, M.D., and Narriman C. Shahrokh
  - 2005 • 352 pages • ISBN 1-58562-203-6
  - Spiralbound • $59.95 • Item #62203

- **Psychiatry, Psychoanalysis, and the New Biology of Mind**
  - Eric R. Kandel, M.D.
  - 2005 • 432 pages • ISBN 1-58562-199-4
  - Hardcover • $57.95 • Item #62199

### Handbooks and Study Guides
- **Handbook of Essential Psychopharmacology, Second Edition**
  - Ronald W. Pies, M.D.
  - 2005 • 528 pages • ISBN 1-58562-168-4
  - Paperback • $65.00 • Item #62168

- **Competency in Combining Pharmacotherapy and Psychotherapy Integrated and Split Treatment Core Competencies in Psychotherapy**
  - Michelle B. Riba, M.D., M.S., and Richard Balon, M.D.
  - Series Editor: Glen O. Gabbard, M.D.
  - 2005 • 160 pages • ISBN 1-58562-143-9
  - Paperback • $33.95 • Item #62143

- **Clinical Study Guide for the Oral Boards in Psychiatry, Second Edition**
  - Nathan R. Strahl, M.D., Ph.D.
  - Paperback • $39.95 • Item #62179
We are pleased to announce the launch of PsychiatryOnline.com. This site features the most trusted and reliable references in psychiatry, including the DSM-IV-TR® and The American Journal of Psychiatry.

PsychiatryOnline.com, an easy-to-use reference and research tool, harnesses the power of the Internet to bring you instant access to classic, must-have resources such as:

- Diagnostic and Statistical Manual of Mental Disorders, the most widely used psychiatric reference in the world
- The American Journal of Psychiatry and four other APPI psychiatric journals
- DSM-IV-TR® Handbook of Differential Diagnosis
- DSM-IV-TR® Casebook and its Treatment Companion
- APA Practice Guidelines for the Treatment of Psychiatric Disorders

All available with the convenience of state-of-the-art searching and cross-referencing tools custom-designed for psychiatric information that is critical to education, research, and practice in psychiatry. Delivering you the information you are looking for – whenever and wherever you need it.

PLUS...

- Access unlimited PDA downloads and self-assessment tools to help you prepare for certification and recertification and earn CME credits

For more information or to subscribe, visit PsychiatryOnline.com.
Please use priority code: AP516
INDUSTRY-SUPPORTED SYMPOSIUM 1
Saturday, May 21, 2005, 12:30 PM - 3:30 PM
Grand Ballroom, Second Floor, Hilton Atlanta

Anxiety: Diverse Populations and Presentations, Unique Individuals and Treatments

Presenters

Unraveling the Role of Gender: The Course and Treatment of Anxiety Disorders in Women
Chairwoman: Naomi M. Simon, MD, MSc
Associate Director, Center for Anxiety and Traumatic Stress Disorders
Massachusetts General Hospital
Assistant Professor of Psychiatry
Harvard Medical School
Boston, MA

Evaluation and Treatment of Anxiety in Patients With Comorbid Mental Health
Peter Ray-Burns, MD
Professor and Vice Chair
Department of Psychiatry & Behavioral Sciences
University of Washington School of Medicine
Seattle, WA

Improving Treatment of Anxiety One Individual at a Time
Jerrold R. Rosenbaum, MD
Chief of Psychiatry
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School
Boston, MA

Objectives

At the conclusion of this activity, the participant should be able to:

- Recognize the diverse manifestations of anxiety in a variety of patient populations and the implications for tailoring care to the unique individual.
- Understand what is known about the impact of gender and comorbid medical conditions on anxiety disorders and treatment.
- Identify predictors of ineffective treatment responses in the anxious patient, and treatment strategies to improve outcomes.
- Demonstrate strategies that address the language limitations and culturally distinct phenomena that complicate the process of offering Western-based psychotherapy to refugee populations.
- Describe the prevalence of the comorbid presence of anxiety and substance abuse disorders, including their common neural circuitry.

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 21, 2005, 12:30 PM - 3:30 PM
Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

The Impact of Depression and Anxiety
ON WELL-BEING ACROSS THE LIFE CYCLE

AGENDA

12:00 Welcome and Introduction
Sharon D. DeRiso, MD
Professor, Psychiatry
Director, Psychiatry Residency Program
University of Washington
Seattle, WA

12:30 Clinical Depression and Anxiety: How to Spot and Cope with
Drs. Onay Demir and Brian Weineck
Psychiatric and Neuropsychological
New York, NY

1:00 Depression and Anxiety in a Family in Confinement, Ohio
Karen E. Kurlan, MD, PhD
Professor of Psychiatry
Chairman, Department of Psychiatry
Case Western Reserve University
Henneman Medical Center
Cleveland, OH

2:30 Impact of Depression and Anxiety in Women of Reproductive Age
Lauren W. Rosenfeld, MD, FAAP
Staff Psychiatrist
Center for Adolescent Psychiatry
Boston Children's Hospital
Boston, MA

2:45 Question and Answer Session
Faculty Panel

3:30 Adjournment

OBJECTIVES

At the conclusion of this program, participants should be able to:

- Review the relationship between maternal anxiety and depression during pregnancy and examine the impact on their lives.
- Discuss the relevance of depression and anxiety in women with comorbid medical conditions.
- Understand the relationship between the symptoms of depression and anxiety with substance use disorders.
- Recognize the importance of anxiety and depression in certain populations.
- Explain how depression and anxiety may affect female reproductive functioning and address the long-term effects of untreated depression on the child.

The American Psychological Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This educational activity is designed to enhance the knowledge, competence, and performance of physicians. It is the responsibility of each participant to determine whether the use of these products in the context of clinical practice would be in the best interest of the patient. The APA has no financial relationship with the manufacturers of any products discussed in this program.

All authors have disclosed that they have no financial relationships with any manufacturers of products discussed in this program.
INDUSTRY-SUPPORTED SYMPOSIUM 3
Saturday, May 21, 2005, 12:30 PM - 3:30 PM
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

Management of Disruptive Behavioral and Pervasive Developmental Disorders
Christopher J. McDougle, MD (Chair)
May 21, 2005 - 12:30 PM - 3:30 PM
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel, Atlanta, GA

Agenda
12:30 PM - 12:35 PM Lunch
12:35 PM - 1:05 PM Welcome and Introduction
  Christopher J. McDougle, MD (Chair)
  Wake Forest University School of Medicine
1:05 PM - 1:15 PM The Comorbidity of Mood and Agitation
  Joel D. Gold, MD
  Children's Hospital, Boston
1:15 PM - 1:25 PM Psychopharmacology of Atypical Antipsychotic Medications
  Marc A. Charney, MD
  Massachusetts General Hospital
1:25 PM - 2:15 PM Pharmacotherapy of Behavioral Symptoms of Pervasive Developmental Disorders
  Christopher J. McDougle, MD
  Wake Forest University School of Medicine
2:15 PM - 2:25 PM Mood and Anxiety Disorders in Autism Spectrum Disorders
  Elizabeth A. Comings, MD
  Children's Hospital, Boston
2:25 PM - 3:15 PM The Treatment of Schizophrenia in Developmental Disabilities
  Vincent A. DeCaro, MD
  University of Pennsylvania
3:15 PM - 3:30 PM Questions and Answers
3:30 PM - 3:35 PM Symposium Adjourned

At the conclusion of this symposium, the participant should be able to:
• Understand how agitation in a comorbid mood disorder is a common finding in children and adolescents with psychiatric/behavioral spectrum disorders
• Recognize the consequences of untreated aggressive behavior in caregivers and society, and the importance of early intervention
• Discuss which types of behavioral symptoms in non-psychiatric/behavioral disorders are responsive to pharmacologic treatment (e.g., aggressive behavior and its subtypes)
• Compare and contrast effectiveness and safety data for current psychopharmacologic options for the treatment of behavioral symptoms in children and adults

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 Category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the educational activity.

Support by unrestricted educational grants from

Sponsored by the American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 4
Saturday, May 21, 2005, 6:00 PM - 9:00 PM
Grand Ballroom, Second Floor, Hilton Atlanta

Psychosomatic Illness: A 21st Century Perspective
A Continuing Medical Education Symposium to be Held at the American Psychiatric Association 158th Annual Meeting
Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Eli Lilly and Company

Saturday, May 21, 2005
5:30 PM - 9:00 PM
Hilton Atlanta
Grand Ballroom (Second Floor)
255 Courtland Street NE
Atlanta, Georgia

Program Objectives
After attending this continuing medical education symposium, the psychiatrist should be able to:
• Understand the complex relationships between physical illnesses and anxiety and mood disorders
• Recognize the role of the psychiatrist in treating chronic pain and health problems unique to women
• Identify ways to improve outcomes in medically ill patients with anxiety problems.

Agenda
5:30 PM Dinner
6:00 PM Welcome, Introduction, and Program Objectives
  Murray B. Stein, MD, MPH, Program Chair
  University of California San Diego
  and
  Prakash S. Masand, MD, Program CoChair
  Duke University Medical Center
6:05 PM Impact of Anxiety and Mood Disorders on Physical Disease: The Worried Not So Well
  Murray B. Stein, MD, MPH
7:05 PM Chronic Pain Syndromes: A Psychiatric Perspective
  Prakash S. Masand, MD
7:35 PM Interface of Women's Mental and Reproductive Health
  Nadine Jaffe, MD, MSc
  Harvard Medical School
8:05 PM Panel Discussion
9:00 PM Adjournment

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 Category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-527-9744 (within the US or Canada) or 732-997-7700.
The Developmental Trajectory of Impulsivity

An educational symposium to be presented at the 2005 Annual Meeting of the American Psychiatric Association

Saturday, May 21, 2005

Dinner: 5:30 PM - 6:00 PM
Scientific Program: 6:00 PM - 9:00 PM

Imperial Ballroom
Convention Level
Marriott Marquis
Atlanta, GA

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Psychiatric Association designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that constitute actual participation in the activity.

Attendance may be recorded for the APA Annual Meeting to attend this symposium. Scoring is limited to those who attend the meeting. Non-attendees for any reason will not receive credit for CME. For more information on scoring or for requests to receive credit for CME, please contact the APA. Visit www.psych.org for more information on the APA. Call 888-338-7994 for the CME Center at 888-338-7994.

Abstract Description

The symposium of the three sessions, participants should be able to describe the psychiatric disorders that may occur during childhood, the impact of these disorders on the development of bipolar disorder and the impact of these disorders on the treatment of attention-deficit disorders. The developmental trajectory and impact for impulsive behavior, and the new trends in treatment of impulsive behavior.

Sponsored by: Forest Pharmaceuticals, Inc.

Integrating Neurobiology and Psychopathology into Evidence-Based Treatment of Social Anxiety Disorder

APA 2005 Annual Meeting • Saturday, May 21, 2005 • 6:00-9:00 pm • Imperial Ballroom, Salons I & II • Convention Level, Marriott Marquis Atlanta • Atlanta, Georgia

AGENDA
6:00 - 6:10 p.m.
Welcome and Introduction
MICHAEL R. WEINWITZ, MD
Symposium Chairperson
Columbia University College of Physicians & Surgeons
New York State Psychiatric Institute
6:10 - 6:40 p.m.
Social Anxiety Disorder: Epidemiology, Diagnosis, and Comorbidities
MICHAEL R. WEINWITZ, MD
6:40 - 6:55 p.m.
Questions
7:15 - 7:45 p.m.
Neurobiological Mechanisms of Social Anxiety Disorder
FRANKLIN A. SCHNEIDER, MD
Columbia University College of Physicians & Surgeons
New York State Psychiatric Institute
7:50 - 7:55 p.m.
Questions
7:55 - 8:25 p.m.
Evidence-Based Pharmacotherapy of Social Anxiety Disorder
CARLOS BLANCO, MD
Columbia University College of Physicians & Surgeons
New York State Psychiatric Institute
8:25 - 9:00 p.m.
Questions

Open completion of this symposium, participants should be able to:
- recognize the demographic and clinical characteristics of SAD and the importance of early intervention;
- understand the neurobiology underlying SAD and its comorbid conditions;
- have gained improved knowledge about emerging evidence-based treatments for the effective pharmacological treatment of SAD, including new biological and psychosocial treatments for younger patients;
- The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA's Physician's Recognition Award. Each physician should claim only those credits that constitute actual participation in the activity.

Attendance may be recorded for the APA Annual Meeting to attend this symposium. Scoring is limited to those who actually attend the meeting. Non-attendees for any reason will not receive credit for CME. For more information on scoring or for requests to receive credit for CME, please contact the APA. Visit www.psych.org for more information on the APA. Call 888-338-7994 for the CME Center at 888-338-7994.

This program is sponsored by the American Psychiatric Association and supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 7
Saturday, May 21, 2005, 6:00 PM - 9:00 PM
Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

Bipolar Disorder:
PSYCHIATRIC AND MEDICAL IMPLICATIONS FOR OPTIMAL PATIENT MANAGEMENT

Saturday, May 21, 2005 • 5:30 pm - 6:00 pm • Dinner • 6:00 pm - 9:00 pm • Symposium
Atlanta Marriott Marquis • Marquis Ballrooms III and IV, Convention Level • Atlanta, Georgia

AGENDA
6:00 PM 
Welcome and Introduction
Paul E. Keck, Jr, MD
University of Cincinnati College of Medicine
Cincinnati, OH

6:10 PM 
Psychiatric Comorbidity in Bipolar Disorder
Susan E. McEvey, MD
University of Cincinnati College of Medicine
Cincinnati, OH

6:25 PM 
Bipolar Disorder Complicated by Medical Comorbidity
Ray A. Earll, MD
Harvard Medical School
Boston, MA

6:40 PM 
Treatment and Monitoring Guidelines for the Patient With Bipolar Disorder
Tedra S. Soper, MD, PhD
University of Texas Southwestern Medical Center at Dallas
Dallas, TX

7:25 PM 
Management of the Complicated Bipolar Patient
Paul E. Keck, Jr, MD

7:55 PM 
Question-and-Answer Session
Gayle Fahey

9:00 PM 
Adjournment

OBJECTIVES
At the conclusion of this program, participants should be able to:
• Recognize and manage the implications of medical and psychiatric comorbidities in the patient with bipolar disorder
• Recognize and manage the complications posed by bipolar disorder and the comorbid conditions that complicate the illness
• Recognize the importance of comprehensive medical and psychiatric evaluations for the patient with bipolar disorder
• Recognize the importance of clinical treatment guidelines while also understanding the need to adapt guidelines to individual patient needs
• Recognize the potential for adverse events when treating the patient with bipolar disorder and adjust patient-management strategy appropriately

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the activity.
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-888-557-7024 within the United States or in Canada at 703-907-7200.

Supported by an unrestricted educational grant from Pfizer Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 8
Saturday, May 21, 2005, 6:00 PM - 9:00 PM
International Ballroom, North Tower, Ballroom Level, Omni Hotel

EXPANDING USES OF ATYPICAL ANTPSYCHOTICS:
ADDRESSING REAL-WORLD CHALLENGES

Chaired by: Kariis Dioso Wagner, MD, PhD

TARGET AUDIENCE
This educational activity is designed for psychiatrists and other mental health care professionals attending the APA Annual Meeting of the American Psychiatric Association (APA).

LEARNING OBJECTIVES
After attending this symposium, participants should be able to:
• Discuss the pharmacodynamics, pharmacokinetics, and clinical implications of atypical antipsychotics
• Discuss the efficacy and safety of atypical antipsychotics in schizophrenia and bipolar disorder
• Discuss the role of atypical antipsychotics in managing the comorbid conditions of bipolar disorder

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the activity.

Supported by an unrestricted educational grant from Elan Pharmaceuticals, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 9
Saturday, May 21, 2005, 6:00 PM - 9:00 PM
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

Achieving Remission in Depression: Is the Bar Set Too High or Too Low?

Jonathan E. Alpert, MD, PhD, Massachusetts General Hospital

5:30 p.m. Dinner
5:50 p.m. Welcome and Announcements
6:00 p.m. Reminiscence in Depression: Definition and Treatment Approaches
   Joshua Israel, MD
   University of California San Francisco

6:30 p.m. Augmentation and Combination Strategies in Partial and non-Responders to Antidepressants
   Charles DeBattista, MD
   Stanford School of Medicine

7:00 p.m. The Role of Psychotherapy to Enhance the Efficacy of Antidepressants
   Timothy Petersen, PhD
   Massachusetts General Hospital

7:30 p.m. Pharmacological Approaches to the Treatment of Residual Symptoms
   Maurizio Fava, MD
   Massachusetts General Hospital

8:00 p.m. Neurotherapeutics in Resistant Depression
   Linda Carpenter, MD
   Butler Hospital, Brown Medical School

8:30 p.m. Discussion

9:00 p.m. Adjourn

INDUSTRY-SUPPORTED SYMPOSIUM 10
Saturday, May 21, 2005, 6:00 PM - 9:00 PM
Peachtree Ballroom, Level 8, Westin Peachtree Plaza

Dealing With Depression: The Added Burden to Medical Patients

Saturday, May 21, 2005
5:30pm-6:00pm Dinner • 6:00pm-6:30pm Educational Activity
The Westin Peachtree Plaza • Level 8, Peachtree Ballroom • Atlanta, Georgia

6:00 Dinner

Welcome and Introduction
   Moshaher R. Karim, MD
   Program Director
   University of Texas Southwestern Medical Center

6:30 GMHSA General Medical Consensus Associated With Depression
   Wayne J. Bannas, MD
   University of Washington Medical Center

6:50 The Impact of Psychosomatic Symptoms (Chronic Pain or Belief in Depression) and its Treatment
   David K. Nolen, MD, MPH
   University of Michigan School of Medicine
   "The Regional Consensus PACE and Rehabilitation Center"

7:30 Learning Objectives
   Upon completion of the activity, participants should be able to:
   1. Identify the major psychosomatic symptoms and their impact on treatment effectiveness.
   2. Describe the importance of addressing psychosomatic symptoms in the treatment of depression.
   3. Recognize the role of comprehensive assessment and management approaches.
   4. Identify strategies for effective treatment of patients with comorbid conditions.

7:45 The Role of Psychotherapists in the Treatment of Depressed Patients
   Ellen Trout, PhD
   Western Psychiatric Institute and Clinic
   University of Pittsburgh School of Medicine

8:15 Meningioma and Other Related Disorders
   James W. Martin, MD
   Hope Pavilion, Sylvester Comprehensive Cancer Center

8:45 Discussion and Answer Session

9:00 Program Adjournment

A Diner Symposium Held During the APA 2005 Annual Meeting

Dealing With Depression: The Added Burden to Medical Patients

Saturday, May 21, 2005
5:30pm-6:00pm Dinner • 6:00pm-6:30pm Educational Activity
The Westin Peachtree Plaza • Level 8, Peachtree Ballroom • Atlanta, Georgia

6:00 Dinner

Welcome and Introduction
   Moshaher R. Karim, MD
   Program Director
   University of Texas Southwestern Medical Center

6:30 GMHSA General Medical Consensus Associated With Depression
   Wayne J. Bannas, MD
   University of Washington Medical Center

6:50 The Impact of Psychosomatic Symptoms (Chronic Pain or Belief in Depression) and its Treatment
   David K. Nolen, MD, MPH
   University of Michigan School of Medicine
   "The Regional Consensus PACE and Rehabilitation Center"

7:30 Learning Objectives
   Upon completion of the activity, participants should be able to:
   1. Identify the major psychosomatic symptoms and their impact on treatment effectiveness.
   2. Describe the importance of addressing psychosomatic symptoms in the treatment of depression.
   3. Recognize the role of comprehensive assessment and management approaches.
   4. Identify strategies for effective treatment of patients with comorbid conditions.

7:45 The Role of Psychotherapists in the Treatment of Depressed Patients
   Ellen Trout, PhD
   Western Psychiatric Institute and Clinic
   University of Pittsburgh School of Medicine

8:15 Meningioma and Other Related Disorders
   James W. Martin, MD
   Hope Pavilion, Sylvester Comprehensive Cancer Center

8:45 Discussion and Answer Session

9:00 Program Adjournment
INDUSTRY-SUPPORTED SYMPOSIUM 11
Sunday, May 22, 2005, 8:00 AM - 11:00 AM
Grand Ballroom, Second Floor, Hilton Atlanta, GA, USA

STATEMENT OF NEED:
In 1998, the NIMH sponsored Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) began to conduct effectiveness studies for patients with bipolar disorder. The project utilized a common approach to disease management based on evidence and expert guidelines available at the start of enrollment, but planned to revise recommendations regularly as new data accumulated.

New findings also imply that bipolar disorder is a clinical entity. An interesting picture of bipolar disorder emerges from the assessments completed by 1,500 individuals wearing treatment at STEP-BD treatment centers. In this sample of older, more frequent episodes, the most common comorbidities are anxiety disorders, substance abuse, obesity, and ADHD. Gender, severity, and socioeconomic status appear to play a role in the initiation of treatment. Early-onset, high-risk individuals respond to depression, and depression accounts for 50% of these episodes. Quasi-experimental data comparing outcomes for acute bipolar depression treated with or without standard antidepressants finds little evidence that standard antidepressants offer significant advantage.

This symposium presents the STEP-BD disease management model and a broad review of treatment study data for depression, mania, and rapid cycling that has become available over the course of the project. Based on this information, new treatment practices are discussed to guide clinical management.

INTEGREDIUM:

Scientific Agenda and Distinguished Faculty:

8:00 am
Efficiency of Management:
Curtin and Hackett

Gary Sachs, MD, Harvard Medical School

10:30 am
Approach to Treatment: Management and Measurement
Andrew N. Zilberg, MD

Massachusetts General Hospital

12:30 pm
View of the Future: Controversy and Controversy:
Claudia Balsells, MD, University of Pennsylvania

3:00 pm
What is the Best Treatment for Manic and Mixed Episodes?

Gary Sachs, MD, Harvard Medical School

5:00 pm
What is the Best Treatment for Bipolar Depression?

Michael J. Otto, MD, MPh, Harvard Medical School

INDUSTRY-SUPPORTED SYMPOSIUM 12
Sunday, May 22, 2005, 8:00 AM - 11:00 AM
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

Too Little, Too Much: What Is Disordered Eating?

An educational symposium to be presented at the
2005 Annual Meeting of the American Psychiatric Association
Sunday, May 22, 2005

8:00 AM - 8:00 AM
Welcome and Introduction
Joel Eiger, MD, Program Chairperson
University of Hong Kong, School of Medicine

8:00 AM - 8:15 AM
Medical Morbidity of Eating Disorders
Laurer Mayer, MD
Columbia College of Physicians and Surgeons/NYU

8:15 AM - 9:00 AM
Questions and Answers

9:00 AM - 9:45 AM
Genetic Epidemiology of Eating Disorders
James J. Hudson, MD, PhD
Harvard Medical School/McLean Hospital

9:45 AM - 10:15 AM
Psychiatric Comorbidity of Eating Disorders
Understanding the Consequences of Impulsivity
Susan L. McElroy, MD
University of Cincinnati College of Medicine

10:15 AM - 10:45 AM
Questions and Answers

10:45 AM - 11:15 AM
Pharmacotherapy Trends in the Eating Disorder Spectrum
Scott Crow, MD, University of Minnesota

11:15 AM - 11:45 AM
Questions and Answers

11:45 AM - 12:00 PM
Panel Discussion

12:00 PM - 12:15 PM
Adjudication

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The American Psychiatric Association designates this educational activity for a maximum of 3 category 1 credits in the AMA Physician's Recognition Award. Each physician should determine whether this activity qualifies for credit in the activity.

Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-serve basis. Contact the APA at (800) 832-7726 (within the United States or Canada) or (212) 471-1620 (outside of the United States or Canada)

Educational Objectives:
At the completion of this symposium, participants should be able to:

1. Describe the impact of eating disorders on mental and physical health.

2. Discuss specific treatments for eating disorders.

3. Apply knowledge of eating disorders in clinical practice.

This symposium is supported by an unrestricted educational grant from Eli Lilly and Company, Inc.

Sponsored by Eli Lilly and Company, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 22, 2005, 8:00 AM - 11:00 AM
Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

Spotlight on the Uniqueness of Depression & Anxiety in the Elderly

7:50 AM  Breakfast
8:00  Introduction
     Katherine Shear, MD—Chairman
     University of Pittsburgh School of Medicine
8:15  Late-Onset Depression: A Distinctive Disease
     Associated With the Elderly
     Steven P. Roose, MD
     Columbia University College of Physicians & Surgeons
8:45  Recognizing Depressive Disorders Comorbid
     With Medical Illnesses in the Elderly
     Eric Larson, MD—University of Pittsburgh School of Medicine
9:15  Bereavement-Related Depression and Anxiety
     Katherine Shear, MD
9:45  Antidepressants and Anxiolytics
     in the Elderly: A Focus on Safety
     George Alexopoulos, MD
     Weill Medical College of Cornell University
10:15  Question-and-Answer Session
11:00  Conclusion

Sponsored by the American Psychiatric Association
Supporting educational grants from
Cyberonics, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 22, 2005, 8:00 AM - 11:00 AM
Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

BRAIN STIMULATION:
New Treatments for Mood Disorders

AGENDA
7:30-8:00 AM  Breakfast
8:00-8:10 AM  Welcome and Introductions
              A. John Rush, MD
8:10-8:30 AM  Optimizing the Therapeutic Elements of
              Electroconvulsive Therapy (ECT)
              Harold A. Sackeim, PhD
8:30-9:50 AM  Current Status of Repeated Transcranial
              Magnetic Stimulation (rTMS)
              Mark L. George, MD
9:50-9:55 AM  Current Status of Magnetic Stimulation Therapy (MST)
              Sarah R. Lisanby, MD

Current Status of Vagus Nerve Stimulation (VNS)

Lauren B. Marangell, MD
9:50-10:15 AM  Discussion and Q&A

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the APA Physician's Recognition Award. Faculty disclosure and the ACCME's program requirements will be observed. The faculty is required to disclaim any conflicts of interest related to this activity.

Sponsored by Cyberonics, Inc.
Panic Disorder: Current Concepts and Future Directions
Mark H. Pollack, MD - Chair
Sunday, May 22, 2005
8:00 AM - 11:00 AM
International Ballroom, Ballroom Level

Agenda
7:30 AM - 8:00 AM
Breakfast
8:00 AM - 8:05 AM
Welcome and Opening Remarks
Mark H. Pollack, MD, Massachusetts General Hospital, Boston, Massachusetts
8:05 AM - 8:30 AM
Symptom-Induced Panic Disorder and the Neurobiological Core
Justine M. Gier, MD, Columbia University, New York, New York
8:30 AM - 8:55 AM
Current Status of Panic Disorder: What Have We Learned?
Jordan S. Smoller, MD, Massachusetts General Hospital, Boston, Massachusetts
8:55 AM - 9:20 AM
Cross-Cultural Aspects of Panic and Other Anxiety Disorders
Michael R. Liebowitz, MD, Columbia University, New York, New York
9:20 AM - 9:45 AM
Panic Symptoms at the Interface of Mind and Body
Arapahko C. Evans, MD, Harvard Medical School, Boston, Massachusetts
9:45 AM - 10:10 AM
Treating Panic Disorder: Acute Therapy and Beyond
Mark H. Pollack, MD, Massachusetts General Hospital, Boston, Massachusetts
10:10 AM - 10:55 AM
Discussion/Questions and Answers
10:55 AM - 11:00 AM
Closing Remarks
11:00 AM
Adjournment

Target Audience
This activity is designed specifically for psychologists.

Learning Objectives
Upon completion of this symposium, the participants should be able to:
• List current pharmacologic and psychological therapies for the treatment of panic disorder and discuss their use for both acute and long-term therapy.
• Discuss cross-cultural issues that influence prevalence and expression of anxiety disorders and their symptoms.
• Review recent developments in the identification of the genetic basis of panic disorder.

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 Category 1 credits toward the APA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Participation
Attendees must register for the APA Annual Meeting or institute Psychiatric Services to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website (www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 15
Sunday, May 22, 2005, 8:00 AM - 11:00 AM
International Ballroom, North Tower, Ballroom Level, Omni Hotel

Antipsychotic Drugs, Mood Stabilizers, and the Metabolic Syndrome
Herbert Y. Meltzer, MD (Chair), and Donald C. Goff, MD (Co-Chair)
May 22, 2005 - 8:00 AM - 11:00 AM
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel, Atlanta, GA

Agenda
7:30 AM - 8:00 AM
Breakfast
8:00 AM - 8:15 AM
Welcome and Introduction
Herbert Y. Meltzer, MD (Chair), Psychiatric Hospital of Westchester University
Donald C. Goff, MD (Co-Chair), Massachusetts General Hospital
8:15 AM - 8:30 AM
Effect of Antipsychotic Drugs on Weight, Glucose Metabolism, and Diabetes Mellitus
Daniel W. Hart, MD, Washington University in St. Louis
8:30 AM - 9:00 AM
The Effect of Antipsychotic Drugs on Lipids and Other Elements of the Metabolic Syndrome
Herbert Y. Meltzer, MD
9:00 AM - 9:25 AM
Insulin Resistance, Dyslipidemia, and Cardiovascular Disease
Gerald M. Reaven, MD, Stanford University
9:25 AM - 9:50 AM
Metabolic Syndrome of Antipsychotics: Obesity and Type 2 Diabetes
Marshallyn Adams, PhD, University of Southern California
9:50 AM - 10:15 AM
A Clinician's Guide to Managing Cardiac Risk Factors
Donald C. Goff, MD
10:15 AM - 11:00 AM
Questions and Answers
11:00 AM
Symposium Adjourned

At the conclusion of this symposium, the participant should be able to:
• Assess the effect of antipsychotic drugs and mood stabilizers on induction of the elements of the metabolic syndrome, with major attention to weight gain, diabetes mellitus, and lipid changes.
• Understand the metabolic syndrome and its clinical significance for the risk of diabetes mellitus and cardiovascular disease.
• Understand the pathophysiology of the metabolic syndrome.
• Weigh the metabolic side-effect profiles and clinical effectiveness of antipsychotic drugs and mood stabilizers.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 Category 1 credits toward the APA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Supports an unrestricted educational grant from APA. APA is the U.S. or Canada on 703-907-7300.

At the conclusion of this symposium, the participant should be able to:
• Assess the effect of antipsychotic drugs and mood stabilizers on induction of the elements of the metabolic syndrome, with major attention to weight gain, diabetes mellitus, and lipid changes.
• Understand the metabolic syndrome and its clinical significance for the risk of diabetes mellitus and cardiovascular disease.
• Understand the pathophysiology of the metabolic syndrome.
• Weigh the metabolic side-effect profiles and clinical effectiveness of antipsychotic drugs and mood stabilizers.

Sponsored by the American Psychiatric Association.
Sunday, May 22, 2005
7:30 AM - 11:00 AM Educational Activity
The Westin Peachtree Plaza
Level 8, Peachtree Ballroom
Atlanta, Georgia

7:30 AM - 8:00 AM Breakfast
8:00 AM - 11:00 AM Educational Activity

INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 22, 2005, 8:00 AM - 11:00 AM
Peachtree Ballroom, Level 8, Westin Peachtree Plaza

Borderline Personality Disorder: Pathophysiology, Treatment, and Course

7:30 AM - 8:00 AM Breakfast
8:00 AM - 11:00 AM Educational Activity

The Westin Peachtree Plaza
Level 8, Peachtree Ballroom
Atlanta, Georgia

A Breakfast Symposium Held During the APA 2005 Annual Meeting

INDUSTRY-SUPPORTED SYMPOSIUM 18
Sunday, May 22, 2005, 1:30 PM - 4:30 PM
Grand Ballroom, Second Floor, Hilton Atlanta

Sponsored by the American Psychiatric Association
APA 2005 Annual Meeting
Joining Night and Day:
Insomnia and the Sleep/Wake Cycle
Sunday, May 22, 2005 1:00 – 4:30 p.m. 2nd Floor Grand Ballroom Hilton Atlanta Atlanta, Georgia

Program Chair
Karl Doghrimi, MD
Professor of Psychiatry and Human Behavior
Jefferson Medical College
Director, Sleep Disorders Center
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Agenda

1:00 - 1:30 pm
Lunch
1:30 - 1:40 pm
Welcome and Introduction
Karl Doghrimi, MD Chair
Jefferson Medical College

1:40 - 2:15 pm
Insomnia: Prevalence, Impact and Current Approaches to Evaluation and Management
Karl Doghrimi, MD
Jefferson Medical College

2:15 - 2:30 pm
Medical Causes of Insomnia
Karl Doghrimi, MD
Jefferson Medical College

2:30 - 3:00 pm
The Sleep/Wake Cycle and Circadian Phase in Psychiatric Disorders
James Buysse, MD
University of Pittsburgh School of Medicine

3:00 - 3:30 pm
Current and Emerging Treatments for Insomnia
Karl Doghrimi, MD
University of Pittsburgh School of Medicine

3:30 - 3:45 pm
Special Concerns in Aging
Karl Doghrimi, MD
University of Pittsburgh School of Medicine

3:45 - 4:15 pm
Questions and Answer Session

Learning Objectives

Recognize the variety of disorders that are associated with insomnia and develop a rational approach in their evaluation and management.

Identify risk factors of mental health disorders associated with sleep disorders.

Recognize the role of the sleep/wake cycle and circadian rhythms in psychiatric disorders.

Discuss currently available medications for sleep and review their mechanisms of action and clinically relevant characteristics.

Discuss emerging pharmacological treatments for sleep disorders which feature novel mechanisms of action.

Identify behavioral and pharmacological interventions for insomnia in elderly patients.

Identify risk factors for sleep disturbances in elderly populations.

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and to the CME requirement of the APA. Each physician should only claim those credits that actually were spent in the activity.
Alzheimer's Disease Pathways To Practice:
ASSSESSING DIAGNOSIS AND OUTCOME MEASURES

AGENDA
1:30 PM - Lunch
1:30 PM - Introduction
George E. Grossberg, MD (Chairman)
Professor, Department of Psychiatry, University of Rochester

1:45 PM - The Role of Neuroplasticity in Alzheimer's Disease
Paul J. Hause, MD
Northwestern University, Chicago, IL

2:00 PM - Formulating a Clinical Practice Plan for the Diagnosis and Assessment of Alzheimer's Disease
Wendy Heaton, MD
Assistant Professor, Department of Neurology, University of South Carolina

2:15 PM - Utilizing Advanced Imaging and Serological Markers Across the Spectrum of Alzheimer’s Disease
Ray A. Muenter, MD
Professor & Chair, Department of Radiology, University of Pittsburgh

2:30 PM - Rationalizing Therapeutic Approaches in Alzheimer’s Disease
George E. Grossberg, MD
Professor of Psychiatry, University of Rochester

3:00 PM - Concluding Remarks & Q&A
George E. Grossberg, MD

OBJECTIVES

At the conclusion of this program, participants should be able to:

- Identify the need for careful evaluation of Alzheimer's disease
- Understand the severity and dynamics of different diagnostic subtypes
- Distinguish the need for treatment of cognitive complaints in Alzheimer's disease
- Discuss the innovative techniques and emerging therapies in Alzheimer's disease
- Recognize the roles of innovative biologic techniques and new diagnostic tools in Alzheimer's disease
- Analyze the current and developed applications in Alzheimer's disease
- Assess the impact of biologic techniques and new diagnostic tools on the management of Alzheimer's disease

This program is sponsored by the Alzheimer's Association.

Alzheimer’s Association (APA) 15th Annual Meeting

Sunday, May 22, 2005, 1:30 PM - 4:30 PM
Marriott Marquis, Ballrooms 1 and 2, Convention Level, Atlanta, Georgia
INDUSTRY-SUPPORTED SYMPOSIUM 21
Sunday, May 22, 2005, 1:30 PM - 4:30 PM
International Ballroom, North Tower, Ballroom Level, Omni Hotel

Anxiety Disorders: Understanding the Interconnection Between Emotional and Physical Symptoms
Mark H. Rapaport, MD - Chair
Sunday, May 22, 2005, 1:30 PM - 4:30 PM
International Ballroom, Ballroom Level

Agenda
1:00 - 1:30 PM Lunch
1:30 - 1:35 PM Welcome and Opening Remarks
Mark H. Rapaport, MD, Cedars-Sinai Medical Center
Los Angeles, California
1:35 - 2:10 PM Wound Care: How Patients Experience General Anxiety Disorder
R. Peter Lowndes, MD, Southeast Health Consultants
Charleston, South Carolina
2:10 - 2:45 PM Addressing the Full Spectrum of Symptoms of Social Anxiety Disorder
Natalie Maulin, MD, Cedars-Sinai Medical Center
Los Angeles, California
2:45 - 3:20 PM Pharmacotherapy and Psychotherapy: The Treatment of PTSD
Kathy Rostavitz, MD, Emory School of Medicine
Atlanta, Georgia
3:20 - 3:50 PM Panic Disorder: The Interconnection Between Emotional and Physical Symptoms
Mark H. Rapaport, MD, Cedars-Sinai Medical Center
Los Angeles, California
3:50 - 4:20 PM Discussion/Questions and Answers
4:20 - 4:30 PM Closing Remarks
4:30 - 4:40 PM Adjournment

Target Audience
This activity is designed specifically for psychiatrists.

Learning Objectives
Upon completion of this symposium, the participants should be able to:

- Discuss the importance of physical symptoms that coexist with anxiety disorders
- Recognize the interplay between emotional and physical symptoms in pain disorder and the treatment interventions that seem to work most effectively
- Describe the presentation and impact of social anxiety disorder and current treatment options available to best achieve remission

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Participation
Attendees must be registered for the APA Annual Meeting or Institute on Psychiatric Services to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7204 (within the United States) or 703-907-7200.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from JANSSEN

INDUSTRY-SUPPORTED SYMPOSIUM 22
Sunday, May 22, 2005, 1:30 PM - 4:30 PM
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

Relapse Prevention in Schizophrenia: Defining a Path from Pharmacologic Intervention to Long-term Functional Recovery
Sunday, May 22, 2005
1:00 PM Lunch, 1:30 - 4:30 PM Symposium
Omni Hotel, North Tower, Grand Ballroom, Atlanta, Georgia

Agenda
1:00 - 1:30 PM Lunch
1:30 - 1:45 PM Opening Remarks
John M. Kane, MD
The Zucker Hillside Hospital
The Albert Einstein College of Medicine
1:45 - 2:00 PM The Neurobiology of Relapse in Schizophrenia—Implications for Disease Course and Patient Outcomes
Robert R. Zipursky, MD
University of Toronto
2:00 - 2:10 PM Question and Answer Session
2:10 - 2:30 PM Defining Key Clinical Parameters That Contribute to Relapse in Schizophrenia
Stefan Leucht, MD
Technische Universität München
2:30 - 2:40 PM Question and Answer Session
2:40 - 3:00 PM Can Relapse Be Prevented Through Pharmacologic Intervention?
John M. Kane, MD
3:00 - 3:15 PM Question and Answer Session
3:15 - 3:35 PM Remission and Functional Recovery in Schizophrenia—Raising the Bar for Clinical Outcomes
Nina R. Schotten, PhD
Washington DC VA Medical Center
Georgetown University
School of Medicine
3:35 - 3:45 PM Question and Answer Session
3:45 - 4:25 PM Panel Discussion
4:25 - 4:40 PM Concluding Remarks
John M. Kane, MD

Accreditation and Credit Information:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Learning Objectives:
At the end of the presentation, participants should be able to:

- Understand the current state of the science with regard to the neurochemistry of relapse in schizophrenia
- Describe the potential pathophysiologic consequences of relapse, as well as the impact on patient outcomes
- Describe the key clinical factors that contribute to relapse in patients with schizophrenia
- Understand how relapse can be reduced/prevented from a pharmacologic perspective
- Discuss the criteria for determining functional recovery in schizophrenia

Sponsored by JANSSEN
Supported by an unrestricted educational grant from JANSSEN

APA 2005 Annual Meeting
INDUSTRY-SUPPORTED SYMPOSIUM 23
Sunday, May 22, 2005, 1:30 PM - 4:30 PM
Peachtree Ballroom, Level 8, Westin Peachtree Plaza

Fibromyalgia:
A DISORDER AT THE MEDICINE AND PSYCHIATRY INTERFACE
Sunday, May 22, 2005 • 1:30 pm - 4:30 pm • Westin Peachtree Plaza Hotel • Peachtree Ballroom, Level 8 • Atlanta, Georgia

AGENDA
1:00 pm  Lunch
1:30 pm  Welcome and Introduction
        Philip T. Nemeroff, MD
        Emory University
2:05 pm  Recent Developments in the Pharmacology of Fibromyalgia
        Philip T. Nemeroff, MD
        Emory University

OBJECTIVES
At the conclusion of this program, participants should be able to:
1. Recognize the possible pathophysiological links between fibromyalgia and mood and anxiety disorders.
2. Discuss the emerging evidence for the etiology of fibromyalgia.
3. Manage patients with fibromyalgia in a psychiatric setting using both pharmacological and non-pharmacological treatments.

The American Psychiatric Association (APA) is accredited by the Commission on Accreditation of Educational Programs in Psychiatry (APA-CAP). Participation in this program is available for one contact hour, which is credited toward the APA-CAP requirement for continuing education. The program is eligible for the American Academy of Family Physicians (AAFP) Program Recognition Program (PRR). The program is approved for one contact hour for the American Psychiatric Association (APA) and the American Academy of Family Physicians (AAFP).

The authors and planners have no conflicts of interest to disclose.

INDUSTRY-SUPPORTED SYMPOSIUM 24
Sunday, May 22, 2005, 7:00 PM - 10:00 PM
Grand Ballroom, Second Floor, Hilton Atlanta

Exploring Cognitive Function:
From Brain to Bedside
Presented at the APA 158th Annual Meeting
Sunday, May 22, 2005 • 7:00-10:00 PM

PROGRAM AGENDA
6:30-7:00 PM  Dinner
7:00-7:10 PM  Welcome and Introduction
              Philip T. Nemeroff, MD (Chair)
              Emory University
7:10-7:35 PM  The Neurology of Cognition: A Glimpse into the Brain
              Daniel E. Weinberger, MD
              NIMH, Clinical Brain Disorders Branch
7:35-8:00 PM  Reminiscence in Major Depression: The Vitality of Cognition
              Philip T. Nemeroff, MD
              Emory University
8:00-8:25 PM  Can Clinicians Impact Cognition in Schizophrenia?
              Ron J. Hsu, MD
              Stanford University
8:25-8:50 PM  The Composites of Cognitive Dysfunction in Late-Life Depression
              George E. Alexopoulos, MD
              Weill Medical College of Cornell University
8:50-9:15 PM  The Evidence and Relevance of Cognitive Dysfunction in ADHD
              Scott M. Kellam, PhD
              Duke University Medical Center
9:15 - 10:00 PM  Panel Discussion/Q&A

LEARNING OBJECTIVES
1. Identify pathways in the brain that are linked to cognitive functioning.
2. Evaluate targeted pharmacological and non-pharmacological treatments for executive dysfunction to improve patient outcomes.
3. Translate the evidence related to the treatment of executive dysfunction in late-onset depression, major depressive disorder, schizophrenia, and ADHD to improved functional outcomes.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the APA Physician Recognition Award and for the CME requirement of APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-935-7300.

Sponsored by the American Psychiatric Association
**Industry-Supported Symposium 25**

**Sunday, May 22, 2005, 7:00 PM - 10:00 PM**

**Imperial Ballroom, Convention Level, Marriott Marquis Atlanta**

---

**Bipolar Disorder: Treating Through the Entire Spectrum**

**Sunday, May 22, 2005, 7:00 PM - 10:00 PM**

**Imperial Ballroom, Convention Level, Marriott Marquis Atlanta, Atlanta, Georgia**

**Agenda:**
- 6:30-7:00 PM: Dinner
- 7:00-7:15 PM: Welcome and Introductions
  - Trisha Suppes, MD, PhD
  - (Chairperson)
  - University of Texas Southwest Medical Center
- 7:15-7:45 PM: The Neuroscience of Bipolar Disorder Across the Age Spectrum
  - Gary S. Sachs, MD
  - Massachusetts General Hospital
- 7:45-8:15 PM: Issues in Treating Bipolar Depression
  - Joseph L. Calabrese, MD
  - Case Western Reserve University

**Learning Objectives:**
- Understand the current data and theories regarding the neurobiology of bipolar disorders from childhood to adulthood
- Identify the unmet needs in the treatment of bipolar depression, describe the recent advances in the treatment of bipolar depressive episodes, and apply these data to current treatment paradigms of bipolar depression
- Outline the treatment goals for acute stabilization of patients diagnosed with mania associated with bipolar disorder, as well as describe the expanding data supporting current and emerging treatments
- Understand the significance of the enriched designs employed by studies demonstrating prophylactic benefit for bipolar disorder

**CME Statement:**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA website at apa.org or contact the APA toll-free at 1-888-357-7526 within the US or outside the US at 202-962-7500.

**Educational Objectives:**
- Understand the role neurogenetics plays in anxiety and depression
- Recognize the functional importance of serotonin and its receptors in depression and anxiety
- Convey knowledge about brain circuits implicated in the pathophysiology of mood and anxiety disorders
- Recognize, define, and understand the manifestations of comorbid major depression and anxiety disorders
- Treat patients who present with comorbid major depression and anxiety disorders

**Industry-Supported Symposium 26**

**Sunday, May 22, 2005, 7:00 PM - 10:00 PM**

**Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta**

---

**Untangling Depression and Anxiety: A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

**Agenda:**
- 6:30 PM: Dinner
- 7:00 PM: Introduction
  - Martin Kryl, MD - Chair
  - Brown University School of Medicine
- 7:10 PM: Genetic Models of Depression and Anxiety
  - Rene Hess, PhD
  - Columbia University College of Physicians and Surgeons
- 7:30 PM: Serotonin Targets as Mediators of Anxiety
  - Alexander Neumeister, MD
  - Yale University School of Medicine
- 8:00 PM: Neuroanatomical Pathways Underlying Major Depression and Anxiety Disorders
  - John Krystal, MD
  - Yale University School of Medicine
- 8:25 PM: Presentation and Diagnosis of Comorbid Major Depressive and Anxiety Disorders
  - Naomi Simon, MD
  - Massachusetts General Hospital
- 8:50 PM: Making Treatment Decisions for Comorbid Major Depression and Anxiety Disorders
  - Martin Keller, MD
- 9:15 PM: Question-and-Answer Session
- 10:00 PM: Conclusion

**Held at the APA 2005 Annual Meeting**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Industry-Supported Symposium 26**

**Sunday, May 22, 2005, 7:00 PM - 10:00 PM**

**Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---

**Untangling Depression and Anxiety**

**A Challenge for Scientists and Clinicians**

**Sunday, May 22, 2005**

**Marriott Marquis Atlanta**

**Marquis Ballrooms I & II, Convention Level, Atlanta, Georgia**

---
INDUSTRY-SUPPORTED SYMPOSIUM 27
Sunday, May 22, 2005, 7:00 PM - 10:00 PM
Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

AP A 2005 Annual Meeting
ADHD Through the Lifecycle: New Findings and Clinical Implications

8:00 PM
Welcome/Introduction
Thomas J. Spencer, MD, Chair

8:10 PM
Adult ADHD Diagnostic and Self-Report Symptom Scales: Assessment Methodology for Diagnosing and Monitoring Treatment of Adults With ADHD
Craig B. Sumran, MD

8:15 PM
Functional Impairments in Adult ADHD: Implications for Diagnosis
Stephen S. Faraone, MD
Joseph Biederman, MD, Co-author

Learning Objectives
1. Identify the different instruments and rating scales available to use in the diagnosis of ADHD in adults.
2. Recognize the functional impairments commonly seen in adults with ADHD and understand their implications for diagnosis.
3. Identify the developmental relationships of ADHD and SUD, the course of substance abuse in ADHD individuals, the preventive influence of ADHD medications on later SUD, and empirically based treatment strategies for patients with ADHD and SUD.
4. Discuss long-term study outcomes of mixed amphetamines in both children and adults with ADHD.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates the educational activity to be 3 hours of category 1 credit and/or the APA Physician's Recognition Award and/or the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 28
Sunday, May 22, 2005, 7:00 PM - 10:00 PM
International Ballroom, North Tower, Ballroom Level, Omni Hotel

Emerging “Best Practices” in the Management of Behavioral Emergencies

Chairperson Peter P. Buckley, MD

AGENDA

6:30 to 6:30 PM
Welcome and Introductions
Pam J. Baskin, MD
Medical College of Georgia
Augusta, Georgia

6:30 to 7:00 PM
Drugs for Agitation: Antipsychotics and Antidepressants
Joseph F. Breggin, MD
University of New Mexico Health Sciences Center
Albuquerque, New Mexico

6:45 to 7:00 PM
Acute Stabilization with Antipsychotics: New Therapeutic Options
Peter J. Buckley, MD
Northwestern University
Chicago, Illinois

7:00 to 7:15 PM
Assessment of the Agitated Patient: A New Mexico Approach
Joseph P. Breggin, MD
University of New Mexico Health Sciences Center
Albuquerque, New Mexico

7:30 to 8:00 PM
Conducting Consumer Choices in the Management of Behavioral Emergencies
Michael A. Atkins, MD
University of Colorado Health Sciences Center
Denver, Colorado

8:00 to 8:15 PM
Are Antipsychotics a Precursor to Aggression?
Richard W. Waddell, MD
University of Colorado Health Sciences Center
Denver, Colorado

8:15 to 9:15 PM
Acute Management of Agitation
Joseph P. Breggin, MD
University of New Mexico Health Sciences Center
Albuquerque, New Mexico

9:15 to 9:30 PM
Panel Discussion
Moderator: Peter P. Buckley, MD

9:30 to 9:45 PM
Closing Remarks
Peter J. Buckley, MD

Supporting this symposium is an unrestricted educational grant from Shire

TARGET AUDIENCE
The symposium is directed to psychiatrists and other mental health care professionals attending the 2005 Annual Meeting of the American Psychiatric Association (APA).

LEARNING OBJECTIVES
After attending this symposium, participants should be better able to:
- Differentiate between agitation as a symptom and agitation as a phenomenon in behavioral emergencies.
- Apply current practice standards (including the appropriate use of antipsychotic and antidepressant medications) to the management of behavioral emergencies.
- Discuss the role of antipsychotics in behavioral emergencies and discuss the mechanism of action for the antipsychotic and antidepressant effects in the acute management of agitation.
- Discuss the role of the role of antipsychotics and antidepressants in the acute management of agitation and aggression.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates the educational activity for a maximum of 3 hours of category 1 credit toward the APA Physician’s Recognition Award and/or the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association.
INDUSTRY-SUPPORTED SYMPOSIUM 31
Monday, May 23, 2005, 7:00 a.m. - 8:30 a.m.
Tuesday, May 24, 2005, 7:00 a.m. - 8:30 a.m.
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

AGITATION and PSYCHOSIS, ALZHEIMER'S DISEASE, and PARKINSON'S DISEASE

AGENDA:
MONDAY MAY 23
9:30 a.m. - 10:00 a.m. Welcome and Introductions
JEFFREY L. CLINGING, MD
University of California, Los Angeles
10:00 a.m. - 10:15 a.m. Session Chair: Daniel Wentaub, MD
10:15 a.m. - 10:45 a.m. The Impact of Agitation on Quality of Life
S. Vancaelenbroeck, MD
University of California, Los Angeles
10:45 a.m. - 11:15 a.m. Agitation and Dementia: A Clinical Approach
J. D. Storandt, MD
University of California, Los Angeles
11:15 a.m. - 11:30 a.m. Session Chair: Daniel Wentaub, MD
11:30 a.m. - 12:00 p.m. The Impact of Agitation on Quality of Life
S. Vancaelenbroeck, MD
University of California, Los Angeles
12:00 p.m. - 1:30 p.m. Lunch

TUESDAY MAY 24
All day. Welcome and Introductions
JEFFREY L. CLINGING, MD
University of California, Los Angeles
All day. Session Chair: Daniel Wentaub, MD
All day. The Impact of Agitation on Quality of Life
S. Vancaelenbroeck, MD
All day. Agitation and Dementia: A Clinical Approach
J. D. Storandt, MD
All day. Session Chair: Daniel Wentaub, MD
All day. The Impact of Agitation on Quality of Life
S. Vancaelenbroeck, MD
All day. Lunch

LEARNING OBJECTIVES:
- Understand how agitation and delusions present differently in Parkinson's disease (PD), Alzheimer's disease (AD), and related disorders, such as mixed dementia of Lewy bodies (DLB), and understand how to assess psychosis and agitation in PD, AD, and related disorders.
- Explain the role of diagnostic instruments for psychiatrists and neurologists in the management of patients with PD, AD, and related disorders.
- Discuss the impact of agitation and delusions on caregiver burden and quality of life.
- Identify the role of pharmacological and non-pharmacological interventions in managing agitation and delusions in PD, AD, and related disorders.

CME STATEMENT:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Psychiatric Association designates this educational activity for a maximum of 9 Category 1 credits toward the APA's Maintenance of Certification (MOC) Program. Physicians should only claim credits that reflect actual participation in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 32
Monday, May 23, 2005, 7:00 a.m. - 8:30 a.m.
Tuesday, May 24, 2005, 7:00 a.m. - 8:30 a.m.
International Ballroom, North Tower, Ballroom Level, Omni Hotel

MANAGING THE SPECTRUM OF BIPOLAR DISORDER: MINIMIZING THE BURDEN OF DISEASE

AGENDA:
Monday, May 23, 2005
9:30 a.m. - 10:00 a.m. Breakfast
10:00 a.m. - 10:30 a.m. Welcome and Introduction
Robert E. Holmes, MD, MPH
University of California, San Francisco
10:30 a.m. - 11:00 a.m. The Impact of Bipolar Disorder on Health Care Utilization
Kevin T. O'Connor, MD
University of California, San Francisco
11:00 a.m. - 11:30 a.m. The Impact of Bipolar Disorder on Work Performance
Jennifer L. Segal, MD
University of California, San Francisco
11:30 a.m. - 12:00 p.m. The Impact of Bipolar Disorder on Family Functioning
Steven C. H. Kupfer, MD
University of California, San Francisco
12:00 p.m. - 1:30 p.m. Lunch

Tuesday, May 24, 2005
8:30 a.m. - 9:00 a.m. Welcome and Introduction
Robert E. Holmes, MD, MPH
University of California, San Francisco
9:00 a.m. - 9:30 a.m. The Impact of Bipolar Disorder on Medical Morbidity
Jennifer L. Segal, MD
University of California, San Francisco
9:30 a.m. - 10:00 a.m. The Impact of Bipolar Disorder on Psychosocial Functioning
Steven C. H. Kupfer, MD
University of California, San Francisco
10:00 a.m. - 10:30 a.m. The Impact of Bipolar Disorder on Quality of Life
Jennifer L. Segal, MD
University of California, San Francisco
10:30 a.m. - 11:00 a.m. The Impact of Bipolar Disorder on Work Performance
Kevin T. O'Connor, MD
University of California, San Francisco
11:00 a.m. - 11:30 a.m. The Impact of Bipolar Disorder on Health Care Utilization
Robert E. Holmes, MD, MPH
University of California, San Francisco
11:30 a.m. - 12:00 p.m. The Impact of Bipolar Disorder on Family Functioning
Steven C. H. Kupfer, MD
University of California, San Francisco
12:00 p.m. - 1:30 p.m. Lunch

LEARNING OBJECTIVES:
- Discuss the latest research on the etiology and treatment of bipolar disorder.
- Identify the relationship between bipolar disorder and other psychiatric disorders, such as anxiety disorders, substance use disorders, and personality disorders.
- Discuss the impact of bipolar disorder on quality of life, work performance, and social functioning.
- Identify the role of pharmacological and psychological treatments in managing bipolar disorder.
- Discuss the importance of early identification and treatment of bipolar disorder in minimizing the burden of disease.

CME STATEMENT:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Psychiatric Association designates this educational activity for a maximum of 9 Category 1 credits toward the APA's Maintenance of Certification (MOC) Program. Physicians should only claim credits that reflect actual participation in the activity.

ATTENDANCE INFORMATION:
For more information about attendance and credit earning, please contact the APA at 800-343-8900.
INDUSTRY-SUPPORTED SYMPOSIUM 35
Monday, May 23, 2005, 7:00 PM - 10:00 PM
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

DUAL DIAGNOSIS:
THE SCOPE OF THE PROBLEM

Monday, May 23, 2005 • Dinner: 6:30-7:00 PM • Symposium: 7:00 – 10:00 PM
Imperial Ballroom, Convention Level • Marriott Marquis Atlanta • Atlanta, Georgia

AGENDA:

6:30-7:00 pm  Dinner
7:00-7:10 pm  Welcome and Introductions
ALAN J. GREEN, MD
Chairman
Georgia Institute of Medicine
7:10-7:35 pm  Prevalence and Consequences of Dual Diagnosis
PETER L. BUCKLEY, MD
Medical College of Georgia
7:35-8:00 pm  Adolescent Substance Abuse and Psychiatric Comorbidities
DEBORAH DEAS, MD, MPH
Medical University of South Carolina
8:00-8:25 pm  Psychosocial Intervention for Dual Diagnosis
MARY F. BRUNETTE, MD
Marine Medical School

LEARNING OBJECTIVES:

- Understand the prevalence and etiologic mechanisms underlying the association between substance abuse, schizophrenia and bipolar disorder
- Identify the risk factors of substance use and their role in the comorbidity among adolescents
- Demonstrate an understanding of the symptoms of treatment of dual disorders, recognize which psychosocial interventions are appropriate at each treatment stage and comprehend the skills necessary to deliver these psychosocial interventions
- Discuss the available literature on the treatment of substance abuse in patients with bipolar disorder
- Describe the potential pharmacological treatment approaches to lowering committed alcohol and substance use in patients with schizophrenia and learn about the likely neurobiologic basis of the effects of these pharmacological agents

CME STATEMENT:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physicians Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that were actually spent in the activity.

If any participant is not satisfied with a CME evaluation or any other aspect of a course, please contact the APA at 1-888-357-3744 within the U.S., or 703-907-3300 after hours.

INDUSTRY-SUPPORTED SYMPOSIUM 36
Monday, May 23, 2005, 7:00 PM - 10:00 PM
Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

Insomnia in Special Populations:  Is This Insomnia or Something Else?
May 23, 2005 • 7:00 – 10:00 PM • Marriott Marquee, Atlanta, Georgia • Salons 1 and 2, Convention Level

APA 2005 Annual Meeting • INTERACTIVE, DEBATE-STYLE FORMAT!

Agenda

6:30-7:06 pm  Dinner
7:00 pm  Introduction - Chair
Ruth M. Benca, MD, University of Wisconsin Medical School, Madison, Wisconsin
7:10 pm  Insomnia in the Elderly
Sara Ancoli-Israel, PhD, University of California San Diego, San Diego, California
5 Minutes Audience Question and Answer
7:45 pm  Insomnia in Depressed Patients
Ruth M. Benca, MD, University of Wisconsin Medical School, Madison, Wisconsin
5 Minutes Audience Question and Answer
8:20 pm  Insomnia in Women: An Overlooked Epidemic?
Claudio N. Santos, MD, Massachusetts General Hospital, Boston, Massachusetts
5 Minutes Audience Question and Answer
8:55 pm  Novel Strategies to Treat Insomnia
John W. Winnekranz, MD, Brigham and Women's Hospital, Newton, Massachusetts
9:20-10:00 pm  Audience Question and Answer
10:00 pm  Meeting Adjourns

Learning Objective

At the conclusion of this symposium, the participant should be able to recognize the impact of insomnia in the elderly, in depressed patients, and among subgroups of women. The participants will also have the opportunity to learn about treatment options in these special populations.

Registration Policy

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7124 (within the U.S.) or 703-907-7300.

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physicians Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that were actually spent in the activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Sepracor
INDUSTRY-SUPPORTED SYMPOSIUM 37
Monday, May 23, 2005, 7:00 PM - 10:00 PM
International Ballroom, North Tower, Ballroom Level, Omni Hotel

INDUSTRY-SUPPORTED SYMPOSIUM 38
Monday, May 23, 2005, 7:00 PM - 10:00 PM
Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel
INDUSTRY-SUPPORTED SYMPOSIUM 39
Tuesday, May 24, 2005, 7:00 PM - 10:00 PM
Grand Ballroom, Second Floor, Hilton Atlanta

To be held at the APA 2005 Annual Meeting

SEASONAL AFFECTIVE DISORDER
NEW CONCEPTS, PRACTICAL STRATEGIES

TUESDAY ~ MAY 24
HILTON ATLANTA & TOWERS

9:30-7 PM DINNER
7-10 PM CLINICAL PROGRAM

7:00 PM — Introduction
Norman E. Rosenthal, MD
Symposium Chair & Speaker

7:10 PM — The Clinical Picture & Epidemiology of SAD
Norman E. Rosenthal, MD
Georgetown University Medical School

7:30 PM — Pathophysiology of SAD
Thomas A. Wehr, MD
Bethesda, Maryland

8:00 PM — Light Treatment for Winter Depression: Status Report
Raymond W. Lam, MD
University of British Columbia Hospital

Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits.
In order to obtain the CME credit, each physician must claim only those credits
that he/she actually spent in the activity.

Sponsored by an unrestricted educational grant from Alliermes, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 40
Tuesday, May 24, 2005, 7:00 PM - 10:00 PM
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

ALCOHOLISM TRANSLATING EMERGING SCIENCE INTO CLINICAL PRACTICE

Tuesday, May 24, 2005 • 6:30 PM — 7:00 PM Dinner • 7:00 PM — 10:00 PM Scientific Session
Imperial Ballroom • Marriott Marquis • 265 Peachtree Center Ave • Atlanta, GA 30303

FACULTY
Raymond Antoon, MD (Co-chair/Moderator)
Distinguished University Professor in Psychiatry
Department of Psychiatry and Behavioral Sciences
Director, Center for Drug and Alcohol Programs
Medical University of South Carolina
Charleston, South Carolina

George E. Koob, PhD
Professor
Department of Neuroscience
The Scripps Research Institute
La Jolla, California

Charles O’Brien, MD, PhD (Co-chair)
Vice-Chair, Department of Psychiatry
Director, Treatment Research Center
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Helen M. Petraitis, PhD
Research Professor, Department of Psychiatry
Research Division Director, Treatment Research Center
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Hugh Myrick, MD
Associate Professor
Department of Psychiatry and Behavioral Sciences
Medical University of South Carolina
Charleston, South Carolina

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
The APA designates this educational activity for a maximum of 3 category 1 credits toward
the APA Physician’s Recognition Award and for the CME requirements of the APA.
Each physician should claim only those credits that he/she actually spent in the activity.

REGISTRATION
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is
limited and will be based on first come, first served.
For more information about the meeting, please visit the APA website at www.psych.org, or
contact the APA toll free at 1-888-357-7324 (within the U.S. or Canada) or 703-907-7300.

SYNDROME PROGRAM AGENDA
7:00 PM — 7:10 PM
Welcome and Introduction
Raymond Antoon, MD (Co-chair)

7:10 PM — 7:30 PM
Animal Models: Point the Way to Novel Therapies
George Koob, PhD

7:40 PM — 7:50 PM
Question-and-Answer Session

7:50 PM — 8:15 PM
Brain Imaging of Craving and the Effects of Anti-craving Medications
Charles O’Brien, MD, PhD (Co-chair)

8:10 PM — 8:20 PM
Question-and-Answer Session

8:20 PM — 8:45 PM
Advances in the Pharmacotherapy of Alcoholism
Helen Petraitis, PhD

8:45 PM — 9:05 PM
Question-and-Answer Session

9:05 PM — 9:20 PM
Treatment of Alcoholism Combined With Other Mental Disorders
Hugh Myrick, MD

9:20 PM — 9:40 PM
Question-and-Answer Session

9:40 PM — 10:00 PM
Panel Discussion: Questions and Answers
Raymond Antoon, MD (Moderator)

Meeting Adjourns
Advances in Cholinergic Therapy
ALZHEIMER'S DISEASE AND BEYOND

Tuesday, May 24, 2005, 7:00 PM - 10:00 PM
Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

AGENDA
6:30 PM DINNER

7:00 PM WELCOME AND INTRODUCTION

153

1. Clinical Trials in Mild Cognitive Impairment
2. Pharmacological Treatment of Cognitive Impairment in Schizophrenia
3. Behavioral Treatment in Alzheimer's Disease

OBJECTIVES
At the conclusion of this program, participants should be able to:

- Identify the impact of cholinergic therapy beyond symptomatic treatment for Alzheimer's disease (AD).
- Recognize the potential role of autonomic neurotransmitters (ACHs) in AD treatment.
- Describe the benefits of magnetic resonance imaging in assessing AD.
- Discuss the outcome of recent clinical trials in mild cognitive impairment.
- Describe the rationale for cholinergic treatment of schizophrenia.
- Treat behavioral disturbances associated with AD.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity as a hands-on of a category 1 credit toward the APA Physician's Recognition Award and for the Lifelong Learning Program. Each physician who claims these credits should keep a log of credits he/she actually earned in the activity.

Attendees must register for the American Psychiatric Association's Annual Meeting to attend this symposium. Seating is limited to first come, first served basis. For more information about the meeting, please visit the APA web site or write to American Psychiatric Association, 7550 Wisconsin Avenue, Rockville, MD 20852-3719. At the meeting, please visit the APA Web site and request a copy of the program for APA 2004 - 2005 (before the meeting, please visit the APA Web site at www.apa.org or contact the APA toll free at 1-888-200-7784 to order the United States and Canada at 1-800-341-1700).
INDUSTRY-SUPPORTED SYMPOSIUM 43
Tuesday, May 24, 2005, 7:00 p.m. - 10:00 p.m.
Peachtree Ballroom, Level 8, Westin Peachtree Plaza

APA 2005 Annual Meeting
It's Not Just for Kids: ADHD in Adolescence and Adulthood

6:30 PM - 7:00 PM
Dinner

7:00 PM
Welcome/Introduction
Timothy E. Wilens, MD, Chair

7:10 PM
The Course of ADHD From Adolescence into Adulthood
Christopher J. Kratochvil, MD

7:30 PM
Neurobiological Update on ADHD in Adolescence and Adulthood
Stephen V. Farone, PhD
Joseph Biederman, MD, Co-author

8:00 PM
College Considerations in Young Adults With ADHD
Sharon B. Wigal, PhD

8:25 PM
New Psychopharmacologies Directed at Young Adults With ADHD
Steven A. Saffin, PhD

9:00 PM
Medication Considerations in Young Adults With ADHD
Timothy E. Wilens, MD

9:15 PM - 10:00 PM
Question & Answer Session

The American Psychiatric Association (AMA) is accredited by the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians.

The provider, American Psychiatric Association, designates this educational activity for a maximum of category 1 credits toward the AMA Physician's Recognition Award. This activity is approved for 15 category 1 credits in the field of psychiatry, for a total of 15 credits. Physicians should only claim credits that reflect actual participation in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 44
Wednesday, May 25, 2005, 7:00 a.m. - 8:30 a.m.
Thursday, May 26, 2005, 7:00 a.m. - 8:30 a.m.
Grand Ballroom, Second Floor, Hilton Atlanta

BIPOLAR DISORDER ACROSS THE LIFE CYCLE: Special Considerations

158th APA Annual Meeting
Wednesday, May 25 & Thursday, May 26, 2005
6:30 am - 8:30 am
Atlanta, Georgia
Grand Ballroom, Second Floor
Hilton Atlanta

REGISTRATION STATEMENT:
Attendance is required for the American Psychiatric Association Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-557-7024 (within the United States) or 703-907-7300.

ACCREDITATION STATEMENT:
The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT:
The APA designates this educational activity for a maximum of 3 credits in the field of psychiatry, for a total of 3 credits. Physicians should only claim credits that reflect actual participation in the activity.

STATED NEED:
Bipolar disorder (BD) affects 1.5 to 2.5 percent of individuals in the United States and has several well-recognized subtypes depending on the frequency and characteristics of the mood episodes. Current guidelines for the treatment of BD are available from the American Psychiatric Association, but additonal issues arise when applying these guidelines to children, adolescents, women across the reproductive life span, and the elderly. This symposium will address the critical issues of these guidelines in such special populations. For example, the usual age of onset in patients with BD is late adolescence or early adulthood; the diagnostic and treatment issues encountered in pre-pubertal and early adolescence will be discussed. Also, additional emphasis will be placed on the treatment of BD in women across the reproductive life span, specifically the impact of medications in terms such as the menstrual cycle, pregnancy, postpartum, and the transition to menopause, as well as critical components of the risk/benefit assessment for treatment options during pregnancy and lactation. The symposium will close with the final phase of life: treatment issues in the diagnosis and treatment of BD in the elderly. Overall, the symposium will provide special emphasis on the therapeutic monitoring guidelines for mood stabilizers in these special populations. These presentations will be augmented by a panel discussion at the end of the session.

INTENDED AUDIENCE:
Psychiatrists

EDUCATIONAL OBJECTIVES:
At the conclusion of this session, participants should be able to:

- Assess the risks and benefits of pharmacological treatment in order to best manage the treatment of children who are diagnosed with bipolar disorder, and identify appropriate timeframe for assessing the effectiveness of a treatment regimen before adding a second or third medication.
- Assess the impact of reproductive hormones on women with bipolar disorder and identify any associated side effects related to treatments in order to optimize patient management strategies.
- Assess the risks and benefits of pharmacological treatment in order to control, educate, and manage patients with bipolar disorder who are currently pregnant or may potentially become pregnant.
- Discuss issues related to the diagnosis and treatment of bipolar disorder in the elderly.

Program Administration and Americans with Disabilities Act. Event staff will be glad to assist you with any special needs such as physical disability. Please contact Sandy Cooper or Erin Hamlet prior to the live event at 720-740-9400 or e-mail scouper@treestreet.com or ehamlet@treestreet.com.
# Impact of Stress and Anxiety on Brain and Body

**Samantha Meltzer-Brody, MD** Symposium Chairperson

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 p.m.</td>
<td>Dinner</td>
</tr>
<tr>
<td>6:55 p.m.</td>
<td>Welcome and Announcements</td>
</tr>
<tr>
<td>7:00 p.m.</td>
<td><strong>Sick &amp; Tired: Anxiety, Stress and Insomnia</strong></td>
</tr>
<tr>
<td></td>
<td>Murray B. Stein, MD, MPH, FRCPC</td>
</tr>
<tr>
<td>7:30 p.m.</td>
<td><strong>Impact of Anxiety on Women’s Health: Focusing on the Link between Trauma and Chronic Pain</strong></td>
</tr>
<tr>
<td></td>
<td>Samantha Meltzer-Brody, MD</td>
</tr>
<tr>
<td>8:00 p.m.</td>
<td><strong>Health Effects of Exposure to Violence in Women</strong></td>
</tr>
<tr>
<td></td>
<td>Soraya Seedat, MD</td>
</tr>
<tr>
<td>8:30 p.m.</td>
<td>Neuroimaging and the Traumatized Brain: PTSD and Emotion</td>
</tr>
<tr>
<td></td>
<td>Ruth A. Lanius, MD, PhD</td>
</tr>
<tr>
<td>9:00 p.m.</td>
<td><strong>Treatment of Anxiety: The Pharmacotherapy of Psyche and Soma</strong></td>
</tr>
<tr>
<td></td>
<td>Mark Pollack, MD</td>
</tr>
<tr>
<td>9:30 p.m.</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>10:00 p.m.</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

**Overview:** After attending this continuing medical education symposium, the participant should be able to:
- Understand the relationship between anxiety and stress-related disorder and sleep problems, including the impact of treatments on health-related outcomes.
- Describe the presentation of functional somatic pain syndromes and the association of chronic pain with a history of maltreatment and PTSD.
- Recognize psychiatric and general medical health effects of intimate partner violence.
- Recognize the neural circuitry proposed to underlie PTSD and its relationship to chronic pain.
- Understand the impact of pharmacotherapy on both somatic and psychologic symptoms of anxiety.

**Accreditation/Registration Information:** The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 Category I credits toward the AMA Physician's Recognition Award and for the CM Lifelong Learning program requirement of the APA. Each physician should claim only those credits that reflect actual participation in the activity.

Attendance must be recorded for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-866-327-7924 within the U.S. or Canada or 1-925-947-7000.
Visit the APA Member Center
Find out how APA can help you in your professional life

Learn about the benefits of membership in the nation's oldest medical specialty society. APA's mission is to promote the highest quality care for individuals with mental disorders and their families, promote psychiatric education and research advances, represent the profession of psychiatry, and serve the professional needs of its members. Whether you're a prospective, new, long-time, or international member, visit the APA exhibit and find out how APA can help you in your professional life.

At the APA Member Center you can:
- Apply for APA membership on-site and find out how you may be eligible for a rebate
- Pick up your APA Membership Information and Resource Handbook
- Participate in APA advocacy efforts
- Search the Job Bank for the latest employment opportunities
- Activate your online subscriptions to APA journals
- Find out about the new Medicare pharmacy benefit and how it impacts your practice
- Learn how "OMNA On Tour" can help your community eliminate mental health disparity
- Find out about CME training for office-based treatment of opiate addiction
- Pick information about updates on the APA Practice Guidelines
- Check out training and clinical resources on HIV psychiatry
- Find out about the new ParentsMedGuide.org
- Keep up to date on the DSM-V Prelude Project: Research and Outreach
- Learn how the APA Foundation's public education programs promote awareness of mental illness
- And more!

While at the exhibit, learn about the key roles of these APA subsidiaries

Our mission is to contribute to psychiatry's science base and to improve the quality of psychiatric care through research, education, health policy analysis and dissemination.

The charitable and educational subsidiary, our mission is to advance public understanding that mental illnesses are real and can be effectively treated.

The Member Center is located in the exhibit hall next to the APPI Bookstore

Hours:
Saturday, May 21 10:00-5:00
Sunday, May 22 10:00-4:30
Monday, May 23 10:00-5:30
Tuesday, May 24 10:00-6:00
Wednesday, May 25 10:00-3:00